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ABSTRACT 
Barbituric acids have been historically classified as compounds that act on the 
central nervous system, and as such provide therapeutic uses as anxiolytics, sedatives, 
hypnotics, and anti-convulsants.  Recent investigations of barbituric acid derivatives have 
provided scientists with information that barbituric acids may have applications in 
antibacterial, anti-chlamydial, anti-viral, as well as anti-cancer treatments.  Additionally, 
recent literature accounts have indicated that barbituric acid derivatives may also act as 
immune modulators.   
 The recent explorations of barbiturates and their potential anti-cancer and immune 
modulating properties are the subject of this work.  Novel synthetic approaches to the 
development of new barbituric acid derivatives were explored thoroughly, and the 
mechanisms of these novel syntheses were detailed by experiment and spectroscopic 
characterizations.  In many cases the reaction procedures were designed for large scale, 
efficient syntheses, that are directly applicable to pharmaceutical production of these 
potentially valuable therapeutic compounds.   
 Several new products unique to barbituric acid reactions were characterized 
spectroscopically.  Barbituric acid derivatives were the subject of biological evaluation, 
and the results are reported in this work.  Overall, unique synthetic approaches to the 
production of novel barbituric acid derivatives were accomplished to create several new 
classes of barbiturates with potential applications in cancer treatment. 
 
 1
INTRODUCTION 
Ia. History of Barbituric Acid 
 In 1864, German chemist Adolph von Bayer, future founder of Bayer 
Pharmaceuticals, discovered one of the most notorious therapeutics known to chemists, 
malonylurea, more commonly known as barbituric acid (1).1  During the scientific era of 
Bayer, chemists had none of the tools available to modern day scientists, and analyses of 
compounds thought to possess biological activity were routinely characterized by taste, 
giving chemists first hand knowledge of the physiological effects of potential 
therapeutics.  Curiously, after this routine analysis was performed, barbituric acid in itself 
was determined to be without therapeutic significance.1  However, the discovery of 
barbituric acid subsequently led to the introduction of many other barbiturate derivatives, 
fueling the discoveries of a broad new class of therapeutics that would quickly dominate 
both the medical and social circles in the early 20th century.1  
 
NH2
O
NH2 EtO
O
EtO
O
urea malonic ester
N
N O
O
O
H
H
barbituric acid (1)
base
 
 
Figure I.1:  Synthesis of barbituric acid (1). 
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Ia.1 Modifications to original barbituric acid 
 Among the early derivatives of barbituric acid was 5,5’-diethylbarbituric acid.  In 
1903 Fischer and von Mering synthesized the first therapeutically active derivative of 
barbituric acid, done by replacing the C-5 hydrogens of the barbituric acid ring with ethyl 
substituents.1  Upon administration of this new barbiturate derivative, human subjects fell 
into a state of hypnosis, or deep sleep.  This new diethyl barbiturate, commonly called 
Veronal (3) (Figure I.2), is the first known active derivative of hypnotics derived from 
barbituric acid.1,2 
H2N
O
NH2
EtO
OEtO
O
N
N O
O
O
H
H
1. NaOMe
2.  CH3CH2Cl
EtO O
EtO
O
Veronal (3)
2
base
 
Figure I.2: Original synthesis of Veronal (5,5’-diethylbarbituric acid) (3). 
 
 Even in the early 20th Century, chemists realized that there was a serious problem 
with the metabolic degradation of Veronal.  The hypnotic drug was slow to take effect, 
and very slowly metabolized.  According to early scientific accounts, human subjects 
administered this compound would sleep for several days, unable to be roused from the 
coma-like state induced by the drug.1,2  From this point on, medicinal chemists have been 
exploring the therapeutic effects of barbituric acids, barbituric acid derivatives and new 
substitutions and derivations of barbituric acids as compounds with therapeutic value.  
Since the synthesis of Veronal, improvements have been made to this class of 
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therapeutics, which in turn elicited new structures belonging to perhaps one of the most 
valuable medicinal classes of compounds known to date.1   
Early advances in the structure-activity relationship of barbiturates and their 
therapeutic effects produced, in 1912, the active drug Phenobarbital 1 (4) (Figure I.3).  
Phenobarbital has been classically described as a medicinal compound possessing 
hypnotic and anticonvulsant activity, and given twice daily, keeps epileptic seizures 
under control.2 
 
N N
O
H
O
O
H
phenobarbital (4)  
Figure I.3:  Structure of the active anti-epileptic Phenobarbital (4). 
 
Subsequent research pertaining to the structure-activity relationship of 
barbiturates produced further understanding that the lack of drug activity and subsequent 
metabolism of the earlier derivatives, such as original barbituric acid (1) and Veronal (3), 
existed due to the same physical property, namely negligent passage across tissues lining 
the gastrointestinal tract (GI) of the human body.  This negligent passage inhibited the 
drugs’ passage into the circulatory system.  These early scientific discoveries led to the 
production of barbiturates that contained larger hydrocarbon groups, similar to those in 
the fatty tissue of the gastrointestinal tract.1,2 
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Ia.2 Effects of subsequent barbituric acid modification 
The modifications of barbiturates led to the yield of lipophilic compounds able to 
quickly pass through both the GI tract and the blood-brain barrier (BBB), enabling the 
transformation of barbiturates into widely used anesthetics, anxiolytics, and sedatives.  
Functional substitutions of the original barbituric acid stem from either C-5 substitutions 
or C-2 substitutions, each producing compounds with varying activities.  For example, 
manipulations of the C-5 position have resulted in the production of amobarbital (5), 
pentobarbital (6), secobarbital (7) and hexobarbital (8).  Substitutions at C-2 have 
resulted in the production of the short acting barbiturates, thiopental (9), and thiamylal 
(10) (Figure I.4).1,2 
 
N N
O
H
O
O
H
pentobarbital (6)
N N
O
H
O
O
H
secobarbital (7)
N N
O
H
O
O
H
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O
H
O
O
H
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N N
O
H
S
O
H
N N
O
H
S
O
H
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* *
* *
C-5 substituted
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Figure I.4: Substitutions of the original barbituric acid at either C-5 or C-2. 
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Ib. Classifications of Barbiturates 
 Barbituric acids and their subsequent derivatives are broken down into four 
classes, and are classified according to their metabolic degradation and tissue deposition.2  
The duration of the effects of barbiturates as well as the protein binding affinity of 
barbiturates are directly proportional to the chain length of the hydrocarbon attached to 
the C-5 position of the barbituric acid ring.2  For example, the classes include the 
following: 
1) Ultra short-acting barbiturates.  Include compounds that are metabolized rapidly 
and are highly lipid soluble.  These are typically used as intravenous anesthetics.  
Examples include hexobarbital (8), thiopental (9), thiamylal (10), all of which 
have C-5 substituents that are hydrocarbons of four or more carbon units.2 
2) Short-acting barbiturates.  Include compounds that are lipid soluble and bind to 
proteins.  Renal clearance of these derivatives is very low and they are generally 
used as hypnotics for patients who need help falling asleep.  These compounds 
typically have a half life of about three hours, and are advantageous because they 
do not cause next-day drowsiness.  While these are compounds with similar 
structures of ultra-short acting counterparts, they lack the additional C-2 
substitution.  Several examples of short acting barbiturates include pentobarbital 
(6) and secobarbital (7). 2  
3) Intermediate-acting barbiturates.  These derivatives are typically used as 
hypnotics for persons waking in the middle of the night.  They generally have a 
half life of three to six hours, and cause next-day drowsiness.  Several examples 
in this class include butabarbital and amobarbital (5). 2  
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4) Long acting barbiturates.  These compounds exert a hypnotic effect for longer 
than six hours, causing sedation and subsequent drowsiness.  They are 
traditionally used for anti-convulsant effects rather than hypnotic effects, due to 
the side effects.  Examples include Phenobarbital (4) and veronal (3). 2 
 
Ic. Physical Properties of barbituric acids 
 Barbituric acids and the active derivatives of barbituric acid are considered both 
hydrophilic, due to the 2,4,6-pyrimidinetrione ring system, and lipophilic, depending on 
the nature of the 5,5’-substituents.  Barbituric acid in itself is a strong acid, having a pKa 
of 4.01 in water.3a  It is partially soluble in polar solvents, such as methanol and water, 
and in these solvents retains its acidic properties, as well as be converted into the 
corresponding salt when treated with a base.3b  Generally speaking, barbiturate 
derivatives having at least one unsubstituted NH hydrogen retain their acidic properties, 
but the relative acidity of barbituric acid derivatives depends not only on the N-
substitution, but the C-5 substitution as well (Figure I.5).3b 
  
N
N
O
OO
H
H H
H N
N
O
OO
CH3
H R
R'N
N
O
OO
H
H R
R'
barbituric acid
pKa = 4.01
5,5'-disubstituted
barbituric acid pKa = 6.5-8
3,5,5'-trisubstituted
barbituric acid pKa = >8  
Figure I.5:  Acidic properties of barbituric acids.3 
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The barbituric acid ring itself contains one sp3 hybridized carbon atom, and is treated as 
an achiral ring system unless the 5,5’-substituents differ from one another and one of the 
NH moieties is substituted.3b 
 
Id. Pharmacological effects of barbiturates and barbituric acids as building blocks 
for large heterocycles with pharmaceutical value 
 Historical literature accounts describe barbituric acids as exhibiting a primary 
mode of action on the central nervous system.  The primary binding site of barbiturates is 
the GABAa-ion receptor complex, which will be described in further detail.  Once bound 
to this ion-receptor complex, barbiturates elicit effects that can be manifested in several 
ways:2,3 
1) hypnosis and anesthesia. 
2) Anti-convulsant 
3) Miscellaneous, including analgesic, autonomic nervous system actions, 
respiratory effects etc. 
 
While traditional roles of barbiturates in medicinal chemistry have been identified as 
GABAa-ion receptor complex, 3 there have been more recent literature documentation 
that barbiturates can exhibit biological activities in other areas, such as anti-bacterial, 
anti-fungal, possess anti-cancer activity, anti-osteoporosis activity to name just a few.4  
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Id.1 The traditional barbiturate target: the GABAa-ion Receptor Complex 
 The human nervous system is composed of specialized cells known as neurons.  
Communication between neurons via chemical synapses is vital to the normal function of 
both the central and peripheral nervous systems.5  Neurons are separated from one 
another by a space called the synaptic cleft, which effectively prohibits direct 
communication between adjacent neurons.  Instead, neurotransmitters that bind to 
specific receptors present in post-synaptic terminals are used as a means of 
communication between two neurons.5  Neurotransmitters can be of two types; excitatory 
or inhibitory.  Excitatory neurotransmitters act by depolarizing the next cell, which 
increases the probability that an action potential will be fired.  Inhibitory 
neurotransmitters act by causing the next cell to hyperpolarize, which decreases the 
probability that an action potential will be fired.5,6 
 The main inhibitory neurotransmitter in the central nervous system (CNS) is 
gamma-aminobutyric acid (GABA).  Release of this neurotransmitter into the synaptic 
cleft allows the interaction with the corresponding post-synaptic ligand gated GABAa 
receptor.5,6  Chloride channels are then activated and the rapid influx of chloride ions into 
the neuron makes the intracellular charge negative, and in turn depresses the excitatory 
depolarization of that neuron, making it less likely to fire an action potential.5,6  The 
release of GABA and its subsequent post-synaptic recognition by the corresponding 
GABAa receptor essentially inhibits the excitatory responses that result from fear or 
anxiety and ensures a tranquilizing effect.  In this respect, GABA can be deemed one of 
the most important neurotransmitters in the CNS, ensuring a level of homeostasis of 
neuron firing in the CNS.5,6 
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 The GABAa receptor has a structure common to most ligand-gated receptors.  
The receptor is made up of five protein subunits of approximately 50 kD, arranged in a 
circle, labeled α, β, or γ, which forms a channel that traverses the cell membrane (Figure 
I.6).5-7   
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Figure I.6: Cartoon of the GABAa receptor.7 
 
This channel remains closed until GABA binds to the site of recognition of the receptor 
and causes several conformational changes, including the rotation of the five subunits 
until the diameter of the channel is widened.  This widening of the channel allows for the 
passage of the chloride ion into the neuron.  Each protein subunit is a string of amino 
acids that pass both in and out of the cell membrane as a trans-membrane 4 helix bundle.  
The extracellular end, the N-terminus, is traditionally described as the mediator of the 
interaction between GABA and the GABAa receptor (Figure I.7).5-7 
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Figure I.7:  Cartoon of protein subunits of GABAa that traverse the cell membrane. 
 
GABAa receptors are common targets for many therapeutic drugs, including anti-
epileptic drugs, general anesthetics, barbituric acids and benzodiazepines.  When certain 
chemical structures, such as barbituric acid, bind to the GABAa-ion receptor complex 
associated with the neuron, the chloride current, activated by GABA, is enhanced.5,6  
Barbituric acids bind to the β-subunit of the GABAa-ion receptor complex and cause a 
conformation in the ion channel which allows more chlorine ions into the intracellular 
matrix of the cell.  The mediating factor of barbituric acid activity within the human body 
is the ability of the compound to pass through the blood brain barrier.5,6  Therefore, most 
barbiturate derivatives that are lipophilic enough to pass the blood brain barrier do 
enhance the chloride ion influx into the cell, and inhibit the firing of the action potential 
to the next cell.   
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Id.2 Discovery of Benzodiazepines 
 The vast research surrounding barbiturates has indirectly led to the discovery of 
another potent class of anxiolytic compounds known and benzodiazepines.  The 
benzodiazepine family consists of a large class of compounds that have a variety of 
substitutions on a basic tricyclic ring structure.  Among these are clinically used 
chlorodiazepoxide (11), flurazepam (12), triazolam (13), diazepam (valium) (14), 
lorazepam (15), and nitrazepam (16) (Figure I.7a).5,6   
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Figure I.7a:  Benzodiazepines commonly used today. 
 
The structural changes on the tricyclic ring are responsible for the widely variant half-
lives of each compound.8  Benzodiazepines act as sedatives, anxiolytic, muscle relaxants, 
and anti-convulsants, and do so with a moderate degree of selectivity.5  However, each of 
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the physiological characteristics elicited by benzodiazepines typically are a result of the 
same action.  Benzodiazepines tend to enhance the inhibitory activity of GABA at the 
GABAa receptors.5,6  Once bound to the GABAa receptor-ion complex, benzodiazepines 
cause an allosteric change in the receptor, which ultimately increases the number of 
chloride channels opened at once.5-7  One other advantage to using benzodiazepines as 
therapeutics is that they exhibit a much lesser degree of toxicity than do their barbiturate 
counterparts.5  While accidental overdoses of persons using barbiturates became a serious 
problem for the medical community, this problem is almost non-existent with the use of 
benzodiazepines.  To this end, benzodiazepines have largely replaced barbiturates in the 
pharmaceutical marketplace.5 
 
Id.3 Other possible physiological targets for barbiturates:  Histone 
deacetylase enzymes 
 Chromatin is classically defined as a complex of protein/DNA material within a 
given cell.  Nucleosomes are the basic units of chromatin within the cell, and they consist 
of an octamer of core histones.  These histones, labeled H2A, H2B, H3, and H4 wrap 1.8 
turns of DNA and form a compact structure within the cell.  Localized changes within the 
chromatin structure are one of the main components of transcriptional gene regulation.8   
 Several of the localized changes in the chromatin structure are a consequence of 
post-translational modifications of the histone tails.  These modifications include 
acetylation, methylation, phosphorylation, ubiquitination and poly-ADP-ribosylation, all 
playing important roles in gene regulation (Figure I.8).9  Perhaps one of the best studied 
post-translational histone modifications is histone acetylation and deacetylation.  
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Acetylation of histones generally occurs at lysine residues, and there are two classes of 
enzymes involved in determining the degree of acetylation of histones.  These enzymes 
are histone acetylases (HATs) and histone deacetylases (HDACs).12  Generally, 
hyperacetylated histones are associated with transcriptional permissiveness, and 
hypoacetylated histones mediate gene repression.10  Histone deacetylases (HDAC) are 
enzymes found in association with large protein complexes that are involved in gene 
expression.12  HDACs both regulate gene expression by deacetylating transcription 
factors and participate in cell cycle regulation.12  Compounds that inhibit HDAC increase 
histone acetylation by preventing deacetylation, and regulating a small subset of genes 
(approximately 2%).10   
 
N-ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKP
Ac-SGRGKGGKGLGKGGAKRHRKV
N-PEPSKSAPAPKKGSKKAITKA
Ac-SGRGKQGGKA
H3
H4
H2B
H2A  
Figure I.8: Cartoon of targets for post-translational histone modification via acetylation 
of lysine residues (K).11  
 
 There are several known compounds that act as histone deacetylase inhibitors 
(HDACIs).  Among these are sodium butyrate, phenylbutyrate, PhthalimidoCaproyl 
Hydroxamic Acid (PCHA) (17), trichostatin A (18), SuberoylAnilide Hydroxamic Acid 
(SAHA) (19), apicidin (20), and trapoxin (21) (Figure I.9).10,12 
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Figure I.9: Several known histone deacetylase inhibitors. 
In cellular cultures, the physiological effects of each of these compounds include cell 
growth inhibition, cell differentiation, apoptosis (programmed cell-death), as well as 
inhibition of cancer cell growth in animal models.12  Development through the cell cycle 
requires that gene expression be synchronized to the activities of proteins.10,13  Several 
small polar hydroxamic acids act as HDAC inhibitors and mediate cell growth, arrest 
and/or differentiation.  SAHA (19) and PCHA (17) are in fact two of those compounds.  
SAHA (19), perhaps one of the most widely studied hydroxamic acid HDACI’s, has been 
shown both in vitro and in vivo to increase the accumulation of acetylated histones in 
both tumor tissue and normal tissue, however, the growth suppression and apoptotic 
activity of SAHA appears to be limited to only transformed (cancerous) cells.12,14 
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Treatment of normal cells with these small polar compounds causes no growth inhibition 
or apoptosis, even though the increases of histone acetylation are detected in both normal 
and transformed cells.14a   
 Recent advances have been made with respect to the active site of the HDAC.  
For instance, scientists have been able to analyze the enzyme active site of an HDAC-like 
protein (HDLP) isolated from a species of anaerobic bacteria.  Through these studies, it 
was shown that the catalytic site of the enzyme has a tubular pocket with a zinc binding 
site at the base of the pocket and two Asp-Histadine charge relay systems.12  The 
hydroxamic acid part of SAHA was shown to bind with the zinc atom (Figure I.10).12  
Furthermore, these hydroxamic acid HDACI’s have been shown to bind directly to the 
enzyme active site, thereby blocking the substrate access, and causing an accumulation of 
acetylated proteins.14b 
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Figure I.10:  HDLP Enzyme catalytic site with suberylanilido hydroxamic acid (19) 
bound.14b 
The ensuing pharmacophore developed using this model consists of a metal 
binding domain that actively interacts with the catalytic binding site, a linker domain that 
occupies the tubular channel of the protein, and a surface recognition domain that 
interacts with the residues on the rim of the active site (Figure I.11).14b  Since HDACI’s 
have been shown to cause growth arrest, differentiation, and apoptosis in a wide variety 
of in vitro cell cultures, including neuroblastoma, melanoma, leukemia, breast, prostate, 
lung, ovarian, and colon cancers,12 we felt that exploration of the potential HDAC 
inhibition effects of novel barbiturates structured to resemble in many ways both SAHA 
and PCHA, were ideal starting points for the discovery of novel compounds that could 
mediate cell differentiation, or arrest tumor cell division by acting as HDACI’s, while 
maintaining some structural resemblance of the previously described pharmacophore.  
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For instance, that can be accomplished by replacing the aromatic moiety of SAHA or 
PCHA with the barbituric acid moiety.  In doing so, we would effectively increase the 
number of hydrogen bonding interactions between the new inhibitor and the targeted 
enzyme.  Based on this logic, our hypothesis was that barbituric acid analogs could be 
designed to retain the pharmacophore of potent HDACIs by either utilizing barbituric 
acid as the metal binding moiety of the pharmacophore or the surface recognition moiety 
of the pharmacophore and in turn create a new class of HDACIs with ideally the same 
biological activity as observed in SAHA and PCHA. 
O
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metal binding
 
Figure I.11: Pharmacophore of potential histone deacetylase inhibitors. 
 
Id.4 Barbiturates as Potential Immuno-Modulating Compounds 
 From an immunological point of view, cancer cells can be defined as cells that 
have somehow escaped the normal cell growth regulatory mechanisms, producing non-
functional cells.15  These non-functioning cells then give rise to clone cells which are 
constantly replicating, leading to the development of a tumor.15  While the human 
immune system has genes and cells that have many functions, including maintaining 
homeostasis of normal tissue by regulating cellular proliferation and cell death, it is 
clearly indicated by the number of annual cancer deaths worldwide that the level of 
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effectiveness of the immune response to tumor cells is often inadequate or poorly 
expressed.  Because of this, scientists have been increasing focus on the exploration of 
the immune system response to the regulation and destruction of cancer cells, designing 
vaccines as well as molecular systems that enable the reactivation of human immune 
responses to cancer cells.15   
 
Overview of the Immune System 
 An effective immune response involves two cellular groups.  These groups are 
known as lymphocytes and antigen-presenting cells.  There are many types of 
lymphocytes, and these cells are produced as white blood cells from bone marrow.  Once 
the lymphocyte leaves the bone marrow, it circulates in the blood and the lymphatic 
systems, and finally resides in lymphoid organs in the body.  Lymphocytes have antigen 
(foreign body) binding cell surface receptors that mediate immunological responses, such 
as specificity, diversity, memory, and self-nonself recognition.15   
 T lymphocytes leave the bone marrow and travel to the thymus to mature.  Here, 
these cells differentiate to express a unique antigen binding molecule, the T-cell receptor, 
on its membrane.  These T-cell receptors can only recognize antigens bound to cell 
membrane proteins, known as major histocompatibility complex (MHC) molecules.  
MHCs function in recognition, termed “antigen presentation” in which the recognition 
occurs between the molecule and glycoproteins found on cell membranes.15 
Dendritic cells (DC) are antigen-presenting cells of the human immune system 
that are involved in the initiation of the immune response.16a  DCs are responsible for the 
acquisition of antigens or cancer cells, and their subsequent transport to T-lymphocyte 
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rich areas.  They are present in lymphatic tissues and lymphoid organs.  Once the DCs 
interact with antigens and become activated, they are able to derive specific immune 
responses.  Secondary lymphoid organs, such as the skin, recruit both naive T-
lymphocytes and antigen-stimulated DCs into T-cell rich lymphoid areas, and the co-
localization of these early immune response constituents is representative of T-cell 
activation. 16a  Effective anti-tumor responses elicited from the immune system require 
the presence of both antigen presenting cells and T lymphocytes.16b   
In order for a T-cell to become activated, which in turn initiates the immune 
response of antigen destruction, a T-cell activation signal is required.  This signal is 
triggered by the recognition of the peptide-MHC molecular complex by the T-cell 
receptor as well as by a co-stimulatory signal.  The co-stimulatory signal is usually 
triggered by an interaction between cell surface glycoproteins of the antigen presenting 
cell and the T-cell (Figure I.12).15  Because tumor cells express low levels of MHCs and 
lack necessary co-stimulatory molecules, both necessary to initiate the proliferation of T-
cells, they are not effective modulators of antigen presenting cells.15, 16c  Without 
sufficient antigen presenting cells in the vicinity of a tumor, T-cells receive only partial 
activating signals, and tumors are allowed to proliferate.15 
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Figure I.12:  Antigen initiated human immune response. 
 
Immunotherapy is an approach in cancer treatment that attempts to supplement 
the natural immune defenses of the human body.15  To that end, one compound that has 
been clinically shown to demonstrate significant anticancer activities is 4,4’-
dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007 (22) Figure I.13).17  X-ray 
crystallography data revealed that A-007 (as monoclinic crystals) exists as two unique 
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Figure I.13:  Structural crystallography characteristics of A-007 (22). 18  
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rotamers. These rotamers differ only in the orientation of the bis-diphenylmethane group, 
where the rings are approximately perpendicular to each other and rotated approximately 
90o from the orientation of the rings in each rotamer (Figure I.13).18a   Both rotamers 
show strong intramolecular hydrogen bonds between the -NH of the -HN-N=C- moiety 
and an oxygen of the o-nitro group.  Examining the structure of A-007, one can see that 
there are three unique functional moieties present in A-007 that may contribute to its 
overall biological activity.  These three moieties are the dihydroxy-bis-diphenylmethane 
rings, the hydrazone moiety and the dinitrophenyl moiety.  However, despite A-007's 
high electrophilicity, it has no chemical reactivity with cell surface glycoproteins, making 
this compound and analogs of this compound promising new anti-cancer treatments.18b   
A-007 and its structural analogs appear to act as T-cell activators via CD45+ 
surface receptors on lymphoendothelial cells, and in particular with dendritic cells.  Thus 
far, thirty-three people have been treated with topical A-007 (22) (as a 0.25% gel) in the 
Phase I study, and of these subjects, 31% objective remissions have been observed with 
two complete responses.17  During the Phase I study, it was discovered that A-007 was 
not acting through a cytotoxic mechanism.  There was no local or systemic toxicity noted, 
and histochemical reviews of biopsies of human skin topically treated with A-007 
revealed that increased infiltrates of T-lymphocytes containing the membrane 
glycoproteins CD4+ (T-helper cells), CD3+(T-cytotoxic cells), CD8+(T-cytotoxic cells), 
and CD45+ had occurred after treatment.17   Increased skin infiltrates of CD11c+ 
dendritic cells (function as antigen presenters to T-helper cells) were also observed in 
treated areas.19  Further immunohistochemical studies suggested that immune modulation 
had occurred in vitro and in vivo following exposure to A-007.17,19 
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 A-007 is a simple organic molecule that appears to act as an antigen, possibly due 
to the unique electronic properties associated with this molecule.  It has been 
hypothesized by Morgan, et al. that up-regulation of the CD45+ receptor is an initiation 
site for the A-007-induced immune modulations that are being observed in patients with 
cancer.19  Our hypothesis is that if this is in fact the initiation site for up-regulation of 
receptor glycoproteins involved in immune modulation, then other structural analogs of 
A-007 should be able to elicit the same, or greater responses.  
 CD45+ is expressed on dendritic cells, lymphocytes, monocytes, and leukocytes, 
as well as some neoplastic cells, as a protein tyrosine phosphatase (PTP), which together 
with other members of the PTPs, are responsible for phosphorylating tyrosine residues.16d 
Blocking the CD45+ sites with anti-CD45 antibodies has been shown to inhibit T-cell 
activation and prevent mitogen (lectin) activation of naïve T-cells.20a   CD45+ receptor 
surfaces contain the amino acid residues of arginine, serine/threonine, and cysteine, and 
these residues can bind to or transfer natural ligands to the surface of antigen presenting 
cells and hydrolyze tyrosyl phosphates.20b  Morgan et al. hypothesized that A-007 does 
not inhibit or block CD45+, but up-regulates lymphocytes and dendritic cells (to antigen 
presenting cells) via electrostatic and/or non-covalent binding with the Arg, Cys, Ser/ 
Threo residues, as depicted in Figure I.14.19   Furthermore, A-007-activated DCs are 
capable of initiating mitotic events with naïve human blood peripheral mononuclear cells 
(PBMC) and up-regulating both CD45+ and CD11c+ receptors in human peripheral 
dendritic cells,20c all exemplifying the fact that A-007 is not an inhibitor of CD45+, but 
rather an up-regulator or modulator of the molecular sites (Figure I.14).  The influence 
that functional group substitutions may have on A-007's intra-/inter-molecular hydrogen 
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bonding and electrostatic interactions is presented below (This figure illustrates several 
possible interactions, and is not meant to illustrate the fact that all interactions occur). 
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Figure I.14: Postulated possible interactions of A-007 with the CD45 receptor (modified 
from Ref.  16d). 
 
 Considering this, we felt that one possibility of a moiety that would elicit the 
same up-regulation of CD receptors was the barbituric acid moiety.  Since the possibility 
exists for barbituric acid to make the same types of non-covalent interactions as A-007 
with the active site of the CD45 receptor, and was a versatile functional group in itself, 
we chose barbituric acid as the starting point for our explorations into the possibility of 
designing new and more potent immune modulating compounds.  Outlined through the 
remaining portion of this thesis are our synthetic and spectroscopic studies outlining the 
designed barbituric acid derivatives.  While several classes of compounds were selected 
and designed for future in vitro studies as HDACI’s, (namely those compounds 
designated in chapters IIa-d of this dissertation) several other classes were outlined as 
potential immune modulating compounds (chapters IId-i).  In both cases, the 
explorations of the reaction procedures, spectroscopic characterizations of the intended 
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products, and explorations of the reaction mechanisms are thoroughly outlined.  All 
obtained in vitro results are also included in the subsequent chapters of this dissertation. 
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RESULTS AND DISCUSSION 
IIa. Condensation Products 
IIa.1 Preamble 
Because barbituric acid has an active methylene group located at the C-5 position 
the molecule is easily involved in condensation reactions with aldehydes or ketones that 
do not contain an α-hydrogen.  This general type of reaction is known as the 
Knoevenagel condensation reaction.21  The reaction of barbituric acid with carbonyl 
compounds was studied as early as 1864, traditionally using urea and derivatives of 
malonate, and the isolated products obtained from these reactions were typically the 
mono C-5 or C-5,5’-disubstituted products (Figure I.4).22  However, to perform such 
reactions, the acid chloride of the alkyl substituent was necessary and due to the nature of 
the reaction, this procedure was applicable to a limited variety of reagents.  
Benzylidene barbituric acids are generally considered important biologically 
active compounds.  Benzylidene barbituric acids are useful as potential organic 
oxidizers,23 as building blocks in the preparation of oxadeazaflavines,24 and for the 
unsymmetrical synthesis of disulfides.25  Other applications have been reported, such as 
several studies indicating that benzylidene barbiturates could be used as nonlinear optical 
materials.26  Considering the discussed uses of benzylidene barbiturates, we felt that a 
straightforward and simple synthesis of a large variety of these compounds was virtually 
essential for both the scientific and pharmaceutical marketplaces. 
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To achieve the formation of the mono condensation product between aromatic 
aldehydes and barbituric acid, various methods utilizing acid or base catalyzed reactions 
have been previously employed such as clay mediated catalysis, radiation, and reactions 
without solvents just to name a few.27-33  There are some drawbacks to using previously 
described literature procedures.  For example, in basic conditions, the product of the 
reactions between barbituric acids and alkyl or aryl halides is not only the C-5 substituted 
alkyl or aryl product, but the N, N’-disubstituted alkyl or aryl products as well.  Even so, 
literature accounts dictate several very interesting approaches utilized for obtaining high 
yields of benzylidene barbituric acids as a product of condensation.  For instance, 
Villemin and Labiad microwaved a mixture of barbituric acid, aromatic aldehydes, and 
clay (Montmorillonite KSF) without solvent.29 The product of the condensation was 
obtained in high yield after extraction from the solid reaction residue using the solvent 
DMF (Figure IIa.1).  
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Figure IIa.1:  Villemin et.al. preparation of Knoevenagel condensation products.29 
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Another interesting approach to the preparation of Knoevenagel condensation 
products utilized a solid state reaction using clay and infrared radiation to obtain 
relatively high yields of the desired product (Figure IIa.2).34-35  
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Figure IIa.2:  Formation of Knoevenagel products from solid state reactions.35 
 
 While both of these methods provided the mono-condensation products of 
benzaldehydes and barbituric acid in adequate yields, the cost and availability of the 
necessary instruments and acidic clay catalysts provided a limitation for the production of 
large quantities of these compounds, therefore there was still a need for the development 
of a better synthetic procedure for our future studies utilizing these derivatives.   
 
IIa.2 Results and Discussion 
The synthetic procedure that we subsequently developed proved to be 
exceptionally simple and allowed the Knoevenagel condensation between aromatic and 
α,β-conjugated aromatic aldehydes with both N,N’-disubstituted and unsubstituted 
barbituric acids in methanol solution.  The reaction was performed utilizing the barbituric 
acids ability for self-catalysis in the case of unsubstituted barbituric acid to ensure the 
formation of the product.  In the case of N,N’-disubstituted barbituric acids, such as 1,3-
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dimethylbarbituric acid, a catalytic amount of either sulfuric acid or formic acid was used 
to ensure reactant conversion.  The general procedure involved mixing aldehydes with 
barbituric acid in a sufficient amount of alcohol to dissolve both reactants.  Based on the 
reactivity of the aldehydes used as reactants, the reaction was allowed to stir at room 
temperature for several hours to one full day (Figure IIa.3).  While typically, the 
reactions were performed at room temperature, we determined that in some cases, namely 
in the case of reactive aromatic aldehydes, the reaction mixtures could also be refluxed in 
methanol to give quantitative yields of the respective products in shorter time periods 
(~1-2 h).  However, when refluxing conditions are used, care must be taken with the 
length of the reaction time.  After extended refluxing time (12 h), we observed 
spectroscopically the products of decomposition in the reaction mixture solution, the 
formation of which hinders the isolation and purity of the desired product. 
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Figure IIa.3:  General procedure for obtaining Knoevenagel condensation products. 
 
 Our experiments indicated that aldehydes possessing electron-donating 
substituents, such as OH, and N(CH3)2 react much faster, and the condensation product, 
visually observable by the change in color (darker) of the reaction mixture due to 
extended conjugation of the product, was detected as early as one minute after the 
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reaction progression.  Similarly, trans-cinnamaldehyde and its counterparts reacted with 
similar reaction rates as did the electron-donating aldehydes.  For example, the α,β-
conjugated aromatic aldehydes such as trans-cinnamaldehyde and trans-3-(2-
furyl)acrolein produced a dark solid precipitate after a few minutes in methanol at room 
temperature, and was subsequently characterized spectroscopically as the condensation 
product.   
 The products generally had a very low solubility in methanol, and the separation 
of the product from the reactants was done by simple filtration and ensuing washes with 
cold methanol, which provided highly pure condensation products.  The products of 
condensation were thermally sensitive and decomposed rapidly at temperatures 
exceeding 260º C in the solid state.  In solution, the products of condensation were even 
more thermally sensitive, and purification by hot crystallization was deemed not a 
preferred method of purification for these products. 
 To obtain a 90% conversion in the less reactive aldehydes such as unsubstituted 
benzaldehydes, a longer reaction time was typically required.  Generally, the reaction 
could be performed in 1-2 days in methanol at room temperature.  Careful monitoring of 
the reaction was needed, because once the volume of alcohol decreased, starting materials 
as well as our condensation products precipitated from the methanol solution, determined 
through 1H-NMR spectroscopy in DMSO-d6 of the solid precipitate present after 
evaporation of methanol occurred.  In our spectral analyses, there were clear differences 
in the chemical shift for the NH signals of the Knoevenagel condensation product 
(~11.25 and 11.35 ppm) and the starting barbituric acid (11.11 ppm).  The ratios of these 
signals were used to determine the percentage of reaction conversion, which, depending 
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on the time elapsed varied from 50%-80% conversion.  To prevent obtaining impure 
products, the reactions with less reactive aldehydes were subsequently performed in 
closed flasks as opposed to open beakers.   
As previously mentioned, crystallization using hot liquid was not a preferable 
method of purification, due to low thermal stability of the products in solution, for any of 
the desired products.  Purification of the product from the starting material using solvents 
such as ethyl acetate or petroleum ether slightly improved the isolated yield, but 
elimination of unreacted barbituric acid was not accomplished. It was also necessary to 
perform the purification procedures several times, which ultimately lowered the yields of 
the condensation products.  Our best purification procedure involved the evaporation of 
methanol at reduced pressure and room temperature to a solid residue.  Elimination of 
barbituric acid was accomplished by adding water to the resulting solid residue and after 
stirring at room temperature for 30 minutes, the solid was separated by filtration.  To 
eliminate any starting aldehydes and to remove traces of water, the solid was washed 
with ether, providing highly pure (> 98%) products of condensation obtained in high 
yields. 
 Our reaction procedure was only applicable to aromatic and α,β−conjugated 
aromatic aldehydes (Table IIa.1).  All attempts to isolate the Knoevenagel condensation 
product of aliphatic aldehydes, such as hexanal, and barbituric acid were unsuccessful.  
Following the reaction by 1H-NMR spectroscopy in methanol-d4 (CD3OD) as a solvent, 
we observed the formation of 5-10% of the condensation product (23, Figure IIa.4).  
This was done by monitoring the intensity of the olefinic (CH=C) proton in the spectra 
(typically appearing around 8 ppm).  The reaction conversion ratio remained the same 
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after several days at room temperature.  One can assume that the preparation of the 
aliphatic C-5 substituted compounds could have been facilitated by using different 
solvents or elevated temperatures.  However, the formed products were exceptionally 
sensitive to both high temperatures and acidic solvents, and decomposed rapidly.  If the 
reaction was carried out for several days in a closed flask at room temperature, then 
traces of other products, including the Aldol condensation product (24) were detected by 
spectroscopy (Figure IIa.4).  This was also the case when the reaction was attempted 
using aliphatic or aromatic ketones.  For instance, when acetophenone was used as the 
carbonyl source we were unable to detect even a trace of the condensation product in the 
reaction mixture. 
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Figure IIa.4: Spectroscopically detected products in reaction between barbituric acid and 
aliphatic aldehydes. 
 
Likewise, performing the reaction with aromatic aldehydes containing electron-
withdrawing substituents, such as NO2, COOH, or pyridinium moieties was unsuccessful 
in producing the desired Knoevenagel products of condensation.  While literature reports 
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indicated that it would be possible to form the Knoevenagel condensation product using 
5-nitro-2-furaldehyde and barbituric acid,35 our own results suggested that the nature of 
the condensation product was not the single addition, but the products of double 
condensation, and the products obtained from these reactions will be discussed in further 
detail in IIe of this dissertation. 
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Figure IIa.5:  Products of described reactions in Table IIa.1. 
Table IIa.1:  Description of Knoevenagel condensations.  
Product Y R n Procedure Yield (%) 
A1 4-Me2N H 0 A 98 
A2# H H 2 A 95 
A3# 4-Me2N H 2 A 99 
A4# 4-OH H 0 A 95 
A5*,# C5H4O2 H 0 B 81 
A6# H H 0 B 85 
A7 3,4-(CH)4 H 0 B 83 
A8 2,4-OH H 0 B 85 
A9**,# C9H7NO H 0 B 96 
A10 2-OH H 0 B 80 
A11 2,4,6-OCH3 CH3 0 C 81 
A12 2,3,4-OCH3 CH3 0 C 79 
A13 4-OH CH3 0 C 80 
A14 2,4-OH CH3 0 C 79 
A15 H CH3 2 C 81 
*2-furaldehyde used for this relation;  **2-indoylaldehyde used for this reaction.  Procedure A:  reactions stirred at room 
temperature overnight.  Procedure B: stirred at room temperature in closed reaction vessels over several days.  Procedure C: 
additional acid catalyst used.  # Indicate compounds synthesized by Jursic. 
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IIb. Reductive C-5 alkylation and C-5 benzylation of barbituric acids 
 
IIb.1 Preamble 
 The majority of barbituric acid derivatives available for pharmaceutical use 
consist of compounds that are C-5 mono or C-5 dialkylated or benzylated barbituric 
acids.  Several examples of these include common sedatives such as veronal (3), 
pentobarbital (6), and phenobarbital (4).  Considering the availability and use of these 
compounds by the pharmaceutical industry, it seems logical that there would be a simple 
general procedure for the production of derivatives of such widely used compounds.  
Surprisingly, there is no simple synthetic procedure for preparing many derivatives of 
these compounds in the literature, and the methodology used to prepare mono and di-C-5 
substituted barbiturates has changed little from the century old method that uses malonic 
esters and urea as starting materials.36-38    
 Also noteworthy, mono C-alkylated and benzylated barbiturates are highly 
important intermediate compounds necessary for the production of assymmetrical 
barbiturates of pharmacological importance.  Typically, chiral barbiturates can be 
classified in one of two categories, one in which chirality is associated with the 
heterocyclic ring system making C-5 a prochiral center if R1 is not equal to R2 (Type I, 
Figure IIb.1), and the other in which chirality exits outside the ring system, wherein R3 
or R4 have optical activity (Type II, Figure IIb.1).  
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Figure IIb.1:  Examples of asymmetric barbiturates 
 
All chiral barbiturates currently marketed are in the racemic form, even though it has 
been classically shown that different enantiomers of chiral barbiturates exhibit different 
physiological effects.39 In 2000, Trost et al. described experimental work performed 
toward the palladium catalyzed asymmetric allylic alkylation reaction (AAA) as an 
advancement toward the production of enantioenriched barbituric acid derivatives, a feat 
not yet accomplished by literature accounts.  In these experiments the mono C-5 
alkylated intermediate (25), Pd2dba3-CHCl3 and a chiral ligand (26) were utilized in 
producing several chiral barbiturates (e.g. 27) of pharmaceutical value obtained as 
enantioenriched products (Figure IIb.2).39   
 
 36
N N
O
H H
O O
OCO2CH3
Pd2dba3-CHCl3
(S,S)-ligand
N N
O
H H
O O
H
39% yield
84% ee
O
NH
PPh2
HN
O
Ph2P
(S,S)-ligand
25
27
26  
Figure IIb.2:  Trost utilization of mono C-5 alkylated barbiturates.39 
 
While the isolated yields of Trost’s experiments are less than desirable (39%),39 the initial 
results of enantioenriched products prepared open an avenue of barbituric acid chemistry 
that has been under explored to date.  Given these current advancements, we felt it clearly 
relevant explore reaction conditions necessary to develop new methodology that would 
enable the mono C-5 alkylated and benzylated products to be produced by a synthetically 
simple method in large scale quantities. 
 
IIb.2 Results and Discussion 
IIb.2.1 Alkylation 
 The preparation of both mono and di-C-5-alkylated barbituric acids was done 
using catalytic reductive alkylation procedures.  While our developed procedures remain 
general and almost all 5-alkyl and 5,5’-dialkyl products were prepared easily, some of the 
analog preparations required different solvents, catalysts, and order of reactant mixing.  
Through our experimentation, we determined that the best catalysts for these reactions 
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was 5 wt% (dry basis) Pd or Pt on active carbon with the water content normally 50%.  
Combining the catalyst with a specific order of addition of reactants as well as 
monitoring solvent selection, the selective mono and di-C-5-alkylation and benzylation of 
three classes of barbituric acids were achieved, utilizing unsubstituted (barbituric acid), 
N-substituted (1-phenylbarbituric acid), and N,N’-disubstituted (1,3-dimethylbarbituric 
acid) derivatives.   
 Based on our previous experiments described in section IIa of this dissertation, 
we hypothesized that the first step of the reductive alkylation process between aliphatic 
aldehydes and ketones would be the formation of the Knoevenagel condensation product 
(~5% conversion), which would immediately yield upon catalytic hydrogenation of the 
newly formed C=C bond our desired mono C-5 substituted barbiturate.  Through 
experimentation, our initial hypothesis appeared correct, and we were able to perform the 
selective mono C-alkylation of barbituric acids with aliphatic aldehydes and ketones 
under described catalytic reductive alkylation conditions.  The initial condensation 
reactions were catalyzed by acid, either by auto-catalysis of barbituric acid (R1 or R2 = 
H), or by the addition of an acid catalyst such as concentrated HCl (several drops to 1 
mL).  The reactions were carried out as one pot syntheses in either methanol or ethanol as 
a reaction media (Figure IIb.3).  In cases where the carbonyl reagent in the reaction was 
used in high excess as a solvent and a reactant, such as in the case of acetone, the mono 
C-5 alkylated product was the only detectable product.  Despite our previous 
experiments’ indications of only a small conversion of reactants to the Knoevenagel 
condensation products, both aliphatic aldehydes and ketones were excellent alkylating 
agents.  Additionally, there were no apparent structural restrictions on the aldehydes or 
 38
ketones, with the exception being that there can be no reductive hydrogenation sensitive 
functionalities on any reactant (Table IIb.1).   
 
N
N
O
O
O
R1
R2
O
R3
R4
N
N
O
O
O
R1
R2
R3
R4
N
N
O
O
O
R1
R2
R3
R4
solvent
Knoevenagel Condensation
H2/5% Pd/C
R1=H, Ph, CH3 R2=H, CH3 R3=H, n-C11H23, CH3, n-C6H7, n-C6H13, -(CH2)5- R4=H, CH3, C6H5, n-C6H13
B1-4
 
Figure IIb.3:  General reaction for synthesis of mono C-5 alkylated barbiturates. 
 
Table IIb.1:  Selected representative mono C-alkylated products (General Procedure D) 
Product R1 R2 R3 R4 Solvent Yield (%) 
B1 H C6H5 CH3 H Acetic Acid 96 
B2 CH3 CH3 CH3 CH3 Acetic Acid 97 
B3 H H -(CH2)5-  Methanol 95 
B4 H H n-C6H13 H Methanol 97 
 
If R1 or R2 of the barbituric acid was not hydrogen, then acidic conditions were 
required to perform the reaction.  In such cases, the solvent for the reaction was acetic 
acid, and a few drops of sulfuric acid were sufficient to catalyze the initial condensation 
reaction. 
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IIb.2.2 Benzylation 
We determined through experiment that it was not possible to utilize the one-pot 
synthesis for the monobenzylated products due to the fact that even when one equivalent 
of the aldehyde was used, we obtained the di-C-5 benzylated product.  We hypothesized 
that this was due to the additional stability provided by the aromatic ring to the 
intermediate formed in situ, which subsequently facilitated the second aldehyde addition.  
Nevertheless, the mono C-benzylation of barbituric acid with aromatic aldehydes seemed 
to be a particularly straightforward process that afforded the mono C-benzylated products 
in high yields. The first step consisted of the synthesis of the Knoevenagel condensation 
product between the barbiturate and corresponding aromatic aldehyde.  The second step 
was the catalytic reduction of the condensation product using catalytic amounts of Pd/C 
(50% water content).  Extended conjugation on the aromatic aldehydes or electron 
donating groups, such as methoxy and dimethylamino, substantially decreased the 
reaction time.  For instance, the condensation reaction between 4-
(dimethylamino)benzaldehyde and barbituric acid was complete in several seconds in hot 
methanol (60º C).  The catalytic reduction of this compound was carried out in the same 
reaction mixture without isolation of the condensation product.   
Our initial experiments determined that the conjugated double bonds of the 
condensation product hydrogenated first, as determined by 1H-NMR of the reaction 
mixture after 20 minutes hydrogenation at 15 psi.  However, both Pt and Pd catalysts 
produced total aromatic hydrogenation when the benzaldehydes used possessed an 
electron donating substituent, such as -OCH3, -OH, or –N(CH3)2,.  For example, while 
reduction of the double conjugated bond of these derivatives was complete after 2 hours 
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at relatively low hydrogen pressure (15 psi), stopping the reaction this time provided a 
reaction mixture containing both the desired reduced product (B10) and the 
corresponding product of aromatic hydrogenation (28, Figure IIb.4).   
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Figure IIb.4:  Products of mono C-5 benzylation after hydrogenation 
 
Searching the literature for ideas to overcome this problem, we came across one reference 
that indicated that one method utilized to eliminate the reduction of the aromatic ring of a 
molecule was to use benzylic alcohols as a solvent.40  We utilized this method to avoid 
obtaining the mixture of products, using 4-methoxybenzyl alcohol as the reaction media.  
However, several of our condensation products were not sufficiently soluble in 4-
methoxybenzyl alcohol, and through further experiments we determined that using 
benzene as a co-solvent eliminated the aromatic ring reduction upon catalytic 
hydrogenation, even at higher pressures.  Therefore, all electron-rich aromatic aldehydes 
were subjected to reductive benzylation conditions using benzene as a co-solvent (Figure 
IIb.5).  In such cases the only isolated products were the mono-C-benzylation products 
(Table IIb.2). 
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Figure IIb.5:  General synthesis of mono C-5-benzylated products. 
 
Table IIb.2:  Representative mono C-5-benzylated products (General Procedure E) 
Compound R1 R2 R3 Yield (%) 
B5 H H 
 
85 
B6 H H 
 
90 
B7 H H 
 
92 
B8 H H 
N
 
89 
B10 CH3 CH3 N  
97 
B11 CH3 CH3 
 
91 
B12 CH3 CH3 N  
94 
B13 CH3 CH3 
N  
95 
B14 CH3 CH3 OH 91 
B15 H H OH 94 
B16 H H OH
 
75 
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IIb.2.3 C-5 dibenzylation of barbituric acid 
  
 We experimentally determined that by using an excess of reactive aromatic or 
conjugated aldehydes and varying the reaction conditions slightly, it was possible to 
obtain the double benzylation product of barbituric acid C-5 benzylation in quantitative 
yields (Figure IIb.6).  In these cases, it seemed that the addition the excess of the 
reactive aldehydes served as an inhibitor to aromatic reduction, thereby replacing the role 
of benzene as a co-solvent.  Isolation procedures for the C-5 di-benzylated products were 
very simple, and produced the desired compounds in high yields.  As determined 
previously, auto-catalysis by barbituric acid was a sufficient acid catalyst for the initial 
condensation reaction, and no additional acid was needed for the reaction to proceed.  
Likewise, catalytic amounts of sulfuric acid were needed to produce the Knoevenagel 
condensation products when N,N’-disubstituted barbituric acids were used as reactants. 
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Figure IIb.6:  Two representative structures of barbituric acid C-5 dibenzylation 
(General Procedure F). 
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IIb.2.4 Unsymmetrical C-5 alkylation of barbituric acid 
 Finally, we explored the possibility of producing the unsymmetrical C-5 
dibenzylation of barbituric acids.  We experimentally determined that C-5 -benzylation 
can also be performed on mono C-5 alkylated or benzylated barbituric acids through 
reductive alkylation with aromatic aldehydes.  Utilizing the products of mono C-
alkylation, which were described above, we successfully benzylated the mono C-
alkylated barbiturates to yield the desired unsymmetrical alkylated barbituric acid 
derivative (B19, Figure IIb.7).  When R1 and R2 of the barbituric acid were not equal, 
then the racemate was obtained.  However, we were unsuccessful in producing the 
second alkylation when aliphatic aldehydes or ketones were used as the second alkylating 
agent.  Therefore, in the cases where unsymmetrical double alkylation products having 
one C-5 substituent of aliphatic nature are necessary, aliphatic alkylation must be the first 
step of the reaction.   
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Figure IIb.7: Representative synthesis of unsymmetrical double alkylation products. 
(General Procedure G). 
 44
IIc. Development of 5-cyclohexylmethyl barbituric acids-Precursors for Asymmetric 
Synthesis 
IIc.1 Preamble 
In our literature searches for the preparation of new barbituric acid derivatives, it 
also came as a surprise that there were no available methods for the preparation of other 
simple mono C-5 substituted barbituric acid derivatives, such as 5-cyclohexylmethyl 
barbiturates.  This came as a surprise because C-5-monoalkylated barbiturates could 
potentially be very important intermediates in the preparation of asymmetric biologically 
active barbituric acid derivatives.  Given the fact that generally barbiturates containing 
lipophilic substituents tend have biological activity associated with them,1,2 we focused 
our attention on the development of a model reaction to produce new types of derivatives, 
namely those with a cyclohexylmethyl substituent in the C-5 position of the barbituric 
acid ring.   
 
IIc.2 Results and Discussion 
Our previous research led to the synthetic procedures developed to produce not 
only mono C-alkylated products, but mono C-benzylated products as well, both 
potentially valuable precursors for asymmetric synthesis of barbiturates if the barbituric 
acid in itself is prochiral.39, 41-44  However, while during the course of these studies we 
were able to selectively hydrogenate the activated aromatic rings of compounds such as 
B10 and B14 (Table IIb.1), we were unsuccessful in producing the corresponding 
derivative with unactivated aromatics, such as benzaldehyde and naphthaldehyde.   
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To be able to thoroughly explore the area of asymmetric synthesis with respect to 
barbiturates, we reasoned that it would be pertinent to begin not only with our previously 
synthesized mono C-5 alkylated products, but cyclohexylmethyl barbiturates as well.  To 
perform our future studies, various derivatives of 5-cyclohexylmethyl barbiturates must 
be readily synthesized in order to utilize this potentially important moiety for later 
generations of new and more potent chiral barbiturates.  Based on the previously 
discussed successful results with reductive C-alkylation of barbituric acids, we tailored 
our synthesis for the desired cyclohexylmethyl derivatives.   
Electron-donating substituents increased the reactivity of the aldehydes and due to 
the ease of the preparation of the mono C-5 benzylated products, one would assume that 
the synthesis of 5-cyclohexylmethyl derivatives would be a straightforward process under 
the optimal reaction conditions.  We predicted that -OH and –OCH3 substituted 
benzaldehydes would be the ideal precursors for the preparation of our targeted 
compounds.  Our assumption was based on the fact that in either water or methanol the 
OH or OCH3 substituent would be easy to remove from the cyclohexane ring after ring 
reduction, utilizing the reactivity of the substituent to be protonated. 
Depicted in Figure IIc.1 is our methodological development for the synthesis of 
C-5 cyclohexylmethyl barbiturates.  Condensation of both para hydroxybenzaldehyde 
and para methoxybenzaldehyde with barbituric acids in methanol requires only several 
minutes in refluxing methanol to produce compounds 2a.  The product precipitates from 
the methanol solution and the isolated yields for each of the reactions should be almost 
quantitative (> 90%).  Reduction of these condensation products, either with 5% wt (dry 
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basis) Pd-C or Pt-C with 50% water content, in methanol and benzene as a co-solvent 
generate product 2b with reduction of only the double bond, and not the aromatic ring.   
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Figure IIc.1: Reaction methodology for 5-cyclohexylmethyl barbiturates. 
 
Using this method, product 2b can be isolated in quantitative yields.  If the reduction is 
performed in a 0.01 M methanol suspension with PtO2 as a catalyst at 80 psi hydrogen 
pressure at 70º C for several days, then the product of hydrogenation, product 2c is 
generated.  In our experimental studies, we were able to isolate product 2c when both R1 
and R2 of the barbituric acid ring were CH3 and Y was OH.  To confirm the product 
identity, we crystallized a small amount of 2c, which was subjected to X-ray analysis.  
The ratio of the cis to trans isomer was 4:1, as determined through 1H-NMR 
spectroscopy.  From this point we hypothesized that in acidic media, compound 2c 
should be transformed to compound 2d, which would be further reduced under catalytic 
reduction to our targeted product, compound 2e.   
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To avoid having to isolate and characterize each of these intermediates and to 
increase the overall isolated yield of the respective reactions producing cyclohexylmethyl 
derivatives of barbiturates, we thoroughly explored the possibility of performing the 
reactions as a one-pot synthesis.  Reactions were performed in various acidic solvents, 
such as acetic acid, methanol-dilute sulfuric acid, methanol-trichloroacetic acid, aqueous 
hydrochloric acid, and methanol-hydrochloric acid.  The combination of methanol-
hydrochloric acid as a solvent system gave the best results, and was subsequently chosen 
as the media. In retrospect, the solvent system was logical, considering the low solubility 
of condensation product 2a in many solvents could potentially hinder the reaction 
progression.  The optimal solvent ratios were determined experimentally to be 1:1. While 
the methanol-HCl solvent mixture was determined to be the optimal media for 
performing this reaction, it should also be noted that in several other solvent mixtures, 
some amount of the desired product 2e could be detected in the reaction mixture if 5% 
Pd-C with 50% water was used.  Limited reactant conversion and subsequent product 
isolation hampered the outcome of the reaction in these cases.  Our best results were 
obtained when 5% Pt-C 50% water with methanol-HCl (1:1) were used as a catalyst and 
reaction media (Figure IIc.2), in which case the product of the reaction was obtained 
almost quantitatively in a one-pot synthesis (Table IIc.1).   
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Figure IIc.2:  One pot synthesis of 5-cyclohexylmethyl barbiturates. 
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Table IIc.1:  Aromatic hydrogenation of selected barbituric acid benzylidenes. 
Product R1 R2 Y Yield (%) 
C1 H H OCH3 89 
C2 H CH3 OH 84 
C3 H C6H5 OCH3 93 
C4 CH3 CH3 OH 88 
 
To fully confirm the structure of our compounds, one compound C4 was the 
subject of X-ray structural analysis.  The monoclinic P21/c crystals were grown from a 
methanol solution by allowing methanol to slowly evaporate at room temperature.  The 
X-ray determined structure of 5-(cyclohexylmethyl)-1,3-dimethylbarbiturate is presented 
in Figure IIc.3.  Both amide nitrogens of the barbituric acid ring are blocked with methyl 
groups, therefore the strong hydrogen bonding generally present in crystalline barbituric 
acid derivates cannot be observed in this instance.  The barbituric acid ring is almost 
planar, and almost perpendicular to the cyclohexane ring, which is in the chair 
conformation.   
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Figure IIc.3: Ortep drawing of compound C4 (courtesy of Prof.s E. D. Stevens and K. L. 
Martin).
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IId. Preparation of 5-Formyl and 5-Acetyl Barbiturates and Corresponding Schiff 
Base Products 
IId.1 Preamble 
 Many new drugs can be envisioned using the small 5-formyl or 5-acetyl 
barbiturates as a primary building block.  Synthetic procedures for the preparation of 5-
acetylbarbiturates with acyl groups containing phenyl as well as long alkyl groups are 
well documented in literature.45-46  Direct pharmaceutical and other industrial 
applications for the uses of these derivatives have also been documented in the literature, 
and while the applications exist,46-47 unfortunately, there are no good synthetic 
procedures for the preparation of simple acylbarbiturates, such as formyl and acetyl 
barbiturates.   
 There are several very efficient ways of introducing the formyl group to organic 
molecules.48-49   The general methods for the introduction of a masked formyl group can 
be divided into three classes, according to the nature of the reactant (C, -C, or +C).  The 
first group, C, belong to the Inanaga SmI2-induced masked formylation of carbonyl 
compounds.50 This reaction has a limited synthetic scope because strong oxidants or SmI2 
must be used (Figure IId.1).   
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Figure IId.1:  Inanaga method for introduction of a masked formyl group.50 
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On the other hand, using a masked nucleophile (-C) to introduce the formyl group is 
probably the most widely developed method today (see 31, Figure IId.2), but not 
applicable to our system due to the fact that the C-5 of barbituric acid is a (-C) 
nucleophile.51-54 
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Figure IId.2:  Example of (–C) masked nucleophile to introduce formyl group.54 
 
Other classical examples of the formylation include using cation (+C) equivalents in 
reactions of alkyl orthoformates with organometallics.55-57  Direct formylation of organic 
compounds is also well established in organic chemistry.  The Vilsmeier or Vilsmeier-
Haack reaction is the most common method for the direct formylation of reactive 
aromatic rings, such as anilines or phenols (Figure IId.3).58-60 
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Figure IId.3: Example of direct formylation via Vilsmeier-Haack reaction.60b 
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Another direct formylation that can be applied to phenols and certain heterocyclic 
compounds, such as pyrroles and indoles, is the Reimer-Tiemann reaction.61-63  This 
reaction is performed in basic solution and the yields are generally low, seldom 
overcoming 50%.64  This methodology was employed previously by Panteleimonov and 
Madrik in their preparation of 5-formylbarbituric acid in 30% yield.65  
 
IId.2 Results and Discussion  
 By modifying the Reimer-Tiemann reaction procedure, we simplified the reaction 
procedure and obtained a higher purity and higher yield of 5-formylbarbiturates (Figure 
IId.4).  By following the course of the reaction through 1H-NMR spectroscopy, it was 
apparent that 80% of the barbituric acid was converted to the corresponding formyl 
compound.  Unfortunately, the solubility of barbituric acid and 5-formylbarbituric acid in 
both water and methanol are very similar, and a large quantity of product was lost during 
the purification process.  When phenyl or methyl substituted barbituric acids were used 
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Figure IId.4: Synthesis of 5-formyl and 5-acetyl barbiturates (General procedures I and 
J). 
 
 53
the isolated yields obtained were much higher (Table IId.1).  To our surprise we were 
unable to find in the literature a reliable procedure for the preparation of 5-
acetylbarbiturates as well, although the preparation of some N-substituted 5-
acetlybarbiturates is known.66   If 5-acetylbarbiturates are to be used as precursors in the 
preparation of valuable pharmaceuticals, they should be inexpensive and available in high 
yields.  To meet these requirements, a simple, preferably one-pot synthesis should be 
prepared using readily available starting materials.  Our resulting developed procedure 
adheres to these requirements, utilizing acetic anhydride as a reagent for introducing the 
acetyl substitution in the 5-position of barbituric acids (Table IId.1).   
 
Table IId.1: 5-Formyl and 5-acetyl barbiturates. 
Product R1 R2 R3  Yield (%) 
D1 CH3 CH3 H 75 
D2 H H H 45 
D3 C6H5 H H 67 
D4 H H CH3 95 
D5 C6H5 H CH3 65 
D6 CH3 CH3 CH3 92 
 
IId.3 Preparations of ω-aminoalkanoic acid Schiff Base Products 
 Schiff-base products of 5-formyl and 5-acetylbarbituric acids have been reported 
as showing some interesting biological properties, therefore, the need for the preparation 
of these compounds in larger quantities using simple and effective synthetic procedures 
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was evident.67-70  Based on our previous experience, we felt especially valuable 
biologically active compounds could come as a result of a Schiff base reaction between 
formylated or acetylated barbituric acids and ω-aminoalkanoic acids.  Based on 
previously performed structure-activity relationship studies with already known histone 
deacetylase inhibitors as anticancer compounds, such as PCHA (17) and SAHA (19), we 
hypothesized that our Schiff base products of barbituric acid derivatives and ω-
aminoalkanoic acids , designed to structurally resemble these inhibitors, might also be 
active anticancer compounds (Figure IId.5).71-73  
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Figure IId.5: Formyl barbiturates designed as potential histone deacetylase inhibitors. 
 
Our ensuing procedure used to develop these potentially valuable compounds 
involved the one-pot synthesis of the condensation of the two reactants (barbiturate and 
ω-aminoalkanoic acid) in methanol (Figure IId.6).  The products had physical properties 
that easily set them apart from both starting materials, as well as made them an easy 
N
N
O
R3
O
OO
R2
R1 NH2(CH2)nCOOH
MeOH
N
N
N
R3
O
OO
R2
R1
(CH2)nCOOH
D7-13
 
Figure IId.6: Synthesis of ω-aminoalkanoic acid Schiff bases (General Procedure K). 
 
 55
subject of biological evaluation, being highly water soluble, and having similar structures 
as zwitterionic amino acids.  Furthermore, considering the nature of the physical 
properties of the products, our isolated yields were very high (Table IId.2). 
 
Table IId.2: ω-aminoalkanoic acid and barbituric acid Schiff base products. 
Product R1 R2 R3 n Yield (%) 
D7 CH3 CH3 H 5 90 
D8 H H H 3 95 
D9 H H H 5 91 
D10 C6H5 H H 3 80 
D11 H H CH3 3 89 
D12 H H CH3 5 87 
D13 H H CH3 2 90 
 
IId.3.1 Physical properties of Schiff base products with ω-aminoalkanoic acid 
 The positions of the double bonds in the Schiff base product strongly varied with 
the nature of the solvent and temperature applied.  It is commonly interpreted that Schiff 
bases are compounds that have a carbon-nitrogen double bond,74 which can move 
throughout the molecule to produce the more thermally stable isomer.  This double bond 
isomerization occurs via either proton exchange in solvent, or proton exchange with 
another molecule of the Schiff base product.  Our barbituric acid Schiff bases were 
perfect examples of this type of equilibrium.  The equilibrium was temperature sensitive 
and the two isomers, one containing a C-N double bond, and the other containing a C-C 
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double bond had substantially different proton 1H-NMR chemical shifts, as demonstrated 
in the 1H-NMR spectrum of D13 (Figure IId.7).  D13 was highly soluble in water and 
dimethyl sulfoxide (DMSO), but only slightly soluble in methanol.  At room temperature, 
more than 90% of compound D13 had a C-C double bond (Figure IId.7 A).  This 
structural assignment was based on the chemical shift for β-alanine as a standard in 
DMSO-d6.  β-alanine is slightly soluble in DMSO, and all hydrogens on the nitrogens are 
exchanged with deuterium from the solvent, therefore two triplets, one at 2.789 ppm (J= 
4.5 Hz) for –NCH2- of β-alanine and the other at 2.060 ppm (J= 4.5 Hz) for –CH2CO- of 
β-alanine were observed.  With the assumption that the chemical shift for –NCH2- of 
D13 in the C-C double bond isomer is similar to the chemical shift of our standard, β-
alanine, we assigned the 2.973 ppm peak to the –NCH2-  of the D13 C-C double bond 
isomer (Figure IId.7 A).  The chemical shifts at 3.632 and 3.616 ppm were assigned to –
NHCH2 in the D13 C-N double bond isomer (Figure IId.7 A).  By refluxing a methanol-
water solution for 5 minutes, the ratio of the isomers does not change to a discernable 
degree, as determined by 1H-NMR spectroscopy.   
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Figure IId.7: Spectroscopic following by 1H-NMR (DMSO-d6) of the change in the 
ratios of the two structural isomers of D13.  (A) two isomers isolated from the methanol 
reaction mixture; (B) ratio of isomers after heating DMSO-d6 solution for 1 min; (C) 3 
min heating; (D) 5 min heating then standing at room temperature for 8 h. 
 
It seemed obvious that due to the low boiling point of each of these solvents, the 
temperature necessary to induce the isomerization of D13 could not be reached using 
methanol and water.  On the other hand, DMSO has a boiling point of 189º C, and its heat 
capacity is much higher than that of methanol and water, thus a higher temperature can be 
reached in this refluxing solvent.  By heating the DMSO solution and allowing the 
solvent to reflux for one minute, the amount of the C=N isomer in solution increased 
from 18% to 61% (Figure IId.7 B).  With prolonged heating the C=N isomer ratio 
increased to 89% (Figure IId.7, C), and after 5 minutes, the C=N isomer was practically 
the only observed isomer spectroscopically.  Upon standing at room temperature for 
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several hours, the C=C isomer begins to re-establish, however not to the ratio previously 
observed in spectrum A (Figure IId.7 D).  From this study, it can be stated that the C=C 
isomer is probably the kinetic product of the reaction, while the C=N isomer is probably 
the thermodynamically favored product.  When the Schiff base product D13 was purified 
by crystallization, only the C=C isomer was present in the isolated material.   
 
IId.4 Preparations of Phenylhydrazones of 5-Formyl and 5-Acetyl 
barbiturates 
 It was demonstrated that simple nitrophenylhydrazones of 4-
hydroxybenzophenone have strong anticancer properties.75  With respect to the binding 
capabilities to biomolecules, the barbituric acid moiety should be superior to phenols, due 
to the larger number of hydrogen bonds that can be formed during non-bonding 
interactions.  Because of this rationale, we felt it of interest to develop the 
phenylhydrazones of the simple 5-formyl and 5-acetyl barbiturates previously described 
with the intent to do biological evaluation of these derivatives.  Several methods for this 
synthesis were explored.  The simplest and most effective methods were the direct 
condensation of the corresponding phenylhydrazine with the 5-formyl or 5-acetyl 
barbiturates in methanol at elevated temperatures (Figure IId.8).   
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Figure IId.8: Synthesis of traditional Schiff bases of phenylhydrazines and barbituric 
acids (General Reaction L). 
 
After the reaction was completed, the isolation of the product was dependent on the 
physical properties of the compound; however the products generally tended to be only 
slightly soluble in reduced volumes of methanol.  The optimized isolated yields of several 
derivatives are presented in Table IId.3. 
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Table IId.3: Schiff base products of phenylhydrazines and barbiturates. 
Product R1 R2 R3 R4 R5 Yield (%) 
D14 H H H H NO2 80 
D15 H H H NO2 NO2 88 
D16 Ph H H H NO2 92 
D17 Ph H H H COOH 93 
D18 CH3 CH3 H H NO2 95 
D19 CH3 CH3 H H COOH 91 
D20 H H CH3 H NO2 73 
D21 H H CH3 NO2 NO2 86 
D22 Ph H CH3 H NO2 84 
D23 Ph H CH3 NO2 NO2 81 
D24 CH3 CH3 CH3 H NO2 63 
D25 CH3 CH3 CH3 NO2 NO2 84 
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IIe. Aromatic-dibarbiturates- Pyridine and Quinoline Derivatives 
IIe.1 Preamble 
 There are some molecular systems that are capable of modulating immune 
responses, effectively opening an avenue for new and innovative treatments that combat 
terrible diseases such as AIDS and cancer.76-78    Until recently, barbiturates were mostly 
used as sedative and anesthetic drugs.79-81   However,  there are a few recent literature 
reports that suggest that some aromatic-dibarbiturates may also possess modulating 
activity, and initiate the human immune response.82-83  One could argue that the reason 
that aromatic dibarbiturates have not yet been thoroughly explored is due to the lack of 
availability of these derivatives.  Additionally, even in the few cases reported, once the 
derivatives were prepared, the low water solubility of these synthetic compounds 
hampered further the biological evaluation of their immune modulating activities.  One 
can propose that both of these problems can be eliminated if the aromatic moieties of the 
dibarbiturates are substituted with either a pyridine or quinoline moiety, thereby 
providing aromatic heterocycles that are more water soluble than corresponding benzene 
or naphthalene derivatives.  Unfortunately, procedures for the preparation of aromatic 
and heterocyclic dibarbiturates were not available at the time of our initial literature 
searches, indicating that we would need to devise our own synthetic design to produce 
these analogs in sufficient quantities for future testing.   
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 IIe.2 Results and Discussion 
 We hypothesized that the ideal starting materials for the preparation of these types 
of barbiturate analogs would be aromatic and heteroaromatic aldehydes and nitrogen 
substituted barbituric acids (Figure IIe.1).  In general, barbituric acid condenses  
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Figure IIe.1: Possible starting materials for the preparation of heterocyclic 
dibarbiturates. 
 
with aromatic aldehydes to form Knoevenagel condensation products.84  However, the 
outcome of these types of condensations is not always the simple arylidenebarbiturate.   
Some very interesting condensation products can be formed by simply varying either the 
nature of the aldehydes or the position of the heterocyclic atom of the aldehyde.  In 
general, the nature of the condensation product is determined by the arylcarboxaldehyde.  
For instance, when 1,3-dimethylbarbituric acid is condensed with 2-
pyridinecarboxaldehyde, regardless of the reaction solvent used (DMSO, methanol, acetic 
acid, etc.) the final product is the unique dipyridine-dibarbituric acid ylide (Figure IIe.2), 
which will be discussed at length in subsequent chapters of this manuscript.  When 
barbituric acid is used instead of 1,3-dimethylbarbituric acid the reaction outcome is 
different.  For example, in trifluoroacetic acid (TFA) the condensation product between 
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2-pyridinecarboxaldehyde and barbituric acid is 2-pyridinemethylenedibarbiturate i rather 
than the corresponding dipyridine-dibarbituric acid ylide ii (Figure IIe.2).  This is not 
true for all reaction conditions.  Even with barbituric acid as a starting material (R=H) the 
reaction conditions can be optimized in such way that ylide ii (R=H) becomes the major 
product of the condensation.   This finding suggests that through careful exploration of 
the reaction conditions, a variety of aromatic-dibarbiturates can be prepared from the 
same starting materials, and specific reaction conditions required to produce the desired 
bis barbiturate must be thoroughly explored.   
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Figure IIe.2: Two different products of barbituric acid (R=H) and 1,3-dimethylbarbituric 
acid (R=CH3) condensation with 2-pyridinecarbaldehyde. 
 
 Therefore, we outlined and performed a systematic study of aromatic and 
heteroaromatic aldehydes in condensation with barbituric acids, with the target being to 
prepare both aromatic and heteroaromatic-dibarbiturates.  The fact that the major product 
of the Knoevenagel condensation between aromatic aldehydes and barbituric acid is the 
5-arylidenebarbituric acid was perfectly demonstrated in our 1H-NMR spectra, recorded 
throughout the course of the reaction of the condensation between 1-naphthaldehyde and 
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barbituric acid (Figure IIe.3).  Regardless of the nature of the reaction media (neutral, 
acidic, or basic) only one product of the reaction was detected and isolated, and that 
product was 5-naphthalen-1-ylmethylenebarbituric acid (A7).  This reaction could be 
performed in many different solvents (methanol, dioxane, tetrahydrofuran, and dimethyl 
sulfoxide to name some of them) in a period of 20-40 hours at room temperature, each 
giving the respective Knoevenagel condensation product.  In acidic solvents, such as 
trifluoroacetic acid, the reaction was practically over in two hours at room temperature.  
Even when the reaction was conducted using a ten-fold molar excess of barbituric acid 
and higher temperatures (~70-120º C) overnight, we were not able to obtain the double 
barbituric acid addition product with 1-naphthaldehyde.  Furthermore, the same reaction 
outcome was obtained when the reaction was carried out with benzaldehyde instead of 
naphthaldehyde, indicating that the nature of the formation of the bis-barbiturate required 
some other stabilization, not found in the unsubstituted aromatic aldehydes. 
 
 
Figure IIe.3:  1H-NMR (500 MHz) reaction following for 1-naphthaldehyde (1 mM) 
condensation with barbituric acid (5 mM) in CF3COOH to produce A7. 
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 Through the course of our experiments, we were also able to demonstrate the 
influence of both the solvent and the nature of the substituents attached to benzaldehyde 
on the outcome of the condensation reaction.  For instance, in our previous studies, 
outlined in Chapter IIa, we demonstrated that benzaldehydes with electron donating 
substituents, such as the dimethylamino or hydroxyl groups, form the Knoevenagel 
condensation product easily.  The reaction was completed and the product isolated as 
quickly as one hour after refluxing in methanol, or several hours stirring at room 
temperature.  The same product can be detected if the condensation reaction is performed 
in dimethyl sulfoxide as a reaction media, therefore, we chose to use dimethyl sulfoxide 
as the reaction media for our 1H-NMR spectroscopic studies of the reaction progression 
for several reasons.  In both methanol and DMSO, the initial reaction mixture is a 
solution, but when methanol is used as a reaction media the condensation product 
precipitates from the reaction mixture.  Due to this precipitation, we were unable to 
determine through 1H-NMR the existence of any product in solution.  In DMSO the 
Knoevenagel condensation reaction was completed after fourteen hours at room 
temperature (Figure IIe.4).  In our 1H-NMR spectra following the reaction, we could not 
detect traces of the double barbituric acid addition product E1.  One can argue that this is 
due to the fact that the addition of the second barbituric acid to the condensation product 
A1 is a slow process.  The second addition of barbituric acid in many ways resembles the 
Michael-type of nucleophilic addition to α,β-unsaturated carbonyl compounds, and85  to 
be able to perform this reaction it would be necessary to utilize a strong nucleophile.  
Consequently, the second addition of barbituric acid could only be accomplished with the  
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Figure IIe.4:  The 1H-NMR (500 MHz) reaction following of 4-
dimethylaminobenzaldehyde condensation with barbituric acid in DMSO (a, b, and c) to 
yield A1 and CF3COOH (d, e, and f) to yield E1. 
 
enol form of barbituric acid.  In such a case, we hypothesized that strong acidic media 
would be the required reaction media in order to perform the double addition reaction 
with barbituric acid acting as a nucleophile.   
 Through our 1H-NMR spectroscopic monitoring of the reaction progression using 
acidic media, such as D2O-HCl, CH3CO2H, H2SO4, CF3CO2H, CF3SO3H, and H2SO4, we 
noted that we obtained the best results for the formation of the double addition products 
using CF3CO2H as our strong acid.  The reaction was practically complete in one hour, 
and the formation of the Knoevenagel condensation product A1 was observed 
spectroscopically (Figure IIe.4-spectrum e) during the course of the reaction.  This 
intermediate was a very good α,β-unsaturated carbonyl compound that facilitated the 
second barbituric acid addition in CF3CO2H, which resulted in the dibarbituric acid 
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adduct E1 (Figure IIe.4 spectra e and f).  We were able to fully convert 4-
dimethylaminobenzaldehyde into the double barbituric acid adduct E1.  At this point, and 
based on our experimental evidence, one argument could be made.  In order for the 
double barbituric acid addition to aromatic aldehydes to occur, a strong electron-
withdrawing group attached to the aldehyde’s aromatic ring is required.  This argument 
can be validated examining the following facts.  In DMSO-d6 as a reaction media the 
electron-donating (CH3)2N group attached to the aromatic ring is not protonated, 
therefore only the Knoevenagel condensation product A1 is detected and isolated.  
However, in CF3CO2H media (pKa=0.0) the dimethylamino group is protonated, 
(CH3)2HN+, and the substituent becomes electron-withdrawing.   The pKa of anilines (10-
12) is considerably higher than the pKa of trifluoroacetic acid, therefore the aniline 
should be protonated in TFA.  On the other hand, the pKa for protonated phenols and 
anisoles is between -6 and -8, and in TFA would exist primarily in the OH and OCH3 
forms.86 
 The 1H-NMR barbituric acid condensation with both 4-methoxy and 4-
hydroxybenzaldehyde (Figure IIe.5) in trifluoroacetic acid further validates this 
argument.  Aromatic aldehydes with strong electron-donating groups, such as hydroxy 
and methoxy, react selectively with barbituric acid derivatives to produce only the 
Knoevenagel condensation product in quantitative yield, regardless of the applied 
reaction media (methanol, H2O-HCl, H2SO4, CH3CO2H, CF3CO2H).86  This is clearly 
demonstrated in the 1H-NMR reaction following experiment for the 4-
hydroxybenzaldehyde condensation with barbituric acid in trifluoroacetic acid.  Only the 
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condensation product A4 was detected in the NMR spectra of the reaction mixture 
(Figure IIe.5). 
 
 
Figure IIe.5:  1H-NMR reaction following of 4-hydroxybenzaldehyde condensation with 
barbituric acid in CF3CO2H yielding A4. 
 
 We hypothesized that if it was in fact true that strong electron-withdrawing 
substituents on the aromatic ring facilitate the second barbituric acid addition to 
benzaldehyde, then the preparation of aromatic-dibarbiturates from nitrobenzaldehyde 
should occur in protic as well as aprotic solvents.  This hypothesis was confirmed, and 
was demonstrated by the H-NMR spectroscopic study following the progression of the 
reaction for the barbituric acid addition to benzaldehyde in both dimethyl sulfoxide and 
trifluoroacetic acid as reaction media (Figure IIe.6).  The same double addition product 
E2 was obtained regardless of the nature of the solvent, the difference being only the time 
required for the reaction completion.  For example, the reaction was completed in 40 
minutes in trifluoroacetic acid media and in 24 hours in dimethyl sulfoxide media, both at 
room temperature. 
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Figure IIe.6:  1H-NMR reaction following in DMSO-d6 -300 MHz Varian Unity and 
CF3COOH with electron-deficient aromatic aldehydes to yield E2.  
 
 Regarding reactivity, nitrogen heterocycles are similar to corresponding 
nitroaromates.87  Heterocyclic compounds similar to substituted benzenes have 
preferences for nucleophilic and electrophilic reactions.  In the case of pyridine87 it is not 
the free base that is involved in the electrophilic reaction, rather the conjugate acid of 
pyridine.  This is also true if a neutral nucleophile such as barbituric acid, malonic ester, 
phenylacetonitrile, etc. is added to the heterocyclic carboxaldehyde N-oxide.88  
 A similar parallel can be drawn between the reactivity of nitronaphthaldehydes 
and quinolinecarboxaldehydes.  If this assumption is true then the addition of barbituric 
acid to quinolinecarboxaldehyde in any solvent should afford the double addition product 
and the required reaction time should be relatively short.  This was completely 
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demonstrated in the H-NMR spectra following the reaction between barbituric acid and 
4-quinolinecarboxaldehyde E3 (Figure IIe.7).  The reaction was complete after one hour 
at room temperature.  It appeared that the second addition of barbituric acid to the 
Knoevenagel intermediate was a faster reaction than the first addition of barbituric acid to 
4-quinolinecarboxaldehyde, we were not able to detect even a trace of the condensation 
intermediate by NMR spectroscopy. 
 
Figure IIe.7: The 1H-NMR (DMSO-d6 -300 MHz Varian Unity, 500 MHz) reaction 
following for 4-quinolinecarboxaldehyde condensation with barbituric acid to yield E3. 
 
 Given the previously described results, it is also logical to assume that larger 
barbituric acid adducts can be formed if two or more heterocyclic carboxaldehydes are 
covalently bound together.  With respect to biological activity, we had a curiosity to 
prepare these compounds in order to determine whether the doubles of the structural 
moieties necessary for activity would have additive effects on the biological activity. 
Synthetically, this could be a daunting task because increasing the size and the number of 
the heterocycles makes the new target molecule harder to handle with respect to the 
formation of various reaction intermediates, their solubility in the course of the reaction, 
and the solubility of the final compound.  These problems are perfectly demonstrated on 
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the example for the tetra barbituric acid addition to the dipyridinedicarboxaldehyde 
(Figure IIe.8).  Although the reaction can occur in any given solvent that can dissolve 
both barbituric acid and dipyridinedicarboxaldehyde, the solubility of various reaction 
intermediates as well as tetra-adduct E4 limits us to using only dimethyl sulfoxide as a 
solvent and the reaction concentration must not be higher than 0.1 mM.  In the course of 
the NMR reaction, signals for every intermediate of the barbituric acid adducts can be 
detected (the first Knoevenagel adduct, the second Knoevenagel adduct, the first 
Michael-type of adduct and the second Michael-type of adduct (compound E4, Figure 
IIe.8).  There are many more intermediates involved in the barbituric acid tetra-addition 
to dipyridinedialdehyde DPDA.  With close evaluation of the NMR spectra five minutes 
after the reagents are mixed (Figure IIe.9) two new aldehyde hydrogen signals around 
9.9 ppm and a signal for α-CHOH at 6.7 ppm (besides the signals for the starting 
aldehyde DPDA) indicate the formation of iii.  Signals at 10.15 ppm and 8.2 ppm are 
assigned to the aldehyde and the vinyl hydrogen of intermediate iv and v, respectively.  
A small singlet at 8.25 ppm belongs to intermediate vi, and the singlet at 6.08 ppm 
belongs to the α-CH(Ba)2 of intermediate vii, while the singlet at 6.15 ppm belongs to the 
same hydrogen (α-CH(Ba)2 ) of the tetra-adduct E4 (Figures IIe.8 and IIe.9).  This 
analysis is performed with the assumption that the barbituric acid addition to the C=O is 
faster than the addition to the C=C double bond, and that elimination of water is faster 
from intermediates iii and v than both the barbituric acid additions.  Further spectroscopic 
study of the mechanism of the tetra-addition of barbituric acid is currently underway 
using positive electro spray studies and NMR studies. 
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Figure IIe.8:  All reactive intermediates that were detected in our NMR following 
experiments of the barbituric acid addition to 2,2’-dipyridine-4,4’-dicarboxaldehyde. 
 
 
Figure IIe.9:  1H-NMR (500 MHz) following of barbituric acid (10 mM) condensation 
with 2,2’-bipyridine-4,4’-carboxaldehyde (2.5 mM) in TFA-DMSO (3:1) at room 
temperature yielding E4. 
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 Additionally, we carefully explored the double addition reaction through NMR 
experiments in various organic solvents, as well as various acid-base conditions, and 
simple and very efficient reaction conditions were developed for the preparation of these 
valuable compounds (Figure IIe.10).  Isolated yields are almost quantitative and in many 
cases isolation and purification of the product simply involve filtration and washing the 
precipitate with solvent (Table IIe.1).   In these cases, the previously described NMR 
experiments utilizing both aromatic and heteroaromatic carboxaldehydes in both protic 
and aprotic solvents provided optimal reaction conditions for the preparation of double 
barbituric acid addition adducts to aromatic aldehydes.  Our preparation procedures 
developed are applicable to multi-gram as well as multi kilogram scales and considering 
the simplicity of the preparation and isolation of these compounds, the procedures are 
directly applicable to the industrial scale preparation with little or no modification.  
Crystals of E3 were obtained by slow evaporation of methanol at room temperature.  The 
structure of compound E3 was confirmed by X-ray structural analysis (Figure IIe.11). 
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Figure IIe.10: Preparation of heteroaromatic dibarbiturates (General Procedure M). 
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Table IIe.1: Barbituric acid condensation with aromatic aldehydes 
Product R1 R2 Aldehyde 
CHO  
Yield (%) 
E5 CH3 CH3 
N
N
 
92 
E7 H H 
N 
97 
E8 CH3 CH3 
N 
92 
 
E9 H CH3 
N 
97 
E10 H C4H9 
N 
81 
E11 H C6H5 
N 
93 
E12 H H 
N  
97 
E13 H CH3 
N  
98 
E14 H C4H9 
N  
92 
E15 H C6H5 
 
N  
92 
 
E16 CH3 CH3 
N  
86 
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E17 H C6H5 
N  
93 
E18 CH3 CH3 
N  
84 
E19 H CH3 
N  
78 
E20 H C6H5 
N  
95 
 
 
 
 
Figure IIe.11: ORTEP drawing of compound E3 (courtesy of E. D. Stevens). 
 
Table IIe.1 continued… 
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IIf. Unique Molecules: Charge Separated Pyridinium-Barbiturate Zwitterions 
IIf.1 Preamble 
Pyridinium zwitterions are widely used in organic synthesis, either as nucleophilic 
agents or as reagents in dipolar cycloaddition reactions.  The latter are used to synthesize 
fused heterocyclic systems that are otherwise very difficult to synthesize.  Figure IIf.1 is 
an example of the dipolar nature of pyridinium zwitterions and how they can be involved 
in dipolar cycloaddition reactions.89-92 
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Figure IIf.1: Dipolar nature of pyridinium zwitterions.91 
 
Usually, pyridinium zwitterions are compounds that are very reactive toward activated 
olefins and alkynes, and should be kept at low temperatures and in an inert atmosphere 
(Figure IIf.1).  The majority of pyridinium zwitterions were synthesized by first 
preparing the pyridinium salt, followed by the elimination of an acid in reaction with a 
base.  However, there are some other routes that are one-step syntheses which utilize the 
capability of pyridine derivatives to add to reactive double bonds or to trap carbenes 
(Figure IIf.2).93 
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Figure IIf.2: Formation of pyridinium zwitterions.93b 
 
Another application is the 1,4-dihydropyridine addition to alkoxycarbene complexes of 
transition metals, which has been shown to produce pyridinium zwitterions whose 
negative charge resides on the transition metal (Figure IIf.3, viii).  These reactive 
zwitterions have been shown to be successful in a number of reactions, one of which is 
selective cyclopropanation (Figure IIf.3, ix).94-96 
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Figure IIf.3: Pyridinium zwitterions used in cyclopropanation reactions.95 
 
However, in the majority of cases, the negative charge resides on the carbon attached to 
the pyridinium nitrogen and is delocalized by the presence of electron-withdrawing 
substituents.89-92  For example, pyridinium-cyclopentadienylide (Figure IIf.4, x) is 
probably the most theoretically explored pyridinium zwitterion with aromatic 
stabilization of a negative charge.97   Yet, even in this case, the molecule has low stability 
and little is known about its reactivity.98-99   To make pyridinium cyclopentadienylide 
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sufficiently stable for structure determination in order to evaluate its reactivity, the 
cyclopentadienide moiety must have strong electron-withdrawing groups, as in the case 
of pyridiniotetrabromocyclopentadienides (Figure IIf.4, xi).100 
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4-CO2Me, 3-CO2Me, 4-CN, 4-N(Me)2N
unstable stable
x xi  
Figure IIf.4: Pyridinium zwitterions with aromatic stabilization of a negative charge 
 
IIf.2 Results and Discussion 
In our previous attempts to outline reaction procedures for the double addition of 
substituted barbituric acid to electron withdrawing aromatic aldehydes described in the 
previous chapter, we were surprised to find that under comparable reaction conditions, 
the 2-pyridine and 2-quinolinecarboxaldehydes did not give our desired Michael type 
adduct.  Instead, through these reaction conditions, we obtained a unique compound that 
we were unable to immediately assign a structure to, based on our spectroscopic data.  
Later, we characterized the compound through X-Ray structural analysis (Figure IIf.5), 
as a unique, stable pyridinium zwitterion, and therefore set out to design and explore the 
reaction requirements more thoroughly to form our unique molecule.   
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Figure IIf.5:  ORTEP drawing of X-ray determined structure of F1 (courtesy of E. D. 
Stevens). 
 
We subsequently developed an efficient synthetic procedure for the preparation of a 
unique pyridinium zwitterion (F1), synthesized through the controlled condensation 
between 1,3-dimethyl barbituric acid and 2-pyridinecarbaldehyde, with an aromatic 
stabilization of the negative charge.  In the case of barbituric acids, amide resonance 
dominates over aromaticity.  With a negative charge localized on the barbituric acid ring, 
it is reasonable to assume that π−π atomic orbital overlap between the atoms in the ring 
should increase, thereby stabilizing the negative charge, which is indicated by the 
planarity of one of the barbituric acid rings of F1.   
Previous literature data suggests that if the reaction between a barbituric acid and 
an electron-rich aromatic aldehyde is performed, then the Knoevenagel condensation101-
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102 product (F4) must be the major product isolated (Figure IIf.8).29, 84, 103-104  However, 
this application does not apply to electron poor aldehydes, such as nitrobenzaldehyde, in 
which there are unexpected products and the double addition product (Michael Addition, 
F2) is obtained (Figure IIf.6).105-107 
N
N OO
R2
R1
O
CHO N
NO O
R2
R1
O
N
N OO
R2
R1
O
NO2
CH3OH
NO2
F2  
Figure IIf.6: Typical reaction product of barbituric acids and electron-deficient aromatic 
aldehydes. 
Considering the similarities in the electronic properties of 2-nitrobenzaldehyde and 2-
pyridinecarbaldehyde, one would expect that the isolated product of the condensation 
between 2-pyridinecarbaldehyde and substituted barbituric acids should be of the Michael 
Type adduct.  This is not the case and the isolated product of this condensation is (F1) in 
almost quantitative yield (Figure IIf.7). 
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Figure IIf.7: Reaction outcome when 2-pyridinecarboxaldehyde is used as electron-
deficient aromatic aldehydes. 
To explain the formation of our unique compound, we hypothesized that two 
intermediates must exist.  The first intermediate, and one that we have had previous 
spectroscopic evidence that lends to its formation during the course of double addition 
reactions, is the intermediate Knoevenagel product (F4).  The second intermediate would 
be an unstable pyridinium barbiturate zwitterion (F5) (Figure IIf.8), which should 
undergo rearrangement to produce the more stable compound F1.  
N N
N
N
N
N
O
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O
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CH3O
O
H3C
H3C
O
N
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CH3
H3C
O
N
F4 F5  
Figure IIf.8: Two proposed reactive intermediates in formation of F1. 
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Our attempt to actually isolate the Knoevenagel condensation product (F4) in the reaction 
between 1,3-dimethyl barbituric acid and 2-pyridinecarbaldehyde was not successful, 
regardless of the nature of solvent or base and acid used in this reaction.  From NMR 
spectra taken during the reaction, we know that intermediate (F4) is formed and almost 
instantly consumed in nucleophilic addition of the barbituric acid (leading to product F1). 
We hypothesized that when a better nucleophile was not present in the reaction mixture, 
then the nitrogen of the pyridine moiety of F4 acted as a nucleophile to another molecule 
of F4, producing the pyridinium zwitterion F5.  This zwitterion subsequently rearranged 
into the more stable pyridinium zwitterion F1.  Both of these zwitterions contain 
negatively charged barbituric acid rings.  Although we do not have direct evidence for the 
formation of pyridinium zwitterion F5, we have indirect experimental information that 
strongly supports our hypothesis of its existence.  For instance, if the reaction is 
performed in a strong acid, such as sulfuric acid, then the only isolated product is the 
sulfonate salt of the 2-pyridinium Knoevenagel condensation product.  If the reaction is 
done in acetic acid, then a virtually insoluble polymeric product is obtained.  While we 
were unable to spectroscopically determine the structure of this compound, due to its 
insolubility in solvents such as DMSO, methanol, water, acetic acid, chloroform, 
nitromethane, benzene and pyridine, we hypothesized that the insoluble material could be 
the polymer formed between two molecules of the reactive intermediate F5.  This 
assumption was based on the fact that acetic acid should be strong enough to protonate 
the carbon of the negative barbituric acid ring of F5, facilitating the nucleophilic addition 
of the pyridine-N of one molecule of F5  to the double bond of a second molecule of F5 
(Figure IIf.9). 
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Figure IIf.9: Possible polymeric material of F5 in acetic acid. 
Another indication of the existence of F5 as a reactive intermediate comes from the fact 
that we were unable to prepare type F1 zwitterions if 1-methyl, 1-phenyl, or 
unsubstituted barbituric acid was used as a starting reagent instead of the disubstituted 
1,3-dimethyl barbituric acid in the condensation reaction with 2-pyridinecarbaldehyde.   
Performing the reaction with these barbiturates in methanol also gave an insoluble 
material, appearing to be the same as the polymer like material obtained from the 
previous reaction in acetic acid.  We hypothesized that the insoluble material was indeed 
the polymeric material obtained from reactions of F5, catalyzed by the free NH of the 
barbituric acids used.  From this point, we ceased exploration of the characterization of 
the insoluble material obtained through these reactions, due to solubility problems with 
further characterization.  In the absence of solvents strong enough to either protonate the 
N of the pyridine ring, resulting in the Knoevenagel condensation product, or protonate 
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the barbituric acid ring, resulting in the polymer, the zwitterion F5 would readily 
rearrange to the more stable isomer, F1. 
IIf.3 Physical properties of Pyridinium-barbituric acid Zwitterion F1 
Pyridinium zwitterion F1 shows some interesting chemical properties.  One 
would expect that due to the negative charge localized on the barbituric acid ring, 
zwitterion F1 would be very sensitive to protic solvents. However, it is stable in water, 
alcohol, and acetic acid.  In fact, the compound is stable in hot acetic acid, which was 
determined by the lack of formation of decomposition products upon heating.  The 
formation of decomposition products was monitored by (1) spectroscopic 
characterization by VT 1H-NMR (80º C over 24 hours) and (2) by Thin Layer 
Chromatography of F1 before extensive heating and periodic examination of the reaction 
mixture following several days of heating in acetic acid.  In a more extensive, long-term 
NMR experiment using acetic acid and following the possible decomposition at room 
temperature over a period of 30 days, the only observable changes in the spectra were 
proton-deuterium exchange products.  This proton exchange in a modest acid such as 
acetic acid is characteristic of an aromatic ring.108 
Another surprise comes from the stability of the pyridinium zwitterion skeleton in 
basic solution.  It was expected that in aqueous sodium hydroxide, the five-membered 
ring of F1 would open.  Instead, the second barbituric acid ring, the ring not part of the 
pyridinium zwitterion substructure, opens and the decarbonylation product F6 is isolated 
(Figure IIf.10), again indicating the stability of zwitterion F1. 
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Figure IIf.10:  The decarbonylation of F1. 
 
This decarbonylation is a typical reaction for highly substituted barbituric acids, 
the reaction previously developed by Jursic.109   Given this information, we hypothesized 
that if the reaction were performed in polar solvents such as DMSO or methanol, the 
formation of pyridinium zwitterions F1 and F6 should be favored, and we were able to 
confirm this by spectroscopic characterization by NMR of the subsequent products.  On 
the other hand, less polar solvents, such as chloroform or dichloromethane, should inhibit 
the formation of pyridinium zwitterions F5, subsequently inhibiting the formation of the 
more stable F1 zwitterion, and the less polar product (F3, Figure IIf.11) should be 
favored. In our NMR experiment using chloroform as the solvent and reaction media, we 
detected the formation of both F3 and F1 in an approximate ratio of 7:3.  If even less 
polar solvents such as carbon tetrachloride were used, then completion of the reaction 
was prolonged but the ratio of F3 to F1 became ~9:1.  
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Figure IIf.11:  Formation of F3 in non-polar solvents. 
What is the source of this unique stability of pyridinium-barbituric acid 
zwitterion?  The unique structure of zwitterion F1 allows direct comparison of the X-ray 
structural parameters.  Jursic previously postulated that uniformity of the ring bond order 
is directly related to high stability.110  This postulate can be supported through X-ray data 
obtained for zwitterion F1.  The negative charge that resides mostly on the barbituric acid 
ring makes that ring more aromatic and adds to the bond order-bond distance uniformity. 
The barbituric acid ring with the negative charge becomes almost planar.  The 
experimental dihedral angles are almost zero and the dihedral angles for C(16)-N(17)-
C(18)-N(19) and C(20)-C(15)-C(16)-N(17) are -0.22 and -3.90º, respectively.  Even the 
carbonyl oxygen and methyl carbon reside close to the plane of the negatively charged 
barbituric acid.  For instance, the dihedral angle for C(27)-N(17)-C(18)-O(28) is -0.89º 
and the dihedral angle for O(26)-C(16)-N(17)-C(27) are 2.61º.  Given this data, it is quite 
obvious that the second barbituric acid ring is out of the plane.  The dihedral angle for 
C(10)-C(9)-C(14)-N(13) is -40.64º.  Comparison of bond distances between two of the 
barbituric rings further indicates the aromatic character of the ring that bears the negative 
charge.  For instance, bond distances in the nonaromatic barbituric acid ring for C(9)-
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C(10), C(10)-N(11), and N(11)-C(12) are 1.5128, 1.3934, and 1.3996 Å, respectively, 
while for the same kind of bonds in the aromatic barbituric acid moiety these distances 
for C(15)-C(16), C(16)-N(17), and N(17)-C(18) are 1.4138, 1.4220, and 1.3769 Å.  On 
the other hand, structural changes regarding pyridine and pyridinium rings are not 
substantial.  
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IIg. Syntheses of Heteroaromatic, Electron Rich, and Aliphatic Bis-barbiturate 
Ammonium Salts. 
IIg.1 Preamble 
 In previous chapters, we reported our successful synthesis of pyrilidene and 
quinolidine bis-barbiturates via the Michael-type addition of barbituric acid to 
intermediate Knoevenagel condensation products.84  While this methodology proved 
successful for the synthesis of a wide variety of bis-barbiturates containing heterocyclic 
or electron poor aromatics, it was equally unsuccessful in producing bis-barbiturates with 
either electron rich aromatic or aliphatic substituents.  During the course of our 
exploration of barbituric acid double addition of heteroaromatic aldehydes we discovered 
that it was necessary for the aldehydes to be electron deficient in order for the reaction to 
occur.  Thus, in order to obtain the Michael type adducts rather than the Knoevenagel 
product with aldehydes such as 4-(dimethylamino)benzaldehyde, it was necessary to do 
the reaction in highly acidic media, such as TFA.  This effectively transformed the 
electron rich N(CH3)2 group into the electron deficient N(CH3)2H+ group, and the 
reaction was facilitated. 
 While we were able to use certain electron rich aromatic aldehydes in reaction 
with barbituric acids to form the double adducts, as mentioned above, this method was 
not comprehensive.  Many electron rich derivatives, such as aldehydes with OH 
substitutions, as well as unsubstituted aldehydes were not successfully transformed into 
the double adduct.  Additionally, the dimethylamino derivatives and nitro derivatives 
were unstable compounds prone to decomposition.  Therefore, we began exploring new, 
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comprehensive methods that would be applicable to all types of aldehydes, inherently 
necessary for our through exploration of bis-barbiturate adducts.   
 We did find sporadic literature reports describing the condensations of aromatic 
electron deficient aldehydes, such as nitrobenzaldehyde, with barbituric acids in pyridine 
as a reaction media, where the formation of the mono and di pyridinium salts were 
formed.111  While this method seemed to produce the corresponding double adduct in 
relatively high yields (65-95%), the synthesis was again only applicable to electron 
deficient aromatic aldehydes.   
 
IIg.2 Results and Discussion 
Based on our previous studies, we hypothesized that transformation of the 
electron rich substituent to the electron poor substituents was not the only barrier 
necessary to overcome to produce our desired products.  We hypothesized that during the 
course of the reaction between barbiturates and aldehydes to form the double addition 
adduct, it may also be necessary to stabilize the charge formed on the barbituric acid ring, 
yet still maintain the acidic conditions required to produce the enolate needed 
(nucleophile) for the second addition of barbituric acid to the intermediate Knoevenagel 
product.  To this end, we began exploring the use of ammonium compounds, such as 
triethylamine, N-methylmorpholine, morpholine, and piperidine, as both a hydrogen 
acceptor and conjugate acid to form our bis-barbiturates with electron donating and 
aliphatic aldehydes.  We experimentally determined that the best ammonium bases were 
morpholine, ethanolamine, and piperidine, and when used in a 0.1 molar excess, we were 
able to generate corresponding bis-barbiturate ammonium salts using electron-donating, 
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electron-withdrawing, and aliphatic aldehydes in a one-pot synthesis (Figure IIg.1).  
Table IIg.1 gives a description of the electron-withdrawing aldehydes used to produce 
the bis-barbiturate ammonium salts. 
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Figure IIg.1: Reaction scheme for the synthesis of bisbarbiturate ammonium salts 
(General Procedure N). 
Table IIg.1:  Bis-barbiturate ammonium salts of electron-withdrawing aldehydes 
Compound R1  R2 R3 XH+ Yield (%) 
G1 H H 
N 
N
H H  
93 
G2 H H 
N  
N
O
H H  
97 
G3 H H 
N  
H3N
OH
 
92 
G4 H H 
N  N
O
H H  
82 
G5 H H 
NO2
 
N
O
H H  
92 
G6 CH3 CH3 
N  NH H  
97 
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G7 CH3 CH3 
N  
N
O
H H  
93 
G8 CH3 CH3 
N N
H H  
95 
G9 CH3 CH3 
N  
N
H H  
82 
G10 CH3 CH3 
NO2  
N
O
H H  
84 
G11 H CH3 
N 
NH3
HO  
87 
G12 H CH3 
N  
N
H H  
87 
G13 H CH3 
N  
N
H H  
69 
G14 H CH3 
N  
N
O
H H  
89 
G15 H  CH3 
N  
N
H H  
94 
G16 H Ph 
N  
N
H H  
95 
G17 H Ph 
N      
N
O
H H  
89 
 
Table IIg.1 continued… 
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 Our main objectives in preparing bis-barbiturates having the electron donating 
substituents centered on the novelty of these types of barbiturates.  To the best of our 
knowledge, there were no experimental reports indicating the existence of these types of 
compounds.  Furthermore, the ammonium salts of these compounds were highly water 
soluble, making possible biological evaluation of these types of compounds relatively 
easy.  Table IIg.2 lists a description of the electron-donating aldehydes used, and the bis-
barbiturate ammonium salts synthesized as a one-pot synthesis (Figure IIg.1).   The 
reaction proceeded to completion and the isolated yields were quantitative, regardless of 
the electron-donating benzaldehyde used during the course of the reaction.  Additionally, 
substitutions of the benzaldehydes could be in ortho, meta, or para positions without 
altering the outcome of the reaction.  N-methylmorpholine was used in several of the 
reaction mixtures as the source of the ammonium counterion, however, in each of these 
cases, we isolated the Knoevenagel condensation products in quantitative yields and from 
this point on, the only ammonium compounds used were bases with at least one free NH 
moiety.   
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Table IIg.2: Bis-barbiturate ammonium salts of electron-donating aldehydes 
Compound R1 R2 R3 XH+ Yield(%) 
G18 H H 
CH3  
N
O
H H  
95 
G19 H H 
CH3  
N
O
H H  
90 
G20 H H 
OCH3  
N
O
H H  
95 
G21 H H 
N
H3C CH3  
N
O
H H  
96 
G22 H H 
 
N
O
H H  
95 
G23 H H 
OH
 
N
O
H H  
90 
G24 H H 
OH  
N
O
H H  
 
G25 H H 
OCH3
OCH3
OCH3  
N
O
H H  
96 
G26 
 
CH3 CH3 OCH3
 
N
O
H H  
93 
 94
G27 CH3 CH3 
OCH3
OCH3
H3CO
H3N
OH 
93 
G28 CH3 CH3 
OH  
N
O
H H  
92 
 
 Considering that the most biologically potent barbituric acid derivatives are 
usually those with an aliphatic C-5 moiety, we decided to develop the synthetic procedure 
for the preparation of aliphatic bisbarbiturate salts.  In such cases, we were able to 
condense simple aliphatic aldehydes, barbituric acids, and amines, and the appropriate 
ammonium salts are listed in Table IIg.3. 
 While there seemed no apparent restriction on the aliphatic aldehydes used in the 
course of this reaction, we were unable to isolate pure products of higher aldehydes, such 
as dodecanal using the method outlined in Figure IIg.1.  In the reactions between 
aldehydes containing more than 12 carbons and barbituric acids, the outcomes of the 
reactions were a viscous oily material that we were unable to re-crystallize.  The H-NMR 
spectra of these products provided evidence of both the unreacted starting material, and 
the bis barbiturate ammonium salt.  Re-crystallization in solvents such as ether, 
dichloromethane, chloroform, and petroleum ether resulted in the re-precipitation of the 
oily material, and re-crystallization in solvents such as ethyl acetate, methanol, ethanol, 
and THF provided the precipitation only of the unreacted barbituric acid.  While we did 
not attempt further methods of purification for these compounds, but expect that 
separation by column chromatography would provide the pure products of aliphatic 
aldehydes greater than 12 carbons in reaction with barbituric acids. 
Table IIg.2 contiued… 
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 To avoid using column chromatography as a method of purification, we attempted 
to change the reaction conditions to encompass aliphatic aldehydes greater than 12 
carbons.  Unfortunately, while the aldehydes are soluble in virtually all reaction media 
attempted, such as THF, ether, ethanol, propanol, and ethyl acetate, the respective 
barbituric acids were insufficiently soluble to perform these reactions.   
 
Table IIg.3:  Bis-barbiturate ammonium salts of aliphatic aldehydes 
Compound R1 R2 R3 XH+ Yield (%) 
G29 H H 
 
N
O
H H  
92 
G30 H H  
N
O
H H  
75 
G31 H H  
N
O
H H  
94 
G32 H H  
N
H H  
82 
G33 H Ph  
N
O
H H  
73 
 
 Because there are different biological properties elicited when a substitution is 
made on the C-2 atom of barbituric acids (Figure IIg.2), such as shorter retention times, 
or changes of potency, we employed the use of thiobarbituric acids to synthesize novel C-
2 substituted bis barbiturates using electron withdrawing, electron donating, and aliphatic 
aldehydes using the general method outline in Figure IIg.1.  The products were insoluble 
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in methanol and immediately precipitated out, regardless of the nature of the aldehydes 
used (Table IIg.4).   
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H
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Figure IIg.2:  Example of C-2 substitution of barbituric acids. 
 
Table IIg.4: Thiobisbarbiturate ammonium salts of electron-poor, electron-rich and 
aliphatic aldehydes. 
Compound R1 R2 R3 XH+ Yield (%) 
G34 H H 
NO2
 
N
H H 
97 
G35 H H 
OCH3
OCH3
H3CO
 
N
O
H H  
91 
G36 H H 
N  
H3N
OOC
NH3 
90 
 
 The H-NMR spectra of bis-barbiturate ammonium salts are very similar to the 
spectra of the corresponding bis-barbiturates described in Chapter IIe of this manuscript.  
The singlet for –CH- of the bis-barbiturate structure, located between 5.5 and 6.5 ppm, is 
indicative of double barbituric acid addition.  In the ammonium salts, this singlet remains 
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between 5.5 and 6.5 ppm (Figure IIg.4).  The signals for the corresponding ammonium 
base integrate to show a ratio of one molecule of the cation per one molecule of the 
corresponding bis-barbiturate.   
 
 
 
Figure IIg.4:  A portion of the typical H-NMR spectra of morpholinium aromatic 
bisbarbiturates.  
 
Aliphatic bis barbiturates give a triplet (J=   8.1 Hz) between 4.5 and 5.5 ppm, indicative 
of the addition of the aliphatic moiety to the barbiturate. To confirm the structure of the 
bis-barbiturate ammonium salts, compound G37 was crystallized from DMSO at room 
temperature (Figure IIg.5).   
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Figure IIg.5:  ORTEP drawing of G37 (courtesy of E. D. Stevens). 
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IIh. Syntheses of Substituted and Unsubstituted 5-benzoylbarbituric acids and 
Corresponding Phenylhydrazones 
IIh.1 Preamble 
 There have been recent reports that indicate that some aromatic substituted 
barbiturates, aromatic substituted barbituric acid phenylhydrazones, and other Schiff 
bases containing barbituric acid moieties may actually possess immuno-modulating 
properties.83, 111-114  Compounds, such as A-007 (22) (Figure IIh.1), have been shown to 
possess these immuno-modulating properties, yet little is known about the mechanism(s) 
underlying this biological activity.  To thoroughly explore the possibility of immune-
modulation within aromatic substituted barbiturate Schiff bases, structural variants of the 
A-007 molecule, as well as to explore the structural requirements necessary for immune 
modulating activity, a large variety of both substituted and unsubstituted 5-
benzoylbarbiturates were necessary precursors for the synthesis of the targeted 
phenylhydrozone Schiff bases.   
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Figure IIh.1:  4,4’-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007). 
 
 There are literature reports indicating that some substituted and unsubstituted 5-
benzoyl barbiturates have been previously synthesized and are used as herbicides and 
insecticides.47, 115-116  However, the typical synthetic procedure for the preparation of 
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these compounds involves several steps.  In one of the preparation procedures, Zn(CN)2 
in acetonitrile was used as a catalyst for the acylation and benzoylation of barbituric acid 
with corresponding acid chlorides.  Isolated yields are ~80%.  Nevertheless, this synthetic 
approach is not applicable for the preparation of a wide variety of substituents attached to 
both aryl and barbituric moieties of 5-benzoylbarbituric acids.  Therefore, there is a need 
for developing new synthetic methods for the preparation of these compounds. 
 
 IIh.2 Synthesis of benzoyl barbiturates 
 Through our experimental exploration, we determined that the simplest way to 
prepare benzoyl substituted barbituric acids was to condense N-substituted barbituric 
acids (R1, R2=H, alkyl, or aryl, Figure IIh.2) with the corresponding acid chloride.   
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Figure IIh.2:  Syntheses of 5-benzoyl and 5-(methoxybenzoyl)barbiturates H1-7. 
 
Many of these starting materials are commercially available, however if the desirable 
starting materials are not available they can be readily prepared.117  Pyridine seems to be 
an ideal solvent for this reaction.  It was not necessary to fully dissolve the reactants for 
the reaction to be completed; therefore a relatively small amount of pyridine is sufficient 
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for the reactant conversion (~25 mL).  In many instances the reaction is completed after 
30 minutes.  Isolation involves pouring the pyridine reaction mixture into hydrochloric 
acid (conc. HCl:H2O 3:1).  The formed crystalline product is of sufficient purity (~98%) 
that further purification is not necessary (Table IIh.1). 
 
Table IIh.1:  Isolated yields of 5-benzoylbarbiturates. 
Product R1 R2 R3 Yield (%) 
H1 H H H 90 
H2 Ph H H 83 
H3 CH3 H H 77 
H4 CH3 CH3 H 84 
H5 C4H9 H H 97 
H6 H H OCH3 87 
H7 CH3 CH3 OCH3 90 
 
 These preparation procedures were not applicable to the preparation of 5-
benzoylbarbiturates with strong electron-withdrawing groups, such as nitro groups, and a 
separate synthetic procedure was developed to produce these derivatives of our Schiff 
base precursors.  The nitro compounds could also be prepared in pyridine as reaction 
media, but the isolation and separation from both pyridine and the resulting pyridinium 
chloride was very difficult.  Therefore, another synthetic route utilizing N-methyl 
morpholine as a base and dioxane or tetrahydrofuran as the reaction solvent was 
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developed (Figure IIh.3).  In such cases, the desired product was isolated in higher than 
90% yield (Table IIh.2). 
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Figure IIh.3:  General route for preparation of 5-(nitrobenzoyl)barbiturates H8-13. 
 
Table IIh.2: 5-(nitrobenzoyl)barbiturates 
Product R1 R2 R3 R4 Yield(%) 
H8 H H H NO2 93 
H9 CH3 H H NO2 91 
H10 H H NO2 H 93 
H11 CH3 H NO2 H 95 
H12 H NO2 H NO2 90 
H13 CH3 NO2 H NO2 93 
 
IIh.2.1 Physical properties 
 All of the 5-benzoylbarbiturates are relatively strong carbon acids due to the 
mobility of the hydrogen atom attached at the C-5 position of the barbituric acid ring.  
This acidity is responsible for the keto-enol equilibrium that is present in solution.  The 
equilibrium is relatively slow and it is possible follow the change in the equilibrium 
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constant by 1H-NMR.  Depending on the method of purification and crystallization of the 
5-benzoylbarbiturate, one can isolate either the keto only or enol only product.  This was 
perfectly demonstrated on the example of 5-(3-nitrobenzoyl)-1,3-dimethylbarbituric acid 
(H9, Figure IIh.4).  The precipitated product formed by the condensation reaction 
between 3-nitrobenzoyl chloride and barbituric acid in THF and N-methylmorpholine as 
a base was exclusively in the keto form.  If the product is purified by crystallization from 
large quantities of water, then the enol form was present in crystalline form.  It is also 
obvious that the enol form was the thermally more stable species as demonstrated by 
NMR following thermal distribution of keto-enol forms in DMSO at 80º C (Figure 
IIh.4). 
 
 
Figure IIh.4:  The NMR following of thermal induced transformation of keto form of 
H9 into it enol form in DMSO-d6 at 80º C. 
 
 There are couple of very interesting points that can be concluded from the NMR 
following of the keto-enol equilibrium presented in Figure IIh.4.  The presence of the 
enol form of H9 is determined by the nature of the solvent as well as the temperature.  In 
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solvents that cannot form strong hydrogen bonding with N, N’-disubstituted barbiturates, 
such as H9, the keto form is dominant or the only present tautomer.  In solvents such as 
DMSO and water, which can form strong hydrogen bonding with the enol alcohol group, 
the enol tautomer is dominant.  Our AM1 computational studies agree that the enol form 
is thermally more stable (by 0.8 kcal/mol).  Structural properties for these two tautomers 
are considerably different.  The carbonyl group of the p-nitrobenzoyl moiety of the keto 
form of H9 is almost perpendicular to the barbituric ring (the O16-C10-C9-C14 dihedral 
is 79.4º) while in its enol form, it is almost coplanar with the barbituric acid ring (O16-
C10-C9-C14 dihedral ring is 5.7º) (Figure IIh.5).  The structural orientation of carbonyl 
group toward the p-nitrophenyl moiety is exactly opposite (almost coplanar in its keto-
form) and perpendicular in its enol-form, Figure IIh.5).  There is also very short distance 
between H27 and O15 of the enol-form (1.914 A), indicating strong hydrogen bonding in 
the gas phase.  This might not be the case with such polar solvents as DMSO because the 
DMSO oxygen is a much better proton acceptor than the amide carbonyl of barbituric 
acid.  This is also evident by the fact that the barbituric acid hydrogen was not observed 
in the NMR spectra of the DMSO-d6 solution of H9 due to the H-D exchange. 
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Figure IIh.5:The AM1 semi-empirical computed structures of keto and enol forms of H9 
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 NMR spectroscopic studies of H9 in chloroform is much closer to our AM1 gas-
phase computational studies, therefore one can assume that the enol form with 
intramolecular hydrogen bonding is present.  Furthermore, the existence of C9-C10 
double bond in the enol-form makes the two methyl barbituric acid groups 
spectroscopically nonequivalent.  In other words, the aromatic portion of the NMR 
spectra in chloroform at room temperature is very similar to the NMR in DMSO-d6 at 
elevated temperatures.  The methyl range is different from the previous spectrum (Figure 
IIh.4) because at 80º C in DMSO, due to low rotational barrier, the two methyl groups 
are equivalent and in chloroform at room temperature they are not (Figure IIh.6).  The 
strongest evidence for the enol-form of H9 comes from the fact that at 17.8 ppm there is a 
broad singlet with an integral of 1H, corresponding to the enol hydrogen involved in 
internal hydrogen bonding interactions with one of carbonyl oxygens of the barbituric 
acid moiety (Figure IIh.6). 
 
Figure IIh.6:  The NMR (500 MHz) spectra of chloroform solution of H9 at room 
temperature 
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  IIh.3 Hydroxy-benzoyl barbiturate precursors 
 None of the discussed procedures applied for the preparation of methyl, methoxy, 
and nitrobenzoyl barbiturates could be used for the preparation of hydroxybenzoyl 
barbiturates.  Furthermore, our exhaustive literature searches provided no evidence that 
there is a method of preparation for hydroxybenzoyl barbiturates.  Naturally, the hydroxyl 
group attached to the benzoyl moiety must be protected during the course of the 
preparation of hydroxybenzoyl barbiturates.  Because we already developed the 
preparation procedures for methoxybenzoyl barbiturates, we attempted to use these 
compounds as starting materials for the preparation of the corresponding hydroxybenzoyl 
barbiturates.  Unfortunately, using various methods of deprotection, during the course of 
the methoxy group transformation into the unprotected hydroxyl group, the barbituric 
acid part of the molecule decomposed.118  After exploring several routes for the 
preparation of these compounds, we developed a simple and high yield preparation 
(Figure IIh.7).  The preparation starts with acetyloxybenzoic acid, which is converted 
into the corresponding acid chloride.  Then, by following the previously described 
procedure for the benzoyl chloride condensation with barbituric acid in pyridine, the 
hydroxyl-protected product was produced.  The final step involved hydrolysis of the 
acetic acid ester protecting group, followed by the isolation of pure product upon 
acidification (Table IIh.3). 
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Figure IIh.7:  Synthetic partway for preparation hydroxybenzoylbarbiturates H14-18 
 
Table IIh.3: Isolated yields of hydroxybenzoylbarbiturates 
Compound R1 R2 Acid chloride Yield(%) 
H14 H H m-OCOCH3 91 
H15 C4H9 H p-OCOCH3 77 
H16 CH3 CH3 p-OCOCH3 85 
H17 H H p-OCOCH3 80 
H18 H Ph p-OCOCH3 83 
 
 With our successful developments of synthetic procedures for the preparation of 
aryl substituted 5-benzoylbarbiturates we turned our attention to the preparation of the 
corresponding phenylhydrazones.  As mentioned above, the preparation of various Schiff 
bases between amines and amino acids with acylbarbiturates was previously described 
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and some of these derivatives were used as herbicides.47  None of the patented work 
focused on 5-benzoylbarbituric phenylhydrazones.  Our attempt to apply the patented 
synthetic procedures for the preparation of our phenylhydrazones of benzoylbarbiturates 
was not successful.  From these experiments it was obvious that our benzoylbarbiturates 
were substantially less reactive toward hydrazine condensation reactions.  In some 
instances, products were formed but isolation and purification from the reaction mixture 
was very difficult.  Furthermore, our experiments suggested that both the reactants and 
the products of the reaction were very sensitive to reaction solvent and the pH of the 
reaction media.  Therefore, we carefully explored reaction conditions with the target 
being to select the optimal reaction conditions for the preparation of these valuable 
compounds.  Wanting to find and optimize appropriate reaction conditions for the 
preparation of phenylhydrazones of benzoylbarbiturates, we performed several NMR 
experiments following these types of reactions.  A typical 1H-NMR experiment for these 
compounds was demonstrated by the transformation of p-nitrophenylhydrazine and 5-(4-
methoxybenzoyl)-1,3-dimethyl pyrimidine-2,4,6-trione (H7) into 5-{(4-Methoxyphenyl)-
[N'-(4-nitrophenyl)hydrazino]methylene}-1,3-dimethyl-pyrimidine-2,4,6-trione (H25) 
(Figure IIh.8).  The reaction was followed by taking a sample of the reaction mixture 
(one drop), evaporating the solvent under a nitrogen stream at room temperature and 
preparing the sample in a DMSO-d6 solution.  p-Nitrophenylhydrazine was used in slight 
excess in the reaction mixture.  After the reaction mixture was refluxed for fifteen 
minutes all benzoylbarbiturate H7 was consumed.  It was obvious that there are two 
major products of the condensation reaction.  When sulfuric acid was added, one of the 
products was transformed into the other.  Prolonged refluxing of the reaction mixture  
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Figure IIh.8: The 1H-NMR (DMSO-d6, 500 MHz) reactions following for condensation 
reaction in 1-propanol without and with sulfuric acid as catalyst to yield H25. 
 
does not noticeably change the composition of the product.  After cooling down the 
reaction mixture, a solid precipitate containing only one molecular species, compound 
H25 (Figure IIh.8) was isolated.  Following this synthetic procedure, or by slight 
modification of this procedure, the phenylhydrazones of benzoylbarbiturates (Figure 
IIh.9) were prepared.  It is important to mention that for the preparation of these 
compounds, precipitation of the product from the reaction mixture during the reaction is 
crucial for obtaining both high yield of the product, as well as high product purity.  In 
some cases, solvents such as methanol and ethanol can be used, but 1-propanol seems to 
be applicable to almost all reactions performed, and the yields and purities of the 
products prepared in 1-propanol are high.  To obtain better isolated yields for some 
specific cases of the phenylhydrazones, specific reaction conditions were developed and 
are mentioned in the experimental section of this paper.  The designed phenylhydrazones 
were necessary to explore the structural requirements necessary to elicit the immune 
modulation, as in the case of A-007 (Table IIh.4). 
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Figure IIh.9: Preparation path for phenylhydrazones of benzoylbarbiturates 
 111
Table IIh.4:  Phenylhydrazones of benzoylbarbiturates 
Product R1 R2 R3 R4 R5 R6 Yield(%) 
H19 H H H H H NO2 73 
H20 H H H H H COOH 79 
H21 CH3 CH3 H H NO2 NO2 83 
H22 H Ph H H NO2 NO2 88 
H23 H H H H NO2 NO2 84 
H24 CH3 CH3 H H H COOH 79 
H25 CH3 CH3 OCH3 H H NO2 82 
H26 CH3 CH3 OCH3 H NO2 NO2 81 
H27 H H OCH3 H NO2 NO2 81 
H28 H H H OH NO2 NO2 88 
H29 H CH3 OH H NO2 NO2 88 
H30 H C4H9 OH H NO2 NO2 80 
H31 H H OH H NO2 NO2 91 
H32 H Ph OH H NO2 NO2 83 
H33 H CH3 OH H NO2 NO2 84 
H34 CH3 CH3 OH H NO2 NO2 91 
H35 CH3 CH3 NO2 H NO2 NO2 89 
H36 H H NO2 H NO2 NO2 91 
 
 As in the cases of 5-benzoylbarbiturates, phenylhydrazones of 5-
benzoylbarbiturates have several tautomeric forms.  In solution, equilibrium can be 
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reached where several tautomeric forms are present.  It is often the case that one 
tautomeric form can crystallize from nonpolar aprotic solvents where the other form 
crystallizes from polar aprotic solvents.  For instance, phenylhydrazone H23 crystallizes 
from the 1-propanol reaction mixture as the hydrazone with a double bond between 
nitrogen and carbon (H23-CN).  In pure DMSO solution 1H-NMR shows that the 
solution actually contains this isomer as a major isomer (Figure IIh.10).  After the 
addition of trifluoroacetic acid, the nitrogen of the C=N is protonated and equilibrium is 
shifted toward the enamine form H23-CC (Figure IIh.10).  In the DMSO-CF3CO2H 
solution after one hour H23-CC is the only detectable isomer.  Similar behavior was 
observed with other prepared hydrazones. 
 
 
Figure IIh.10:  1H-NMR (500 MHz) isomerization following of H23-CN transformation 
into H23-CC in CF3CO2H. 
 
 A major problem in the evaluation of biological properties for 5-
benzoylbarbiturates comes from the low solubility of these compounds in aqueous media 
and most common organic solvents.  This is even more evident for aryl substituted 
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derivatives.  Considering that by increasing the size of the aliphatic or aromatic moieties 
of 5-benzoylbarbiturates makes these compounds even less water soluble, in order to 
evaluate the potential activities it is important to make them water soluble.  Both acyl and 
benzoylbarbiturates have acidic hydrogens in the 5 position of the barbituric acid moiety, 
therefore preparation of their ammonium salts with secondary amines is straightforward.  
Preparation procedures included mixing benzoylbarbituric acid derivatives with the 
amine in a solvent, such as tetrahydrofuran or dioxane or even propanol, evaporating the 
solvent, and finally purification of the product (Figure IIh.11, Table IIh.5). 
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Figure IIh.11: Preparation of substituted ammonium salts of substituted 
benzoylbarbiturates 
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Table IIh.5: Ammonium salts of substituted benzoylbarbiturates 
Product R1 R2 R3 X Yield(%) 
H37 H H H HN(CH2)5 80 
H38 CH3 H H HN(CH2)5 95 
H39 H H OCH3 HN(CH2)5 88 
H40 CH3 CH3 OCH3 HN(CH2)5 93 
H41 H H NO2 HN(CH2)5 95 
H42 H H NO2 HN(CH2CH2)2O 90 
H43 H H NO2 CH3N(CH2CH2)2O 91 
H44 H H NO2 NH2CH2CH2OH 98 
H45 H H NO2 4-(CH3)2NPy 97 
H46 CH3 CH3 NO2 HN(CH2)5 92 
H47 CH3 CH3 NO2 HN(CH2CH2)2O 94 
H48 CH3 CH3 NO2 CH3N(CH2CH2)2O 89 
H49 CH3 CH3 NO2 NH2CH2CH2OH 92 
H50 CH3 CH3 NO2 4-(CH3)2NPy 93 
 
 Similar to benzoylbarbiturates, phenylhydrazones also have low solubility in 
aqueous media.  These compounds are strong carbon acids due to the mobility of 
hydrogen attached to C-5 of the barbituric acid moiety of compounds H19-36.  
Preparation of the corresponding salts with almost any amine was a straightforward 
process.  Reaction components were dissolved in methanol, ethanol, or 1-propanol, 
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stirred at room temperature for a few hours and the resulting salt was isolated from the 
reaction mixture (see experimental procedures G and H) (Figure IIh.12). 
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Figure IIh.12:  Preparation of piperidinium salts of phenylhydrazones (General 
Procedure O). 
 
 It is very important to emphasize again that both 5-benzoylbarbiturates and their 
phenylhydrazones can exist in several different tautomeric forms.  Therefore, the NMR 
spectra of the same compound in different solvents can show different ratios of two 
tautomeric forms, as it was demonstrated in Figure IIh.13.  To confirm these findings, x-
ray structural analysis of H25 obtained from a 1-propanol solution with a few drops of 
sulfuric acid was performed (Figure IIh.14).  According to our NMR spectroscopic 
studies, hydrazones in acidic polar media should be in an enamine form (CC) while in 
neutral polar media, the Schiff base form (CN) should be present, as it was demonstrated 
on the NMR equilibrium experiment with hydrazone H25.  Considering this finding, even 
if hydrazone H25 is present in its Schiff base H25-CN form in neutral solution, in the 
acidic polar media the enamine isomer H25-CC (Figure IIh.13) should be a dominate 
 116
species.  This isomer should also be present in the crystalline state if H25 is crystallized 
from 1-propanol with sulfuric acid present.  
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Figure IIh.13:  Schiff base H25-CN and enamine H25-CC tautomeric forms present in 
solutions. 
 
 The x ray structure of H25 (Figure IIh.14) fully confirms our structural 
assignment based on the NMR spectroscopy.  Compound H25 is in its enamine form 
(double bonds are C6C7 and C56C57) with strong hydrogen bonding between the 
hydrazine hydrogen and the barbituric acid carbonyl (N8-H----O20 and N58-H----O70).  
Two of the molecular units of H25 are combined through stacking the nitrophenyl and 
methoxyphenyl moieties of two hydrazones of H25, as well as hydrogen bonding 
between two of these units N9-H-----O66. 
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Figure IIh.14: The ORTEP drawing x-ray determined structure of H25 
 
 The x-ray structure of piperidinium salt H52 was obtained from a single crystal 
grown from acetonitrile as a solvent.  The structure is in full agreement with our 
spectroscopic characterization of this compound.  The hydrogen from C6, rather than 
from O33 of the phenol moiety, is removed by the base to form perfect conjugation 
throughout entire molecule (Figure IIh.15).  Hydrogen bonding no longer exists between 
the nitrogen of the hydrazone moiety and barbituric acid moiety, as in H25 due to fact 
that the acidic α-hydrogen of the barbituric acid moiety is removed with piperidene as a 
base.  Negative charge is mostly located on O22 and O26 of the barbituric acid moiety. 
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Figure IIh.15:  The ORTEP drawing of x-ray determined structure of H52. 
 
 At this point it is very interesting to compare structural features of H52 obtained from 
x-ray experimental data and ones obtained by AM1 semi-empirical modeling of the anion 
portion of H52 in the gas phase (Table IIh.6).  Both experiment and theory agree that the 
barbituric acid moiety is almost planar (the bond angles dihedral ring for O22-C1-C6-C5 
is close to 180º, Table IIh.6).  There is relatively good agreement between experimental 
and computed structural properties.  The biggest discrepancy comes from estimating 
dihedral angels and hydrogen bond distances.  For instance, from x-ray structural studies 
it is obvious that there is very strong hydrogen bonding between N9H and the nitro O17 
oxygen (the O17-H9 bond distance is 1.937 Å, Table 1), while there is a little bonding 
interaction with the barbituric acid carbonyl O26 that bears the partial negative charge.  
The AM1 estimates fairly well the first hydrogen bond distances, while substantially 
overestimates the latter one (Table IIh.6).  It is obvious that both experimental (x-ray) 
and computational (AM1) data agree that the hydrogen in the barbituric acid ring is more 
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acidic than the phenolic hydrogen, therefore it is removed by piperidene.  Negative 
charge is localized on two oxygens (O22 and O27) and one carbon (C6) atom of 
barbituric acid moiety (the AM1 computational studies estimates 1/3 of negative charge 
being on each of these three atoms).  Strong hydrogen bonding between the NH hydrogen 
and the oxygen of the nitro group of the dinitrophenylhydrazine moiety of H52 keeps this 
portion of the molecule in one plane. 
 
Table IIh.6: The X-ray determined and AM1 computed properties for anionic part of 
H52 salt 
X-Ray AM1  X-Ray AM1 
Atoms Bond distance in Å Atoms Bond angles in (º) 
C1-C6 1.417 1.439 C1-C6-C5 121.5 121.6 
C5-C6 1.411 1.433 C1-C6-C7 119.3 118.9 
C6-C7 1.483 1.448 C6-C7-N8 123.8 128.7 
C7-N8 1.303 1.323 Atoms Dihedral angles in (º) 
N8-N9 1.373 1.354 O22-C1-C6-C5 -171.2 175.6 
O22-C1 1.231 1.253 C1-C6-C7-N8 123.7 131.0 
O26-H9 2.740 2.098 C6-C7-N8-N9 -5.7 0.0 
O17-H9 1.936 2.116 C32-C27-C7-N8 156.2 130.4 
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IIi. A Barbituric Acid Initiated Rearrangement Reaction: Formation of 5-5’-(2-
pyrilidine)bis barbituric acids 
IIi.1 Preamble 
While we were able to perform the preparation of a wide variety of 5,5’-(3-
pyrilidene) and 5,5’-(4-pyrilidene)bisbarbituric acids and their ammonium salts through 
the condensation of pyridine carboxaldehydes and the corresponding barbituric acid, the 
similar condensation between 2-pyridinecarboxaldehyde and 1,3-dimethylbarbituric acid 
yields a unique pyridinium barbiturate ylide F1.  Moreover, the desired 5,5’-(2-
pyrilidine)bisbarbituric acid analogs were not obtained when either N,N’-unsubstituted or 
N-substituted barbiturates were used as the starting reagents.  We were able to obtain the 
desired bisbarbiturate when dimethylbarbituric acid was used, and the reaction was 
performed in carbon tetrachloride, but this procedure was not applicable to other 
barbiturates, nor was it a very practical synthesis for obtaining the desired material in 
large quantities. 
Considering that the 5,5’-(2-pyrilidine)bisbarbiturates could not be prepared by 
our previously developed methods, we searched for a 2-pyridinecarboxaldehyde synthetic 
equivalent in order to pursue the preparation of this compound type.  In searching the 
literature, we discovered that in many chemical reactions the phenyl moiety of a molecule 
can be substituted with pyridine without altering the side chain reaction.  We 
hypothesized that if this is in fact true for benzil (PhCOCOPh), then the corresponding 
pyridine synthetic equivalent of benzil (PyCOCOPy) could be of use in the preparation of 
our targeted compounds.  There is an abundance of literature reports that indicate that it is 
possible to transform benzyl benzoates or even benzaldehydes into benzil derivatives.  
 121
One example, reported by Zheng et.al, demonstrated this with the discovery that O-
Benzoylbenzaldehyde cyanohydrin was found to form benzil in a base-catalyzed 
reversible reaction in DMF.119-120  Examining these reports, we hypothesized that if it is 
possible to enforce the reverse benzyl reaction of the pyridine synthetic equivalent, then 
2,2’-bipyridil should be the logical starting point for this preparation, used as the 
equivalent of 2-pyridinecarboxaldehyde.  It was interesting to note, however, that there 
was a lack of benzyl-benzylic acid rearrangements in the literature.  We believed that this 
was due to the fact that the base present was too weak to promote the desired 
rearrangement, but with the addition of a strong base, the desired rearrangement may be 
possible to enforce.   
 
IIi.2 Results and Discussion 
Based on the information provided for the benzil model, the acid catalyzed 
rearrangement mechanism proposed for the conversion of 2,2’-pyridil into our desired 
5,5’-(2-pyrilidene)bisbarbituric acid is presented in Figure IIi.1.  
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Figure IIi.1:  Proposed mechanism for preparation of I-1. 
 
It was expected that the most energy demanding transformation would be the 
rearrangement of keto alcohol I-a into ester I-d.  The third step of the transformation (I-d 
to I-1) would be the nucleophilic substitution by barbituric acid on ester I-d.  One can 
envision at least two pathways in the preparation of 5,5’-(2-pyrilidene)bisbarbituric acid; 
one through the addition of the first barbituric acid, followed by the elimination of 
picolinic acid and finally the addition of the second barbituric acid; and the other by 
simple nucleophilic substitution of the picolinic acid moiety of ester I-d with barbituric 
acid.  We experimentally determined that depending on the solvent and temperature, both 
of these reactions can occur.  For instance, if the reaction is performed in refluxing 
methanol, the only product is the product of condensation I-1 in more than 80% isolated 
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yield.  In our extended time experiment at room temperature, it seemed that the reaction 
proceeded through either elimination-addition, or the elimination-addition and 
nucleophilic substitution reactions compete.  This determination was based on the fact 
that from a closed-bottle mixture of 2,2’-pyridil (2mg) and 1,3-dimethylbarbituric acid (5 
mg) in 1 mL of methanol, a single crystal was grown after 30 days at room temperature 
and present in the crystal are both products F-1 (pyridinium zwitterions) and I-1 in a ratio 
of 32:68.   
To determine the validity of the mechanism, we followed the reaction through H-
NMR spectra recorded at room temperature in various solvents, including methanol, 
tetrahydrofuran, acetic acid, chloroform, and dimethyl sulfoxide.  In DMSO the reaction 
mixture was solution.  In all other solvents a precipitate formed.  From this experiment it 
was obvious that the formation of ester I-d was required for a high yield transformation 
of 2,2’pyridil and barbituric acid into pyrilidene I-1 and picolinic acid (Figure IIi.3).  In 
prolonged DMSO experiments a low field NMR aromatic compound was formed, which 
was not detected when the preparation of I-1 was performed in methanol. 
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Figure IIi.3:  H-NMR (DMSO-d6 -300 MHz Varian Unity) spectra over the course of 
the reaction time to yield I-1. 
 
Finally, to confirm the general applicability of this reaction method in the 
preparation of a wide variety of 2-pyrilidenes, we used the barbituric acid derivatives 1-
phenyl, 1-methyl, 1-butyl, and barbituric acid in itself.  In every case, the corresponding 
I-1 pyrilidene was isolated in almost quantitative yields.  Additionally, we were not able 
to detect the presence of any other byproducts of the reactions performed through 
subsequent spectroscopic analysis.  Structural properties of I-1  when R1 and R2= CH3  
were determined using x-ray analysis.  The single crystal of the I-1 analog was obtained 
from slow crystallization in acetic acid, and the structure shows interesting 
characteristics.  In solution, we were unable to determine the location of the 5 and 5’ 
hydrogens.  We determined that this was due to the fact that in solution one hydrogen is 
on the pyridine ring and the other is involved in hydrogen bonding interactions between 
both barbituric acid rings.  In the crystalline state I-1 has a zwitterionic structure with a 
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positive charge located on the pyridinium molecule and a negative charge located almost 
equally on both barbituric acid rings (Figure IIi.4).  The plane with the pyridinium ring 
is almost perpendicular to the plane that separates the two barbituric acid rings.  The 
C(1)-C(4) bond distance is 1.365 Å in comparison with the C(1)-C(2) distance of 1.4275 
Å, and the C(1)-C(7) distance of 1.5201 Å, indicating a strong double bond character of 
the first two bonds, and delocalization of the negative charge.  All atoms in the ring and 
the ones attached to the ring are basically in the ring plane, indicating aromaticity. 
 
Figure IIi.4:  ORTEP drawing of X-ray determined structure of I-1 (courtesy of E. D. 
Stevens and K. L. Martin). 
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BIOLOGICAL EVALUATIONS OF NOVEL BARBITURATES  
IIIa. Introduction 
  In order to gather preliminary information on the concept that A-007 and analogs 
of A-007 may be binding to a CD45+ surface receptor, or other CD surface receptors, and 
upgrading dendritic cells and /or T- lymphocytes, we have successfully synthesized and 
tested a number of phenylhydrazones, all structural analogs of our lead compound, A-
007.  To date, the synthesized compounds were tested in vitro on various cell lines to 
determine if they have the ability to bind to (or up-regulate) surface CD receptors, with 
cytotoxicity or apoptosis.  Structural changes made to A-007 include changes to the a) 
bis-diphenyl methane and b) the phenylhydrazone moieties. 
 
IIIb. Biology Methods 
  The T-leukemia cell line, HH (CRL-2105), available from ATCC, Manassas, VA 
,having the receptors, CD45+, CD3+, CD4+ and CD11C+, all dendritic cell surface CD 
receptors, was used to screen A-007 and analogs for up-regulation of CD surface receptor 
expression, loss of agglutination properties and cell death (Tables III.1-III.5).  
Multicolor immunofluorescence staining and analysis were performed by standard 
procedures.20b  Primary and secondary antibodies were conjugated to biotin, fluorescin 
isothiocyanate (FITC), phyco-erythrin (PE), peridinin-chlorophyl protein or allo-
phycocyanin.  Antibodies and conjugates for CD3, CD4, CD8, CD11C, CD19, and 
CD30, were obtained from Becton-Dickinson; CD45 was obtained from PharMingen.  
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Cells were analyzed using a FACSscan flow cytometer (Becton-Dickinson).  HH T-
lymphocytic leukemia cells were cultured in RPMI 1640 media (BioCell) supplemented 
with activated 10% fetal calf serum, 10 mcg/mL streptomycin and 100 U/mL penicillin 
(Sigma) in a CO2 incubator at 36º C.  All analogs were prepared in DMSO and stored in a 
1:15 ratio of DMSO/RPMI1640 media.  CD marker assays and standard 
cytotoxicity/apoptosis studies were conducted in Corning Cell WellsTM.  Assys involved 
105 HH-cells incubated with the analogs for 24 hours, cells were removed, washed with 
RPMI media and analyzed by a BD fluorescent-activated cell sorter.  Agglutination was 
documented using scanning density assays.20c  Cytotoxicity analysis was conducted using 
the MTT assay. 20c  Apoptosis was followed with - Annexin V – FITC and fluorescein 
Fragel DNA kits (Oncogene, Inc, San Diego, CA) and DNA fragmentation/cell death 
analyzed with a FACScanner.  
 
IIIc. Results and Discussion 
 Table III.1 reviews toxicity and binding intensity values for the A-007 molecule.  
A-007 prevented HH cells from agglutination, resulting in well-differentiated cells with 
up-regulation of CD45+ and CD11C+ binding affinities.  Apoptosis, or programmed cell 
death, occurred 12-24 hours post A-007 exposure, as determined by the DNA fragments 
detected.  The up-regulation of CD receptors varied depending on the structural analogs 
tested, and are indicated in the data provided in the tables.  All biological evaluations 
were performed by Dr. Lee Roy Morgan and Dekk-Tec, Inc. 
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Table III.1:  Toxicity and binding intensity values for the A-007, our lead compound*. 
Compound Structure Cytotoxicity 
IC50 µg/mL) 
Binding 
Intensity  
@ 5 
µg/mL 
for CD4+ 
Binding 
Intensity  
@ 5 
µg/mL 
CD11C+ 
Binding 
Intensity  
@ 5 
µg/mL 
CD45+ 
A-007 
N
N
H
O N
HO
HO O
N
O
O
3.2 aNC 30% 100% 
aVs HH leukemia cells. *All in vitro evaluations were performed by Lee Roy Morgan 
through Dekk-Tec, Inc. 
 
Subsequent modification of the bis-diphenyl and the phenylhydrazone moieties, such as 
replacement of this structural motif with the corresponding bis-barbiturate moiety 
resulted in loss of activity.  The compounds of this type tested and the results obtained 
are indicated in Table III.2.  
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Table III.2:  Anticancer and up-regulation for quinoline and pyridine bis-barbituric acid 
analogs.a,* 
Compound Structure Cytotoxicity 
IC50 µg/mL) 
Binding 
Intensity  
@ 5 
µg/mL 
CD4+ 
Binding 
Intensity  
@ 5 
µg/mL 
CD11C+ 
Binding 
Intensity  
@ 5 
µg/mL 
CD45+ 
E3 
N
N
O
O
O
H
H N
N
O
O O
H
H
N  
>10 bNC  NC  ↑25% 
E18 
N
N
O
O
O
H3C
H3C
N
N
O
O O
CH3
CH3
N
>10 cNA  NA  NA 
E7 HN
HN
O
O
O
NH
H
N
O
O O
N  
>10 NA  NA  NA 
aVs HH leukemia cells; bNC – no change in CD; cNA – not available.  *All in vitro 
evaluations were performed by Lee Roy Morgan through Dekk-Tec, Inc. 
 
The replacements of A-007's bis-diphenyl rings with a barbituric acid moiety with retention of 
nitrophenylhydrazone moiety resulted in some retention of activity, but no surface CD up-
regulation was noted.  The compounds belonging to this class of analogs tested are presented in 
 130
the following table (Table III.3).  These analogs utilized the 5-formyl and acetyl barbiturate 
analogs as well as some benzoyl analogs.   
 
Table III.3: Anticancer and up-regulation for formyl and acetylbarbituric 
phenylhydrazone analogs.a,* 
Compound Structure Cytotoxicity 
IC50 µg/mL) 
Binding 
Intensity  
@ 5 
µg/mL 
CD4+ 
Binding 
Intensity  
@ 5 
µg/mL 
CD11C+ 
Binding 
Intensity  
@ 5 
µg/mL 
CD45+ 
D25 N
NH
O2N
NO2
H3C
O
N
N
OH3C
CH3O  
>10 bNA NC NA  
 N
NH
O2N
NO2
H
O
N
N
OH3C
CH3O  
>8 NA NA NA 
D21 N
NH
O2N
NO2
H3C
O
N
N
OH
HO  
3.5 cNC NC NC 
D14 
N
NH NO2
H
O
N
N
OH
HO  
>6  NC  NC  NC 
D20 
N
NH NO2
H3C
O
N
N
OH
HO  
>10  NC  NC  NC 
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H23 
N
NH NO2
O
N
N
OH
HO
O2N
 
>10  NC  NC  NC 
H28 
N
NH NO2
O
N
N
OH
HO
HO
O2N
 
>10  NC  NC  NC 
aVs HH leukemia cells; bNC – no change in CD; cNA – not available. *All in vitro 
evaluations were performed by Lee Roy Morgan through Dekk-Tec, Inc. 
 
 
Further modifications that consisted of the elimination of the phenylhydrazone moiety 
(Table III.4) provided at least one analog with equivalent properties to A-007.  Table 
III.4 reviews Schiff base analogs of barbituric acids that have been prepared and 
screened.  Analog D8 is a very encouraging lead that also has slight (~25%) binding with 
CD45+. Similarly, effects on cell agglutination, but with less apoptosis (25% vs 100% for 
A-007) were noted. 
 
 
 
 
 
 
 
 
Table III.3 continued… 
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Table III.4:  Anticancer and up-regulation for formylbarbituric acid Schiff base 
analogs.a,* 
Compound Structure Cytotoxicity 
IC50 µg/mL) 
Binding 
Intensity  
@ 5 
µg/mL 
CD4+ 
Binding 
Intensity  
@ 5 
µg/mL 
CD11C+ 
Binding 
Intensity  
@ 5 
µg/mL 
CD45+ 
D13 
N
NO
H
N O
(CH2)2
H
O
H
CO2H  
 >12  bNC  NC  NC 
D8 
N
NO
H
N O
(CH2)3
H
O
H
CO2H  
 3.5  NC  NC  ↑25% 
D9 
N
NO
H
N O
(CH2)5
H
O
H
CO2H  
 >10  NC  NC  NC 
 
N
NO
N O
(CH2)3
H
O
H
CO2H  
 >10  NC  NC  NC 
aVs HH leukemia cells; bNC – no change in CD. *All in vitro evaluations were performed 
by Lee Roy Morgan through Dekk-Tec, Inc. 
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 To date, no analog with improved immune modulating activity over A-007, which 
includes apoptosis without direct cytotoxicity, has been identified.  In designing these 
potential cell surface modulators, the new products cannot be cytotoxic to the point of  
the therapeutic index being surpassed.121, 122   Based on our initial screenings of these 
compounds, the biological properties for some of the described simple analogs appeared 
to be associated with modulation which resulted in programmed cell death.  This is in 
contrast to previously described analogs containing fused ring systems, such as 
anthracenes, xanthenes, thioxanthenes, fluorenes and phthalazenes.  In these cases, only 
intracellular changes occurred with immediate cancer cell death, as well as toxicity to 
normal tissues.121   A-007’s  –NH moiety could be involved in intramolecular –H---O= 
bonding, which would cause it to have little reactivity with any cell surface receptors.18  
As a result, A-007 and its active analogs may be initiating the CD4+/8+ T-cell cascade 
via up-regulation of the CD45+ receptor at the level of antigen presenting cells (APC).16-
17  The potential use of the immune modulating properties of these compounds in 
malignant, as well as infectious disease processes, is encouraging.   
 It appears that in order for the CD45+ up-regulation to occur, several structural 
features must be present within the phenylhydrazones molecule.  At least one NO2 
moiety, or an isostere of this moiety, such as a pyridine ring, appears necessary for up-
regulation.  In the absence of these groups, compounds containing the COOH moiety, 
also elicit CD45+ up-regulation, lending to the fact that at least one strong electron-
deficient moiety is necessary for activity.    
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CONCLUSIONS 
 Through the synthetic explorations described in the previous chapters, we have 
made available a new class of compounds containing the barbituric acid moiety as a 
functional moiety that could potentially elicit histone deacetylase inhibition, immune 
modulation, apoptotic effects on various cancer cell lines.  Our hypothesis that barbituric 
acids could replace the hydroxamic acid moieties of potent HDACI’s is currently being 
investigated.  While the in vitro biological evaluations are still underway for a large 
number of these derivatives, we have successfully synthesized several novel barbituric 
acid derivatives that do act as CD45+ up-regulators, or as compounds with a therapeutic 
index within the range of several other potent drugs, such as A-007, which are currently 
undergoing clinical trials. 
 Through the course of our synthetic preparations, several new and interesting 
molecular systems were designed, studied, and explained.  These systems include the 
5,5’-barbituric acid initiated rearrangement reactions, as well as the preparation of the 
novel pyridinium-barbituric acid zwitterions.  Spectroscopic studies evaluating the 
physical properties, as well as reaction mechanisms were performed to enable us to 
outline synthetic procedures that could be performed in the multi-gram quantities, or that 
could be easily adapted to industrial applications should our target molecules show 
promise after subsequent in vitro evaluation. 
 Our target molecules were identified as either histone deacetylase inhibitors, 
modeled after the successful HDACIs SAHA and PCHA, or as immune modulators, 
 135
modeled after the potent drug A-007.  All targets containing the barbiturate moiety were 
successfully synthesized. While not all tested compounds proved active, valuable 
research was performed surrounding the synthesis of these analogs, enabling future 
scientists to find other potential uses for either the compounds designed or the reactions 
performed.  
 136
REFERENCES 
1. For a review of the history of barbiturates, see 
http://science.kennesaw.edu/~mhermes/pheno/pheno01.htm.  ChemCases.com, 
sponsored by NSF, written by Professor Sally Boudinot. 
 
2. Goth, A.  Medical Pharmacology Principles and Concepts. 4th ed.  C. V. Mosby 
Co., St. Louis, MO. 1968. 
 
3. (a) Windholtz, M. Editor, The Merck Index. 10th ed.  Rahway; 1983;  (b) 
DeRuiter, J.  Principles of Drug Action 2.  
http://web6.duc.auburn.edu/~deruija/GABA_BarbAnalogs2002.pdf 
 
4. For examples, see: (a) Gulliya, K. S. U. S. Patent 5,869,494; Chem Abstr. 1999; 
(b) Gulliya, K. S. U. S. Patent 5,674,870; Chem Abstr. 1997; (c) Sakai, K.; Satoh, 
Y. International Patent WO9950252A3; Chem Abstr. 2000. 
 
5. For examples see: (a) Stone, T. W. Neuropharmacology.  W. H. Freeman & 
Company, Limited:  New York, N. Y. 1995. (b) 
http://www.williams.edu.:803/imput/IIIA2.html   
 
6. Hardie, D. G. Biochemical Messengers: Hormones, Neurotransmitters, and 
Growth Factors.  Chapman & Hall: London: 1991. Birnir, B.  Lund University 
Faculty of Medicine.  GABAa Receptors: Brakes in the Brain.  
http://www.medfak.lu.se/forkskning/medfak/projects. 
 
7. For examples of other structures, see: Feldman, R. S.; Meyer, J. S.; Quenzer, L. F.  
Principles of Neuropsychopharmacology. Sinauer Associates, Sunderland, MA: 
1997.  
 
8. Workman, J. L.; Kingston, R. E. Annu. Rev. Biochem. 1998, 67, 545. 
 
9. For examples, see: (a) Marmorstein, R. Nat. Rev. Mol. Cell. Biol. 2001, 2, 422; (b) 
Spencer, V. A.; Davie, J. R. Gene 1999, 240, 1. 
 
10. Moreira, J. M-A.; Scheipers, P.; Serensen, P. BMC Cancer 2003, 3, 30: and 
references cited therein.  
 
11. Structure modeled from Scott Briggs faculty page at Purdue University: 
http://www.biochem.purdue.edu/~biochem/faculty/briggs.htm. 
 
 137
12. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.  Clin. Can. Res. 2001, 7, 
759: and references cited therein. 
 
13. Said, T. K.; Moraes, R. C. B.; Sinha, R.; Medina D.  Breast Cancer Res. 2003, 3. 
and references cited therein. 
 
14. (a) Butler, L. M.; Agus, D. B.; Scher, H. I.; Higgins, B.; Rose, A.; Cordon-
Cardos, C.; Thaler, H. T.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.  Cancer 
Res. 2000, 60, 5165; (b) Miller, T. A.; Witter, D. J.; Belvedere, S.  J. Med. Chem. 
2003, 46, 5097. 
 
15.  Goldsby, R. A.; Kindt, T. J.; Osborne, B. A.; Kuby, J.  Immunology. 5th ed. W. H. 
Freeman & Company.  New York, N. Y. 2003.  
 
16. (a) Banchereau, J.; Steinmann, R. M. Nature (London) 1998, 392, 245; (b) Cyster, 
J. G. J. Exp. Med. 1999, 189, 447; (c) Huang, A. Y. C.; Golumbek, P.; 
Ahmadzadeh, M.; Jaffee, E.; Pardoll, D.; Levitski, H. 1994, 264, 961; (d) 
Urbanek, R. A.; Suchard, S. J.; Steelman, G. B.; Knappenberger, K. S.; Sygo, L. 
A.; Veale, C. A.; Chapdelaine, M. J.; J. Med. Chem. 2001, 44, 1777. 
 
17. For examples, see: (a) Eilender, D. E.; LoRusso, P.; Krementz, E. T.; Tornyos, K.; 
Thomas, L.; McCormick, C. Proc. Of 10th NCI-EORTC Symp. On New Drugs in 
Cancer Ther., 1998, abst. #477; (b) Eilender, D. E.; McCormick, C.; Tornyos, K. 
Proc. Amer. Soc. Clin. Oncol. 1999, 18, Abst.#96.  
 
18. (a) Klein, C. L.; Gray, D.; Stevens, E. D. Struct. Chem. 1993, 4, 377; (b) 
Thangaraj, R.; Morgan, L. R. Synth. Commun. 1994, 24, 2063. 
 
19. Morgan, L. R.; Hooper, C. L. Proc. 11th Int. Congress on Anticancer Therapy 
2001, 11, 16. 
 
20. (a) Lazarovits, A. I.; Poppema, S.; Zhang, Z.; Khandaker, M.; LeFeuvre, C. E.; 
Singhal, S. K.; Garcia, B. M.; Ogasa, N.; Jenikar, A. M.; White, M. J.; Singh, G.; 
Stiller, C. R.; Zhong, R. Z. Nature 1996, 380, 717; (b) Caligaris-Cappio, F. 
Lancet 2001, 358, 49; (c) Morgan, L. R.; Hooper, C. L.; Culotta, V. J. Proc. Am. 
Assoc. Cancer Res. 2002, 43, 4825.  
  
21.  For a review, see Jones, G.  Org React., 1967, 15, 204; (b) Tietze, L. F.; Beifuss, 
U. Comprehensive Organic Synthesis, Trost, B. M., Fleming, I., Heathcock, C. H., 
Eds. Pergoman Press;Oxford, 1919: Vol 2, Ch 1.11, pp 341-394. 
 
22. Baeyer, A., Liebigs Ann. Chem. 1864, 130, 129. 
 
23. Tanaka, K.; Cheng, X.; Kimura, T.; Yoneda, F.  Chem. Pharm. Bull., 1986, 34, 
3945. 
 
 138
24. Figueroa-Villar, J. D.; Rangel, C. E.; Dos Santos, L. N., Synth. Commun. 1992, 22 
(8), 1159. 
 
25. Tanaka, K.; Cheng, X.; Yoneda, F. Tetrahedron, 1988, 44, 3241. 
 
26. Ikeda, A.; Kawabe, Y., Sakai, T.; Kawasaki, K., Chem. Lett., 1989, 1803. 
 
27. For uncatalyzed Knoevenagel condensation involving malonitrile see: Bigi, F.; 
Conforti, M. L., Maggi, R.; Piccinno, A.; Satori, G.  Green Chemistry, 2000, 2, 
101.  
 
28. Vvedenskii, V. D., Khim. Geterotski. Soedin, 1969, 5, 1092.   
 
29. Villemin, D.; Labiad, B. Synth. Commun., 1990, 20, 3333. 
 
30. Villemin, D.  Chem. Commun. 1983, 1092.  
 
31. Bandgar, B. P., Zirange, S. M., Wadgaonkar, P. P., Synth. Commun., 1997, 27, 
1153. 
 
32. Kim, S., Kwon, P., Kwon, T., Synth. Commun.  1997, 27, 533. 
 
33. Jourdain, F., Pommelet, J. C., Synth. Commun. 1997, 27, 483. 
 
34. Obrador, E., Castro, M., Tamariz, J., Zepeda, G., Miranda, R., Delgado, F. Synth. 
Commun.  1998, 28, 4696.    
 
35.  Alcerreca, G., Sanabria, R., Miranda, R., Arroyo, G., Tamariz, J., Delgado, F., 
Synth. Commun. 2000, 30, 1295. 
 
36. See:  a. A Textbook of Practical Organic Chemistry(Vogel), 3rd ed.:Wiley: New 
York, 1966; 1001. 
 
37. Weygand/Hilgetag Preparative Organic Chemistry; Wiley: New York, 1972; 
493. 
 
38. Dickey, J. B., Gray, A. R. Org. Syn. Coll Vol II  1943, 60. d. Beres, J., Pearson, D. 
E., Bush, M. T. J. Med. Chem. 1967, 10, 1078. 
 
39. Trost, B. M.; Schroeder, G. M. J. Org. Chem. 2000, 65, 1569. 
 
40. Tanaka, K.; Chen, X.; Kimura, T.; Yoneda, F.  Chem. Pharm. Bull. 1988, 36, 60. 
 
 
 
 
 139
41. Bojarski, J. Chapter 4: Chiral Barbiturates: Synthesis, Chromatographic 
Resolutions, and Biological Activity; The impact of Stereochemistry on drug 
Development and Use; Aboul-Enein, H. Y.; Wainer, I. W., Eds; Wiley & Sons: 
New York, 1997, pp. 201-235.  
 
42. Tomlin, S. L.; Jenkins, A.; Lieb, W. R.; Franks, N. P. Anesthesiology 1999, 90, 
1714.  
 
43. For some reviews, see: Bojarski, J. T.; Mokrosz, J. L.; Barton, H. J.; 
Paluchowska, M. H. Adv. Heterocyclic Chem. 1985, 38, 229. 
 
44. Doran, W. J. J. Med. Chem, 1959, 4, 1.    
 
45. Sakai, K.; Satoh, Y.  Barbituric acids Derivative and Preventative and Therapeutic 
Agent for Bone and Cartilage containing the same.  International Patent 
WO99/50252. 
 
46. Grosscurt, A. C.; Terpstra, J.W.  Preparation of 5-Acetylbarbituric acid 
Derivatives as Insecticides.  Eurpoean Patent EP 455300, 1991. 
 
47. Hirono, Y.; Ishikawa, H.; Iwataki, I.; Sawaki, M.; Nomura, O.  Herbicidal 
Barbituric Acid Derivatives.  German Patent DE 2524578, 1975. 
 
48. Smith, M. B.; March, J. March’s Advanced Organic Chemistry, 5th ed.; Wiley & 
Sons: New York, 2001; p. 715. 
 
49. Corey, E. J.; Chang, X. M.  The Logic of Chemical Synthesis; Wiley & Sons: New 
York, 1989.   
 
50. Matsukawa, M.; Inanaga, J.; Yamaguch, M.  Tetrahedron Lett. 1987, 28, 5877. 
 
51. For instance, see Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic 
Synthesis; Wiley & Sons: New York, 1991.  
 
52. Corey, E. J.; Seebach, D. J. J. Org. Chem.  1966, 31, 4097. 
 
53. Ogura, K.; Tsushihashi, G.  Tetrahedron Lett. 1971, 3151. 
 
54. Kocienski, P. J. Tetrahedron Lett. 1980, 21, 1559.   
 
55. Deno, N. C. J. Chem. Soc.  1947, 2233. 
 
56. Sondheimer, F. J. Chem. Soc., 1952, 4040. 
 
57. Wibault, J. P.; Huls, R. Rec. Trav. Chim. 1952, 71, 1021. 
 
 140
58. Vilsmeier. A.; Haack, A. Ber. 1927, 60, 119. 
 
59. Blaser, D.; Calmes, M.; Daunis, J.; Natt, F.; Tardy-Delussus, A.; Jacquier, R. Org. 
Prep. Proc. Int. 1993, 25, 338. 
 
60. (a) Jutz, C. Adv. Org. Chem. 1976, 9, 255. (b) Lai, G.; Anderson, W. K. 
Tetrahedron, 2000, 56, 2583. 
 
61. Reimer, K.; Tiemann, F. Ber. 1876, 9, 824. 
 
62. Wynberg, H. Chem. Rev. 1960, 60, 169.  
 
63. Wynberg, H.; Meijer, E. W. Org. React. 1982, 28, 1.  
 
64. For some variations of the method and improved yields see (a) Cochran, J. C.; 
Melville, M. G. Synth. Commun. 1990, 20, 609; (b) Theor, A.; Denis, G.; Delmas, 
M.; Gaset, A. Synth. Commun. 1988, 18, 2095. 
 
65. Panteleimonov, A. G.; Mandrik, V. S. Ukr. Khim. Zh. 1970, 36, 696. 
 
66. For some examples (a) Kende, A. S.; Koch, K.; Smith, C. A. J. Am. Chem. Soc. 
1988, 110, 2210; (b) Strekowski, L.; Ismail, M. A.; Zoorob, H. H. Heterocycl. 
Commun. 1999, 5, 107. 
 
67. For examples, see Toth, I.; Dekany, G.; Kellam, B.  Preparation of Cyclic 
Compounds as Protecting and Linking Groups for Organic Synthesis.  
International Patent WO 9915510, 1999. 
 
68. Sasaki, I.; Gaudemer, A.; Chiaroni, A.; Riche, C. Inorg. Chim. Acta 1986, 112, 
119. 
 
69. Hasegawa, S.; Imamura, S.; Muto, M.; Okamato, Y. Japanese Patent Jpo1163129, 
1989. 
 
70. Moshen, M. K. Pharmazie 1982, 37, 147. 
 
71. Finnin, M. S.; Donigan, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, 
P. A.; Breslow, R.; Pavletich, N. P. Nature 1999, 401, 188. 
 
72. Coffey, C. D.; Kutko, M. C.; Glick, R. D.; Butler, L. M.; Heller, G.; Rifkind, R. 
A.; Marks, P. A.; Richon, V. M.; La Quaglia, M. P. Cancer Res. 2001, 61, 3591. 
 
73. Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; 
Marks, P. A. Proc. Natl. Acad. Sci. USA 1988, 95, 3003. 
 
 141
74. Cordes, E. H.; Jencks, W. P. J. Am. Chem. Soc. 1963, 85, 2843, and references 
cited therein. 
 
75. Morgan, L. R.; Rodgers, A. H.; LeBlanc, B. W.; Boue, S. M. Biorg. Med. Chem. 
Lett. 2001, 11, 2193, and references cited therein. 
 
76. Kresina, T. F. Editor Immune-Modulating Agents.  Deker, New York, N. Y. 1998. 
 
77. Gomez, G. G.; Hutchison, R. B., Kruse, C. A. Cancer Treat. Rev. 2001, 27, 375. 
 
78. Lori, F. AIDS [London],1999, 13, 1433. [d] Baba, H.; Kunimoto, T.; Nitta, K.; 
Sato, K.; Hashimoto, S.; Kohno, M.; Kita, Y.; Ogawa, H. Int. J. 
Immunopharmacol. 1986, 8, 569. 
 
79. Watanabe, I.; Andoh, T.; Furuya, R.; Sasaki, T.; Kamiya, Y.; Itoh, H. Anasthesia 
& Analgesia (Baltimore), 1999, 88, 1406. 
 
80. Gonzales, J. M. J. Neurochem. 1995, 64, 2559. 
 
81. Hirota, K.; Kudo, M.; Kudo, T.; Kitayama, M.; Kushikata, T.; Lambert, D. G.; 
Matsuki, A.  Neuroscience Lett. 2000, 291, 175. 
 
82. Bailey, T. R., Young, D. C. International Patent WO 13708 (2000); CAS 132, 
203127 (2000). 
 
83. Morgan, L. R.; Jursic, B. S.; Hooper, C. L.; Neumann, D. M.; Thangaraj, K.; 
LeBlanc, B. Bioorg. Med. Chem. Lett. 2002, 12, 3407. 
 
84. Jursic, B. S. J. Heterocyclic Chem. 2001, 38, 655. 
 
85. For Reviews of Michael reactions, see: [a] Bergmann, E. D.; Ginsburg, D.; Pappo, 
R. Org. React., 1959, 10, 179. [b] Yanovskaya, L. A.; Kryshtal, G. V.; Kulganek, 
V. V.  Russ. Chem. Rev. 1984, 53, 744. 
 
86. For more information, see: Lowry, T. H.; Richardson, K. S.  Mechanism and 
Theory in Organic Chemistry.  Third Ed., Harper and Row, Publishers, New 
York, N. Y. 1987 and references therein. 
 
87. For instance, see: [a]. Katritzky, A. R. Handbook of Heterocyclic Chemistry, 
Pergamon Press, New York, N. Y. 1985. [b] Comins, D. L.; Connor, S. Adv. 
Heterocycl. Chem. 1988, 44, 199. [c] Olah, G. A., Olah, J. A., Overchuk, N. A. J. 
Org. Chem., 1965, 30, 3373. 
 
88. Jursic, B. S.; Neumann, D. M. unpublished results. 
 
89. Litvinov, V. P. Russ. J. Org. Chem. 1993, 29, 1722. 
 142
 
90. Litvinov, V. P. Russ. J. Org. Chem. 1994, 30, 1658. 
 
91. Litvinov, V. P. Russ. J. Org. Chem. 1995, 31, 1301. 
 
92. Litvinov, V. P. Zh. Org. Chem. 1997, 33, 903. 
 
93. For instance, see (a) Visser, P.; Zuhse, R.; Wong, M. W.; Wentrup, C. J. Am. 
Chem. Soc. 1996, 118, 12598; (b) Kuhn, A.; Plug, C.; Wentrup, C. J. Am. Chem. 
Soc. 2000, 122, 1945; (c) Jackson, J. E.; Platz, M. S. In Advances in Carbene 
Chemistry, Brinker U. H., Ed.; JAI Press: Greenwich, CT, 1994; Vol 1, p 89.  
 
94. Rudler, H.; Parlier, A. Trends in Organomet. Chem. 1999, 3, 113. 
 
95. Rudler, H.; Durand-Reville, T. J. Organomet. Chem. 2001, 617-18, 571. 
 
96. Rudler, H.; Goumont, R.; Audouin, M.; Parlier, A.; Martin-Vaca, B.; Durand-
Reville, T.; Vaissermann, J. J. Am. Chem. Soc. 1996, 118, 12045. 
 
97. For instance, see (a) Schweig, A. Z. Naturforsch, 1967, 22, 724; (b) Pranata, J.; 
Murray, C. J. J. Phys. Org. Chem. 1993, 6, 531. 
 
98. Reaction with tetracyanoethylene has been mentioned. (a) Kreitsberga, Ya. N.; 
Kampar, V. E.; Neiland, O. Ya. Russ. J. Org. Chem. 1975, 11, 1488; (b) 
Kreitsberga, Ya. N.; Kampar, V. E.; Neiland, O. Ya. Russ. J. Org. Chem. 1975, 
11, 1959.   
 
99. The 1,4-dipolar character of the molecule was demonstrated by its reaction with 
acetylenedicarboxylates see:  Gompper, R. Angew. Chem., Int. Ed., Engl. 1969, 8, 
312. 
 
100. Figala, V.; Gessner, T.; Gompper, R.; Hadicke, E.; Lensky, S. Tetrahedron Lett. 
1993, 34, 6375. 
 
101. Jones, G. Org. Rect. 1967, 15, 204. 
 
102. Wilk, B. K. Tetrahedron 1997, 53, 7097. 
 
103. Alcerreca, G.; Sanabria, R.; Miranda, R.; Arroyo, G.; Tamariz, J.; Delgada, F. 
Synth. Commun. 2000, 30, 1295. 
 
104. Figueroa-Villard, J. D.; Cruz, E. R.; dos Santos, N. R. Synth. Commun. 1992, 22, 
1159. 
 
105. Tecilla, P. Tetrahedron 1995, 51, 435. 
 
 143
106. Peizner, B. A. International Patent WO 25699, 1999. 
 
107. Chen, X.; Tanaka, K.; Yoneda, F. Chem. Pharm. Bull. 1990, 38, 307. 
 
108. For reviews of arenium ions formed by the addition of a proton to an aromatic 
ring, see: Brouwer, D. M.; Mackor, E. L.; MacLean, C.; Olah, G. A.; Schleyer, P. 
V. Carbonium Ions; Wiley: New York, 1970; Vol. 2, p837. (b) Perkampus, H. H. 
Adv. Phys. Org. Chem. 1966, 4, 195. 
 
109. Jursic, B. S. Tetrahedron Lett. 2000, 41, 5325. 
 
110. Jursic, B. S. J. Heterocycl, Chem. 1996, 33, 1079. 
 
111. Ashkinazi, R. I. “Salts of 5,5'-arylidenebis[barbituric acids] and 5,5'-
arylidenebis[2-thiobarbituric acids] having antibacterial, antichlamydial, antiviral 
and immuno-modulating activity” International Patent WO 25699 (1999). 
 
112. Guilliya, K. S.  “Barbituric acid analogs for treatment of cancer, infection, 
depression, and modulating the immune system.”  United States Patent 5869494 
(1999). 
 
113. Bailey, T. R.; Young, D. C “Methods for treating or preventing viral infections 
and associated diseases using barbituric acid and thiobarbituric acid derivatives” 
International Patent WO 13708 (2000).  
 
114.  Andre, P.; Tedone, R.; Evreux, J. C. J. Immunopharmacology, 1985, 7, 171. 
 
115.  Lee, D. L; Carter, C. G. “Herbicidal Method and Composition Utilizing Certain 
5-(2-Substituted Benzoyl)-Barbituric Acids” United States Patent 4,797,147 
(1989). 
 
116.  Kay, I. T.; Peacock, F. C.; Waring, W. S. “5-Acyl Barbituric Acid Derivatives” 
United State Patent 3,828,043 (1974). 
 
117. Buzz, Recreational Drugs, Loompanics Unlimited, 1989. 
 
118. For methods of transformation of methyl aryl ethers into phenol derivatives 
(deprotection of phenol OH group) see: Greene, T. W.;  Wuts, P. G. M. Protective 
Groups in Organic Synthesis 3rd Ed., John Wiley & Sons, Inc., New York, 1999. 
 
119. Zheng, Z. R.; Kjaer, N. T.; Lund, H. acta. Chem. Scand. 1998, 52, 362.  
 
120. For base-catalyzed rearrangement of symmetrically substituted benzils, see: 
Bowden, K.; Williams, K. D. J. Chem. Soc., Perkin Trans. 2, 1994, 77, and 
references therein. 
 
 144
121. Easmon, J.; Heinisch, G.; Purtinger, G.; Hofmann, J.  Proc. Am. Cancer Res. 
2000, 41, 656. 
 
122. Thangaraj, K.; Morgan, L. R.; Benes, E. N.; Jursic, B. S.; Fan, D.  Breast Cancer 
Res. Treat. 1993, 27, 77. 
  
 145
EXPERIMENTALS 
All solvents and starting materials in this synthesis were obtained from Aldrich and used 
without further purification. Thin-layer chromatography was performed using plastic-
based 0.25 mm thick silica gel 60 F-254 plates (E. Merc, Inc.).  All 1H and 13C NMR are 
recorded in DMSO-d6 on a Gemini 2000 Varian instrument with the chemical shift of the 
solvent at 2.49 and 36.0 ppm as referenced in hydrogen and carbon NMR spectra. All 
DMSO-d6 samples were clear solutions.  The CF3COOH samples contained a few drops 
of DMSO-d6 as an internal reference and part of barbituric acid was not in the solution.  
All electro-spray mass spectral analyses were performed on a Micromass Quattro 2 Triple 
Quadropole Masspectrometer.  Melting points were determined on Electrothermal 9100 
melting point apparatus and they are not corrected.  The ES-MS parameters (i.e., 
pressure, temperature, and voltage on the needle, etc.) were kept constant in each series 
of solutions. A flow rate of 10 µL/min was applied using 100 µL of sample solution. 
Elemental analyses were performed by Atlantic Microlab, Inc. X-ray structure 
determination was performed on a Bruker SMART 1KCCD automated diffractometer.
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General Procedure A: 
Synthesis of 5-(4-Dimethylamino-benzylidene)-pyrimidine-2,4,6-trione (A1) 
A mixture of barbituric acid (12.8 g; 0.1 mol) and 4-(dimethylamino)benzaldehyde (14.9 
g; 0.1 mol) in methanol (500 mL) were stirred at room temperature.  After a few minutes 
the solution became a suspension, and the color of solid went from yellow to dark purple.  
The suspension was allowed to stir at room temperature overnight.  The solid product 
was separated by filtration and washed with cold methanol (3×50 mL).  The isolated 
yield was 35.4 g (98%).  An analytical sample after drying in vacuum had m.p. 277º C 
with decomposition; lit. m.p. 275º C with decomposition.  IR (KBr) 3095-3080, 1700, 
1640, 1500, cm-1.  1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.04 (s, 1H, NH), 
10.91 (s, 1H, NH), 8.42 (d, J= 12.4 Hz, 2H, Ar), 8.13 (s, 1H, CH), 6.78 (d, J= 12.4 Hz, 
2H, Ar), 3.11 (s, 6H, N(CH3)2).  13C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 161.2, 
159.2, 152.0, 150.7, 146.8, 135.6, 116.5, 107.7, 106.0, and 38.0 ppm.  MS (CI+-NH3) 259 
(5%, M+) 215 (100%), 172 (96%), 166 (11%), 144 (7%), 128 (18%), 101 (15%).  Anal. 
Calcd. For C13H13N3O3:  C, 60.23: H, 5.05; N, 16.21.  Found: C, 60.11; H, 5.13; N, 
16.08. 
 
Synthesis of 5-(3-Phenyl-allylidene)-pyrimidine-2,4,6-trione (A2) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and trans-cinnamaldehyde (1.32 g; 0.01 
mol) in methanol (100 mL) were stirred at room temperature.  After a few minutes the 
solution became a suspension, and the color of solid went from white to yellow.  The 
suspension was allowed to stir at room temperature overnight.  The solid product was 
separated by filtration and washed with cold methanol (3×20 mL).  The isolated yield 
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was 2.30 g (95%).  An analytical sample after drying in vacuum had m.p. 260º C with 
decomposition.  1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.27 (s, 1H, NH), 
11.20 (s, 1H, NH), 8.42 (m, 1H, CH), 7.99 (d, J= 11.4, 1H, CH), 7.65 (m, 3H), 7.45 (m, 
3H) ppm.  13C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 159.6, 159.4, 150.1, 149.1, 
146.8, 131.8, 127.6, 125.7, 125.0, 120.7, and 112.2 ppm. MS (ESI-) in methanol: 241 
(50%, M-1), 273 (100%, M+MeOH). 
 
Synthesis of 5-[3-(4-Dimethylamino-phenyl)-allylidene]-pyrimidine-2,4,6-trione (A3) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and 4-amino-trans-cinnamaldehyde (1.75 
g; 0.01 mol) in methanol (100 mL) were stirred at room temperature.  After a few 
minutes the solution became a suspension, and the color of solid went from yellow to 
dark purple.  The suspension was allowed to stir at room temperature overnight.  The 
solid product was separated by filtration and washed with cold methanol (3×20 mL).  The 
isolated yield was 2.82 g (99%).  An analytical sample after drying in vacuum had m.p. 
250º C.  1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.01 (s, 1H, NH), 10.95 (s, 1H, 
NH), 8.19 (m, 1H, CH), 7.94 (d, J= 16.8 Hz, 1H, CH), 7.59 (d, J= 19.6 Hz, 1H, CH), 
7.51 (d, J= 11.6 Hz, 2H, Ar), 6.76 (d, J= 12.0, 2H, Ar), 3.02 (s, 6H, N(CH3)2).  13C-NMR 
(DMSO-d6 -400 MHz Varian Unity) δ 161.2, 159.7, 152.3, 150.9, 146.6, 131.1, 126.8, 
125.5, 125.0, 119.9, and 112.1 ppm. 
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Synthesis of 5-(4-Hydroxy-benzylidene)-pyrimidine-2,4,6-trione (A4) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and 4-hydroxybenzaldehyde (1.22 g; 0.01 
mol) in methanol (100 mL) were stirred at room temperature.  After a few minutes the 
solution became a suspension, and the color of solid went from white to yellow.  The 
suspension was allowed to stir at room temperature overnight.  The solid product was 
separated by filtration and washed with cold methanol (3×20 mL).  The isolated yield 
was 2.20 g (95%).  An analytical sample after drying in vacuum had m.p. 280º C with 
decomposition.  1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.24 (s, 1H, NH), 
11.11 (s, 1H, NH), 10.81 (s, 1H, OH), 8.31 (d, J= 8.8 Hz, 2H, Ar), 8.19 (s, 1H, CH), 6.86 
(d, J= 8.8 Hz, 2H, Ar).  13C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 164.6, 163.4, 
162.7, 155.9, 150.7, 138.7, 124.2, 115.9, and 114.6 ppm.  MS (ESI-) in methanol: 231 
(100%, M-1), 263 (45%, M+MeOH). 
 
General Method B: 
Synthesis of 5-Furan-2-ylmethylene-pyrimidine-2,4,6-trione (A5) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and 2-furaldehyde (0.96 g; 0.01 mol) in 
methanol (150 mL) was stirred at room temperature for 5 days.  Methanol was 
evaporated at room temperature under reduced pressure.  The solid residue was slurred in 
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by 
filtration.  The crystalline product was washed with cold water (3×50 mL) and then 
slurred in ether  After the second filtration, crystalline material was washed with ether 
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product (1.67 g; 
81%).  An analytical sample after drying in vacuum had a m.p. 264º C with 
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decomposition.  The reported literature melting point is 260º C with decomposition.  IR 
(KBr) 3520-3480, 1730, 1690, 1645, 1615-1590, 1560-1530 cm-1.  1H-NMR (DMSO-d6 -
400 MHz Varian Unity) δ 11.35 (s, 1H, NH), 11.26 (s, 1H, NH), 8.45 (d, J= 3.6 Hz, 1H, 
Ar), 8.24 (s, 1H, CH), 8.01 (s, 1H, Ar), 6.90 (d, J= 2.4 Hz, 1H, Ar) ppm.  13C-NMR 
(DMSO-d6 -400 MHz Varian Unity) δ 159.8, 158.6, 147.7, 133.4, 123.0, 111.8, and 109.3 
ppm.  Anal. Calcd. .  For C9H6N2O4:  C, 52.44; H, 2.93; N, 13.59.  Found: C, 52.36; H, 
3.07; N, 13.40.  
 
Synthesis of 5-Benzylidene-pyrimidine-2,4,6-trione (A6) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and benzaldehyde (1.06 g; 0.01 mol) in 
methanol (150 mL) was stirred at room temperature for 5 days.  Methanol was 
evaporated at room temperature under reduced pressure.  The solid residue was slurred in 
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by 
filtration.  The crystalline product was washed with cold water (3×50 mL) and then 
slurred in ether  After the second filtration, crystalline material was washed with ether 
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product (1.84 g; 
85%).  An analytical sample after drying in vacuum had m.p. 250º C with decomposition.  
The reported literature melting point is 250º C with decomposition.  1H-NMR (DMSO-d6 
-400 MHz Varian Unity) δ 11.39 (s, 1H, NH), 11.23 (s, 1H, NH), 8.27 (s, 1H, CH), 8.06 
(d, J= 6.6 Hz, 2H, Ar), 7.52 (t, J= 4.8 Hz, 1H, Ar), 7.45 (t, J= 8.2, 2H, Ar).  13C-NMR 
(DMSO-d6 -400 MHz Varian Unity) δ 159.9, 158.1, 151.2, 146.7, 129.6, 129.2, 124.6, 
and 115.6 ppm.  MS (ESI-) in methanol 172 (10%), 215 (75%, M-1), 247 (100%, 
M+MeOH). 
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Synthesis of 5-Naphthalen-2-ylmethylene-pyrimidine-2,4,6-trione (A7) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and naphthaldehyde (1.56 g; 0.01 mol) in 
methanol (100 mL) were stirred at room temperature.  After a few minutes the solution 
became a suspension, and the color of solid went from white to yellow.  The suspension 
was allowed to stir at room temperature overnight.  The solid product was separated by 
filtration and washed with cold methanol (3×20 mL).  The isolated yield was 2.20 g 
(83%).  An analytical sample after drying in vacuum had m.p. 250º C with 
decomposition.  1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.46 (s, 1H, NH), 
11.17 (s, 1H, NH), 8.78 (s, 1H, CH), 8.01 (m, 2H, Ar), 7.84 (m, 2H, Ar), 7.56 (m, 3H, 
Ar) ppm.  13C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 163.4, 161.5, 152.1, 150.8, 
133.1, 131.5, 131.1, 129.2, 128.8, 127.5, 126.8, 125.4, 124.8, and 122.4 ppm.  MS (ESI-) 
in methanol 265 (M-1), 297 (100%, M+MeOH) 
 
Synthesis of 5-(2,4-Dihydroxy-benzylidene)-pyrimidine-2,4,6-trione (A8) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and 2,4-dihydroxybenzaldehyde (1.38 g; 
0.01 mol) in methanol (150 mL) was stirred at room temperature for 36 h.  Methanol was 
evaporated at room temperature under reduced pressure.  The solid residue was slurred in 
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by 
filtration.  The crystalline product was washed with cold water (3×50 mL) and then 
slurred in ether  After the second filtration, crystalline material was washed with ether 
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product (2.11 g, 
85%).  An analytical sample after drying in vacuum had a m.p. 264º C with 
decomposition.  1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.10 (s, 1H, NH), 
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10.96 (s, 1H, NH), 10.80 (broad s, 2H, OH), 8.75 (s, 1H, CH), 8.71 (d, J= 9.2 Hz, 1H, 
Ar), 6.38 (d, J= 2.0 Hz, 1H, Ar), 6.30 (d, J= 11.6 Hz, 1H, Ar) ppm.  13C-NMR (DMSO-
d6 -400 MHz Varian Unity) δ 162.1, 161.1, 159.8, 159.1, 146.8, 146.3, 132.7, 108.8, 
107.9, 104.5, and 97.9 ppm.  MS (ESI-) in methanol: 247 (M-1). 
 
Synthesis of 5-(1H-Indol-2-ylmethylene)-pyrimidine-2,4,6-trione (A9) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and 2-indolecarboxaldehyde (1.45 g; 0.01 
mol) in methanol (150 mL) was stirred at room temperature for 36 h.  Methanol was 
evaporated at room temperature under reduced pressure.  The solid residue was slurred in 
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by 
filtration.  The crystalline product was washed with cold water (3×50 mL) and then 
slurred in ether.  After the second filtration, crystalline material was washed with ether 
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product of 2.44 g, 
(96%) yield.  An analytical sample after drying in vacuum had a m.p. 260º C with 
decomposition. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 12.71 (s, 1H, NH), 11.10 
(s, 1H, NH), 11.02 (s, 1H, NH), 9.48 (s, 1H, CH), 8.69 (s, 1H, Ar), 7.85 (d of d, J1= 4.0 
Hz, J2= 8.0 Hz, 1H, Ar), 7.56 (d of d, J1= 4.0 Hz, J2= 8.0 Hz, 1H, Ar), 7.29 (d of d, J1= 
8.4 Hz, J2= 2.4 Hz, 2H, Ar).  13C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 161.0, 
159.7, 146.9, 140.2, 136.2, 132.9, 125.6, 120.1, 119.1, 114.1, 109.6, 107.9, and 105.1 
ppm.  MS (CI+) 256 (100%, M+), 145 (10%), 130 (40%), 118 (45%), 79 (5%). 
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Synthesis of 5-(2-Hydroxy-benzylidene)-pyrimidine-2,4,6-trione (A10) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and 2-hydroxybenzaldehyde (1.22 g; 0.01 
mol) in methanol (150 mL) was stirred at room temperature for 36 h.  Methanol was 
evaporated at room temperature under reduced pressure.  The solid residue was slurred in 
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by 
filtration.  The crystalline product was washed with cold water (3×50 mL) and then 
slurred in ether.  After the second filtration, crystalline material was washed with ether 
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product of 1.85 g, 
(80%) yield.  An analytical sample after drying in vacuum had a m.p. 230º C with 
decomposition. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.29 (s, 1H, NH), 11.12 
(s, 1H, NH), 10.61 (s, 1H, OH), 8.60 (s, 1H, CH), 8.14 (d, J= 10.4 Hz, 1H, Ar), 7.35 (t, 
J= 10 Hz, 1H, Ar), 6.91 (d, J= 11.2 Hz, 1H, Ar), 6.80 (t, J= 10 Hz, 1H, Ar) ppm.  13C-
NMR (DMSO-d6 -400 MHz Varian Unity) δ  160.2, 158.2, 155.4, 146.8, 131.1, 129.2, 
116.3, 114.7, 113.6, and 111.9 ppm.  MS (ESI-) in methanol: 231 (M-1). 
 
General Procedure C: 
1,3-Dimethyl-5-(2,4,6-trimethoxy-benzylidene)-pyrimidine-2,4,6-trione (A11) 
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and 2,4,6-
trimethyoxybenzaldehyde (1.98 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric 
acid was stirred at room temperature for 12 h.  Methanol was evaporated at room 
temperature under reduced pressure.  The solid residue was slurred in cold water (100 
mL), stirred for 2 hours and then the solid residue was separated by filtration.  The 
crystalline product was washed with cold water (3×50 mL) and then slurred in ether (20 
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mL).  After the second filtration, crystalline material was washed with ether (3×10 mL) 
and dried in the air, resulting in a pure crystalline product of 2.72 g (81%) yield.  An 
analytical sample after drying in vacuum had a m.p. 200º C with decomposition.  1H-
NMR (DMSO-d6 -500 MHz Varian Unity) δ 8.71 (s, 1H, CH), 8.45 (s, 1H, Ar), 6.65 (s, 
1H, Ar), 3.90 (s, 6H, OCH3), 3.71 (s, 3H, OCH3), 3.16 (s, 3H, CH3), 3.14 (s, 3H, CH3) 
ppm.  13C-NMR (DMSO-d6 -500 MHz Varian Unity) δ 159.4, 157.4, 154.7, 152.9, 147.6, 
146.0, 138.0, 112.3, 109.7, 109.2, 92.6, 53.2, 52.6, 52.3, 25.0, and 24.5 ppm. 
 
Synthesis of 1,3-Dimethyl-5-(2,3,4-trimethoxy-benzylidene)-pyrimidine-2,4,6-trione 
(A12) 
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and 2,3,4-
trimethyoxybenzaldehyde (1.98 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric 
acid was stirred at room temperature for 12 h.  Methanol was evaporated at room 
temperature under reduced pressure.  The solid residue was slurred in cold water (100 
mL), stirred for 2 hours and then the solid residue was separated by filtration.  The 
crystalline product was washed with cold water (3×50 mL) and then slurred in ether (20 
mL).  After the second filtration, crystalline material was washed with ether (3×10 mL) 
and dried in the air, resulting in a pure orange crystalline product of 2.65 g (79%) yield.  
An analytical sample after drying in vacuum had m.p. 200º C with decomposition. 1H-
NMR (DMSO-d6 -500 MHz Varian Unity) δ 8.52 (s, 1H, CH), 8.22 (d, J= 8.5 Hz, 1H, 
Ar), 6.89 (d, J= 9.5 Hz, 1H, Ar), 3.89 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.75 (s, 3H, 
OCH3), 3.19 (s, 3H, CH3), 3.16 (s, 3H, CH3) ppm.  13C-NMR (DMSO-d6 -500 MHz 
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Varian Unity) δ 158.9, 156.9, 154.6, 151.5, 147.5, 146.7, 137.1, 125.6, 115.4, 112.6, 
103.5, 58.4, 56.9, 52.7, 25.0, and 24.4 ppm. 
 
Synthesis of 5-(4-Hydroxy-benzylidene)-1,3-dimethyl-pyrimidine-2,4,6-trione (A13) 
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and 4-hydroxybenzaldehyde 
(1.22 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric acid was stirred at room 
temperature for 12 h.  Methanol was evaporated at room temperature under reduced 
pressure.  The solid residue was slurred in cold water (100 mL), stirred for 2 hours and 
then the solid residue was separated by filtration.  The crystalline product was washed 
with cold water (3×50 mL) and then slurred in ether (20 mL).  After the second filtration, 
crystalline material was washed with ether (3×10 mL) and dried in the air, resulting in a 
pure orange crystalline product of 2.08 g (80%) yield.  An analytical sample after drying 
in vacuum had m.p. 180º C with decomposition. 1H-NMR (DMSO-d6 -500 MHz Varian 
Unity) δ 10.80 (s, 1H, OH), 8.26 (d, J= 8.5 Hz, 2H, Ar), 8.22 (s, 1H, CH), 6.85 (d, J= 10 
Hz, 2H, Ar), 3.18 (s, 3H, CH3), 3.16 (s, 3H, CH3) ppm.  13C-NMR (DMSO-d6 -500 MHz 
Varian Unity) δ 163.8, 163.3, 161.4, 157.0, 151.7, 138.9, 124.4, 116.1, 114.4, 29.2, and 
28.6 ppm.  MS (ESI-) in methanol: 259 (M-1). 
 
Synthesis of 5-(2,4-Dihydroxy-benzylidene)-1,3-dimethyl-pyrimidine-2,4,6-trione (A14) 
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and 2,4-
dihydroxybenzaldehyde (1.38 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric 
acid was stirred at room temperature for 12 h.  Methanol was evaporated at room 
temperature under reduced pressure.  The solid residue was slurred in cold water (100 
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mL), stirred for 2 hours and then the solid residue was separated by filtration.  The 
crystalline product was washed with cold water (3×50 mL) and then slurred in ether (20 
mL).  Material was washed with ether (3×10 mL) and dried in the air, resulting in a pure 
orange crystalline product of 2.18 g (79%) yield.  An analytical sample after drying in 
vacuum had m.p. 220º C with decomposition.  1H-NMR (DMSO-d6 -500 MHz Varian 
Unity) δ 10.80 (s, 1H, OH), 10.68 (s, 1H, OH), 8.78 (s, 1H, CH), 8.63 (d, J= 11 Hz, 1H, 
Ar), 6.37 (s, 1H, Ar), 6.28 (d, J= 11.5 Hz, 1H, Ar), 3.14 (s, 3H, CH3), 3.11 (s, 3H, CH3) 
ppm.  13C-NMR (DMSO-d6 -500 MHz Varian Unity) δ 162.3, 160.1, 159.7, 157.5, 147.7, 
147.3, 132.6, 109.0, 107.5, 104.5, 97.9, 25.0, and 24.4 ppm.  MS (CI+-NH3) 277 (70%, 
M+1), 261 (75%), 139 (30%), 96 (95%), 79 (100%). 
 
Synthesis of 1,3-Dimethyl-5-(3-phenyl-allylidene)-pyrimidine-2,4,6-trione (A15) 
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and trans-cinnamaldehyde 
(1.32 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric acid was stirred at room 
temperature for 12 h.  Methanol was evaporated at room temperature under reduced 
pressure.  The solid residue was slurred in cold water (100 mL), stirred for 2 hours and 
then the solid residue was separated by filtration.  The crystalline product was washed 
with cold water (3×50 mL) and then slurred in ether (20 mL).  After the second filtration, 
crystalline material was washed with ether (3×10 mL) and dried in the air, resulting in a 
pure orange crystalline product of 2.20 g (81%) yield.  An analytical sample after drying 
in vacuum had m.p. 200º C with decomposition.  1H-NMR (DMSO-d6 -500 MHz Varian 
Unity) δ 8.44 (m, 1H, CH), 8.06 (d, J= 15.6, 1H, CH), 7.73 (d, J= 20.8 Hz, 1H, CH), 
7.66 (m, 2H, Ar), 7.46 (t, J= 3.8 Hz, 3H, Ar), 3.18 (s, 6H, CH3) ppm. 
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13C-NMR (DMSO-d6 -500 MHz Varian Unity) δ 158.1, 157.8, 150.8, 149.4, 147.5, 131.6, 
127.6, 125.6, 125.0, 120.7, 111.8, 24.7, and 24.2 ppm. 
 
General Procedure D: Preparation of mono C-alkylated barbituric acids with aliphatic 
aldehydes and ketones 
Synthesis of 5-isopropyl-1-phenylbarbituric acid (B1) 
A suspension of 1-phenylbarbituric acid (2.04 g, 10.0 mmol) and 5% Pt-C with 50% 
water (0.200 g) in acetone (30 mL) and acetic acid (100 mL) was hydrogenated under 
hydrogen pressure of 50 psi for ~20 hours.  The catalyst was separated by filtration, the 
filtrate was evaporated to an oily residue and benzene (3×50 mL) was added successively 
and evaporated to eliminate residue of acetic acid to give racemic 5-isopropyl-1-
phenylbarituric acid (2.35 g, 96%).  Product decomposes at temperatures above 200º C.  
1H-NMR (DMSO-d6 -500 MHz Varian Unity): δ 11.58 (1H, s, NH), 7.43 (3H, m) 7.22 
(2H, d, J= 8.1 Hz), 3.41 (1H, d, J= 3.9 Hz) 2.48 (1H, m), 1.08 (6H, d, J= 5.7 Hz) ppm.  
13C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 165.6, 165.4, 147.3, 131.2, 125.2, 
125.2, 125.1, 124.7, 124.6, 51.3, 28.8, 16.0, and 15.9 ppm.  MS (EI): m/z 69 (40%, 
CH3CH=CHCO+), 77 (5%, Ph) 83 (40%) 91, 119 (80%, PhN=C=O+), 176 (25%, 
PhNHCOCH2CONH2+), 204 (100%, M-C(CH3)2+), 231 (20%, M-CH3+), 246 (20%, M+).  
Anal. Calcd.  for C13H14N2O3:  C, 63.40; H, 5.73; N, 11.38.  Found: C, 63.21; H, 5.92; N, 
11.14.  
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Synthesis of 5-Isopropyl-1,3-dimethyl-pyrimidine-2,4,6-trione (B2)  
A suspension of 1,3-dimethylbarbituric acid(1.56 g, 10.0 mmol), 2 drops sulfuric acid 
and 5% Pt-C with 50% water (0.2 g) in acetone (30 mL) and acetic acid (100 mL) was 
hydrogenated under hydrogen pressure of 50 psi for ~20 hours.  The catalyst was 
separated by filtration, the filtrate was evaporated to an oily residue and benzene (3×50 
mL) was added successively and evaporated to eliminate residue of acetic acid to give 
1.92 g (97%) of racemic 5-isopropyl-1,3-dimethylbarituric acid.  m.p. 157.2-159.1º C.  
1H-NMR (DMSO-d6 -500 MHz Varian Unity): δ 3.42 (1H, d, J= 3.3 Hz), 3.144 (6H, s), 
0.976 (6H, d, J= 6.9 Hz) ppm.  13C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 164.9, 
148.3, 51.1, 29.0, 24.2, and 15.8 ppm. 
 
Synthesis of 5-Cyclohexyl-pyrimidine-2,4,6-trione (B3) 
A suspension of barbituric acid (1.28 g, 10 mmol), cyclohexanone (1.55 mL, 1.47 g, 15 
mmol) and 5% Pt-C with 50% water (0.2 g) in methanol (100 mL) was hydrogenated 
under hydrogen pressure of 50 psi for ~20 hours.  The catalyst was separated by 
filtration, the filtrate volume was reduced to 1/10 the original volume, and diluted with 
water (100 mL) to precipitate the product.  The precipitate was separated by filtration and 
dried on the air to afford 2.00 g (95%) 5-Cyclohexyl-pyrimidine-2,4,6-trione.  Product 
decomposes at temperatures above 150º C.  1H-NMR (DMSO-d6 -500 MHz Varian 
Unity): δ 11.19(2H, s, NH), 3.11(1H, d, J= 3.6 Hz, CH), 2.11(1H, m), 1.67(6H, m), 
1.23(4H, m) ppm.  13C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 166.7, 147.6, 50.5, 
50.4, 38.0, 25.9, 22.4, 21.9 ppm.  MS (CI+-NH3) 129 (100%, ba +), 211 (55%, M+). 
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Synthesis of 5-Heptyl-pyrimidine-2,4,6-trione (B4) 
A suspension of barbituric acid (1.28 g, 10 mmol), heptaldehyde (2.10 mL, 1.71 g, 15 
mmol) and 5% Pt-C with 50% water (0.2 g) in methanol (100 mL) was hydrogenated 
under hydrogen pressure of 50 psi for ~20 hours.  The catalyst was separated by 
filtration, the filtrate volume was reduced to 1/10 the original volume, and diluted with 
water (100 mL) to precipitate product.  The precipitate was removed by filtration and 
dried on the air to afford 2.19 g (97%) pure product.  Product decomposes at 
temperatures above 160º C.  1H-NMR (DMSO-d6 -500 MHz Varian Unity): δ 11.18 (2H, 
s, NH),  3.49 (1H, t, J= 5.1 Hz, CH), 1.85 (2H, m), 1.20 (10H, m), 0.83 (3H. t. J= 6.8 
Hz) ppm.  13C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 167.0, 147.3, 44.3, 27.6, 
25.3, 24.8, 24.4, 22.2, 18.5, and 10.4 ppm.  MS (CI+-NH3) 129 (100%, ba), 227 (75%, 
M+).  
 
General Procedure E:   
Preparation of C-5 monobenzylated barbituric acids with aromatic aldehydes: 
Synthesis of 5-benzylbarbituric acid (B5) 
Barbituric acid (1.28 g, 10 mmol), and benzaldehyde (1.06 g, 10 mmol) were refluxed in 
methanol (100 mL) for 30 minutes.  The reaction suspension was cooled to room 
temperature and 5% Pd-C with 50% water (0.1 g) was added, together with benzene (50 
mL) and hydrogenated at 30 psi for 4 hours.  The catalyst was separated by filtration and 
the solvent was evaporated to a solid residue.  The solid residue was re-dissolved in 
methanol (10 mL) and diluted with water (300 mL).  The white precipitate was separated 
by filtration and dried in the air to give 1.85 g (85%) pure product.  m.p. > 200º C with 
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decomp.  1H-NMR (DMSO-d6 -500 MHz Varian Unity): δ 11.16 (2H, s, NH), 7.22 (5H, 
broad m, Ar), 3.88 (2H, s, CH2).  13C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 170.6, 
151.1, 137.9, 129.4, 128.9, 127.3, 49.9, and 39.3 ppm.  MS (CI+-NH3) 91 (100%, 
CH2C6H5+), 218 (70%, M). 
 
Synthesis of 5-naphthalen-2-ylmethylbarbituric acid (B6)    
Barbituric acid (1.28 g, 10 mmol), and 2-naphthaldehyde (1.56 g, 10 mmol) were 
refluxed in methanol (100 mL) for 30 minutes.  The reaction suspension was cooled to 
room temperature and 5% Pd-C with 50% water (0.1 g) was added, together with benzene 
(50 mL) and hydrogenated at 30 psi for 4 hours.  The catalyst was separated by filtration 
and the solvent was evaporated to a solid residue.  The solid residue was re-dissolved in 
methanol (10 mL) and diluted with water (300 mL).  The white precipitate was separated 
by filtration and dried in the air to give 2.40 g (90%) 5-naphthalen-2-ylmethylbarbituric 
acid.  m.p. > 200º C with decomp.  1H-NMR (DMSO-d6 -500 MHz Varian Unity): δ 
11.15 (2H, s, NH), 8.13 (1H, d, J= 6.6 Hz), 7.89 (1H, d, J= 6.6 Hz), 7.71 (1H, d, J= 8.7 
Hz), 7.51 (2H, m), 7.41 (1H, t, J= 7.5 Hz), 7.25 (1H, d, J= 6.6 Hz), 3.95 (1H, t, J= 6.6 
Hz), 3.66 (2H, d, J= 6.6 Hz) ppm.  13C-NMR ((DMSO-d6 -500 MHz Varian Unity): δ 
166.0, 146.6, 130.2, 129.2, 127.4, 124.4, 122.9, 122.5, 44.8, and 25.9 ppm.  MS (CI+- 
NH3) m/z  91 (C7H7+), 115 (12%, C8H9+), 128 (17%, ba+), 129 (16%, C10H9+), 141 
(100%, C11H10+), 169 (7%, C11H10CO+), 268 (45%, M+), 269 (10%, M++1).  Anal. Calcd.  
for C16H12N2O3:  C, 67.16; H, 4.51; N, 10.44.  Found: C, 67.01; H, 4.82; N, 10.08. 
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Synthesis of 5-(3-Phenyl-propyl)-pyrimidine-2,4,6-trione (B7)  
Barbituric acid (1.28 g, 10 mmol), and trans-cinnamaldehyde (1.32 g, 10 mmol) were 
refluxed in methanol (100 mL) for 30 minutes.  The reaction suspension was cooled to 
room temperature and 5% Pd-C with 50% water (0.100 g) was added, together with 
benzene (50 mL) and hydrogenated at 30 psi for 4 hours.  The catalyst was separated by 
filtration and the solvent was evaporated to a solid residue.  The solid residue was re-
dissolved in methanol (10 mL) and diluted with water (300 mL).  The formed precipitate 
was separated by filtration and dried in the air to give 2.26 g (92%). 1H-NMR (DMSO-d6 
-300 MHz Varian Unity): δ 11.17 (2H, s, NH), 7.25 (2H, m), 7.16 (3H, m), 3.53 (1H, t, 
J= 5.1 Hz), 2.53 (2H, m), 1.87 (2H, m), 1.54 (2H, m) ppm.  13C-NMR (DMSO-d6 -300 
MHz Varian Unity): δ 166.7, 147.2, 137.9, 124.6, 124.6, 122.1, 44.2, 36.8, 24.3, and 24.1 
ppm. 
 
5-[3-(4-Dimethylamino-phenyl)-propyl]-pyrimidine-2,4,6-trione (B8)  
Barbituric acid (1.28 g, 10 mmol), and 4-dimethylaminocinnamaldehyde (1.75 g, 10 
mmol) were refluxed in methanol (100 mL) for 30 minutes.  The reaction suspension was 
cooled to room temperature and 5% Pd-C with 50% water (0.100 g) was added, together 
with benzene (50 mL) and hydrogenated at 30 psi for 4 hours.  The catalyst was separated 
by filtration and the solvent was evaporated to a solid residue.  The solid residue was re-
dissolved in methanol (10 mL) and diluted with water (300 mL).  The white precipitate 
was separated by filtration and dried in the air to give 2.57 g (89%) pure product.  1H-
NMR (DMSO-d6 -300 MHz Varian Unity): δ 6.960 (2H, d, J= 7.8 Hz), 6.628 (2H, d, J= 
8.7 Hz), 3.157 (2H, s), 2.816 (6H, s), 2.402 (2H, m), 1.484 (2H, m).  13C-NMR (DMSO-
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d6 -300 MHz Varian Unity): δ 164.2, 147.7, 145.4, 125.6, 119.9, 108.0, 45.0, 36.1, 24.4, 
and 21.3 ppm. 
 
Synthesis of 5-(4-Dimethylamino-benzyl)-1,3-dimethyl-pyrimidine-2,4,6-trione (B10)  
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and 4-dimethylaminobenzaldehyde (1.49 
g, 10 mmol) were refluxed in methanol with 2 drops sulfuric acid (100 mL) for 30 
minutes.  The reaction suspension was cooled to room temperature and 5% Pd-C with 
50% water (0.100 g) was added, together with benzene (50 mL) and hydrogenated at 30 
psi for 4 hours.  The catalyst was separated by filtration and the solvent was evaporated 
to a solid residue.  The solid residue was re-dissolved in methanol (10 mL) and diluted 
with water (300 mL).  The precipitate was separated by filtration and dried in the air to 
give 2.80 g (97%) product.  1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 6.80 (2H, d, 
J= 7.8 Hz), 6.56 (2H, d, J= 8.7 Hz), 3.86 (1H, broad t), 3.16 (2H, broad d), 2.99 (6H, s), 
2.80 (6H, s).  13C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 164.9, 147.6, 145.7, 
125.5, 119.8, 108.5, 47.1, 36.8, 32.0, and 24.2 ppm.  
 
Synthesis of 1,3-Dimethyl-5-(3-phenyl-propyl)-pyrimidine-2,4,6-trione (B11)  
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and trans-cinnamaldehyde (1.32 g, 10 
mmol) were refluxed in methanol (100 mL) for 30 minutes.  The reaction suspension was 
cooled to room temperature and 5% Pd-C with 50% water (0.100 g) was added, together 
with benzene (50 mL) and hydrogenated at 30 psi for 4 hours.  The catalyst was separated 
by filtration and the solvent was evaporated to a solid residue.  The solid residue was re-
dissolved in methanol (10 mL) and diluted with water (300 mL).  The formed precipitate 
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was separated by filtration and dried in the air to give 2.49 g (91%).  1H-NMR (DMSO-d6 
-300 MHz Varian Unity): δ  7.24 (2H, t, J= 7.4 Hz), 7.16 (3H, m), 3.71 (1H, t, J= 5.4 
Hz), 3.10 (6H, s), 2.54 (2H, m), 1.95 (2H, m), 1.57 (2H, m).  13C-NMR (DMSO-d6 -300 
MHz Varian Unity): δ 166.6, 164.6, 147.6, 137.4, 124.1, 121.6, 44.3, 30.8, 24.5, 24.0, 
23.8 ppm.  MS (CI+-NH3) 156 (45%, dmba), 170 (80%, C7H9+), 274 (20%, M+).  
 
5-[3-(4-Dimethylamino-phenyl)-propyl]-1,3-dimethylpyrimidine-2,4,6-trione (B12) 
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and 4-(dimethylamino)cinnamaldehyde 
(1.75 g, 10 mmol) were refluxed in methanol with 2 drops sulfuric acid (100 mL) for 30 
minutes.  The reaction suspension was cooled to room temperature and 5% Pd-C with 
50% water (0.100 g) was added, together with benzene (50 mL) and hydrogenated at 30 
psi for 4 hours.  The catalyst was separated by filtration and the solvent was evaporated 
to a solid residue.  The solid residue was re-dissolved in methanol (10 mL) and diluted 
with water (300 mL).  The white precipitate was separated by filtration and dried in the 
air to give 2.99 g (94%) pure product.  1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 
6.960 (2H, d, J= 7.8 Hz), 6.628 (2H, d, J= 8.7 Hz), 3.157 (2H, s), 2.816 (6H, s), 2.787 
(6H, s), 2.402 (2H, m), 1.484 (2H, m).  13C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 
164.2, 147.7, 145.4, 125.6, 119.9, 108.0, 45.0, 36.1, 24.4, 24.1, and 21.3 ppm. 
 
Synthesis of 5-(1H-Indol-3-ylmethyl)-1,3-dimethyl-pyrimidine-2,4,6-trione (B13)   
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and indole-3-carboxaldehyde (1.45 g, 10 
mmol) were refluxed in methanol (100 mL) for 30 minutes.  The reaction suspension was 
cooled to room temperature and 5% Pd-C with 50% water (0.100 g) was added, together 
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with benzene (50 mL) and hydrogenated at 30 psi for 4 hours.  The catalyst was separated 
by filtration and the solvent was evaporated to a solid residue.  The solid residue was re-
dissolved in methanol (10 mL) and diluted with water (300 mL).  The formed precipitate 
was separated by filtration and dried in the air to give 2.70 g (95%).  1H-NMR (DMSO-d6 
-300 MHz Varian Unity): δ 10.87 (1H, s, NH), 7.32 (1H, t, J= 6.0 Hz), 7.28 (1H, s), 7.03 
(1H, t, J= 5.6 Hz), 6.95 (2H, m), 3.89 (1H, t, J= 3.5 Hz), 3.43 (2H, d, J= 3.6 Hz), 2.87 
(6H, s).  13C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 165.5, 147.6, 132.2, 123.0, 
120.0, 117.4, 114.7, 114.5, 107.8, 104.9, 46.8, 24.2, and 23.6 ppm. 
 
Synthesis of 5-(4-Hydroxy-benzyl)-1,3-dimethylpyrimidine-2,4,6-trione (B14) 
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and 4-hydroxybenzaldehyde (1.22 g, 10 
mmol) were refluxed in methanol (100 mL) for 30 minutes.  The reaction suspension was 
cooled to room temperature and 5% Pd-C with 50% water (0.100 g) was added, together 
with benzene (50 mL) and hydrogenated at 30 psi for 4 hours.  The catalyst was separated 
by filtration and the solvent was evaporated to a solid residue.  The solid residue was re-
dissolved in methanol (10 mL) and diluted with water (300 mL).  The formed precipitate 
was separated by filtration and dried in the air to give 2.38 g (91%) product.  1H-NMR 
(DMSO-d6 -300 MHz Varian Unity): δ 9.26 (1H, s, OH), 6.78 (2H, d, J= 8.4 Hz), 6.58 
(2H, d, J= 8.4 Hz), 3.84 (2H, s), 2.97 (6H, s).  13C-NMR (DMSO-d6 -300 MHz Varian 
Unity): δ 165.0, 152.7, 147.6, 126.0, 122.6, 111.5, 47.1, 32.2, 24.2 ppm. 
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Synthesis of 5-(4-Hydroxy-benzyl)-pyrimidine-2,4,6-trione (B15)  
Barbituric acid (1.28 g, 10 mmol), and 4-hydroxybenzaldehyde (1.22 g, 10 mmol) were 
refluxed in methanol (100 mL) for 30 minutes.  The reaction suspension was cooled to 
room temperature and 5% Pd-C with 50% water (0.100 g) was added, together with 
benzene (50 mL) and hydrogenated at 30 psi for 4 hours.  The catalyst was separated by 
filtration and the solvent was evaporated to a solid residue.  The solid residue was re-
dissolved in methanol (10 mL) and diluted with water (300 mL).  The formed precipitate 
was separated by filtration and dried in the air to give 2.2 g (94%) product.  1H-NMR 
(DMSO-d6 -300 MHz Varian Unity): δ 6.85 (2H, d, J= 8.1 Hz), 6.62 (2H, d, J= 8.1 Hz), 
3.73 (1H, broad t), 3.15 (2H, d, J= 3.9 Hz).  13C-NMR (CF3COOH- DMSO-d6 -300 MHz 
Varian Unity): δ 169.6, (162.2, 161.7, 161.1, 160.5-belonging to TFA), 152.4, 134.7, 
120.6, 116.8, 113.1, 109.3, and 38.2 ppm. 
 
Synthesis of 5-(2-Hydroxy-benzyl)-pyrimidine-2,4,6-trione (B16)   
Barbituric acid (1.28 g, 10 mmol), and 2-hydroxybenzaldehyde (1.22 g, 10 mmol) were 
refluxed in methanol (100 mL) for 10 minutes.  The reaction suspension was cooled to 
room temperature and 5% Pd-C with 50% water (0.100 g) was added, together with 
benzene (50 mL) and hydrogenated at 30 psi for 4 hours.  The catalyst was separated by 
filtration and the solvent was evaporated to a solid residue.  The solid residue was re-
dissolved in methanol (10 mL) and diluted with water (300 mL).  The white precipitate 
was separated by filtration and dried in the air to give 1.75 g (75%) of 5-(2-Hydroxy-
benzyl)-pyrimidine-2,4,6-trione. 1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 11.11 
(2H, s, NH), 9.41 (1H, broad s, OH), 6.97 (1H, t, J= 7.4 Hz), 6.88 (1H, d, J= 7.5 Hz), 
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6.71 (1H, d, J= 7.8 Hz), 6.64 (1H, t, J= 7.4 Hz), 3.78 (1H, t, J= 5.4 Hz), 3.14 (2H, d, J= 
5.4 Hz).  13C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 166.6, 151.7, 147.5, 126.5, 
123.9, 120.1, 115.1, 111.2, 84.0, 44.3, 25.3 ppm. 
 
General Procedure F: Preparation of C-5 dibenzylated barbituric acids: 
Preparation of 5,5-di(benzyl)barbituric acid (B17) 
A mixture of barbituric acid (0.64 g, 5.0 mmol) and benzaldehyde (1.59 g, 15 mmol) in 
methanol (100 mL) was refluxed for 15 minutes.  The reaction mixture changed from a 
suspension (low solubility of barbituric acid) to a clear solution, and then again to a new 
suspension.  Into this suspension, 5% Pd-C with 50% water (0.150 g) was added and the 
suspension was hydrogenated at 30 psi at room temperature overnight (14h).  The catalyst 
was separated by filtration and the methanol volume was evaporated to a reduced volume 
(10 mL).  Water was added (100 mL) and the resulting solid precipitate was separated by 
filtration and washed with carbon tetrachloride (3×50 mL), and dried on the air to give 
5,5-di(benzyl)barbituric acid (1.31 g, 86%).  The product decomposed at temperatures 
above 200º C.   1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 11.21 (2H, s, NH), 7.24 
(6H, m), 7.03 (4H, d, J=   5.7 Hz), 3.27 (4H, s).  13C-NMR (DMSO-d6 -300 MHz Varian 
Unity): δ 167.9, 144.8, 131.0, 125.2, 124.4, 123.3, 54.9, 39.7 ppm.  MS (CI+-NH3) m/z 
309 (100%, M+1). 
 
Preparation of 5,5-di(4-dimethyl-aminobenzyl)barbituric acid (B18) 
A mixture of barbituric acid (0.64 g, 5.0 mmol) and 4-dimethylaminobenzaldehyde (2.44 
g, 15 mmol) in methanol (100 mL) was refluxed for 15 minutes.  The reaction mixture 
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changed from a suspension (low solubility of barbituric acid) to a clear solution, and then 
again to a new suspension.  Into this suspension, 5% Pd-C with 50% water (0.150 g) was 
added and the suspension was hydrogenated at 30 psi at room temperature overnight 
(14h).  The catalyst was separated by filtration and the methanol volume was evaporated 
to a reduced volume (10 mL).  Water was added (100 mL) and the resulting solid 
precipitate was separated by filtration and washed with carbon tetrachloride (3 x 50 mL), 
and dried on the air to give 5,5-di(4-dimethyl-aminobenzyl)barbituric acid (1.87 g, 95%).  
The product decomposed at temperatures above 230º C.  1H-NMR (DMSO-d6 -300 MHz 
Varian Unity): δ 11.09 (2H, s, NH), 6.84 (4H, d, J= 8.7 Hz), 6.57 (4H, d, J= 8.7 Hz), 
3.10 (4H, s), 2.81 (12H, s,).  13C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 169.1, 
145.8, 145.7, 126.3, 118.7, 108.6, 56.1, 39.6, 36.5 ppm.  MS (EI): m/z 134 (100%, 
N(CH3)2C6H4CH2+), 261 (12%, M-(N(CH3)2C6H4CH2+), 394 (48%, M+).  Anal. Calcd.  
for C22H26N4O3:  C, 66.99; H, 6.64; N, 14.20.  Found: C, 66.55; H, 6.85; N, 13.97. 
 
General Procedure G:  Preparation of C-5-non-symmetric double alkylated barbituric 
acids:  
Synthesis of 5-(4-dimethylanimobenzyl)-5-(3-phenylpropyl)barbituric acid (B19).  A 
suspension of barbituric acid (0.64 g, 5.0 mmol) and cinnamaldehyde (0.66 g, 5.0 mmol) 
in methanol (100 mL) was heated at 80º C for 2 hours.  The reaction suspension was 
cooled to room temperature and 4-dimethylaminobenzaldehyde (0.75 g, 5 mmol) and 5% 
Pt-C (0.5 g) with 67% water content was added.  The suspension was hydrogenated at 70 
psi at room temperature for 4 hours.  The catalyst was separated by filtration, and the 
filtrate concentrated to a volume of 10 mL.  The concentrated solution was diluted with 
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water (200 mL), and the resulting white precipitate was separated by filtration and dried 
on the air to afford 1.55 g (79%) of pure product. m.p.>250º C with decomp. 1H-NMR 
(DMSO-d6 -300 MHz Varian Unity): δ 7.24 (2H, t, J= 5.7 Hz), 7.20 (1H, t, J= 5.4 Hz), 
7.11 (2H, d, J= 5.7 Hz), 6.77 (2H, d, J= 5.7 Hz), 6.5 4(2H, d, J= 5.7 Hz), 2.98 (2H, s), 
2.79 (6H, s), 2.51 (2H, t, J= 5.4 Hz), 1.91 (2H, m), 1.35(2H, m).  13C-NMR (DMSO-d6 -
300 MHz Varian Unity): δ 169.6, 146.2, 146.2, 137.9, 126.5, 125.1, 125.0, 122.7, 118.8, 
108.8, 54.0, 40.4, 34.3, 31.5, 23.2 ppm.  Anal. Calcd.  for C22H25N3O3:  C, 66.64; H, 6.64; 
N, 11.07.  Found: C, 66.32; H, 6.88; N, 10.83. 
 
General Procedure H: 
Synthesis of 5-(cyclohexylmethyl)barbituric acid (C1).  Into a methanol (100 mL) 
suspension of barbituric acid (0.940 g, 7.35 mmol) and 4-methoxybenzaldehyde (1.00 g, 
7.35 mmol), concentrated hydrochloric acid (100 mL) and 5% Pt-C with 50% water (1.30 
g) were added.  The resulting suspension was shaken under hydrogen pressure (70 psi) 
for 5 hours.  The catalyst was separated by filtration and the filtrate was concentrated to 
50 mL and diluted with water (100 mL).  The formed white precipitate was separated by 
filtration and purified by crystallization from methanol, yielding 1.47 g (89%).  Product 
decomposes at temperatures above 170º C.  1H-NMR (DMSO-d6 -300 MHz Varian 
Unity): δ 11.13 (2H, s, NH), 3.15 (1H, t, J= 8.7 Hz), 1.75 (2H, t, J= 6.0 Hz), 1.61 (4H, 
m), 1.20 (1H, m), 1.10 (4H, m), 0.834 (2H, m).  13C-NMR (DMSO-d6 -300 MHz Varian 
Unity): δ 167.2, 147.3, 42.3, 31.6, 31.2, 28.9, 22.3, 22.1 ppm. 
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Preparation of 5-(cyclohexylmethyl)-1-methylbarbituric acid (C2)   
Into a methanol (100 mL) suspension of 1-methylbarbituric acid (1.16 g, 8.20 mmol) and 
4-hydroxybenzaldehyde (1.00 g, 8.20 mmol), concentrated hydrochloric acid (100 mL) 
and 5% Pt-C with 50% water (1.30 g) were added.  The resulting suspension was shaken 
under hydrogen pressure (70 psi) for 5 hours.  The catalyst was separated by filtration and 
the filtrate was concentrated to 50 mL and diluted with water (100 mL).  The formed 
white precipitate was separated by filtration and purified by crystallization from 
methanol, yielding 1.64 g (84%) pure product. Product decomposes at temperatures 
above 170º C.  1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 11.31 (1H, s, NH), 3.54 
(1H, t, J= 6.0 Hz), 3.04 (3H, s), 1.76 (2H, t, J= 6.3 Hz), 1.60 (5H, m), 1.09 (2H, m), 0.83 
(4H, m).  13C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 168.4, 167.6, 146.7, 71.5, 
43.1, 30.1, 28.8, 24.1, 22.2, 22.1 ppm. 
 
Preparation of 5-(cyclohexylmethyl)-1-phenylbarbituric acid (C3).  Into a methanol 
(100 mL) suspension of 1-phenylbarbituric acid (1.50 g, 7.35 mmol) and 4-
methoxybenzaldehyde (1.00 g, 7.35 mmol), concentrated hydrochloric acid (100 mL) and 
5% Pt-C with 50% water (1.00 g) were added.  The resulting suspension was shaken 
under hydrogen pressure (70 psi) for 5 hours.  The catalyst was separated by filtration and 
the filtrate was concentrated to 50 mL and diluted with water (100 mL).  The formed 
white precipitate was separated by filtration and purified by crystallization from 
methanol, yielding 2.05 g (93%). Product decomposes at temperatures above 200º C. 1H-
NMR (DMSO-d6 -300 MHz Varian Unity): δ 11.70 (1H, s, NH), 7.41 (3H, m), 7.19 (2H, 
broad singlet), 3.73 (1H, t, J=  6.7 Hz), 1.85 (2H, t, J= 6.7 Hz), 1.63 (5H, m), 1.12 (4H, 
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m), 0.855 (2H, m).  13C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 167.5, 167.0, 
145.8, 130.7, 124.9, 124.7, 124.4, 71.5, 42.6, 29.6, 28.3, 26.6, 21.6 ppm. 
 
Synthesis of 5-(cyclohexylmethyl)-1,3-dimethylbarbituric acid (C4).  MW 252.31  
Into a methanol (100 mL) suspension of 1,3-dimethylbarbituric acid (1.27 g, 8.20 mmol) 
and 4-hydroxybenzaldehyde (1.00 g, 8.20 mmol), concentrated hydrochloric acid (100 
mL) and 5% Pt-C with 50% water (1.30 g, 2 molar percent) were added.  The resulting 
suspension was shaken under hydrogen pressure (70 psi) for 5 hours.  The catalyst was 
separated by filtration and the filtrate was concentrated to 50 mL and diluted with water 
(100 mL).  The formed white precipitate was separated by filtration and purified by 
crystallization from methanol, yielding 1.82 g (88%) pure product.  Product decomposes 
at temperatures above 150º C. 1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 3.66 (1H, 
t, J= 6.0 Hz), 3.10 (6H, s), 1.79 (2H, t, J= 6.6 Hz), 1.63 (4H, m), 1.45 (1H, m), 1.12 (4H, 
m), 0.83 (2H, m).  13C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 165.4, 148.1, 42.8, 
32.7, 31.1, 28.8, 24.5, 22.4, 22.0 ppm.  MS (EI): m/z 83 (93%, C6H11+), 97 (30%, 
C6H11CH3+), 157 (100%, dmba + 1), 169 (80%, M-C6H11+), 252 (15%, M+).  Anal. Calcd.  
for C13H20N2O3:  C, 61.88; H, 7.99; N, 11.10.  Found: C, 61.63; H, 5.11; N, 11.02.  
Crystals were obtained by crystallization from methanol by allowing slow solvent 
evaporation.  Crystal data: Mr = 252.31, monoclinic space group P21, a = 24.369(3), b = 
6.3025(8), c = 18.301(2) Å, β + 11.449(2)º, V = 2616.0(6) Å3, Z = 8, ρCalcd.  1.281 Mgm-3, 
F000 = 1088, wavelength (λ) = 0.71073 Å, absorption coefficient (µ) = 0.091 mm-1. 
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Method I: Preparation procedure for formylation of barbituric acid with chloroform.  
The Reimer-Tiemann Reaction.  
Preparation of 5-formyl-1,3-dimethylbarbituric acid (D1) 
Into a 50% ethanol (400 mL) solution of potassium hydroxide (84.0 g, 1.50 mol), the 
chloroform solution of  1,3-dimethylbarbituric acid (33.6 g, 0.20 mol) was added.  The 
rreaction is exothermic, and is controlled by an ice-water bath.  A yellow precipitate 
forms almost immediately.  The reaction mixture was stirred at room temperature for an 
additional 3 hours, then cooled in ice water (5º C).  The solid was separated by filtration 
and slurred in water (100 mL), and the pH was adjusted to ~3 by adding concentrated 
hydrochloric acid.  After cooling at 5º C for 1 hour, the solid was again separated by 
filtration, washed with acetone (3×20 mL) and dried at 110º C for 0.5 hours, resulting in 
isolation of pure product.  If necessary, further purification can be performed using a 
small amount of water-ethanol mixture.  The yield of isolated product was 27.6 g (75%). 
Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6-D2O; 5:1-500 
MHz Varian Unity): δ 9.63 (1H, s), 3.04 (6H, s).  13C-NMR (DMSO-d6- D2O; 5:1-500 
MHz Varian Unity): δ 188.2, 148.5, 147.2, 97.0, 24.0 ppm.  MS (EI): m/z 156 (39%, M-
CO)+, 169 (28%, M-CH3)+, 184 (20%, M+).  Anal. Calcd.  for C7H8N2O4 (MW 184.15):  
C, 45.66; H, 4.38, N, 15.21.  Found: C, 45.34; H, 4.65; N, 15.02. 
 
Synthesis of 5-formylbarbituric acid (D2)  
Into a 50% ethanol (400 mL) solution of potassium hydroxide (84.0 g, 1.50 mol), the 
chloroform solution of barbituric acid (25.6 g, 0.20 mol) was added.  The reaction is 
exothermic, and is controlled by an ice-water bath.  A yellow precipitate forms almost 
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immediately.  The reaction mixture was stirred at room temperature for an additional 3 
hours, then cooled in ice water (5º C).  The solid was separated by filtration and slurred in 
water (100 mL), and the pH was adjusted to ~3 by adding concentrated hydrochloric acid.  
After cooling at 5º C for 1 hour, the solid was again separated by filtration, washed with 
acetone (3×20 mL) and dried at 110º C for 0.5 hours, resulting in isolation of pure 
product.  If necessary, further purification can be performed using a small amount of 
water-ethanol mixture.  The yield of isolated product was 14.0 g (45%). Product 
decomposes at temperatures above 250º C.  1H-NMR (D2O:DMSO-d6  (2:1) 500 MHz 
Varian Unity): δ 9.78 (2H, s, NH), 8.59 (1H, s, HCO).  13C-NMR (D2O:DMSO-d6  (2:1) 
500 MHz Varian Unity): δ 185.3, 150.6, 145.3, and 95.6 ppm. 
 
Synthesis of 5-formyl-1-phenylbarbituric acid (D3)  
Into a 50% ethanol (400 mL) solution of potassium hydroxide (84.0 g, 1.50 mol), the 
chloroform solution of barbituric acid (40.8 g, 0.20 mol) was added.  The reaction is 
exothermic, and is controlled by an ice-water bath.  A yellow precipitate forms almost 
immediately.  The reaction mixture was stirred at room temperature for an additional 3 
hours, then cooled in ice water (5º C).  The solid was separated by filtration and slurred in 
water (100 mL), and the pH was adjusted to ~3 by adding concentrated hydrochloric acid.  
After cooling at 5º C for 1 hour, the solid was again separated by filtration, washed with 
acetone (3×20 mL) and dried at 110º C for 0.5 hours, resulting in isolation of pure 
product.  If necessary, further purification can be performed using a small amount of 
water-ethanol mixture.  The yield of isolated product was 31.1 g (67%). Product 
decomposes at temperatures above 200º C. 1H-NMR (D2O:DMSO-d6  (2:1) 500 MHz 
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Varian Unity): δ 11.38 (1H, s, NH), 7.41 (5H, broad m, Ph), 3.70 (1H, s, CH).  13C-NMR 
(D2O:DMSO-d6  (2:1) 500 MHz Varian Unity): δ 163.3, 163.0, 148.2, 145.3, 131.2, 
125.5, 125.4, 125.2, and 124.7 ppm. 
 
Method J:  Preparation for acetylbarbiturates.  
Preparation of 5-acetylbarbituric acid (D4)    
A mixture of barbituric acid (12.8 g, 0.10 mol) and acetic anhydride (300 mL) with a few 
drops of concentrated sulfuric acid was refluxed for 1 hour.  In the beginning the reaction 
is a suspension, but quickly becomes solution.  The reaction mixture was concentrated to 
½ the original volume and cooled at 5º C, in an ice water bath.  The formed solid was 
separated by filtration, washed with hot water (3×25 mL), then acetone (3×25 mL), and 
dried at 80º C for 30 minutes, yielding 16.1 g product (95%). Product decomposes at 
temperatures above 250º C.1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 11.76 (1H, s, 
NH), 11.03 (1H, s, NH), 2.56 (3H, s, H3C).  13C-NMR (DMSO-d6 -300 MHz Varian 
Unity): δ 191.3, 168.1, 158.7, 145.5, 91.9, and 20.3 ppm.  MS (ESI+) in methanol with 
0.1% acetic acid.  215.2 (M+2Na) and 251.1 (M+Na+HOAc). 
 
Synthesis of 5-acetyl-1-phenylbarbituric acid (D5)  
A mixture of 1-phenylbarbituric acid (20.4 g, 0.10 mol) and acetic anhydride (300 mL) 
with a few drops of concentrated sulfuric acid was refluxed for 1 hour.  In the beginning 
the reaction is a suspension, but quickly becomes solution.  The reaction mixture was 
concentrated to ½ the original volume and cooled at 5º C in an ice water bath.  The 
formed solid was separated by filtration, washed with hot water (3×25 mL), then acetone 
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(3×25 mL), and dried at 80º C for 30 minutes, yielding 16.0 g (65%) pure product.  
Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6 -300 MHz 
Varian Unity): δ 11.48 (1H, s, NH), 7.39 (5H, broad m, phenyl ring), 3.71 (1H, s, CH), 
2.58 (3H, s, CH3).  13C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 163.1, 163.0, 147.9, 
145.5, 131.4, 125.5, 125.3, 125.2, 124.7, 20.5 ppm. 
 
Synthesis of 5-acetyl-1,3-dimethylbarbituric acid (D6) 
A mixture of 1,3-dimethylbarbituric acid (15.6 g, 0.10 mol) and acetic anhydride (300 
mL) with a few drops of concentrated sulfuric acid was refluxed for 1 hour.  In the 
beginning the reaction is a suspension, but quickly becomes solution.  The reaction 
mixture was concentrated to ½ the original volume and cooled at 5º C in an ice water 
bath.  The formed solid was separated by filtration, washed with hot water (3×25 mL), 
then acetone (3×25 mL), and dried at 80º C for 30 minutes, yielding 18.2 g product 
(92%). Product decomposes at temperatures above 190º C.  1H-NMR (DMSO-d6 -300 
MHz Varian Unity): δ 3.13 (6H, s, dmba-CH3), 2.58 (3H, s, CH3).  13C-NMR (DMSO-d6 
-300 MHz Varian Unity): δ 191.0, 165.4, 146.3, 92.2, 24.0, 20.5 ppm. 
 
Method K: Preparation for Schiff bases with ω-aminoalkanoic acids.   
Preparation of 6-[1,3-dimethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylmethylene)-
amino]-hexanoic acid (D7)   
A mixture of 5-formyl-1,3-dimethylbarbituric acid (0.92 g, 5.0 mmol) and 6-
aminohexanoic acid (0.655 g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours.  
Methanol was evaporated to a solid residue and the solid residue was re-dissolved in a 
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small amount of hot methanol (50 mL).  The solution was left at room temperature to 
slowly evaporate to 1/5 the original volume.  The formed white needles were separated 
by filtration, washed with cold methanol (3×5 mL), and dried at 60º C for 30 minutes to 
afford 1.3 g (87%) product.  1H-NMR (DMSO-d6 - D2O (3:1) 500 MHz Varian Unity): δ 
8.08 (1H, s). 3.41 (2H, d, J= 6.7 Hz), 3.08 (6H, d, J= 0.6 Hz), 2.18 (2H, t, J= 7.2 Hz), 
1.48 (4H, m), 1.21 (2H, m).  13C-NMR (DMSO-d6 - D2O (3:1) 500 MHz Varian Unity): δ 
173.0, 161.3, 160.4, 156.6, 149.4, 86.7, 47.1, 30.9, 26.7, 25.0, 24.4, 22.5, 21.3.  MS 
(ESI+) in methanol with 0.1% acetic acid: 320.1 and 320.3 (M+Na), 617 and 618.1 
(2M+Na). 
 
Synthesis of 4-[(2,4,6-Trioxo-hexahydro-pyrimidin-5-ylmethylene)-amino]-butyric acid 
(D8)  
A mixture of 5-formylbarbituric acid (0.85 g, 5.0 mmol) and 4-aminobutanoic acid (0.515 
g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours.  Methanol was evaporated 
to a solid residue and the solid residue was re-dissolved in a small amount of hot 
methanol (50 mL).  The solution was left at room temperature to slowly evaporate to 1/5 
the original volume.  The formed white needles were separated by filtration, washed with 
cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.14 g (95%) 
product.  C=C isomer recorded.  1H-NMR (DMSO-d6:D2O (5:1) 500 MHz Varian 
Unity): δ 8.83 (1H, s), 4.25 (2H, t, J= 5.3 Hz), 3.04 (2H, t, J= 5.5 Hz), 2.58 (2H, m).  
13C-NMR (DMSO-d6:D2O (5:1) 500 MHz Varian Unity): δ 171.0, 162.4, 160.5, 155.2, 
147.5, 85.9, 45.7, 27.8, and 22.3 ppm. 
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Synthesis of 6-[(2,4,6-Trioxo-hexahydro-pyrimidin-5-ylmethylene)-amino]-hexanoic 
acid (D9)   
A mixture of 5-formylbarbituric acid (0.85 g, 5.0 mmol) and 6-aminohexanoic acid 
(0.655 g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours.  Methanol was 
evaporated to a solid residue and the solid residue was re-dissolved in a small amount of 
hot methanol (50 mL).  The solution was left at room temperature to slowly evaporate to 
1/5 the original volume.  The formed white needles were separated by filtration, washed 
with cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.22 g (91%) 
product.  C=C isomer recorded.  1H-NMR (DMSO-d6:D2O (5:1) 300 MHz Varian 
Unity): δ  8.09 (1H, s), 3.43 (2H, t, J= 6.9 Hz), 2.10 (2H, t, J= 7.2 Hz), 1.51 (4H, m), 
1.26 (2H, m) ppm.  13C-NMR (DMSO-d6:D2O (5:1) 300 MHz Varian Unity): δ 171.7, 
162.4, 160.4, 155.1, 147.4, 85.7, 46.0, 31.1, 26.2, 22.0, 20.9 ppm. 
 
Synthesis of 4-[(2,4,6-Trioxo-1-phenyl-hexahydro-pyrimidin-5-ylmethylene)-amino]-
butyric acid (D10)   
A mixture of 5-formyl-1-phenylbarbituric acid (1.16 g, 5.0 mmol) and 4-aminobutanoic 
acid (0.515 g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours.  Methanol was 
evaporated to a solid residue and the solid residue was re-dissolved in a small amount of 
hot methanol (50 mL).  The solution was left at room temperature to slowly evaporate to 
1/5 the original volume.  The formed yellow needles were separated by filtration, washed 
with cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.27 g (80%) 
product.  C=C isomer recorded.  1H-NMR (DMSO-d6:D2O (5:1) 300 MHz Varian 
Unity): δ 8.10 (1H, d, J= 7.0 Hz), 7.38 (3H, m), 7.19 (2H, m), 3.48 (2H, m), 2.15 (2H, 
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m), 1.742 (2H, m).  13C-NMR (DMSO-d6:D2O (5:1) 300 MHz Varian Unity): δ 170.6, 
161.2, 159.3, 155.4, 147.3, 131.6, 125.9, 125.0, 124.4, 86.1, 45.7, 27.4, 22.1 ppm. 
 
Synthesis of 4-[1-(2,4,6-Trioxo-hexahydro-pyrimidin-5-yl)-ethylideneamino]-butyric 
acid. (D11) 
A mixture of 5-acetylbarbituric acid (0.85 g, 5.0 mmol) and 4-aminobutyric acid (0.515 
g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours.  Methanol was evaporated 
to a solid residue and the solid residue was re-dissolved in a small amount of hot 
methanol (50 mL).  The solution was left at room temperature to slowly evaporate to 1/5 
the original volume.  The formed white needles were separated by filtration, washed with 
cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.13 g (89%) 
product. C=C isomer recorded.  1H-NMR (D2O:DMSO-d6  5:1-500 mHz): δ 3.06 (2H, t, 
J= 7.5 Hz), 2.53 (3H, s, CH3), 2.51 (2H, t, J= 7.0 Hz), 1.98 (2H, m).   
 
Synthesis of 6-[1-(2,4,6-Trioxo-hexahydro-pyrimidin-5-yl)-ethylideneamino]-hexanoic 
acid (D12)  
A mixture of 5-acetylbarbituric acid (0.85 g, 5.0 mmol) and 6-aminohexanoic acid (0.65 
g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours.  Methanol was evaporated 
to a solid residue and the solid residue was re-dissolved in a small amount of hot 
methanol (50 mL).  The solution was left at room temperature to slowly evaporate to 1/5 
the original volume.  The formed white needles were separated by filtration, washed with 
cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.23 g (87%) 
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product. 13C-NMR (TFA:DMSO-d6 5:1 500 mHz): δ 200.7, 181.4, 163.3, (161.3, 160.8, 
160.2, 159.6 for TFA), 150.8, 94.5, 40.9, 32.5, 26.1, 24.5, 23.3, 22.9 ppm. 
 
Synthesis of 3-[1-(2,4,6-Trioxo-hexahydro-pyrimidin-5-yl)-ethylideneamino]-propanoic 
acid. (D13)  
A mixture of 5-acetylbarbituric acid (0.85 g, 5.0 mmol) and 3-aminopropanoic acid (0.44 
g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours.  Methanol was evaporated 
to a solid residue and the solid residue was re-dissolved in a small amount of hot 
methanol (50 mL).  The solution was left at room temperature to slowly evaporate to 1/5 
the original volume.  The formed white needles were separated by filtration, washed with 
cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.17 g (90%) 
product. C=C isomer recorded. 1H-NMR (D2O:DMSO-d6 5:1 500 mHz): δ 2.98 (2H, t, 
J=  7.5 Hz), 2.65 (2H, t, J=  7.5 Hz), 2.30 (3H. s). 
 
Method L: Preparation procedure for nitrophenylhydrazones of formylated barbituric 
acids.  
Synthesis of 5-[(4-nitrophenyl)hydrazonomethyl]-pyrimidine-2,4,6-trione (D14) 
A methanol (200 mL) suspension of 5-formylbarituric acid (1.56 g, 10 mmol) and 4-
nitrophenylhydrazine (1.53 g, 10 mmol) was refluxed overnight.  After cooling to room 
temperature, the solid was separated by filtration, slurred in hot water, washed with 
methanol and recrystallized from acetic acid (500 mL) to give 2.3 g (80%) of pure 
compound.  1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 11.22 (1H, broad singlet), 
10.84 (1H, s), 10.74 (1H, s), 9.85 (1H, s), 8.12 (2H, d, J= 9.0 Hz), 7.98 (1H, s), 6.81 (2H, 
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d, J= 9.0 Hz).  13C-NMR (DMSO-d6- 300 MHz Varian Unity): δ 155.4, 150.0, 147.1, 
136.0, 122.1, 108.227, 108.227, 87.0 ppm.  Anal. Calcd.  for C11H9N5O5 (MW 291.2): C, 
45.37; H, 3.11; N, 24.05.  Found: C, 45.04; H, 3.38; N, 23.88.  
 
Synthesis of 5-[(2,4-Dinitro-phenyl)-hydrazonomethyl]-pyrimidine-2,4,6-trione (D15) 
A methanol (200 mL) suspension of 5-formylbarituric acid (1.56 g, 10 mmol) and 2,4-
dinitrophenylhydrazine (1.98 g, 10 mmol) was refluxed overnight.  After cooling to room 
temperature, the solid was separated by filtration, slurred in hot water, washed with 
methanol and recrystallized from acetic acid (500 mL) to give 2.96 g (88%) of pure 
compound.  C=N isomer recorded.  1H-NMR (TFA:DMSO-d6 (5:1)-300 MHz Varian-
Unity): δ 10.92 (1H, s, NH), 10.87 (2H, s, NH), 8.88 (1H, d, J= 2.7 Hz), 8.40 (1H, d of d, 
J1=9.3 Hz, J2=2.7 Hz), 8.11 (1H, s), 7.24 (1H, d, J= 9.6 Hz) ppm.  13C-NMR 
(TFA:DMSO-d6 (5:1)-300 MHz Varian-Unity): δ 160.8, 155.6, 147.2, 143.8, 134.1, 
126.7, 126.4, 119.1, 112.6, 87.8 ppm. 
 
Synthesis of 5-[(4-Nitro-phenyl)-hydrazonomethyl]-1-phenyl-pyrimidine-2,4,6-trione 
(D16)  
A methanol (200 mL) suspension of 5-formyl-1-phenylbarituric acid (2.32 g, 10 mmol) 
and 4-nitrophenylhydrazine (1.53 g, 10 mmol) was refluxed overnight.  After cooling to 
room temperature, the solid was separated by filtration, slurred in hot water, washed with 
methanol and recrystallized from acetic acid (500 mL) to give 3.37 g (92%) of pure 
compound.  C=C isomer recorded.  1H-NMR (DMSO-d6 -300 MHz Varian-Unity): δ 
11.24 (2H, broad singlet, NH), 11.13 (1H, s, NH), 9.93 (1H, s), 8.13 (2H, d, J= 8.4 Hz), 
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7.42 (3H, m), 7.24 (2H, m), 6.82 (2H, d, J= 7.5 Hz) ppm.  13C-NMR (DMSO-d6 -300 
MHz Varian-Unity): δ 161.1, 159.8, 155.5, 147.9, 147.1, 136.5, 132.2, 125.7, 125.4, 
124.0, 122.2, 108.0, 86.6 ppm. 
 
Synthesis of 4-[N'-(2,4,6-Trioxo-1-phenyl-hexahydro-pyrimidin-5-ylmethylene)-
hydrazino]-benzoic acid (D17)  
A methanol (200 mL) suspension of 5-formyl-1-phenylbarituric acid (2.32 g, 10 mmol) 
and 4-hydrazinobenzoic acid (1.52 g, 10 mmol) was refluxed overnight.  After cooling to 
room temperature, the solid was separated by filtration, slurred in hot water, washed with 
methanol and recrystallized from acetic acid (500 mL) to give 3.40 g (93%) of pure 
compound.  C=C isomer recorded.  1H-NMR (DMSO-d6 -300 MHz Varian-Unity): δ 
11.40 (2H, broad s, NH), 11.09 (1H, s, NH), 9.37 (1H, s), 8.07 (2H, m), 7.80 (2H, d, J= 
8.7 Hz), 7.41 (3H, m), 6.78 (2H, d, J= 8.1 Hz) ppm.  13C-NMR (DMSO-d6 -300 MHz 
Varian-Unity): δ 164.5, 162.0, 159.9, 155.3, 147.7, 147.2, 132.1, 127.8, 125.5, 125.4, 
124.8, 118.0, 108.9, and 86.1 ppm.  
 
Synthesis of 1,3-Dimethyl-5-[(4-nitro-phenyl)-hydrazonomethyl]-pyrimidine-2,4,6-
trione (D18) 
A methanol (200 mL) suspension of 5-formyl-1,3-dimethylbarituric acid (1.84 g, 10 
mmol) and 4-nitrophenylhydrazine (1.53 g, 10 mmol) was refluxed overnight.  After 
cooling to room temperature, the solid was separated by filtration, slurred in hot water, 
washed with methanol and recrystallized from acetic acid (500 mL) to give 3.03 g (95%) 
of pure compound.  C=C isomer recorded.  1H-NMR (DMSO-d6 -300 MHz Varian-
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Unity): δ 11.40 (1H, s, NH), 11.30 (1H, s, NH), 9.95 (1H, s), 8.13 (2H, d, J= 7.8 Hz), 
6.82 (2H, d, J= 7.2 Hz), 3.18 (3H, s), 3.153 (3H, s) ppm.  13C-NMR (DMSO-d6 -300 
MHz Varian-Unity): δ 159.4, 158.1, 156.0, 149.8, 147.8, 136.1, 122.0, 108.1, 87.0, 23.8, 
23.2 ppm.   
 
Synthesis of 4-[N'-(1,3-Dimethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylmethylene)-
hydrazino]-benzoic acid (D19) 
A methanol (200 mL) suspension of 5-formyl-1,3-dimethylbarituric acid (1.84 g, 10 
mmol) and 4-hydrazinobenzoic acid (1.52 g, 10 mmol) was refluxed overnight.  After 
cooling to room temperature, the solid was separated by filtration, slurred in hot water, 
washed with methanol and recrystallized from acetic acid (500 mL) to give 2.89 g (91%) 
of pure compound.  C=C isomer recorded.  1H-NMR (DMSO-d6 -300 MHz Varian-
Unity): δ 11.27 (1H, s, NH), 11.24 (1H, s, NH), 9.36 (1H, s), 7.79 (2H, d, J= 8.4 Hz), 
6.74 (2H, d, J= 8.7 Hz), 3.14 (3H, s), 3.11 (3H, s) ppm.  13C-NMR (DMSO-d6 -300 MHz 
Varian-Unity): δ 163.6, 159.6, 158.4, 156.5, 148.1, 148.0, 127.5, 118.6, 108.4, 86.6, 24.0, 
23.4 ppm.  
 
Synthesis of 5-{1-[(4-Nitro-phenyl)-hydrazono]-ethyl}-pyrimidine-2,4,6-trione (D20)   
A methanol (200 mL) suspension of 5-acetylbarbituric acid (1.70 g, 10.0 mmol) and 4-
nitrophenylhydrazine (1.53 g, 10.0 mmol) was refluxed overnight.  After cooling to room 
temperature, the solid was separated by filtration, slurred in hot water (~15 mL) and 
washed with methanol (3×20 mL), yielding 2.23 g (73%). (C=C isomer recorded). 1H-
NMR (DMSO-d6- 300 MHz Varian Unity): δ 13.22 (1H, s, NH), 10.73 (2H, s, NH), 9.66 
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(1H, s, NH), 8.13 (2H, d, J= 9.0 Hz), 6.83 (2H, d, J= 9.0 Hz), 2.61 (3H, s, CH3).  13C-
NMR (DMSO-d6- 300 MHz Varian Unity): δ 171.5, 162.0, 148.8, 146.0, 136.0, 122.4, 
107.7, 85.6, 12.1.  
 
Synthesis of 5-{1-[(2,4-dinitrophenyl)-hydrazono]-ethyl}-pyrimidine-2,4,6-trione (D21) 
A methanol (200 mL) suspension of 5-acetylbarbituric acid (1.70 g, 10.0 mmol) and 2,4-
dinitrophenylhydrazine (1.98 g, 10.0 mmol) was refluxed overnight.  After cooling to 
room temperature, the solid was separated by filtration, slurred in hot water (~15 mL) and 
washed with methanol (3×20 mL) to give 3.01 g (86%) of pure compound.  (C=C isomer 
recorded).  1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 13.18 (1H, s, NH), 10.92 
(1H, s, NH), 10.64 (1H, s, NH), 10.546 (1H, s, NH), 8.86 (1H, d, J= 2.4 Hz), 8.34 (1H, d 
of d, J1=9.4 Hz, J2=2.4 Hz), 7.17 (1H, d, J= 9.6 Hz), 2.59 (3H, s, CH3).  
 
Synthesis of 5-{1-[(4-Nitro-phenyl)-hydrazono]-ethyl}-1-phenyl-pyrimidine-2,4,6-trione 
(D22)  
A methanol (200 mL) suspension of 5-acetyl-1-phenylbarbituric acid (2.46 g, 10.0 mmol) 
and 4-nitrophenylhydrazine (1.53 g, 10.0 mmol) was refluxed overnight.  After cooling to 
room temperature, the solid was separated by filtration, slurred in hot water (~15 mL) and 
washed with methanol (3×25 mL), yielding 3.20 g, (84%) pure product.  (C=C isomer 
recorded).  1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 13.19 (1H, s, NH), 11.13 
(1H, s, NH), 9.72 (1H, s, NH), 8.14 (2H, d, J= 9.3 Hz), 7.41 (3H, m), 7.24 (2H, d, J= 7.2 
Hz), 6.84 (2H, d, J= 9.3 Hz), 2.62 (3H, s, CH3).  13C-NMR (DMSO-d6- 300 MHz Varian 
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Unity): δ 171.8, 148.7, 146.0, 136.0, 125.7, 125.3, 125.1, 125.0, 124.6, 124.2, 122.4, 
107.8, 85.9, and 12.5 ppm. 
 
Synthesis of 5-{1-[(2,4-Dinitro-phenyl)-hydrazono]-ethyl}-1-phenyl-pyrimidine-2,4,6-
trione (D23)  
A methanol (200 mL) suspension of 5-acetyl-1-phenylbarbituric acid (2.46 g, 10.0 mmol) 
and 2,4-dinitrophenylhydrazine (1.98 g, 10.0 mmol) was refluxed overnight.  After 
cooling to room temperature, the solid was separated by filtration, slurred in hot water 
(~15 mL) and washed with methanol (3×20 mL), yielding 3.45 g, (81%) pure product.  
(C=C isomer recorded).  1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 13.10 (1H, s, 
NH), 11.12 (1H, s, NH), 10.60 (1H, s, NH), 8.87 (1H, d, J= 2.7 Hz), 8.37 (1H, d of d, J1= 
9.3 Hz, J2= 2.4 Hz), 7.42 (3H, m), 7.24 (3H, m), 2.61 (3H, s CH3).  
 
Synthesis of 1,3-Dimethyl-5-{1-[(4-nitro-phenyl)-hydrazono]-ethyl}-pyrimidine-2,4,6-
trione. (D24)  
A methanol (200 mL) suspension of 5-acetyl-1,3-dimethylbarbituric acid (1.98 g, 10.0 
mmol) and 4-nitrophenylhydrazine (1.53 g, 10.0 mmol) was refluxed overnight.  After 
cooling to room temperature, the solid was separated by filtration, slurred in hot water (5 
mL) and washed with methanol (3×20 mL), yielding 2.08 g (63%) pure product. (C=C 
isomer recorded).   1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 13.25 (1H, s, NH), 
9.73 (1H, s, NH), 8.12 (2H, d, J= 9.3 Hz), 6.82 (2H, d, J= 9.3 Hz), 3.15 (6H, s, dmba-
CH3), 2.63 (3H, s, CH3).   
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Synthesis of 5-{1-[(2,4-Dinitro-phenyl)-hydrazono]-ethyl}-1,3-dimethyl-pyrimidine-
2,4,6-trione (D25)  
A methanol (200 mL) suspension of 5-acetyl-1,3-dimethylbarbituric acid (1.98 g, 10.0 
mmol) and 2,4-dinitrophenylhydrazine (1.98 g, 10.0 mmol) was refluxed overnight.  
After cooling to room temperature, the solid was separated by filtration, slurred in hot 
water (~15 mL) and washed with methanol (3×20 mL), yielding 3.17 g (84%) pure 
product.  (C=C isomer recorded).  1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 
13.23 (1H, s, NH), 10.62 (1H, s, NH), 8.86 (1H, d, J= 2.7 Hz), 8.36 (1H, d of d, J1= 9.6 
Hz, J2= 2.4 Hz), 7.16 (1H, d, J= 9.3 Hz), 3.16 (6H, s, dmba-CH3), 2.63 (3H, s, CH3).  
13C-NMR (DMSO-d6- 300 MHz Varian Unity): δ 172.4, 161.6, 146.9, 143.3, 134.2, 
127.2, 126.7, 119.2, 111.7, 86.7, 24.1, 13.1 ppm. 
 
General Procedure M; 
Preparation of 5,5’-(4-dimethylaminobenzylidene)dibarbituric acid (E1) 
Into a clear trifluoroacetic acid solution (30 mL) of barbituric acid (0.270 mg; 0.0021 
mol), 4-dimethylaminobenzaldehyde (0.149g 0.001mol) was added.  Clear reaction 
mixture was left at room temperature and the solvent was slowly evaporated at room 
temperature almost to dryness (eight days).  Formed white crystalline product was 
separated by filtration and washed with trifluoroacetic acid.  The yield of the product is 
0.37 g (95%).  This compound is very sensitive to elevated temperature and other 
solvents that are not strong acids, such as alcohol.  It immediately decomposes to 
barbituric acid and the benzylidene product.  It is stable in crystalline form and in strong 
acid at room temperature.  The trifluoromethanesulfonic acid solution was stable for 
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several months at 0º C.  The NMR spectra were recorded in CF3SO3H with three drops of 
DMSO-d6 as an internal standard and source of the deuterium lock signal. Product 
decomposition occurs at temperatures above 285º C.  1H-NMR(CF3SO3H-DMSO-d6, 300 
MHz) δ 7.57 (1H, broad singlet), 6.94 (2H, d, J= 8.7 Hz), 6.87 (2H, d, J= 8.4 Hz), 5.48 
(1H, s), and 2.71 (6H, d, J= 5.1 Hz); 13C-NMR(CF3SO3H-DMSO-d6, 300 MHz) δ 167.6, 
and 152.8 (two carbonyl carbons), 143.9, 138.0, 131.7, and 122.7 (four aromatic 
carbons), 95.5 (benzyl carbon), 49.8 (two dimethylamino carbons), and 34.2 ppm 
(barbituric acid C-5 carbon). 
 
Preparation of 5,5’-(4-nitrobenzylidene)dibarbituric acid (E2) 
Into a clear trifluoroacetic acid solution (30 mL) of barbituric acid (0.270 mg; 
0.0021mol), p-nitrobenzaldehyde (151 mg; 1 mmol) was added.  The clear reaction 
mixture was left at room temperature for solvent to slowly evaporate.  A hard white 
precipitate was formed.  Solid was separated by fitration, washed with cold trifluoroacetic 
acid (3×3 mL), with methanol (3×10 mL), and dried in vacuum at 60º C for three hours to 
afford pure white product in 87% yield (340 mg).  Compound decomposes in neutral 
solvents such as DMSO.  In this solvent an equilibrium is established between 
dibarbiturate and its decomposition products, free barbituric acid and 5-(4-
nitrobenzylidene)pyrimidine-2,4,6-trione.  The amount of 5-(4-
nitrobenzylidene)pyrimidine-2,4,6-trione can be diminished if the concentration of 
barbituric acid is increased in the solution.  On the other hand, the acetic acid solution is 
sufficiently stable that 1H-NMR spectra can be recorded.  Product decomposes at 
temperatures above 200º C.  1H-NMR (CF3SO3H-DMSO-d6, 300 MHz) δ 7.66 (2H, d, J= 
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7.5Hz, 3H-benzene hydrogens), 6.88 (2H, d, J= 7.5 Hz, benzene 2H hydrogens), and 
5.49 ppm (1H, benzyl hydrogen).  13C-NMR (CF3SO3H-DMSO-d6, 300 MHz) δ 167.7 
and 152.5 (two different barbituric acid carbonyls), 148.6, 144.8, 130.6, and 127.1 (four 
aromatic carbons), 127.0, 122.8, 118.6, 114.5 (quartet from solvent – CF3SO3H), 94.9 
(benzyl carbon, and 34.8 ppm (barbituric C-5 carbon). 
 
Preparation of 5,5’-(4-nitrobenzylidene)di(1,3-dimethylbarbituric acid) (E2a) 
A trifluoroacetic acid solution (30 mL) of 1,3-dimethylbarbituric acid (328 mg; 2.1 
mmol) and 4-nitrobenzaldehyde (151 mg; 1 mmol) was left at room temperature for 
solvent to slowly evaporate for four days.  In this period the volume of the solvent was 
reduced to approximately 10 mL and a hard white solid was formed.  Solid was separated 
by filtration, washed with ice-cold trifluoroacetic acid (3× 2mL), ice-cold methanol (3×3 
mL) and dried on open air to afford 365 mg (82%) pure product.  This compound has 
very low solubility in DMSO, and it is temperature sensitive.  The NMR sample was 
prepared in ice-cold trifluoromethanesulfonic acid by keeping a suspension of 70 mg/0.7 
mL of CF3SO3H at room temperature for approximately one hour.  Two drops of DMSO-
d6 were added as both internal reference signal as well as solvent for the NMR signal 
lock. Product melting point is 179.2-181.1º C.  1H-NMR (CF3SO3H-DMSO-d6, 300 
MHz), δ 7.67 (2H, d, J= 8.4 Hz, 3H aromatic hydrogens), 6.85 (2H, d, J= 8.4Hz, 2H 
aromatic hydrogens), 5.50 (1H, s, benzyl hydrogen), 3.05 ppm (12H, s, methyl 
hydrogens).  13C-NMR (CF3SO3H-DMSO-d6, 300 MHz) δ 166.2, 153.8 (two different 
carbonyls), 148.8, 144.0, 130.5, 127.4 (four aromatic carbons), 127.0, 122.8, 118.6, and 
144.4 (quartet from CF3SO3H), 96.2 (benzyl carbon), 37.3 (barbituric C-5 carbon), and 
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34.0 ppm (methyl carbons).  Anal. Calcd.  for C19H19N5O8: C, 51.24; H, 4.30; N, 15.72 
Found: C, 51.15; H, 4.43; N, 15.61. 
 
Preparation of 5,5’-(4-quinolidinylmethylene)dibarbituric acid (E3).  4-
Quinolinecarboxaldehyde (0.160 g; 0.001 mol) was added into refluxing methanol (400 
mL) solution of barbituric acid (0.256 g; 0.002 mol).  Reaction mixture was refluxed for 
three hours and the volume was reduced to 1/5 by evaporation of methanol at 
atmospheric pressure.  Solid product was separated by filtration, washed with ice-cold 
methanol (3×30 mL) and dried at 110º C for three hours to give 0.36 g (91%) product.  
Product decomposes at temperatures e×ceeding 280º C.  1H-NMR(DMSO-d6, 300 MHz) 
δ 10.32 (4H, s, NH), 9.09 (1H, d, J= 0.020, quinoline 2-H), 8.48 (1H, d, J= 0.030, 
quinoline 8-H), 8.15 (1H, d, J= 0.029, quinoline 5-H), 8.03 (1H, t, J= 0.024, quinoline 7-
H), 8.40 (1H, t, J= 0.021, quinoline 6-H), 7.83 (1H, d, J= 0.019, quinoline 3-H), and 6.76 
ppm (1H, s, benzyl H);  13C-NMR (DMSO-d6, 300 MHz) δ 161.1 and 161.0 (two 
different carbonyl carbons), 146.8, 139.9, 133.8, 130.0, 125.4, 123.6, 121.9, 117.9, 117.6 
(nine quinoline carbons), 86.4 (benzyl carbon), and 27.4 ppm (barbituric C-5).  Anal. 
Calcd.  for C22H21N5O6: C, 58.53; H, 4.69; N, 15.51 Found: C, 58.35; H, 4.81; N, 15.42. 
 
Preparation of 2,2’-di[4,4’-di(2,4,6-trioxa-3,5-diazacyclohexyl)methyl]pyridine (E4).  
Into a clear trifluoroacetic acid solution (30 mL) of barbituric acid (0.320 g; 0.0025 mol) 
the trifluoroacetic acid solution (5 mL) of 2,2’-bipyridine-4,4’-carboxaldehyde (0.106 
mg; 0.0005 mol) was kept at room temperature for three days.  Formed white precipitate 
was separated by filtration, washed with trifluoroacetic acid (3×1 mL), methanol 
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(3×5mL) and dried in vacuum at 90º C for one hour to afford 0.330 g (97%) of pure 
product. Product decomposition occurs at temperatures exceeding 290º C.  1H-NMR 
(DMSO-d6, 300 MHz) δ 10.32 (8H, s, NH), 8.60 (2H, d, J= 5.4Hz, 6H of pyridine ring), 
8.03 (2H, s, 3H of pyridine ring) 7.47 (2H, d, J= 5.4Hz, 5H of pyridine ring), and 6.06 
(2H, s, benzyl hydrogen). 13C-NMR (DMSO-d6, 300 MHz) δ 161.4 and 158.6 (two 
barbituric acid carbonyls), 147.3, 144.4, 142.4, 121.8, and 118.4 (five pyridine 
carbonyls), 84.5 and 29.1 ppm (two aliphatic carbons). MS-ES+ (CH3COOH) m/z 115 
(100%), 277 (50%), 387 (45%), 483 (83%), 505 (43%), and 689 (M+1, 70%).  Anal. 
Calcd.  for C28H20N10O12: C, 48.84; H, 2.93; N, 20.34 Found: C, 48.74; H, 2.98; N, 20.22. 
  
Preparation of 2,2’-di[4,4’-di(2,4,6-trioxa-3,5-diaza-3,5-
dimethylcyclohexyl)methyl]pyridine (E5) 
A trifluoroacetic acid (50 mL) solution of 2,2’-bipyridine-4,4’-carboxaldehyde (0.106 g; 
0.0005 mmol) and 1,3-dimethylbarbituric acid (0.343 g; 0.0022 mol) was kept at room 
temperature for three days.  Solvent was evaporated to dryness.  Solid material was 
crystallized from large amount of methanol to produce pure product in 92% (0.370 mg) 
yield.  If necessary, further purification can be obtained by crystallization from a small 
amount of acetic acid. Product decomposition occurs at temperatures exceeding 167º C.  
1H-NMR (DMSO-d6, 300 MHz) δ 8.60 (2H, d, J= 5.4Hz, 6H of pyridine ring), 8.02 (2H, 
s, 3H of pyridine ring) 7.56 (2H, d, J= 5.4Hz, 5H of pyridine ring), 6.37 (2H, s, benzyl 
hydrogen), and 3.14 ppm (24H, s, methyl hydrogens). 13C-NMR (DMSO-d6, 300 MHz) δ 
159.2 and 159.0 (two different carbonyls of the barbituric acid moiety), 147.8, 143.5, 
141.9, 122.0, 118.3 (five carbons of the pyridine moiety), 85.1 (benzyl carbon), 31.7 (C-5 
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of the barbituric acid moiety), and 24.5 ppm (methyl carbon).  MS-ES+ (CH3COOH) m/z 
143 (35%), 277 (50%), 415 (44%), 539 (83%), 661 (33%), 677 (22%), 801 (M+1, 42%).  
Anal. Calcd.  for C36H36N10O12: C, 54.00; H, 4.53; N, 17.49 Found: C, 53.88; H, 4.61; N, 
17.36. 
 
Procedure M.  
Preparation of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E7) 
Into a hot (110º C) acetic acid (200 mL) solution of barbituric acid (1.28 g; 10 mmol) 3-
pyridinecarbaldehyde (0.55 g; 0.005 mol) was added.  After a few minutes a pink 
precipitate starts to form.  Resulting suspension was heated at 110°C for 30 minutes and 
the formed precipitate was separated by filtration, washed with acetic acid (3×20 mL), 
acetone (3×20 mL) and dried at 80˚ C under reduced pressure for several hours. Product 
decomposition at temperatures above 250º C.   MS-ES+ (in acetic acid) 140 (38%), 209 
(43%), 223 (100%), 251 (84%), 283 (26%), and 346 (M+1, 10%).  1H-NMR(DMSO-d6- 
300 MHz Varian Unity) δ 10.21 (4H, s, NH), 8.64 (1H,d, J= 5.7 Hz, pyridine 6-H), 8.43 
(1H, s, pyridine 2-H), 8.20 (1H, d, J= 5.7 Hz, pyridine 4-H), 7.89 (1H, d+d, J1= 5.7 Hz, 
J2= 5.7 Hz, pyridine 5-H), and 6.13 (1H, s, pyrilidene H).  13C-NMR (DMSO-d6- 300 
MHz Varian Unity) δ 160.9, 147.0 (two different carbonyls), 141.9, 140.8, 136.4, 135.2, 
122.7 (five pyridine carbons), 85.5 and 25.9 ppm (two aliphatic carbons). Yield 97%. 
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Preparation of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione  (E8)   
After 1,3-dimethylbarbituric acid (0.78 g; 5.0 mmol) was dissolved in refluxing methanol 
(100 mL) 3-pyridinecarboxaldehyde (0.27 g; 2.5 mmol) was added.  After a few minutes 
a white precipitate starts to form.  The resulting methanol suspension was refluxed for an 
additional twenty minutes and the reaction suspension was reduced to a volume of about 
30 mL by evaporating methanol at atmospheric pressure.  Suspension was cooled to room 
temperature.  Solid product was separated by filtration, washed with methanol (3×20 
mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=92%.  1H-NMR 
(DMSO-d6- 300 MHz Varian Unity) δ 8.64 (1H, d, J= 6 Hz, pyridine 6-H), 8.56 (1H, s, 
pyridine 2-H), 8.29 (1H, d, J= 6 Hz, pyridine 4-H), 7.88 (1H, d, J1= 7.8 Hz, J2= 8.1 Hz, 
pyridine 5-H), 6.337 (1H, s, benzyl H), and 3.13 ppm (12H, s, CH3);  13C-NMR (DMSO-
d6- 300 MHz Varian Unity) δ 159.0, 147.8 (carbonyl carbons), 141.4, 141.1, 136.6, 
135.0, 122.7 (aromatic carbons), 84.6, 29.0 and 24.4 ppm (aliphatic carbons). 
 
Preparation of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E9)  
After 1-methylbarbituric acid (0.71 g; 0.005 mol) was dissolved in refluxing methanol 
(100 mL) 3-pyridinecarboxaldehyde (0.27 g; 0.0025 mol) was added.  After a few 
minutes a white precipitate starts to form.  The resulting methanol suspension was 
refluxed for an additional twenty minutes and the reaction suspension was reduced to a 
volume of about 30 mL by evaporating methanol at atmospheric pressure.  Suspension 
was cooled to room temperature.  Solid product was separated by filtration, washed with 
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methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=97%. 
1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.55 (2H, s, NH), 8.65 (1H, d, J= 5.7 
Hz, pyridine 6-H), 8.49 (1H, s, pyridine 2-H), 8.24 (1H, d, J= 7.8 Hz, pyridine 4-H), 7.90 
(1H,d+d, J1= 8.4 Hz, J2= 8.4 Hz, pyridine 5-H), 6.25 (1H, s, benzyl), and 3.08 (6H, s, 
CH3).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 160.8, 158.7, 147.3 (carbonyls 
carbons), 141.7, 141.1, 136.3, 135.0, 122.8 (aromatic carbons), 85.5, 25.7, 23.4 ppm 
(aliphatic carbon). 
 
Preparation of 1-butyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E10)  
Acetic acid solution (300 mL) of 1-butylbarbituric acid (920 mg; 5 mmol) and 3-
pyridinecarbaldehyde (255 mg; 2.5 mmol) was refluxed for four hours.  Almost 
immediately, a dark solution was formed.  Solvent was evaporated to gummy residue.  
This residue was dissolved in refluxing methanol (200 mL).  The methanol solution was 
left at room temperature in a paraffin foil covered beaker with a small opening for solvent 
evaporation.  After seven days at room temperature, the volume of the mixture was 
reduced to 50 mL and an orange precipitate was formed.  From the ice-cooled suspension 
the solid was separated by filtration, washed with cold methanol (3×30 mL) and dried at 
80º C under reduced pressure for five hours. Yield=81%. 1H-NMR (DMSO-d6- 300 MHz 
Varian Unity) δ 10.48 (2H, s, NH), 8.46 (1H, d, J= 4.2 Hz, pyridine 6-H), 8.33 (1H, s, 
pyridine 2-H), 7.79 (1H, d, J= 7.5 Hz), 7.56 (1H, t, J= 5.1 Hz), 6.164 (1H, s, CH), 3.70 
(4H, J= 6.6 Hz, NCH2), 1.46 (4H, m, NCH2CH2), 1.24 (4H, m, CH2CH3), and 0.86 ppm 
(6H, t, J= 6.6 Hz, CH3).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 160.9, 158.9, 
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147.2 (carbonyl carbons), 140.5, 139.7, 138.5, 135.8, 120.9 (aromatic carbons) 86.0, 
27.3, 26.5, 16.1, and 10.1 ppm (aliphatic carbons). 
 
Preparation of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E11)   
After 1-phenylbarbituric acid (1.02 g; 0.005 mol) was dissolved in refluxing methanol 
(100 mL) 3-pyridinecarboxaldehyde (0.27 g; 0.0025 mol) was added.  After a few 
minutes a white precipitate starts to form.  The resulting methanol suspension was 
refluxed for an additional twenty minutes and the reaction suspension was reduced to a 
volume of about 30 mL by evaporating methanol at atmospheric pressure.  Suspension 
was cooled to room temperature.  Solid product was separated by filtration, washed with 
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=93%.  
1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.74 (2H, s, NH), 8.66 (1H, d, J= 6.3 
Hz, pyridine 6-H), 8.63 (1H, s, pyridine 2-H), 8.40 (1H, d, J= 8.7 Hz, pyridine 4-H), 7.93 
(1H, d+d, J1=7.8 Hz, J2=7.2 Hz, pyridine 5-H), 7.392 (4H, t, J= 0.023, phenyl m-H); 
7.319 (2H, t, J= 6.9 Hz, phenyl p-H), 7.19 (4H, d, J= 6.9 Hz, o-H), and 6.23 (1H, s, CH). 
13C-NMR (DMSO-d6- 300 MHz Varian Unity δ 160.8, 159.4, 147.1 (carbonyl carbons), 
141.6, 141.3, 136.5, 135.1, 133.2, 125.8, 124.8, 123.8, 121.8 (aromatic carbons), 85.1, 
and 27.7 ppm (aliphatic carbons). 
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Preparation of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E12)  
Into a hot (110º C) acetic acid (200 mL) solution of barbituric acid (1.28 g; 10 mmol) 4-
pyridinecarbaldehyde (0.55 g; 0.005 mol) was added.  After a few minutes a pink 
precipitate starts to form.  Resulting suspension was heated at 110° C for 30 minutes and 
the formed precipitate was separated by filtration, washed with acetic acid (3×20 mL), 
acetone (3×20 mL) and dried at 80˚ C under reduced pressure for several hours. Product 
decomposition at temperatures above 250º C. Yield=97%. 1H-NMR (DMSO-d6- 300 
MHz Varian Unity) δ 10.24 (4H, s, NH), 8.63 (2H, d, J= 6.4Hz, pyridine 2-H), 7.63 (2H, 
d, J= 6.9Hz, pyridine 3-H), and 6.18 ppm (1H, s, CH). 13C-NMR (DMSO-d6- 300 MHz 
Varian Unity) δ 163.5, 162.3 (carbonyl carbons), 145.5, 121.5, 113.3 (aromatic carbons), 
87.3, and 33.5 ppm (aliphatic carbons). 
 
Preparation of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione  (E13)  
After 1-methylbarbituric acid (0.71 g; 0.005 mol) was dissolved in refluxing methanol 
(100 mL) 4-pyridinecarboxaldehyde (0.27 g; 0.0025 mol) was added.  After a few 
minutes a white precipitate starts to form.  The resulting methanol suspension was 
refluxed for an additional twenty minutes and the reaction suspension was reduced to a 
volume of about 30 mL by evaporating methanol at atmospheric pressure.  Suspension 
was cooled to room temperature.  Solid product was separated by filtration, washed with 
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=98%. 
1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.60 (2H, s, NH), 8.64 (2H, d, J= 6.6 
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Hz, pyridine 2-H), 7.69 (2H, d, J= 5.7 Hz, pyridine 3H), 6.32 (1H, s, CH), and 3.09 ppm 
(6H, s, CH3).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 164.0, 160.9, 158.8 
(carbonyl carbons), 147.3, 137.0, 121.6 (aromatic carbons), 85.6, 30.9, 23.5 ppm 
(aliphatic carbon). 
 
Preparation of 1-butyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E14)   
Acetic acid solution (300 mL) of 1-butylbarbituric acid (920 mg; 5 mmol) and 4-
pyridinecarbaldehyde (255 mg; 2.5 mmol) was refluxed for four hours.  Almost 
immediately, a dark solution was formed.  Solvent was evaporated to gummy residue.  
This residue was dissolved in refluxing methanol (200 mL).  The methanol solution was 
left at room temperature in a paraffin foil covered beaker with a small opening for solvent 
evaporation.  After seven days at room temperature, the volume of the mixture was 
reduced to 50 mL and an orange precipitate was formed.  From the ice-cooled suspension 
the solid was separated by filtration, washed with cold methanol (3×30 mL) and dried at 
80º C under reduced pressure for five hours. Yield=92%.  1H-NMR (DMSO-d6- 300 
MHz Varian Unity) δ 10.54 (2H, s, NH), 8.64 (2H, d, J= 6.9 Hz, pyridine 4-H), 7.63 (2H, 
d, J= 6.3 Hz, pyridine 3-H), 6.32 (1H, s), 3.70 (4H, t, J= 6.6 Hz), 1.46 (4H, m), 1.28 (4H, 
m), and 0.87 ppm (6H, t, J= 6.6 Hz, CH3).  13C-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ 164.2, 160.7, 158.9 (carbonyl carbons), 147.1, 137.1, 121.5 (aromatic carbons) 
85.5, 30.8, 26.5, 16.1, 10.1 ppm (aliphatic carbons). 
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Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E15)  
After 1-phenylbarbituric acid (g; 0.005 mol) was dissolved in refluxing methanol (100 
mL) 4-pyridinecarboxaldehyde (0.27 g; 0.0025 mol) was added.  After a few minutes a 
white precipitate starts to form.  The resulting methanol suspension was refluxed for an 
additional twenty minutes and the reaction suspension was reduced to a volume of about 
30 mL by evaporating methanol at atmospheric pressure.  Suspension was cooled to room 
temperature.  Solid product was separated by filtration, washed with methanol (3×20 
mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=92%.  1H-NMR 
(DMSO-d6- 300 MHz Varian Unity) δ 10.74 (2H, s, NH), 8.67 (2H, d, J= 6.9 Hz, 
pyridine 2-H), 7.84 (2H, d, J= 6.9 Hz, pyridine 3-H), 7.40 (4H, t, J= 6.9 Hz, phenyl m-
H), 7.32 (2H, t, J= 6.9 Hz, phenyl p-H), 7.19 (4H, d, J= 6.9 Hz, o-H), 6.27 ppm (1H, s, 
CH).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 163.7, 160.7, 159.4 (carbonyl 
carbon), 147.0, 137.1, 133.2, 125.9, 124.8, 123.8, 121.7 (aromatic carbon), 85.5, 30.8 
ppm. 
 
Synthesis of 3,dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E16)   
After 1,3-dimethylbarbituric acid (0.78 g; 0.005 mol) was dissolved in refluxing 
methanol (100 mL) 3-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added.  After a 
few minutes a white precipitate starts to form.  The resulting methanol suspension was 
refluxed for an additional twenty minutes and the reaction suspension was reduced to a 
volume of about 30 mL by evaporating methanol at atmospheric pressure.  Suspension 
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was cooled to room temperature.  Solid product was separated by filtration, washed with 
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=86%. 
1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 9.02 (1H, s, quinoline 2-H), 8.80 (1H, 
s,q-2-H), 8.30 (2H, d, J= 8.1 Hz, q-8-H), 8.19 (1H, d, J= 6.0 Hz, q-5-H), 8.02 (1H, t. J= 
8.1 Hz, q-7-H), 7.86 (1H, t, J= 7.2 Hz, q-6-H), 6.43 (1H, s, CH)), and 3.15 ppm (12H, s, 
CH3).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 159.1, 147.9, 142.4, 138.7, 
135.7, 132.8, 129.3, 125.6, 125.2, 124.7, 123.9, 117.3 (two carbonyl and nine aromatic 
carbons), 84.5, 29.4, and 24.5 ppm (aliphatic carbon). 
 
Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E17)  
After 1-phenylbarbituric acid (1.02 g; 0.005 mol) was dissolved in refluxing methanol 
(100 mL) 3-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added.  After a few 
minutes a white precipitate starts to form.  The resulting methanol suspension was 
refluxed for an additional twenty minutes and the reaction suspension was reduced to a 
volume of about 30 mL by evaporating methanol at atmospheric pressure.  Suspension 
was cooled to room temperature.  Solid product was separated by filtration, washed with 
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=93%.  
1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.78 (2H, s, NH), 9.05 (1H, s, q-2-H), 
8.93 (1H, s, q-4-H), 8.36 (1H, d, J= 6.3 Hz, q-8-H), 8.20 (1H, d, J= 6.3 Hz, q-5-H), 8.00 
(1H, t, J= 5.4 Hz, q-7-H), 7.88 (1H, t, J= 5.7 Hz, q-6-H), 7.39 (4H, t, J= 5.7, phenyl m-
H), 7.31 (2H, t, J= 5.7 Hz, phenyl p-H), 7.24 (4H, d, J= 5.7 Hz, phenyl o-H), and 6.34 
ppm (1H, s, CH).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.0, 160.9, 159.6 
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(carbonyl carbons), 147.2, 142.1, 139.1, 135.8, 133.2, 132.6, 129.6, 125.9, 125.3, 124.8, 
124.7, 123.9 117.2 (aromatic carbons), 84.8, and 28.3 ppm (aliphatic carbons).  
 
Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E18)  
After 1,3-dimethylbarbituric acid (0.78 g; 0.005 mol) was dissolved in refluxing 
methanol (100 mL) 4-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added.  After a 
few minutes a white precipitate starts to form.  The resulting methanol suspension was 
refluxed for an additional twenty minutes and the reaction suspension was reduced to a 
volume of about 30 mL by evaporating methanol at atmospheric pressure.  Suspension 
was cooled to room temperature.  Solid product was separated by filtration, washed with 
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=84%.  
1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 9.07, d, J= 5.7 Hz, q-2-H), 8.39 (1H, d, 
J= 8.7 Hz, q-8-H), 8.16 (1H, d, J= 7.8 Hz, q-5-H), 8.03 (1H, t, J= 6.3 Hz, q-C-7), 7.92 
(1H, d, J= 5.7 Hz, q-3-H), 7.84 (1H, t, J= 7.8 Hz, q-6-H), 6.97 (1H, s, CH), 3.69 (1H, s, 
CH), and 3.13 ppm (12H, s, CH3).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) 
δ 160.5, 159.2 (carbonyl carbons), 147.6, 139.9, 133.8, 130.0, 125.6, 123.6, 121.7, 117.9 
(aromatic carbons), 85.9, 30.3, and 24.5 ppm (aliphatic carbons). 
 
Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E19)   
After 1-methylbarbituric acid (0.71 g; 0.005 mol) was dissolved in refluxing methanol 
(100 mL) 4-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added.  After a few 
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minutes a white precipitate starts to form.  The resulting methanol suspension was 
refluxed for an additional twenty minutes and the reaction suspension was reduced to a 
volume of about 30 mL by evaporating methanol at atmospheric pressure.  Suspension 
was cooled to room temperature.  Solid product was separated by filtration, washed with 
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=78%.  
1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.63 (2H, s, NH), 9.06 (1H, d, J= 5.4 
Hz, q-2-H), 8.42 (1H, d, J= 6.0 Hz, q-8-H), 8.14 (1H, d, J= 8.7 Hz, q-5-H), 8.00 (1H, t, 
J= 8.1 Hz, q-7-H), 7.83 (1H, d, J= 5.7 Hz, q-3-H), 7.83 (1H, t, J= 8.7 Hz, q-6-H), 6.87 
(1H, s, CH), and 3.061 ppm (6H, s, CH3). 13C-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ 160.7, 160.2, 159.2 (carbonyl carbons), 147.141, 140.171, 134.257, 129.778, 
125.343, 123.616, 121.788, 118.263, 117.7 (aromatic carbons), 86.5, 29.1, and 23.5 ppm 
(aliphatic carbon). 
 
Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E20)  
After 1-phenylbarbituric acid (1.03 g; 0.005 mol) was dissolved in refluxing methanol 
(100 mL) 4-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added.  After a few 
minutes a white precipitate starts to form.  The resulting methanol suspension was 
refluxed for an additional twenty minutes and the reaction suspension was reduced to a 
volume of about 30 mL by evaporating methanol at atmospheric pressure.  Suspension 
was cooled to room temperature.  Solid product was separated by filtration, washed with 
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=95%. 
1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.83 (2H, s, NH), 912 (1H, d, J= 5.7 
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Hz, q-2-H), 8.49 (1H, d, J= 8.7 Hz, q-8-H), 8.17 (1H, d, J= 8.1 Hz, q-5-H), 8.05 (1H, t, 
J= 7.2 Hz, q-7-H), 7.98 (1H, d, J= 5.7 Hz, q-3-H), 7.90 (1H, t, J= 8.4 Hz, q-6-H), 7.39 
(4H, t, J= 7.5 Hz, phenyl m-H), 7.32 (2H, t, J= 6.0 Hz, phenyl p-H), 7.14 (4H, d, J= 7.5 
Hz, phenyl o-H), and 6.87 ppm (1H,s CH).  13C-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ 160.8, 160.5, 159.9 (carbonyl carbons), 146.9, 140.0, 133.9, 133.0, 130.2, 125.7, 
125.6, 124.9, 123.9, 123.7, 121.8, 118.0, 117.8 (aromatic carbons), 86.2, and 29.2 ppm.  
 
Preparation of Pyridinium-barbiturate Zwitterion (F1).  A methanol solution (100 mL) 
of 1,3-dimethylbarbituric acid (1.56 g; 10 mmol) and 2-pyridinecarbaldehyde (1.1 g; 10 
mmol) was refluxed for 45 min.  The solution was then transferred to an open 300 mL 
beaker and left to stand at room temperature until the solvent evaporated to 
approximately 1/10 of its original volume. The product slowly crystallized from the 
methanol solution during the course of evaporation. Crystals were separated by filtration, 
washed with cold methanol (3×20 mL) and then ether (3×20 mL), and dried at room 
temperature to give 2.1 g (80%) of product. If necessary, further purification should be 
repeated by dissolving the product in a larger amount of methanol (~100 mL) and by 
leaving it at room temperature in open air to crystallize from the reduced volume (1/10) 
of the solvent. Rf = 0.505 in 1:1 CH3OH-CH3COOH. 1H NMR (DMSO-d6- 300 MHz 
Varian Unity)  9.00 (1H, d, J = 6.6 Hz, pyridinium 6-H), 8.41 (1H, t, J =7.8 Hz, 
pyridinium 5-H), 8.34 (1H, d, J = 5.1 Hz, pyridine 6-H), 7.90 (1H, t, J = 6.3 Hz, 
pyridinium, 4-H), 7.85 (1H, t, J = 7.8 Hz, pyridine 5-H), 7.71 (1H, d, J = 6.9 Hz, 
pyridinium 3-H), 7.61 (1H, d, J = 8.4 Hz, pyridine 3-H), 7.36 (1H, d + d, J1 = 7.2 Hz, J2 = 
7.8 Hz, pyridine 4-H), 6.94 (1H, s, pyridinium), 5.82 (1H, s, pyridinebenzyl), 2.99 (6H, 
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1H, CH3), 2.90 (3H, s, CH3), and 2.83 (3H, s, CH3);  13C NMR (DMSO-d6- 300 MHz 
Varian Unity)  162.9, 161.2, 158.5, 154.3, 150.2, 148.9, 147.5, 145.0, 141.8, 141.2, 
135.9, 132.9, 122.0, 121.8, 121.1, 120.1 (six signals for carbonyl carbons and 10 signals 
for two pyridine rings), 70.8, 59.0, and 51.1 (signals for carbons from a five-membered 
ring), 25.4, 25.1, and 23.3 (three different CH3 carbons); MS-ES (CH3OH-CH3COOH-
NaCl), 491 (M + 1), 492 (M + 2), and (M + 22). Anal. Calcd.  For C24H22N6O6: C, 58.77; 
H, 4.52; N, 17.13. Found: C, 58.71; H, 4.63; N 17.03.  
Preparation of 5,5'-(2-Pyrimidine)bis(1,3-dimethyl-barbituric acid) (F3).  A carbon 
tetrachloride solution (500 mL) of 1,3-dimethylbarbituric acid (780 mg; 5 mM) and 2-
pyridinecarbaldehyde (270 mg; 2.5 mM) was stirred at room temperature for 7 days. The 
yellow precipitate was separated by filtration, washed with carbon tetrachloride (3×50 
mL) and then ether (3×50 mL), and dried in air to afford 650 mg (65%) of product: Rf = 
0.640 in 1:1 CH3COOH-CH3OH.  1H NMR (DMSO-d6- 300 MHz Varian Unity)  8.58 
(1H, d, J = 6.0 Hz, pyridine 6-H), 8.40 (1H, t, J = 6.6 Hz, pyridine 5-H), 7.87 (1H, d, J 
=8.1 Hz, pyridine 3-H), 7.81 (1H, t, J =6.6 Hz, pyridine 4-H), 6.33 (1H, s, benzyl 
hydrogen), and 3.13 (12H, s, four methyl group hydrogens);  13C NMR (DMSO-d6- 300 
MHz Varian Unity)  159.3 and 156.0 (two different barbituric acid carbonyls), 147.8, 
142.3, 137.6, 122.3, and 120.5 (five carbons from the pyridine ring), 80.5 (benzylic 
carbon), 32.0 (barbituric acid 5-carbon), 24.5 (barbituric methyl carbon).  ES-MS 
(CH3OH + NaCl) 424 (M + Na). Anal. Calcd.  For C18H19N5O6: C, 53.86; H, 4.77; N, 
17.45. Found: C, 53.68; H, 4.85; N 17.32.  
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Preparation of Amide F6. Sodium hydroxide (80 mg; 2 mM) in water (1 mL) and 
compound F1 (245 mg; 0.5 mmol) was kept at room temperature for 4 h with occasional 
stirring. In the beginning, the reaction mixture was a suspension that became a clear 
solution after ~10 min. Progress of the reaction was followed by TLC chromatography 
and 1H NMR spectroscopy (D2O as a solvent). After approximately 2 h, zwitterion F1 
was fully converted into amide F6.  The Rf of the soluble product in ethanol is 0.295 in 
1:1 CH3COOH-CH3OH.  Into the water solution was added ethanol (200 mL), and the 
solution was dried over anhydrous calcium chloride.  The solid was separated by 
filtration, and ethanol was evaporated in vacuo at room temperature.  The oily residue 
was slurried in anhydrous 1:1 alcohol-benzene, and the solvent was again evaporated. 
This procedure was repeated several times.  The solid residue left after evaporation of the 
solvent was slurried in dry ether, filtered, and dried in a vacuum to give 198 mg (85%) of 
amide.  1H NMR (D2O-KOH -300 MHz Varian Unity)  8.45 (1H, d-d, J = 6.0 Hz, J2 = 
0.1.2 Hz), 8.21 (1H, t, J = 7.2 Hz), 7.84 (1H, t-d, J1 = 7.2 Hz, J2 = 1.2 Hz), 7.64 (1H, t, J 
= 6.6 Hz), 7.60 (1H, d-d, J1 = 7.2 Hz, J2 = 1.2 Hz), 7.53 (1H, d-d, J1 = 7.2 Hz, J2 = 1.2 
Hz), 7.49 (1H, t, J = 7.8 Hz), 7.38 (1H, d-d-d, J1 = 7.2 Hz, J2 = 6.0 Hz, J3 = 1.2 Hz), 3.04 
(6H, s), and 2.46 (6H, s). 13C NMR (D2O-KOH -300 MHz Varian Unity)  171.7, 170.4, 
163.8, 157.4, 120.8, 120.7, 120, 0, 118.6, 85.7, 53.1, 43.6, 23.2, and 21.9; MS-ES 
(CH3OH-H2O-KOH), 502 (M + 38).  
X-ray Single-Crystal Structure Determination of Compound F1 at 155(2) K. Crystal 
Data: C24H22N6O6, Mr = 490.48, monoclinic, space group P21/n, a = 11.6777(6) Å, b = 
13.4416(7) Å, c = 15.0367(8) Å, = 90 , = 111.630(1) , = 90 , V = 2194.1(2) Å3, Z = 
4, Calcd.  1.485 Mg/m3, F000 = 1024, wavelength ( ) = 0.71073 Å, absorption coefficient 
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( ) = 0.110 mm-1. Data Collection and Reduction: crystal size = 0.4×0.5×0.6 mm; theta 
range, 2.10-30.00 ; index ranges, -16 h 16, -18 k 18, -21 l 20; reflections 
collected, 30679; independent reflections, 6390 [Rint = 0.0284]; refinement method, full-
matrix least-squares on F2; data/restraints/parameters, 6390/0/413; final R indices [I > 2
(I)]: R1 = 0.0370, wR2 = 0.1041, GOF on F2 = 1.035. R indices (all data) R1 = 0.0486, 
wR2 = 0.1067; largest difference peak and hole: 0.388 and -0.241 eÅ-3. Measurement, 
Computing, and Graphics: SMART 1K CDD (Bruker, 2000); cell refinement, SMART; 
data reduction, SAINT-Plus (Bruker, 2000); programs(s) used to solve structure, 
SHELXS97 (Sheldrick, 1997); program(s) used to refine structure, SHELX97 (Sheldrick, 
1997); molecular graphics, SHELXTL97 (Sheldrick, 1997); software used to prepare 
material for publication, SHELXTL97. 
General Procedure N: Preparation of bis-barbiturate ammonium salts 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-yl)methyl]pyrimidine-
2,4,6(1H,3H,5H)-trione piperidinium salt (G1)   
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) barbituric acid (0.256 g, 2.00 
mmol), and 3-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol (100 mL) was 
refluxed for approximately 12 h.  The reaction mixture was cooled to room temperature 
and the volume of methanol reduced to ¼ its original volume, and diluted with anhydrous 
ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed with ether (3 x 
15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.400 g (93%) pure product.  
Product decomposes at temperatures above 250º C.  1H-NMR (DMSO-d6- 300 MHz 
Varian Unity) δ 10.09 (s, 4H), 8.21 (d, 1H, J= 4.8 Hz), 8.17 (d, 1H, J= 2.1 Hz), 7.34 (d, 
1H, J= 7.5 Hz), 7.15 (m, 1H), 5.98 (s, 1H), 2.98 (t, 4H, J= 5.4 Hz), 1.60 (m, 4H), 1.51 
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(m, 2H). 13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 160.9, 147.0, 144.7, 142.0, 
136.4, 130.6, 119.1, 86.7, 40.3, 25.1, 18.7, 18.1 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-yl)methyl]pyrimidine-
2,4,6(1H,3H,5H)-trione morpholinium salt (G2)  
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) barbituric acid (0.256 g, 
2.00 mmol), and 4-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol (100 mL) 
was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.420 g (97%) 
pure product.  Product decomposes at temperatures above 250º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ 10.11 (s, 4H), 8.29 (d, 2H, J= 5.1 Hz), 6.98 (d, 2H, J= 5.1 
Hz), 5.93 (s, 1H), 3.72 (t, 4H, J= 4.7 Hz), 3.07 (t, 4H, J= 5.1 Hz).  13C-NMR (DMSO-d6- 
300 MHz Varian Unity) δ 161.3, 150.9, 147.1, 145.0, 118.8, 86.4, 59.8, 39.5, 27.0. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione ethanolaminium salt (G3)   
A suspension of ethanolamine (0.090 mL, 0.092 g, 1.50 mmol) barbituric acid (0.256 g, 
2.00 mmol), and 4-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol (100 mL) 
was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
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with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.420 g (92%) 
pure product.  Product decomposes at temperatures above 250º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ 10.08 (s, 4H), 8.66 (d, 1H, J= 4.8 Hz), 8.14 (d, 1H, J= 7.8 
Hz), 7.91 (d, 1H, J= 8.1 Hz), 7.60 (t, 1H, J= 8.1 Hz), 7.42 (t, 1H, J= 7.2 Hz), 7.28 (d, 
1H, J= 4.5 Hz), 6.48 (s, 1H), 3.54 (t, 2H, J= 5.0 Hz), 2.83 (t, 2H, J= 5.3 Hz).  13C-NMR 
(DMSO-d6- 300 MHz Varian Unity) δ 161.1, 147.7, 146.9, 145.7, 144.1, 125.6, 124.6, 
123.8, 121.9, 121.3, 117.0, 87.2, 53.8, 37.6, 25.6. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G4)   
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) barbituric acid (0.256 g, 
2.00 mmol), and 3-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol (100 mL) 
was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.396 g (82%) 
pure product.  Product decomposes at temperatures above 250º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ 10.09 (s, 4H), 8.52 (d, 1H, J= 2.1 Hz), 7.88 (d of d, 2H), 7.78 
(s, 1H), 7.60 (t, 1H, J= 8.1 Hz), 7.48 (t, 1H, J= 8.1 Hz), 6.17 (s, 1H), 3.73 (t, 4H, J= 5.1 
Hz), 3.09 (t, 4H, J= 5.1 Hz).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.1, 
148.1, 147.7, 147.1, 142.1, 134.0, 128.1, 124.7, 124.4, 124.0, 122.6, 86.7, 59.8, 39.5, 
25.6. 
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Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(2-
nitrobenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G5) 
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) barbituric acid (0.256 g, 
2.00 mmol), and 2-nitrobenzaldehyde (0.151 g, 1.00 mmol) in methanol (100 mL) was 
refluxed for approximately 12 h.  The reaction mixture was cooled to room temperature 
and the volume of methanol reduced to ¼ its original volume, and diluted with anhydrous 
ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed with ether 
(3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.439 g (92%) pure product.  
Product decomposes at temperatures above 250º C.  1H-NMR (DMSO-d6- 300 MHz 
Varian Unity) δ  10.00 (s. 4H), 7.43 (t, 2H, J= 8.3 Hz), 7.24 (m, 2H), 6.08 (s, 1H), 3.75 
(t, 4H, J= 4.8 Hz), 3.09 (t, 4H, J= 4.8 Hz).  13C-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ  160.7, 147.1, 146.4, 134.1, 126.9, 126.0, 122.3, 119.6, 86.5, 59.8, 39.4, 25.2 
ppm. 
 
Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G6)   
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1,3-dimethylbarbituric acid 
(0.312 g, 2.00 mmol), and 4-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.520 g (97%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
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300 MHz Varian Unity) δ  8.65 (d, 1H, J= 4.5 Hz), 8.21 (s, 2H), 8.03 (d, 1H, J= 7.5 Hz), 
7.90 (d, 1H, J= 7.5 Hz), 7.59 (t, 1H, J= 8.3 Hz), 7.42 (t, 1H, J= 8.3 Hz), 7.32 (d, 1H, J= 
3.9 Hz), 6.73 (s, 1H), 3.11 (s, 12H), 2.98 (t, 4H, J= 5.7 Hz), 1.61 (m, 4H), 1.53 (m, 2H). 
13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ  159.0, 147.6, 146.8, 145.9, 144.3, 
125.8, 124.5, 123.7, 122.0, 121.0, 117.2, 87.0, 40.2, 28.4, 24.0, 18.6, 18.0 
 
Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G7)   
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) 1,3-dimethylbarbituric acid 
(0.312 g, 2.00 mmol), and 4-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.454 g (93%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ 8.34 (d, 2H, J= 6.0 Hz), 7.14 (d, 2H, J= 6.0 Hz), 3.73 (t, 4H, 
J= 4.5 Hz), 3.12 (s, 12H), 3.08 (t, 4H, J= 4.5 Hz).   13C-NMR (DMSO-d6- 300 MHz 
Varian Unity) δ  158.9, 153.4, 147.7, 143.2, 119.4, 86.2, 59.7, 39.4, 30.2, 24.4 ppm. 
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Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G8)  
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1,3-dimethylbarbituric acid 
(0.312 g, 2.00 mmol), and 3-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.462 g (95%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ 8.25 (s, 2H), 8.22 (d, 1H, J= 4.8 Hz), 8.19 (d, 1H, J= 2.1 Hz), 
7.37 (d, 1H, J= 7.8 Hz), 7.14 (m, 1H), 3.13 (s, 12H), 3.00 (t, 4H, J= 5.7 Hz), 1.62(m, 
4H), 1.53 (m, 2H). 13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ  159.0, 147.7, 144.8, 
142.0, 135.7, 130.7, 119.1, 86.5, 40.3, 28.0, 24.4, 18.6, 18.0 ppm. 
 
Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G9)   
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1,3-dimethylbarbituric acid 
(0.312 g, 2.00 mmol), and 3-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.440 g (82%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
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300 MHz Varian Unity) δ  8.54 (d, 1H, J= 2.1 Hz), 8.21 (s, 2H), 7.87 (t, 3H, J= 9.3 Hz), 
7.60 (t, 1H, J= 6.9 Hz), 7.48 (t, 1H, J= 6.9 Hz), 6.40 (s, 1H), 3.15 (s, 12H), 3.00 (t, 4H, 
J= 5.7 Hz), 1.62 (m, 4H), 1.54 (m, 2H).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) 
δ  159.2, 148.0, 147.9, 142.3, 133.8, 128.4, 124.8, 124.5, 124.3, 122.7, 86.7, 40.4, 28.6, 
24.6, 18.8, and 18.2 ppm. 
 
Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(3-
nitrobenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G10)  
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) 1,3-dimethylbarbituric acid 
(0.312 g, 2.00 mmol), and 3-nitrobenzaldehyde (0.151 g, 1.00 mmol) in methanol (100 
mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.447 g (84%) 
pure product.  Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ 8.67 (s, 2H), 7.94 (d, 1H, J= 7.8 Hz), 7.82 (s, 1H), 7.48 (m, 
2H), 6.32 (s, 1H), 3.77 (t, 4H, J= 5.1 Hz), 3.12 (t, 4H, J= 5.1 Hz).   13C-NMR (DMSO-d6, 
300 MHz) δ  159.1, 147.8, 144.1, 123.6, 130.3, 125.4, 117.5, 116.3, 86.5, 59.7, 39.4, 
30.1, and 24.4 ppm 
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Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione ethanolaminium salt (G11) 
A suspension of ethanolamine (0.090 mL, 0.092 g, 1.50 mmol) 1-methylbarbituric acid 
(0.284 g, 2.00 mmol), and 3-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.378 g (87%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ 10.40 (s, 2H), 8.22 (d, 1H, J= 4.5 Hz), 8.19 (s, 1H), 7.37 (d, 
1H, J= 8.1 Hz), 7.16 (m, 1H), 6.10 (s, 1H), 3.56 (t, 2H, J= 5.4 Hz), 3.08 (s, 6H), 2.80 (t, 
2H, J= 5.4 Hz). 13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ  160.9, 158.0, 147.3, 
144.7, 142.0, 136.2, 130.6, 119.0, 86.6, 54.5, 37.9, 26.8, and 23.3 ppm. 
 
Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G12)  
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1-methylbarbituric acid 
(0.284 g, 2.00 mmol), and 4-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.399 g (87%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
 209
300 MHz Varian Unity) δ 10.30 (s, 2H), 8.27 (d, 2H, J= 6.0 Hz), 6.96 (d, 2H, J= 6.0 
Hz), 6.07 (s, 1H), 3.06 (s, 6H), 2.99 (t, 4H, J= 5.7 Hz), 1.61 (m, 4H), 1.54 (m, 2H). 13C-
NMR (DMSO-d6- 300 MHz Varian Unity) δ 160.4, 159.0, 150.1, 146.8, 144.6, 118.2, 
85.9, 39.8, 28.3, 22.9, 18.2, and 17.6 ppm. 
 
Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G13) A suspension of 
piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1-methylbarbituric acid (0.284 g, 2.00 mmol), 
and 3-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol (100 mL) was refluxed 
for approximately 12 h.  The reaction mixture was cooled to room temperature and the 
volume of methanol reduced to ¼ its original volume, and diluted with anhydrous ethyl 
ether (100 mL).  The resulting solid precipitate was filtered, washed with ether (3×15 
mL), and oven dried at 110º C for 2-3 hours, yielding 0.351 g (69%) pure product.  
Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 300 MHz 
Varian Unity) δ  10.41 (s, 2H), 8.53 (d, 1H, J= 2.1 Hz), 8.40 (s, 2H), 7.87 (m, 3H), 7.99 
(s, 1H), 7.59 (t, 1H, J= 6.9 Hz), 7.47 (t, 1H, J= 6.9 Hz), 6.28 (s, 1H), 3.09 (s, 6H), 2.98 
(t, 4H, J= 5.1), 1.59 (m, 4H), 1.52 (m, 2H). 13C-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ  161.0, 158.8, 158.3, 147.7, 147.3, 142.0, 133.9, 128.0, 124.6, 124.3, 124.0, 
122.5, 86.6, 40.3, 27.3, 23.4, 18.7, and 18.1 ppm. 
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Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G14)   
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) 1-methylbarbituric acid 
(0.284 g, 2.00 mmol), and 4-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.410 g (89%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ 10.40 (s, 2H), 8.31 (d, 2H, J= 6.0 Hz), 7.04 (d, 2H, J= 6.0 
Hz), 6.10 (s, 1H), 3.74 (t, 4H, J= 5.7 Hz), 3.10 (t, 4H, J= 5.7 Hz), 3.07 (s, 6H). 13C-NMR 
(DMSO-d6- 300 MHz Varian Unity) δ 160.9, 151.9, 147.3, 144.3, 119.0, 86.3, 59.7, 39.4, 
28.9, 23.3 ppm. 
 
Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G15)  
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1-methylbarbituric acid 
(0.284 g, 2.00 mmol), and 4-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.478 g (94%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
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300 MHz Varian Unity) δ  8.67 (d, 1H, J= 3.3 Hz), 8.10 (d, 1H, J= 6.0 Hz), 7.92 (d, 1H, 
J= 6.0 Hz), 7.60 (t, 1H, J= 5.7 Hz), 7.43 (t, 1H, J= 5.7 Hz), 7.30 (d, 1H, J= 3.3 Hz), 6.62 
(s, 1H), 2.98 (t, 4H, J= 3.3 Hz), 1.60 (m, 4H), 1.51(m, 2H). 13C-NMR (DMSO-d6- 300 
MHz Varian Unity) δ  160.9, 159.2, 147.3, 146.0, 144.4, 125.9, 124.7, 123.9, 122.0, 
121.3, 117.2, 87.4, 40.3, 27.3, 23.4, 18.7, 18.1 ppm. 
 
Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G16)   
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1-phenylbarbituric acid 
(0.408 g, 2.00 mmol), and 4-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.601 g (95%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ  10.56 (s, 2H), 8.71 (d, 1H, J= 4.8 Hz), 8.20 (s, 2H), 8.14 (d, 
1H, J= 8.4 Hz), 7.93 (d, 1H, J= 8.4 Hz), 7.62 (t, 1H, J= 7.5 Hz), 7.48 (t, 1H, J= 7.5 Hz), 
7.40 (t, 4H, J= 5.1 Hz), 7.29 (m, 3H), 7.11 (d, 4H, J= 7.5 Hz), 6.59 (s, 1H), 2.95 (t, 4H, 
J= 5.1 Hz), 1.58 (m, 4H), 1.51 (m, 2H).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) 
δ  160.6, 159.6, 147.0, 146.8, 145.9, 144.3, 133.2, 125.8, 125.7, 124.7, 124.6, 123.8, 
123.6, 121.9, 121.1, 117.1, 87.1, 40.2, 27.2, 18.6, 18.0 ppm. 
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Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G17) 
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) 1-phenylbarbituric acid 
(0.408 g, 2.00 mmol), and 3-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol 
(100 mL) was refluxed for approximately 12 h.  The reaction mixture was cooled to room 
temperature and the volume of methanol reduced to ¼ its original volume, and diluted 
with anhydrous ethyl ether (100 mL).  The resulting solid precipitate was filtered, washed 
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.520 g (89%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ  10.60 (s, 2H), 8.36 (s, 1H), 8.30 (d, 1H, J= 3.3 Hz), 7.59 (d, 
1H, J= 5.7 Hz), 7.39 (t, 4H, J= 5.7 Hz), 7.29 (m, 3H), 7.18 (d, 4H, J= 5.7 Hz), 6.10 (s, 
1H), 3.68 (t, 4H, J= 3.6 Hz), 3.02 (t, 4H, J= 3.6 Hz).  13C-NMR (DMSO-d6- 300 MHz 
Varian Unity) δ  160.9, 159.0, 147.0, 144.3, 141.7, 136.4, 133.4, 131.6, 125.8, 124.7, 
123.7, 119.5, 87.7, 59.7, 39.4, 27.0 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(4-
methylbenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G18)  
Into 50 mL of methanol, 4-tolualdehyde (0.121 g; 1.00 mmol), barbituric acid (0.256 g; 
2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and stirred.  The 
resulting reaction suspension was refluxed overnight.  The reaction mixture was cooled to 
room temperature and the volume reduced to ¼ the original volume, resulting in the 
formation of a precipitate.  The precipitate was removed by filtration and washed with 
ether (3×20 mL).  Solid was oven dried at 105º C for 3 hours, to afford 0.424 g (95%) 
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pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ  10.22 (s, 4H), 6.89 (m, 4H), 5.89 (s, 1H), 3.71 (t, 4H, J= 4.8 
Hz), 3.04 (t, 4H, J= 4.8 Hz), 2.19 (s, 3H).  13C-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ  161.9, 147.2, 137.7, 129.6, 124.5, 123.0, 87.7, 59.9, 39.6, 26.6, 16.9 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(3-
methylbenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G19)  
Into 50 mL of methanol, 3-tolualdehyde (0.121 g; 1.00 mmol), barbituric acid (0.256 g; 
2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and stirred.  The 
resulting reaction suspension was refluxed overnight.  The reaction mixture was cooled to 
room temperature and the volume reduced to ¼ the original volume, resulting in the 
formation of a precipitate.  The precipitate was removed by filtration and washed with 
ether (3×20 mL).  Solid was oven dried at 105º C for 3 hours, to afford 0.401 g (90%) 
pure product.  Product decomposes at temperatures above 200º C.  1H-NMR (DMSO-d6- 
300 MHz Varian Unity) δ  10.12 (s, 4H), 7.02 (t, 1H, J= 7.8 Hz), 6.83 (m, 3H), 5.89 (s, 
1H), 3.72 (t, 4H, J= 4.8 Hz), 3.06 (t, 4H, J= 4.8 Hz), 2.19 (s, 3H).  13C-NMR (DMSO-d6- 
300 MHz Varian Unity) δ  162.9, 147.2, 141.0, 132.6, 123.8, 123.7, 121.7, 120.3, 87.6, 
60.0, 39.7, 26.8, 17.8 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(3-
methoxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G2)  
Into 50 mL of methanol, 3-methoxybenzaldehyde (0.136 g; 1.00 mmol), barbituric acid 
(0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and 
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stirred.  The resulting reaction suspension was refluxed overnight.  The reaction mixture 
was cooled to room temperature and the volume reduced to ¼ the original volume, 
resulting in the formation of a precipitate.  The precipitate was removed by filtration and 
washed with ether (3×20 mL).  Solid was oven dried at 105º C for 3 hours, to afford 
0.439 g (95%) pure product.  Product decomposes at temperatures above 200º C.  1H-
NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.12 (s, 4H), 7.06 (t, 1H, J= 7.8 Hz), 6.59 
(m, 3H), 5.92 (s, 1H), 3.73 (t, 4H, J= 4.9 Hz), 3.65 (s, 3H), 3.10 (t, 4H, J= 5.1 Hz).  13C-
NMR (DMSO-d6- 300 MHz Varian Unity) δ  161.7, 155.4, 147.1, 143.0, 124.8, 115.8, 
109.7, 105.5, 87.4, 59.8, 51.2, 39.5, 27.0 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(4-
(dimethylamino)benzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt 
(G21)   
Into 50 mL of methanol, 4-(dimethylamino)benzaldehyde (0.149 g; 1.00 mmol), 
barbituric acid (0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) 
were added and stirred.  The resulting reaction suspension was refluxed overnight.  The 
reaction mixture was cooled to room temperature and the volume reduced to ¼ the 
original volume, resulting in the formation of a precipitate.  The precipitate was removed 
by filtration and washed with ether (3×20 mL).  Solid was oven dried at 105º C for 3 
hours, to afford 0.456 g (96%) pure product.  Product decomposes at temperatures above 
200º C.  1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ  6.86 (d, 2H, J= 8.4 Hz), 6.56 
(d, 2H, J= 8.7 Hz), 5.84 (s, 1H), 3.73 (t, 4H, J= 4.8 Hz), 3.09 (t, 4H, J= 4.8 Hz), 2.79 (s, 
 215
6H).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ  160.0, 147.3, 144.6, 128.6, 123.6, 
108.9, 87.9, 59.9, 39.6, 37.1, 26.0 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(naphthyl)methyl]pyrimidine-
2,4,6(1H,3H,5H)-trione morpholinium salt (G22)  
Into 50 mL of methanol, 2-naphthaldehyde (0.158 g; 1.00 mmol), barbituric acid (0.256 
g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and stirred.  
The resulting reaction suspension was refluxed overnight.  The reaction mixture was 
cooled to room temperature and the volume reduced to ¼ the original volume, resulting 
in the formation of a precipitate.  The precipitate was removed by filtration and washed 
with ether (3×20 mL).  Solid was oven dried at 105º C for 3 hours, to afford 0.458 g 
(95%) pure product.  Product decomposes at temperatures above 200º C.  1H-NMR 
(DMSO-d6- 300 MHz Varian Unity) δ  10.04 (s, 4H), 8.13 (d, 1H, J= 8.1 Hz), 7.78 (d, 
1H, J= 8.1 Hz), 7.60 (d, 1H, J= 8.1 Hz), 7.33 (m, 4H), 6.45 (s, 1H), 3.73 (t, 4H, J= 4.8 
Hz), 3.08 (t, 4H, J= 4.8 Hz).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ  161.2, 
147.0, 137.5, 130.0, 128.4, 124.7, 121.9, 121.8, 121.4, 121.3, 121.2, 121.1, 88.3, 59.8, 
39.5, 25.7 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(2-
hydroxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G23)  
Into 50 mL of methanol, 2-hydroxybenzaldehyde (0.122 g; 1.00 mmol), barbituric acid 
(0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and 
stirred.  The resulting reaction suspension was refluxed overnight.  The reaction mixture 
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was cooled to room temperature and the volume reduced to ¼ the original volume, 
resulting in the formation of a precipitate.  The precipitate was removed by filtration and 
washed with ether (3×20 mL).  Solid was oven dried at 105º C for 3 hours, to afford 
0.403 g (90%) pure product.  Product decomposes at temperatures above 200º C.  1H-
NMR (DMSO-d6- 300 MHz Varian Unity) δ  10.16 (s, 4H), 7.19 (d, 1H, J= 7.8 Hz), 6.88 
(t, 1H, J= 7.7 Hz), 6.59 (m, 2H), 5.94 (s, 1H), 3.75 (t, 4H, J= 4.8 Hz), 3.10 (t, 4H, J= 4.8 
Hz).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.8, 151.5, 146.9, 126.9, 125.2, 
122.3, 114.2, 111.4, 87.1, 59.8, 45.0, 39.6 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(4-
hydroxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G24)  
Into 50 mL of methanol, 4-hydroxybenzaldehyde (0.122 g; 1.00 mmol), barbituric acid 
(0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and 
stirred.  The resulting reaction suspension was refluxed overnight.  The reaction mixture 
was cooled to room temperature and the volume reduced to ¼ the original volume, 
resulting in the formation of a precipitate.  The precipitate was removed by filtration and 
washed with ether (3×20 mL).  Solid was oven dried at 105º C for 3 hours, to afford 
0.358 g (80%) pure product.  Product decomposes at temperatures above 200º C.  1H-
NMR (DMSO-d6- 300 MHz Varian Unity) δ  10.02 (s, 4H), 6.79 (d, 2H, J= 8.4 Hz), 6.53 
(d, 2H, J= 8.4 Hz), 5.82 (s, 1H), 3.72 (t, 4H, J= 4.8 Hz), 3.06 (t, 4H, J= 4.8 Hz).  13C-
NMR (DMSO-d6- 300 MHz Varian Unity) δ  161.1, 150.7, 147.1, 131.1, 123.9, 110.7, 
87.7, 60.0, 39.7, 26.0 ppm. 
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Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(2,3,4-
trimethoxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G25)  
Into 50 mL of methanol, 2,3,4-trimethoxybenzaldehyde (0.198 g; 1.00 mmol), barbituric 
acid (0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added 
and stirred.  The resulting reaction suspension was refluxed overnight.  The reaction 
mixture was cooled to room temperature and the volume reduced to ¼ the original 
volume, resulting in the formation of a precipitate.  The precipitate was removed by 
filtration and washed with ether (3×20 mL).  Solid was oven dried at 105º C for 3 hours, 
to afford 0.501 g (96%) pure product.  Product decomposes at temperatures above 200º 
C.  1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ  10.00 (s, 4H), 6.78 (d, 1H, J= 9.0 
Hz), 6.55 (d, 1H, J= 9.0 Hz), 5.86 (s, 1H), 3.72 (t, 4H, J= 4.8 Hz), 3.69 (s, 3H), 3.65 (s, 
3H), 3.52 (s, 3H), 3.08 (t, 4H, J= 4.8 Hz).  13C-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ  160.9, 147.6, 147.3, 147.1, 138.2, 127.1, 119.4, 102.7, 87.5, 59.9, 56.3, 56.2, 
52.1, 39.5, 23.3 ppm. 
 
Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(2-
methoxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G26)  
Into 50 mL of methanol, 2-methoxybenzaldehyde (0.136 g; 1.00 mmol), 1,3-
dimethylbarbituric acid (0.312 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 
mmol) were added and stirred.  The resulting reaction suspension was refluxed overnight.  
The reaction mixture was cooled to room temperature and the volume reduced to ¼ the 
original volume, resulting in the formation of a precipitate.  The precipitate was removed 
by filtration and washed with ether (3×20 mL).  Solid was oven dried at 105º C for 3 
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hours, to afford 0.481 g (93%) pure product.  Product decomposes at temperatures above 
200º C.  1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 7.15 (d, 1H, J= 7.8 Hz), 7.03 (t, 
1H, J= 7.7 Hz), 6.74 (m, 2H), 6.01 (s, 1H), 3.77 (t, 4H, J= 4.7 Hz), 3.57 (s, 3H), 3.16 (t, 
4H), 3.12 (s, 12H).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ  159.4, 153.6, 
148.0, 128.9, 125.6, 122.6, 115.9, 107.3, 86.7, 59.8, 52.0, 39.6, 27.6, 24.3 ppm. 
 
Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(3,4,5-
trimethoxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione ethanolaminium salt 
(G27) Into 50 mL of methanol, 3,4,5-trimethoxybenzaldehyde (0.198 g; 1.00 mmol), 1,3-
dimethylbarbituric acid (0.312 g; 2.00 mmol), and ethanolamine (0.090 mL; 0.092 g; 1.5 
mmol) were added and stirred.  The resulting reaction suspension was refluxed overnight.  
The reaction mixture was cooled to room temperature and the volume reduced to ¼ the 
original volume, resulting in the formation of a precipitate.  The precipitate was removed 
by filtration and washed with ether (3×20 mL).  Solid was oven dried at 105º C for 3 
hours, to afford ).513 g (93%) pure product.  Product decomposes at temperatures above 
200º C.  1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 6.34 (s, 2H), 6.12 (s, 1H), 3.61 
(s, 6H), 3.60 (s, 3H), 3.57 (t, 2H, J= 5.5 Hz), 3.15 (s, 12H), 2.87 (t, 2H, J= 5.3 Hz).  13C-
NMR (DMSO-d6- 300 MHz Varian Unity) δ  158.6, 148.6, 147.9, 136.5, 131.6, 101.1, 
87.4, 56.4, 54.0, 52.4, 37.8, 24.5, 23.3 ppm. 
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Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(4-
hydroxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G28) 
Into 50 mL of methanol, 4-hydroxybenzaldehyde (0.122 g; 1.00 mmol), 1,3-
dimethylbarbituric acid (0.312 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 
mmol) were added and stirred.  The resulting reaction suspension was refluxed overnight.  
The reaction mixture was cooled to room temperature and the volume reduced to ¼ the 
original volume, resulting in the formation of a precipitate.  The precipitate was removed 
by filtration and washed with ether (3×20 mL).  Solid was oven dried at 105º C for 3 
hours, to afford 0.463 g (92%) pure product.  1H-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ 6.81 (d, 2H, J= 8.1 Hz), 6.54 (d, 2H, J= 8.4 Hz), 6.08 (s, 1H), 3.74 (t, 4H), 3.15 
(t, 4H), 3.11 (s, 12H).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ  158.4, 150.9, 
147.9, 130.4, 124.0, 111.7, 110.8, 59.9, 39.6, 29.1, 24.4 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(butyl)methyl]pyrimidine-
2,4,6(1H,3H,5H)-trione morpholinium salt (G29) Into 100 mL methanol barbituric acid 
(2.56 g; 0.02 mol), valeraldehyde (1.04 mL; 0.840 g; 0.01 mol), and morpholine (1.1 mL; 
1.00 g, 0.011 mol) were mixed with stirring.  The reaction suspension was refluxed 
overnight.  The volume of the mixture was reduced to 1/5 the original volume (~20 mL) 
and was cooled to room temperature.  The white solid precipitate was filtered and washed 
with ether (3×25 mL).  The solid was oven dried at 110 C for 3 hours, affording 3.8 g 
(92%) pure product.  1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 9.86 (s, 4H), 4.46 
(t, 1H, J= 8.5 Hz), 3.73 (t, 4H, J= 5.0 Hz), 3.06 (t, 4H, J= 5.0 Hz), 1.65 (m, 2H), 1.18 
 220
(m, 2H), 1.02 (m, 2H).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.1, 147.0, 
87.5, 60.2, 39.8, 27.0, 26.6, 22.3, 18.7, 10.6 ppm.  
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(hexyl)methyl]pyrimidine-
2,4,6(1H,3H,5H)-trione morpholinium salt (G30) Into 100 mL methanol barbituric acid 
(2.56 g; 0.02 mol), heptaldehyde (1.39 mL, 1.14 g; 0.01 mol), and morpholine (1.10 mL; 
1.00 g, 0.011 mol) were mixed with stirring.  The reaction suspension was refluxed 
overnight.  The volume of the mixture was reduced to 1/5 the original volume (~20 mL) 
and cooled to room temperature.  The solid precipitate was filtered and washed with ether 
(3×25 mL).  The solid was oven dried at 110º C for 3 hours, affording 3.30 g (75%) pure 
product.  Product decomposes at temperatures above 160º C.  1H-NMR (DMSO-d6- 300 
MHz Varian Unity) δ  9.84 (s, 4H), 4.46 (t, 1H, J= 8.4 Hz), 3.75 (t, 4H, J= 4.8 Hz), 3.09 
(t, 4H, J= 4.8 Hz), 1.64 (m, 2H), 1.22 (m, 2H), 1.17 (m, 4H), 1.03 (m, 2H), 0.82 (t, 3H, 
J= 6.6 Hz).  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 151.4, 147.0, 87.6, 59.9, 
39.6, 27.9, 27.4, 25.2, 24.2, 22.4, 18.5, 10.4 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(nonyl)methyl]pyrimidine-
2,4,6(1H,3H,5H)-trione morpholinium salt (G31)  Into 100 mL methanol barbituric acid 
(2.56 g; 0.02 mol), decanal (1.88 mL, 1.56 g; 0.01 mol), and morpholine (1.10 mL; 1.00 
g, 0.011 mol) were mixed with stirring.  The reaction suspension was refluxed overnight.  
The volume of the mixture was reduced to 1/5 the original volume (~20 mL) and cooled 
to room temperature.  The solid precipitate was filtered and washed with ether (3×25 
mL).  The solid was oven dried at 110º C for 3 hours, affording 4.53 g (94%) pure 
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product. Product decomposes at temperatures above 160º C.  1H-NMR (DMSO-d6- 300 
MHz Varian Unity) δ 9.90 (s, 4H), 4.44 (t, 1H, J= 8.1 Hz), 3.73 (t, 4H, J= 4.5 Hz), 3.07 
(t, 4H, J= 4.5 Hz), 1.63 (m, 2H), 1.19 (m, 12H), 1.03 (m, 2H), 0.82 (t, 3H, J= 6.9 Hz) 
ppm.  13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.5, 147.2, 87.9, 60.2, 39.8, 
27.9, 27.4, 25.8, 25.7, 25.6, 25.3, 24.4, 22.5, 18.7, 10.5 ppm. 
 
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(heptyl)methyl]pyrimidine-
2,4,6(1H,3H,5H)-trione piperidinium salt (G32)  Into 100 mL methanol barbituric acid 
(2.56 g; 0.02 mol), octanal (1.56 mL, 1.28 g; 0.01 mol), and piperidine (1.08 mL; 0.937 
g, 0.011 mol) were mixed with stirring.  The reaction suspension was refluxed overnight.  
The volume of the mixture was reduced to 1/5 the original volume (~20 mL) and cooled 
to room temperature.  The solid precipitate was filtered and washed with ether (3×25 
mL).  The solid was oven dried at 110º C for 3 hours, affording 3.70 g (82%) pure 
product. Product decomposes at temperatures above 160º C.  1H-NMR (DMSO-d6- 300 
MHz Varian Unity) δ  9.85 (s, 4H), 4.46 (t, 1H, J= 8.1 Hz), 3.00 (t, 4H, J= 5.6 Hz), 1.64 
(m, 4H), 1.55 (m, 2H), 1.17 (m, 10H), 1.03 (m, 2H), 0.83 (t, 3H, J= 6.8 Hz).  13C-NMR 
(DMSO-d6- 300 MHz Varian Unity) δ  161.7, 147.2, 87.9, 40.4, 27.8, 27.2, 25.6, 25.3, 
24.4, 22.4, 18.7, 18.6, 18.2, 10.4 ppm. 
 
Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-
yl)(nonyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G33) Into 50 
mL methanol 1-phenylbarbituric acid (0.408 g; 0.002 mol), decanal (0.188 mL, 0.156 g; 
0.001 mol), and morpholine (0.110 mL; 0.100 g, 0.0011 mol) were mixed with stirring.  
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The reaction suspension was refluxed overnight.  The volume of the mixture was reduced 
to 1/5 the original volume (~10 mL) and cooled to room temperature.  The solid 
precipitate was filtered and washed with ether (3×25 mL).  The solid was oven dried at 
110º C for 3 hours, affording 0.462 g (73%) pure product. Product decomposes at 
temperatures above 200º C.  1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ  10.36 (s, 
2H), 7.37 (t, 4H, J= 7.4 Hz), 7.30 (t, 2H, J= 7.2 Hz), 7.10 (d, 4H, J= 7.2 Hz), 4.52 (t, 1H, 
J= 8.1 Hz), 3.69 (t, 4H, J= 4.8 Hz), 3.02 (t, 4H, J= 4.8 Hz), 1.76 (m, 2H), 1.22 (m, 12H), 
1.13 (m, 2H), 0.85 (t, 3H, J= 6.6 Hz) ppm.  13C-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ  161.2, 159.2, 147.1, 133.6, 125.9, 124.8, 123.7, 88.2, 59.7, 39.4, 27.9, 27.3, 
27.2, 27.0, 25.7, 25.6, 25.3, 24.4, 18.6, 10.5 ppm. 
 
Synthesis of 5-[(2-thio-4,6-dioxohexahydropyrimidin-5-yl)(2-
nitrobenzyl)methyl]pyrimidine-2-thio-4,6-(1H,3H,5H)-dione piperidinium salt (G34) 
Into 100 mL methanol, 4,6-dihydroxy-2-mercaptopyrimidine (2.88 g; 0.02 mol), 2-
nitrocarboxaldehyde (1.51g; 0.01 mol), and piperidine (1.1 mL; 1.00 g; 0.011 mol) were 
mixed while stirring.  The reaction suspension was refluxed overnight.  The reaction 
suspension was cooled to room temperature and the pale yellow solid was filtered and 
washed with ether (3×20 mL).  The solid was oven dried at 105 C for 3 hours to afford 
5.10 g (90%) pure product.  Product decomposes at temperatures above 200º C.  1H-NMR 
(DMSO-d6- 300 MHz Varian Unity) δ  7.50 (d, 1H, J= 7.5 Hz), 7.43 (t, 1H, J= 7.4 Hz), 
7.26 (m, 2H), 6.05 (s, 1H), 2.95 (t, 4H, J= 5.4 Hz), 1.60 (m, 4H), 1.50 (m, 2H).  13C-
NMR (DMSO-d6- 300 MHz Varian Unity) δ 169.4, 159.2, 146.2, 133.1, 127.4, 126.1, 
122.7, 119.8, 90.7, 40.4, 25.7, 18.7, 18.3 ppm. 
 223
Synthesis of 5-[(2-thio-4,6-dioxohexahydropyrimidin-5-yl)(2, 4, 5-
trimethoxybenzyl)methyl]pyrimidine-2-thio-4,6-(1H,3H,5H)-dione morpholinium salt 
(G35)  Into 100 mL methanol, 4,6-dihydroxy-2-mercaptopyrimidine (2.88 g; 0.02 mol), 
2,4,5-trimethoxybenzaldehyde (1.98 g; 0.01 mol), and morpholine (1.10 mL; 1.00 g; 
0.011 mol) were mixed while stirring.  The reaction suspension was refluxed overnight.  
The reaction suspension was cooled to room temperature and the pale yellow solid was 
filtered and washed with ether (3×20 mL).  The solid was oven dried at 105º C for 3 
hours to afford 5.04 g (91%) pure product.  Product decomposes at temperatures above 
200º C.  1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ  6.71 (s, 1H), 6.51 (s, 1H), 5.87 
(s, 1H), 3.74 (t, 4H), 3.71 (s, 3H), 3.58 (s, 3H), 3.57 (s, 3H), 3.09 (t, 4H).  13C-NMR 
(DMSO-d6- 300 MHz Varian Unity) δ 168.9, 159.2, 148.0, 144.1, 138.0, 120.0, 112.0, 
95.6, 92.7, 60.1, 53.6, 52.9, 52.2, 39.7, 23.1 ppm. 
 
Synthesis of 5-[(2-thio-4,6-dioxohexahydropyrimidin-5-yl)(4-
(dimethylamino)benzyl)methyl]pyrimidine-2-thio-4,6-(1H,3H,5H)-dione lysine salt 
(G36)  Into 100 mL methanol, 4,6-dihydroxy-2-mercaptopyrimidine (2.88 g; 0.02 mol), 
4-dimethylaminobenzaldehyde (1.49 g; 0.01 mol), and lysine monohydrate (1.80 g. 0.011 
mol) were mixed while stirring.  The reaction suspension was refluxed overnight.  The 
reaction suspension was cooled to room temperature and the pale yellow solid was 
filtered and washed with ether (3×20 mL).  The solid was oven dried at 105º C for 3 
hours to afford 3.77 g (90%) pure product.  Product decomposes at temperatures above 
200º C.  1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 6.79 (d, 2H, J= 8.4 Hz), 6.55 
(d, 2H, J= 9.0 Hz), 5.85 (s, 1H), 3.35 (t, 1H, J= 5.9 Hz), 2.78 (s, 6H), 2.75 (t, 2H, J= 7.8 
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Hz), 1.66 (m, 2H), 1.52 (m, 2H), 1.39 (m, 2H).  13C-NMR (DMSO-d6- 300 MHz Varian 
Unity) δ 169.1, 167.5, 160.1, 144.7, 127.3, 123.5, 108.9, 92.7, 49.9, 37.0, 36.8, 26.5, 
25.9, 23.0, 18.2 ppm. 
 
Preparation 5-Benzoyl-1-butylpyrimidine-2,4,6-trione (H5).  Benzoyl chloride (14.1 g; 
0.1 mol) was slowly added over 10 minutes into a stirring pyridine (60 mL) solution of 1-
butylbarbituric acid (18.4 g; 0.1 mol).  The resulting reaction mixture was stirred at room 
temperature for an additional two hours.  The pyridine reaction mixture was then slowly 
added over thirty minutes into a stirring solution of methanol (60 mL), water (50 mL) and 
concentrated hydrochloric acid (150 mL).  The resulting suspension was stirred at room 
temperature for an additional half an hour and then at 0º C for an additional hour.  Solid 
precipitate was separated by filtration, washed (3×15 mL) with diluted hydrochloric acid 
(one part of concentrated hydrochloric acid and nine parts of water).  Solid product was 
dried at 110º C for half an hour to afford pure 1e in 28.0 g (97%).  m.p. 138.9-139.7 º C.  
1H-NMR (DMSO-d6, 500 MHz) δ 11.90 (1H, s), 7.55 (2H, d, J= 7 Hz), 7.53 (1H, t, J= 
7.5 Hz), 7.43 (2H, t, J= 7.5 Hz), 3.71 (2H, t, J= 7.5 Hz), 1.47 (2H, m), 1.24 (2H, m), and 
0.86 ppm (3H, t, J= 7 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 186.9, 164.0, 161.0, 
146.0, 131.7, 127.9, 125.0, 124.0, 91.8, 36.0, 26.1, 16.1, and 10.2 ppm.  MS-ES+ 
(CH3OH) m/z: 289 (M+1+), 311 (M+Na+), 343 (M+CH3OH+Na+). Anal. Calcd.  for 
C15H16N2O4 (288.30): C, 62.49; H, 5.59; N, 9.72; Found C, 62.23; H, 5.56; N, 9.88. 
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Preparation 5-Benzoylpyrimidine-2,4,6-trione (H1).  Benzoyl chloride (14.1 g; 0.1 mol) 
was slowly added over 10 minutes into a stirring pyridine (60 mL) solution of barbituric 
acid (12.8 g; 0.1 mol).  The resulting reaction mixture was stirred at room temperature for 
additional two hours.  The pyridine reaction mixture was then slowly added over thirty 
minutes into stirring solution of methanol (60 mL), water (50 mL) and concentrated 
hydrochloric acid (150 mL).  The resulting suspension was stirred at room temperature 
for additional half an hour and at 0º C for an additional hour.  The solid precipitate was 
separated by filtration, washed (3×15 mL) with diluted hydrochloric acid (one part of 
concentrated hydrochloric acid and nine parts of water).  The solid product was dried at 
110º C for half an hour to afford 20.9 g (90%) of pure product.  1H-NMR (DMSO-d6, 500 
MHz) δ 11.48 (2H, s), 7.5 6(2H, d, J= 8.7 Hz), 7.53 (1H, t, J= 6.3 Hz), and 7.42 ppm 
(2H, t, J= 7.5 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 186, 163, 145, 131, 128, 125, 123, 
and 91 ppm.  Anal. Calcd.  for C11H8N2O4 (232.05): C, 56.90; H, 3.47; N, 12.06; Found 
C, 56.81; H, 3.56; N, 11.91. 
 
Preparation 5-Benzyl-1-phenylpyrimidine-2,4,6-trione (H2).  Benzoyl chloride (14.1 g; 
0.1 mol) was slowly added over 10 minutes into a stirring pyridine (60 mL) solution of 1-
phenylbarbituric acid (20.4 g; 0.1 mol).  The resulting reaction mixture was stirred at 
room temperature for additional two hours.  The pyridine reaction mixture was then 
slowly added over thirty minutes into stirring solution of methanol (60 mL), water (50 
mL) and concentrated hydrochloric acid (150 mL).  The resulting suspension was stirred 
at room temperature for additional half an hour and at 0º C for an additional hour.  The 
solid precipitate was separated by filtration, washed (3×15 mL) with diluted hydrochloric 
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acid (one part of concentrated hydrochloric acid and nine parts of water).  Thesolid 
product was dried at 110º C for half an hour to afford 25.5 g (83%) pure product.  1H-
NMR (DMSO-d6, 500 MHz) δ 12.09 (1H, s), 7.59 (2H, d, J= 7.2 Hz), 7.51 (d, 1H, J= 6.9 
Hz), 7.42 (5H, m J= 7.8 Hz), and 7.29 ppm (2H, d, J= 9.3 Hz).  13C-NMR (DMSO-d6) δ 
186, 164, 161, 145, 131, 131, 127, 125, 125, 124, 124, 123, and 92 ppm. .  Anal. Calcd.  
for C17H12N2O4 (308.08): C, 66.23; H, 3.92; N, 9.09; Found C, 66.11; H, 3.98; N, 10.98. 
  
Preparation of 5-benzoyl-1-methylpyrimidine-2,4,6-trione (H3).  Benzoyl chloride (14.1 
g; 0.1 mol) was slowly added over 10 minutes into stirring pyridine (60 mL) solution of 
1-methylbarbituric acid (14.2 g; 0.1 mol).  The resulting reaction mixture was stirred at 
room temperature for additional two hours.  The pyridine reaction mixture was then 
slowly added over thirty minutes into stirring solution of methanol (60 mL), water (50 
mL) and concentrated hydrochloric acid (150 mL).  The resulting suspension was stirred 
at room temperature for additional half an hour and at 0º C for an additional hour.  The 
solid precipitate was separated by filtration, washed (3×15 mL) with diluted hydrochloric 
acid (one part of concentrated hydrochloric acid and nine parts of water).  The solid 
product was dried at 110º C for half an hour to afford 77%.  1H-NMR (DMSO-d6, 500 
MHz) δ 11.91 (1H, s), 7.56 (2H, d, J= 8.1 Hz), 7.44 (3H, t+t), and 3.09 ppm (3H, s).  
13C-NMR (DMSO-d6) δ 186, 163, 159, 146, 131, 127, 124, 123, 91, and 23 ppm.  Anal. 
Calcd.  for C12H10N2O4 (246.06): C, 58.54; H, 4.09; N, 11.38; Found C, 58.68; H, 4.01; 
N, 11.22. 
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Preparation of 5-(4-methoxybenzoyl)pyrimidine-2,4,6-trione (H6). 4-methoxybenzoyl 
chloride (17.1 g; 0.1 mol) was slowly added over 10 minutes into stirring pyridine (60 
mL) solution of barbituric acid (12.8 g; 0.1 mol).  The resulting reaction mixture was 
stirred at room temperature for additional two hours.  The pyridine reaction mixture was 
then slowly added over thirty minutes into stirring solution of methanol (60 mL), water 
(50 mL) and concentrated hydrochloric acid (150 mL).  The resulting suspension was 
stirred at room temperature for additional half an hour and at 0º C for an additional hour.  
The solid precipitate was separated by filtration, washed (3×15 mL) with diluted 
hydrochloric acid (one part of concentrated hydrochloric acid and nine parts of water).  
The solid product was dried at 110º C for half an hour to afford 22.8 g (87%) pure 
product.  1H-NMR (DMSO-d6, 500 MHz) δ 11.41 (2H, s), 7.61 (2H, d, J= 8.7 Hz), 6.94 
(2H, d, J= 8.7 Hz), and 3.80 ppm (3H, s).  13C-NMR (DMSO-d6) δ 185,162, 159, 145, 
128, 123, 109, 90, and 51 ppm.  Anal. Calcd.  for C12H10N2O5 (262.06): C, 54.97; H, 
3.84; N, 10.68; Found C, 54.86; H, 3.92; N, 10.55. 
  
Preparation 5-(4-methoxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (H7).  4-
Methoxybenzoyl chloride (17.1 g; 0.1 mol) was slowly added to stirring pyridine (60 mL) 
solution of 1,3-dimethylbarbituric acid (15.6 g; 0.1 mol).  The resulting reaction 
suspension was stirred at room temperatures for four hours and then added into aqueous 
hydrochloric acid made from water (50 mL) and concentrated hydrochloric acid (150 
mL).  The resulting suspension was stirred at room temperature for thirty minutes and 
then at 70º C for 30 minutes.  After heating, reaction suspension became clear water 
solution.  Water solution was extracted (4×100mL) with ethyl acetate.  Combined ethyl 
 228
acetate extracts were dried over anhydrous magnesium sulfate and evaporated to an oily 
residue.  Oily residue was dissolved in ethanol (10 mL) and kept at 0º C to form yellow 
crystals that were separated by filtration, washed with ice cold ethanol (3×5 mL) and 
dried on the air to give 26.1 g (90%).  m.p. 143.8-145.1 º C.  1H-NMR (DMSO-d6, 500 
MHz) δ 7.61 (2H, d, J= 8 Hz), 6.98 (2H, d, J= 8 Hz), 3.84 (3H, s), and 3.17 ppm (6H, s).  
13C-NMR (DMSO-d6, 500 MHz) δ 188.7, 162.5, 159.0, 150.1, 126.5, 112.8, 94.7, 55.4, 
and 27.8 ppm.  MS-ES+ (CH3OH) m/z: 291 (M+1+), 313 (M+Na+), 345 
(M+CH3OH+Na+).  Anal. Calcd.  for C14H14N2O5 (290.27): C, 57.93; H, 4.86. Found: C, 
57.83; H, 4.78. 
  
Preparation of 5-benzoyl-1,3-dimethylpyrimidine-2,4,6-trione (H4).  Benzoyl chloride 
(14.1 g; 0.1 mol) was slowly added to stirring pyridine (60 mL) solution of 1,3-
dimethylbarbituric acid (15.6 g; 0.1 mol).  The resulting reaction suspension was stirred 
at room temperatures for four hours and then added into aqueous hydrochloric acid made 
from water (50 mL) and concentrated hydrochloric acid (150 mL).  The resulting 
suspension was stirred at room temperature for thirty minutes and then at 70º C for 30 
minutes.  After heating, reaction suspension became clear water solution.  Water solution 
was extracted (4×100mL) with ethyl acetate.  The combined ethyl acetate extracts were 
dried over anhydrous magnesium sulfate and evaporated to an oily residue.  Oily residue 
was dissolved in ethanol (10 mL) and kept at 0º C to form yellow crystals that were 
separated by filtration, washed with ice cold ethanol (3×5 mL) and dried on the air to 
give 21.8 g (84%) pure product.  1H-NMR (DMSO-d6, 500 MHz) δ 7.53 (3H, d+t, J= 3.0 
Hz), 7.44 (2H, t, J= 8.1 Hz), and 3.17 ppm (s, 6H).  13C-NMR (DMSO-d6, 500 MHz) δ 
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185, 163, 146, 131, 127, 124, 124, 92, and 24 ppm.  Anal. Calcd.  for C12H12N2O4 
(260.25): C, 60.00; H, 4.65; N, 10.76. Found C, 59.91; H, 4.73; N, 10.65. 
  
Preparation of 5-(4-nitrobenzyl)-1,3-dimethylbarbituric acid (H9).  Into tetrahydrofuran 
solution (200 mL) of 1,3-dimethylbarbituric acid (17.2 g; 0.11 mol) and 4-nitrobenzoyl 
chloride (18.5 g; 0.1 mol) with stirring N-methylmorpholine (15.15 g; 0.15 mol) was 
added.  Color of the reaction mixture immediately changes from yellow to deep red and 
white precipitate (N-methylmorpholinium chloride) starts to form.  Tetrahydrofuran was 
distilled off under atmospheric pressure until volume of the reaction suspension was ~50 
mL.  This suspension was poured into ice cooled aqueous hydrochloric acid (800 mL 
water and 200 mL concentrated hydrochloric acid).  Yellow precipitate was separated by 
filtration and washed with ice water (3×20 mL).  Product contains ~3% 4-nitrobenzoic 
acid.  Crude product was added to aqueous sodium bicarbonate (3 g NaHCO3 in 200 mL 
water) and resulting suspension was stirred at room temperature for one hour.  Solid was 
separated by filtration, washed with ice water and added to aqueous ammonium chloride 
(4 g =NH4Cl in 100 mL water).  Resulting suspension was refluxed for five minutes, 
cooled in ice-water.  White crystalline product was separated by filtration, washed with 
ice water (3×15 mL) and dried at 110º C for half an hour to afford 27.8 g (91%) pure 
product.  Product decomposes at temperatures above 190º C.  1H-NMR (DMSO-d6, 500 
MHz) δ 8.21 (2H, d, J= 8 Hz), 7.64 (2H, d, J= 8 Hz), and 3.12 ppm (6H, s).  13C-NMR 
(DMSO- d6, 500 MHz) δ 189.1, 163.9, 151.1, 147.7, 128.6, 122.8, 95.2, and 27.4 ppm. 
MS-ESI+ (CH3OH) m/z: 360 (M+CH3OH+Na+), 382 (NaM+CH3OH+Na+).  Anal. Calcd.  
for C13H11N3O6 (305.24): C, 51.15; H, 3.63; N, 13.77; Found C, 51.08; H, 3.71; N, 13.72. 
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Preparation of 5-(3-nitrobenzoyl)-pyrimidine-2,4,6-trione (H8).  Into tetrahydrofuran 
solution (200 mL) of barbituric acid (14.1 g; 0.11 mol) and 3-nitrobenzoyl chloride (18.5 
g; 0.1 mol) with stirring N-methylmorpholine (15.15 g; 0.15 mol) was added.  Color of 
the reaction mixture immediately changes from yellow to deep red and white precipitate 
(N-methylmorpholinium chloride) starts to form.  Tetrahydrofuran was distilled off under 
atmospheric pressure until volume of the reaction suspension was ~50 mL.  This 
suspension was poured into ice cooled aqueous hydrochloric acid (800 mL water and 200 
mL concentrated hydrochloric acid).  Yellow precipitate was separated by filtration and 
washed with ice water (3×20 mL).  Product contains ~3% 3-nitrobenzoic acid.  Crude 
product was added to aqueous sodium bicarbonate (3 g NaHCO3 in 200 mL water) and 
resulting suspension was stirred at room temperature for one hour.  Solid was separated 
by filtration, washed with ice water and added to aqueous ammonium chloride (4 g 
=NH4Cl in 100 mL water).  Resulting suspension was refluxed for five minutes, cooled in 
ice-water.  White crystalline product was separated by filtration, washed with ice water 
(3×15 mL) and dried at 110º C for half an hour to afford 25.7 g (93%) pure product.  1H-
NMR (DMSO-d6, 500 MHz) δ 8.61 (1H, s), 8.46 (1H, d, J= 11Hz), 8.34 (1H, d, J= 
13Hz), and 7.81 (1H, t, J= 13 Hz) ppm (6H, s).  13C-NMR (DMSO-d6, 500 MHz) δ 
188.2, 161.4, 154.0, 143.8, 131.3, 128.4, 126.5, 119.6, and 95.5 ppm. 
  
Preparation of 1,3-dimethyl-5-(3-nitrobenzoyl)pyrimidine-2,4,6-trione (H11).  Into 
tetrahydrofuran solution (200 mL) of 1,3-dimethylbarbituric acid (17.2 g; 0.11 mol) and 
3-nitrobenzoyl chloride (18.5 g; 0.1 mol) with stirring N-methylmorpholine (15.15 g; 
0.15 mol) was added.  Color of the reaction mixture immediately changes from yellow to 
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deep red and white precipitate (N-methylmorpholinium chloride) starts to form.  
Tetrahydrofuran was distilled off under atmospheric pressure until volume of the reaction 
suspension was ~50 mL.  This suspension was poured into ice cooled aqueous 
hydrochloric acid (800 mL water and 200 mL concentrated hydrochloric acid).  Yellow 
precipitate was separated by filtration and washed with ice water (3×20 mL).  Product 
contains ~3% 3-nitrobenzoic acid.  Crude product was added to aqueous sodium 
bicarbonate (3 g NaHCO3 in 200 mL water) and resulting suspension was stirred at room 
temperature for one hour.  Solid was separated by filtration, washed with ice water and 
added to aqueous ammonium chloride (4 g =NH4Cl in 100 mL water).  Resulting 
suspension was refluxed for five minutes, cooled in ice-water.  White crystalline product 
was separated by filtration, washed with ice water (3×15 mL) and dried at 110º C for half 
an hour to afford 28.9 g (95%) pure product.  1H-NMR (DMSO-d6, 500 MHz) δ 8.34 
(1H, d, J= 12Hz), 8.33 (1H, s), 7.95 (1H, d, J= 11Hz), 7.73 (1H, t, J= 13 Hz), and 3.15 
ppm (6H, s).  13C-NMR (DMSO-d6, 500 MHz) δ 187.3, 164.8, 150.7, 147.3, 137.9, 
134.8, 129.8, 125.7, 123.3, 96.2, and 28.0 ppm.  Anal. Calcd.  for C13H11N3O6 (305.24): 
C, 51.15; H, 3.63; N, 13.77; Found C, 51.05; H, 3.76; N, 13.65. 
  
Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione (H10).  Into tetrahydrofuran 
solution (200 mL) of barbituric acid (14.1 g; 0.11 mol) and 4-nitrobenzoyl chloride (18.5 
g; 0.1 mol) with stirring N-methylmorpholine (15.15 g; 0.15 mol) was added.  Color of 
the reaction mixture immediately changes from yellow to deep red and white precipitate 
(N-methylmorpholinium chloride) starts to form.  Tetrahydrofuran was distilled off under 
atmospheric pressure until volume of the reaction suspension was ~50 mL.  This 
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suspension was poured into ice cooled aqueous hydrochloric acid (800 mL water and 200 
mL concentrated hydrochloric acid).  The yellow precipitate was separated by filtration 
and washed with ice water (3×20 mL).  Product contains ~3% 4-nitrobenzoic acid.  The 
crude product was added to aqueous sodium bicarbonate (3 g NaHCO3 in 200 mL water) 
and resulting suspension was stirred at room temperature for one hour.  The solid was 
separated by filtration, washed with ice water and added to aqueous ammonium chloride 
(4 g =NH4Cl in 100 mL water).  The resulting suspension was refluxed for five minutes, 
cooled in ice-water.  White crystalline product was separated by filtration, washed with 
ice water (3×15 mL) and dried at 110º C for half an hour to afford 25.7 g (93%) pure 
product.  1H-NMR (DMSO-d6, 500 MHz) δ 11.64 (2H, s, NH), 8.27 (2H, d, J= 9.0Hz), 
and 7.79 ppm (2H, d, J= 9Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 188.2, 149.3, 148.6, 
141.7, 129.6, 122.8, and 95.8 ppm. 
  
Preparation of 5-(3,5-Dinitro-benzoyl)-pyrimidine-2,4,6-trione (H12).  Into 
tetrahydrofuran solution (200 mL) of barbituric acid (14.1 g; 0.11 mol) and 3,5-
dinitrobenzoyl chloride (23.0 g; 0.1 mol) with stirring N-methylmorpholine (15.15 g; 
0.15 mol) was added.  Color of the reaction mixture immediately changes from yellow to 
deep red and white precipitate (N-methylmorpholinium chloride) starts to form.  
Tetrahydrofuran was distilled off under atmospheric pressure until volume of the reaction 
suspension was ~50 mL.  This suspension was poured into ice cooled aqueous 
hydrochloric acid (800 mL water and 200 mL concentrated hydrochloric acid).  The 
yellow precipitate was separated by filtration and washed with ice water (3×20 mL).  The 
product contains ~3% 3,5-dinitrobenzoic acid.  The crude product was added to aqueous 
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sodium bicarbonate (3 g NaHCO3 in 200 mL water) and resulting suspension was stirred 
at room temperature for one hour.  Solid was separated by filtration, washed with ice 
water and added to aqueous ammonium chloride (4 g =NH4Cl in 100 mL water).  The 
resulting suspension was refluxed for five minutes, cooled in ice-water.  White crystalline 
product was separated by filtration, washed with ice water (3×15 mL) and dried at 110º C 
for half an hour to afford 29.0 g (90%) pure product.  1H-NMR (DMSO-d6, 500 MHz) δ 
9.90 (2H, s), 8.79 (1H, s), and 8.42 ppm (2H,s).  13C-NMR (DMSO-d6, 500 MHz) δ 
186.3, 165.4, 151.2, 147.5, 147.2, 127.5, 118.1, and 93.3 ppm. 
  
Preparation of 5-(3,5-dinitrobenzoyl)-1-methylpyrimidine-2,4,6-trione (H13). 
Into tetrahydrofuran solution (200 mL) of 1-methylbarbituric acid (15.6 g; 0.11 mol) and 
3,5-dinitrobenzoyl chloride (23.0 g; 0.1 mol) with stirring N-methylmorpholine (15.15 g; 
0.15 mol) was added.  The color of the reaction mixture immediately changes from 
yellow to deep red and white precipitate (N-methylmorpholinium chloride) starts to form.  
Tetrahydrofuran was distilled off under atmospheric pressure until volume of the reaction 
suspension was ~50 mL.  This suspension was poured into ice cooled aqueous 
hydrochloric acid (800 mL water and 200 mL concentrated hydrochloric acid).  The 
yellow precipitate was separated by filtration and washed with ice water (3×20 mL).  
Product contains ~3% 3,5-dinitrobenzoic acid.  The crude product was added to aqueous 
sodium bicarbonate (3 g NaHCO3 in 200 mL water) and resulting suspension was stirred 
at room temperature for one hour.  The solid was separated by filtration, washed with ice 
water and added to aqueous ammonium chloride (4 g =NH4Cl in 100 mL water).  The 
resulting suspension was refluxed for five minutes, cooled in ice-water.  White crystalline 
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product was separated by filtration, washed with ice water (3×15 mL) and dried at 110º C 
for half an hour to afford 31.2 g (93%) pure product.  1H-NMR (DMSO-d6, 500 MHz) δ 
8.78 (1H, s), 8.41 (2H, s), and 3.05 ppm (6H, s).  13C-NMR (DMSO-d6, 500 MHz) δ 
187.1, 163.2, 152.3, 148.2, 147.4, 127.3, 118.1, 93.4, and 27.1 ppm.  Anal. Calcd.  for 
C12H8N3O8 (336.21): C, 42.87; H, 2.40; N, 16.66; Found C, 42.78; H, 2.51; N, 16.55. 
  
Preparation of 5-(3-hydroxybenzoyl)barbituric acid (H14).  Chloroform solution (150 
mL) of 3-acetoxybenzoic acid (1.8 g; 0.01 mol) and oxalyl chloride (2.5 g 0.02 mol) was 
stirred at room temperature for four hours.  After evaporation of solvent the oily residue 
was dissolved in carbon tetrachloride (70 mL) and solvent was again evaporated.  
Chloroform (~30 mL) of this oily residue was slowly added into stirring pyridine (30 mL) 
suspension of barbituric acid (1.28 g; 0.01 mol).  The resulting dark red reaction mixture 
was stirred at room temperature for additional hour and then added slowly over of 20 
minutes into stirring aqueous hydrochloride (10 mL water, 20 mL concentrated 
hydrochloric acid, and 5 mL methanol).  The resulting suspension was stirred at room 
temperature for additional half an hour and kept at 0º C for one hour.  The solid material 
was separated by filtration and it contains both 5-(3-acetyloxybenzoyl)barbituric acid and 
5-(3-hydroxybenzoyl)barbituric acid.  To complete the ester hydrolysis solid material was 
mixed with aqueous sodium hydroxide (0.6 g; 0.015 mol of NaOH in 30 mL water) and 
heated at 70º C for half an hour.  The resulting reaction mixture was acidified to pH=2 at 
ice-water bath temperature.  The formed white solid precipitate was separated by 
filtration, washed with ice-cooled water (3×5 mL) and dried at 110º C for 30 minutes.  
Isolated yield of 5-(3-hydroxybenzoyl)barbituric acid is 91% (2.26 g).  Product 
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decomposes at temperatures above 270º C.  1H-NMR (DMSO-d6, 500 MHz) δ, 11.43 
(2H, s), 9.65 (1H, s), 7.22 (1H, t, J= 8 Hz), 6.97 (1H, d, J= 8 Hz), 6.95 (1H, s), and 6.93 
ppm (1H, d, J= 8 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 190.3, 156.6, 149.4, 136.4, 
128.8, 119.3, 118.6, 115.3, and 95.1 ppm.  MS-ES+ (CH3OH) m/z: 249 (M+1+), 271 
(M+Na+), 313 (M+2CH3OH+1+), 519 (2M+Na+). Anal. Calcd.  for C11H8N2O5 (248.19): 
C, 53.23; H, 3.25; N, 11.29; Found C, 53.42; H, 3.34; N, 11.19. 
  
Preparation of 1-butyl-5-(4-hydroxybenzoyl)pyrimidine-2,4,6-trione (H15).  Chloroform 
solution (150 mL) of 4-acetoxybenzoic acid (1.8 g; 0.01 mol) and oxalyl chloride (2.5 g 
0.02 mol) was stirred at room temperature for four hours.  After evaporation of solvent 
the oily residue was dissolved in carbon tetrachloride (70 mL) and solvent was again 
evaporated.  Chloroform (~30 mL) of this oily residue was slowly added into stirring 
pyridine (30 mL) suspension of 1-butylbarbituric acid (1.84 g; 0.01 mol).  Resulting dark 
red reaction mixture was stirred at room temperature for additional hour and then added 
slowly over of 20 minutes into stirring aqueous hydrochloride (10 mL water, 20 mL 
concentrated hydrochloric acid, and 5 mL methanol).  Resulting suspension was stirred at 
room temperature for additional half an hour and kept at 0º C for one hour.  To complete 
the ester hydrolysis solid material was mixed with aqueous sodium hydroxide (0.6 g; 
0.015 mol of NaOH in 30 mL water) and heated at 70º C for half an hour.  Resulting 
reaction mixture was acidified to pH=2 at ice-water bath temperature.  Formed white 
solid precipitate was separated by filtration, washed with ice-cooled water (3×5 mL) and 
dried at 110º C for 30 minutes to yield 2.34 g (77%) pure product.  1H-NMR (DMSO-d6, 
500 MHz) δ, 11.67(1H, s), 7.51(2H, d, J= 8.5 Hz), 6.80(2H, d, J= 8.5 Hz), 3.70 (2H, t, 
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J= 7.2 Hz), 1.47 (2H, m), 1.25 (2H, m), and 0.86 ppm (3H, t, J= 7.0 Hz).  13C-NMR 
(DMSO-d6, 500 MHz) δ 186, 163, 161, 158, 145, 128, 121, 110, 90, 36, 26, 16, 10 ppm. 
  
Preparation of 5-(4-hydroxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (H16).  
Chloroform solution (150 mL) of 4-acetoxybenzoic acid (18.0 g; 0.1 mol) and oxalyl 
chloride (25.0 g 0.2 mol) was stirred at room temperature for four hours.  After 
evaporation of solvent the oily residue was dissolved in carbon tetrachloride (70 mL) and 
solvent was again evaporated.  Chloroform (~30 mL) of this oily residue was slowly 
added into stirring pyridine (30 mL) suspension of 1,3-dimethylbarbituric acid (15.6 g; 
0.1 mol).  Resulting dark red reaction mixture was stirred at room temperature for 
additional hour and then added slowly over of 20 minutes into stirring aqueous 
hydrochloride (10 mL water, 20 mL concentrated hydrochloric acid, and 5 mL methanol).  
Resulting suspension was stirred at room temperature for additional half an hour and kept 
at 0º C for one hour.  To complete the ester hydrolysis solid material was mixed with 
aqueous sodium hydroxide (6.00 g; 0.15 mol of NaOH in 30 mL water) and heated at 70º 
C for half an hour.  Resulting reaction mixture was acidified to pH=2 at ice-water bath 
temperature.  Formed white solid precipitate was separated by filtration, washed with ice-
cooled water (3×5 mL) and dried at 110º C for 30 minutes yielding 23.4 g (85%) pure 
product.  1H-NMR (DMSO-d6, 500 MHz) δ 7.51(2H, d, J= 6.3 Hz), 6.80 (2H, d, J= 6.9 
Hz), and 3.17 ppm (6H, s).  13C-NMR (DMSO-d6, 500 MHz) δ 185, 161, 158, 146, 128, 
121, 110, 90, and 24 ppm.  Anal. Calcd.  for C13H12N2O5 (276.24): C, 56.52; H, 4.38; N, 
10.14; Found C, 56.45; H, 4.42; N, 10.09. 
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Preparation of 5-(4-hydroxybenzoyl)pyrimidine-2,4,6-trione (H17).  Chloroform 
solution (150 mL) of 4-acetoxybenzoic acid (18.0 g; 0.1 mol) and oxalyl chloride (25.0 g 
0.2 mol) was stirred at room temperature for four hours.  After evaporation of solvent the 
oily residue was dissolved in benzene (70 mL) and solvent was again evaporated.  
Chloroform (~30 mL) of this oily residue was slowly added into stirring pyridine (30 mL) 
suspension of barbituric acid (12.8 g; 0.1 mol).  Resulting dark red reaction mixture was 
stirred at room temperature for additional hour and then added slowly over of 20 minutes 
into stirring aqueous hydrochloride (10 mL water, 20 mL concentrated hydrochloric acid, 
and 5 mL methanol).  Resulting suspension was stirred at room temperature for additional 
half an hour and kept at 0º C for one hour.  To complete the ester hydrolysis solid 
material was mixed with aqueous sodium hydroxide (6.00 g; 0.15 mol of NaOH in 30 mL 
water) and heated at 70º C for half an hour.  Resulting reaction mixture was acidified to 
pH=2 at ice-water bath temperature.  Formed white solid precipitate was separated by 
filtration, washed with ice-cooled water (3×5 mL) and dried at 110º C for 30 minutes 
yielding 19.8 g (80%) pure product.  1H-NMR (DMSO-d6, 500 MHz) δ 11.33 (2H, s), 
7.52 (2H, d, J= 8.0 Hz), and 6.82 ppm (2H, d, J= 8.5 Hz).  13C-NMR (DMSO-d6, 500 
MHz) δ 186, 162, 158, 145, 128, 121, 110, 90 ppm. 
  
Preparation of 5-(4-hydroxybenzoyl)-1-phenylpyrimidine-2,4,6-trione (H18).  
Chloroform solution (150 mL) of 4-acetoxybenzoic acid (18.0 g; 0.1 mol) and oxalyl 
chloride (25.0 g 0.2 mol) was stirred at room temperature for four hours.  After 
evaporation of solvent the oily residue was dissolved in benzene (70 mL) and solvent was 
again evaporated.  Chloroform (~30 mL) of this oily residue was slowly added into 
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stirring pyridine (30 mL) suspension of 1-phenylbarbituric acid (20.4 g; 0.1 mol).  
Resulting dark red reaction mixture was stirred at room temperature for additional hour 
and then added slowly over of 20 minutes into stirring aqueous hydrochloride (10 mL 
water, 20 mL concentrated hydrochloric acid, and 5 mL methanol).  Resulting suspension 
was stirred at room temperature for additional half an hour and kept at 0º C for one hour.  
To complete the ester hydrolysis solid material was mixed with aqueous sodium 
hydroxide (6.00 g; 0.15 mol of NaOH in 30 mL water) and heated at 70º C for half an 
hour.  Resulting reaction mixture was acidified to pH=2 at ice-water bath temperature.  
Formed white solid precipitate was separated by filtration, washed with ice-cooled water 
(3×5 mL) and dried at 110º C for 30 minutes yielding 27.0 g (83%) pure product.  1H-
NMR (DMSO-d6, 500 MHz) δ 11.91 (1H, s), 7.55 (2H, d, J= 8.5 Hz), 7.44 (2H, t, J= 7.5 
Hz), 7.38 (1H, t, J= 7.0 Hz), 7.28 (2H, d, J= 8.0 Hz), and 6.78 ppm (2H, d, J= 8.5 Hz).  
13C-NMR (DMSO-d6, 500 MHz) δ 186, 164, 161, 158, 145, 131, 128, 125, 125, 124, 121, 
and 110, 90 ppm. 
  
Preparation of 5-[[2,4-dinitrophenyl)hydrozono]-(4-methoxyphenyl)methyl]-1,3-
dimethylpyrimidine-2,4,6-trione (H26).  To a 1-propanol (20 mL) suspension of 5-(4-
methoxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (1.0 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield of pure 
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product is 1.30 g (81%).  m.p: 98-99.2º C.  1H-NMR(CF3CO2H- DMSO-d6, 500 MHz), 
δ 9.51 (1H, s), 8.62 (1H, d,  J= 2.5 Hz), 8.01 (1H, d, J= 9 Hz), 6.94 (1H, d, J= 9 Hz), 
6.83 (2H, d, J= 7 Hz), 6.56 (2H, d, J= 7Hz), 3.44 (3H, s), 2.97(6H, s).  13C-NMR 
(CF3CO2H- DMSO-d6, 500 MHz), δ 176.2, 165.5, 163.2, 153.1, 146.5, 139.5, 131.2, 
128.6, 123.8, 123.4, 114.9, 109.3, 92.1, 55.4, and 28.4 ppm.  MS-ES+ (MeOH) m/z 413 
(75%), 423 (55%), 493 (M + 23).  Anal. Calcd.  for C20H18N6O8 (470.39): C, 51.07; H, 
3.86; N, 17.87; Found C, 51.01; H, 3.92; N, 17.82. 
  
Preparation of 5-{[N'-(4-nitrophenyl)hydrazino]phenylmethylene}pyrimidine-2,4,6-
trione (H19).  To a 1-propanol (20 mL) suspension of 5-(benzoyl)-pyrimidine-2,4,6-
trione (0.792 g; 3.4 mmol) and 4-nitrophenylhydrazine (0.520 g; 3.4 mmol) one drop of 
sulfuric acid was added.  The reaction mixture was stirred while refluxing and became a 
clear solution after 30 minutes.  The reaction mixture was refluxed for additional four 
hours and left at 0º C for one hour.  Resulting brown precipitate was separated by 
filtration, washed with 1-propanol (3 x 5 mL), ether (3 x 10 mL) and dried at 50º C for 
twenty minutes.  The isolated yield of pure is 0.913 g (73%).  1H-NMR (CF3CO2H- 
DMSO-d6, 500 MHz), δ 7.72 (2H, d, J= 8.5 Hz), 7.03 (1H, t, J= 7.8 Hz), 6.96 (2H, t, J= 
7.0 Hz), 6.81 (2H, d, J= 8.0 Hz), and 6.38 ppm (2H, d, J= 9.5 Hz).  13C-NMR 
(CF3CO2H- DMSO-d6, 500 MHz), δ 177, 166, 152, 151, 141, 131, 129, 129, 126, 126, 
112, and 89 ppm. 
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Preparation of 4-{N’-[phenyl-(2,4,6-trioxo-1-phenylhexahydropyrimidin-5-
yl)methylene]-hydrazino}benzoic acid (H20).  1-Propanol (20 mL) mixture of 5-benzoyl-
1-phenylpyrimidine-2,4,6-trione (1.0 g; 3.25 mmol) and 4-hydrazino-benzoic acid (0.494 
g; 3.25 mmol) were added.  To the resulting reaction mixture 1 drop of sulfuric acid was 
carefully added.  The reaction was stirred while refluxing and became a clear solution 
after 10 minutes.  The reaction mixture was allowed to reflux for 4 hours.  The resulting 
reaction mixture was then cooled to room temperature, and a solid yellow precipitate 
formed.  The solid was removed by filtration and washed with ether (3 x 15 mL).  The 
resulting solid was oven dried at 110º C for 2 hours.  Isolated yield of pure product is 
1.10 g (79 %).  Product decomposes at temperatures above 200º C.  1H-NMR(CF3CO2H- 
DMSO-d6, 500 MHz), δ  7.57 (d, 2H, J= 4.5 Hz, Ar), 7.06 (d of t, 3H, J= 3.0 Hz, Ar), 
7.01 (t, 1H, J= 7.0 Hz, Ar), 6.93 (t, 2H, J= 7.0 Hz, Ar), 6.86 (d of t, 4H, J= 3.5 Hz, Ar), 
6.37 (d, 2H, J= 4.5 Hz, Ar).  13C-NMR (CF3CO2H- DMSO-d6, 500 MHz), δ 176, 173, 
166, (162, 161, 161, 160 quartet belonging to CF3CO2H), 152, 150, 132, 132, 131, 130, 
130, 130, 129, 128, 126, 121, (120, 116, 113, 109 quartet belonging to CF3CO2H), 113, 
90 ppm.  MS-ES+ (MeOH) m/z 195(75%), 360(100%), 408(60%), 465 (M + 23).  
MW=442.42 g/mol + 0.3 molecules H2O.  Anal. Calcd.  for C24H18N4O5: C, 64.36; H, 
4.19; N, 12.51.  Found C, 64.36; H, 4.21; N, 12.53. 
  
Preparation of 5-{[N'-(2,4-dinitrophenyl)hydrazino]phenylmethylene}-1,3-
dimethylpyrimidine-2,4,6-trione (H21).  To a 1-propanol (20 mL) suspension of 5-
(benzoyl)-1,3-dimethylpyrimidine-2,4,6-trione ( 0.887 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
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reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes to yield 1.24 g (83%) pure 
product.  Mp: 92.2-94.5º C.  1H-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 9.42 (1H, s), 
8.55 (1H, s), 8.01 (1H, d, J= 9.5 Hz), 7.00 (1H, d, J= 6.5 Hz), 6.90 (3H, m), 6.86 (2H, t, 
J= 8.0 Hz), and 2.96 ppm (6H, s).  13C-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 175, 
165, 152, 146, 139, 131, 130, 130, 130, 129, 125, 123, 116, 91, and 28 ppm. 
  
Preparation of 5-{[N'-(2,4-dinitrophenyl)hydrazino]phenylmethylene}-1-
phenylpyrimidine-2,4,6-trione (H22).  To a 1-propanol (20 mL) suspension of 5-
(benzoyl)-1-phenylpyrimidine-2,4,6-trione (1.05 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 1.46 g 
(88%).  1H-NMR (DMSO-d6, 500 MHz) δ 11.51 (1H, s), 10.69 (1H, s), 8.88 (1H, d, J= 
2.4 Hz), 8.37 (1H, d, J1=12.6 Hz, J2=2.7 Hz), 8.10 (1H, d, J= 9.6 Hz),7.83 (2H, d, J= 9.0 
Hz), 7.39 (5H, m), 7.30 (1H, t, J= 7.2 Hz), and 7.21 ppm (2H, d, J= 7.8 Hz).  13C-NMR 
(DMSO-d6, 500 MHz) δ 157, 157, 150, 147, 140, 134, 133, 132, 126, 125, 125, 125, 124, 
124, 124, 123, 119, 113, and 77 ppm.  Anal. Calcd.  for C23H16N6O7: C, 56.56; H, 3.30; 
N, 17.21.  Found C, 56.48; H, 3.41; N, 17.09. 
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Preparation of 5-{[N'-(2,4-dinitrophenyl)hydrazino]phenylmethylene}-pyrimidine-
2,4,6-trione (H23).  To a 1-propanol (20 mL) suspension of 5-(benzoyl)-pyrimidine-
2,4,6-trione ( 0.792 g; 3.4 mmol) and 2,4-dinitrophenylhydrazine (0.683 g; 3.4 mmol) 
one drop of sulfuric acid was added.  The reaction mixture was stirred while refluxing 
and became a clear solution after 30 minutes.  The reaction mixture was refluxed for 
additional four hours and left at 0º C for one hour.  Resulting orange precipitate was 
separated by filtration, washed with 1-propanol (3×5 mL), ether (3×10 mL) and dried at 
50º C for twenty minutes.  The isolated yield is 1.17 g (84%).  1H-NMR (DMSO-d6, 500 
MHz) δ 11.41 (1H, s), 10.74 (2H, s), 8.87 (1H, d, J= 2.7 Hz), 8.39 (1H, d, J1=12.3 Hz, 
J2=2.4 Hz), 8.12 (1H, d, J= 9.9 Hz), 7.79 (2H, t, J= 9.9 Hz), and 7.39 (3H, J= 3.2 Hz).  
13C-NMR (DMSO-d6, 500 MHz) δ 158, 148, 147, 140, 133, 133, 126, 125, 125, 124, 123, 
119, 113, and 78 ppm. 
  
Preparation of 4-{N'-[(1,3-dimethyl-2,4,6-trioxotetrahydropyrimidin-5-
ylidene)phenylmethyl]hydrazino}-benzoic acid (H24).  To a 1-propanol (20 mL) 
suspension of 5-(benzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (0.887 g; 3.4 mmol) and 
4-hydrazinobenzoic acid (0.520 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting brown precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 79%.  
1H-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 7.55 (2H, d, J= 8.5 Hz), 7.01 (1H, t, J= 7.5 
Hz), 6.95 (2H, t, J= 7.5 Hz), 6.81 (2H, d, J= 7.5 Hz), 6.36 (2H, d, J= 8.5 Hz), and 2.95 
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ppm (6H, s).  13C-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 175, 173, 165, 153, 151, 
132, 131, 130, 129, 126, 120, 112, 90, and 28 ppm. 
  
Preparation of 5-{(4-Methoxyphenyl)-[N'-(4-nitrophenyl)hydrazino]methylene}-1,3-
dimethylpyrimidine-2,4,6-trione (H25).  To a 1-propanol (20 mL) suspension of 5-(4-
methoxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (1.0 g; 3.4 mmol) and 4-
nitrophenylhydrazine (0.520 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting brown precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 82%. 
1H-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 9.51 (1H, s), 8.03 (2H, d, J= 9.0 Hz), 7.16 
(2H, d, J= 9.0 Hz), 6.86 (2H, d, J= 9.0 Hz), 6.75 (2H, d, J= 9.0 Hz), 3.73 (3H, s), and 
3.11 ppm (3H, s).  13C-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 162.8, 158.0, 150.5, 
151.6, 149.8, 137.3, 132.6, 128.3, 126.1, 113.1, 110.4, 81.2, 53.4, and 26.5 ppm.  Anal. 
Calcd.  for C2oH19N5O6: C, 56.47; H, 4.50; N, 16.46.  Found: C, 56.33; H, 4.58; N, 16.38. 
  
Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-methoxyphenyl)methylene]-1-
methylpyrimidine-2,4,6-trione (H27).  To a 1-propanol (20 mL) suspension of 5-(4-
methoxybenzoyl)-1-methylpyrimidine-2,4,6-trione (0.942 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
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Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 81%.  
1H-NMR (DMSO-d6, 500 MHz) δ 11.32 (1H, s), 11.01 (2H, s), 8.83 (1H, d, J= 2.7 Hz), 
8.33 (1H, d, J= 6.0 Hz), 8.05 (1H, d, J= 9.6 Hz), 7.73 (2H, d, J= 8.7 Hz), 6.93 (2H, d, J= 
9.0 Hz), and 3.76 ppm (3H, s).  13C-NMR (DMSO-d6, 500 MHz) δ 163, 158, 157, 147, 
140, 133, 126, 125, 125, 119, 113, 110, 109, 78, and 51 ppm. 
  
Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(3-hydroxyphenyl)methylene]-1-
methylpyrimidine-2,4,6-trione (H28).  To a 1-propanol (20 mL) suspension of 5-(3-
hydroxybenzoyl)-1-methylpyrimidine-2,4,6-trione (0.894 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 1.30 g 
(88%).  1H-NMR (DMSO-d6, 500 MHz) δ 11.37 (1H, s), 10.76 (2H, s), 8.87 (1H, d, J= 
2.1 Hz), 8.41 (1H, d, J= 12.0 Hz), 8.06 (1H, d, J= 9.5 Hz), 7.24 (1H, t, J= 7.5 Hz), 7.17 
(2H, d), and 6.79 ppm (1H, d, J= 10.0 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 158, 153, 
148, 147, 140, 135, 133, 126, 125, 125, 119, 114, 113, 112, 110, and 78 ppm. 
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Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)methylene]-1-
methylpyrimidine-2,4,6-trione (H29). To a 1-propanol (20 mL) suspension of 5-(4-
hydroxybenzoyl)-1-methylpyrimidine-2,4,6-trione (0.894 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 1.32 g 
(88%).  1H-NMR (DMSO-d6, 500 MHz) δ 11.44 (1H, s), 10.34 (1H, s), 8.86 (1H, d, J= 
1.5 Hz), 8.33 (1H, d, J= 6.0 Hz), 8.04 (1H, d, J= 4.5 Hz), 7.60 (2H, d, J= 4.0 Hz), 6.75 
(2H, d, J= 4.5 Hz), and 3.03 ppm (3H, s).  13C-NMR (DMSO-d6, 500 MHz) δ 158, 157, 
155, 153, 149, 140, 132, 126, 126, 125, 124, 120, 113, 111, 77, and 22 ppm. 
  
Preparation of 1-butyl-5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)-
methylene]pyrimidine-2,4,6-trione (H30).  To a 1-propanol (20 mL) suspension of 5-(4-
hydroxybenzoyl)-pyrimidine-2,4,6-trione ( 0.894 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 1.20 g 
(80%).  1H-NMR (DMSO-d6, 500 MHz) δ 11.34 (1H, s), 10.98 (1H, s), 8.86 (1H, d, J= 
2.5 Hz), 8.36 (1H, d, J= 12.0 Hz), 8.05 (1H, d, J= 9.5 Hz), 7.63 (2H, d, J= 8.5 Hz), 6.79 
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(2H, d, J= 8.5 Hz), 3.72 (2H, t, J= 7.5 Hz), 1.50 (2H, m), 1.26 (2H, m), and 0.86 ppm 
(3H, t, J= 7.5 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 157, 156, 155, 149, 147, 140, 133, 
126, 125, 125, 124, 119, 113, 111, 78, 26, 26, 16, and 10 ppm. 
  
Preparation of 5-[[N'-(2,4-dinitrophenyl)-hydrazino]-(4-hydroxyphenyl)methylene]-
pyrimidine-2,4,6-trione (H31).  To a 1-propanol (20 mL) suspension of 5-(4-
hydroxybenzoyl)-pyrimidine-2,4,6-trione ( 0.846 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 1.32 g 
(91%).  1H-NMR (DMSO-d6, 500 MHz) δ 11.36 (1H, s), 10.79 (2H, s), 8.85 (1H, d, J= 
2.1 Hz), 8.36 (1H, d, J= 10.5 Hz), 8.04 (1H, d, J= 9.9 Hz), 7.63 (2H, d, J= 8.7 Hz), and 
6.78 ppm (2H, d, J= 9.0 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 158, 156, 147, 147, 
140, 133, 126, 126, 125, 123, 118, 113, 111, and 78 ppm.  Anal. Calcd.  for C17H12N6O8: 
C, 47.67; H, 2.82; N, 19.62.  Found: C, 47.55; H, 2.93; N, 19.54. 
  
Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)methylene]-1-
phenylpyrimidine-2,4,6-trione (H32).  To a 1-propanol (20 mL) suspension of 5-(4-
hydroxybenzoyl)-1-phenylpyrimidine-2,4,6-trione (1.10 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
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The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 1.42 g 
(83%).  1H-NMR (DMSO-d6, 500 MHz) δ 11.52 (1H, s), 10.37 (1H, s), 8.87 (1H, d, J= 
2.7 Hz), 8.33 (1H, d, J= 12.0 Hz), 8.03 (1H, d, J= 9.9 Hz), 7.67 (2H, d, J= 9.0 Hz), 7.38 
(2H, t, J= 7.4 Hz), 7.28 (1H, t, J= 7.5 Hz), 7.19 (2H, d, J= 8.4 Hz), and 6.76 ppm (2H, d, 
J= 8.4 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 158, 157, 156, 149, 147, 140, 133, 132, 
126, 126, 125, 125, 125, 124, 124, 119, 113, 111, and 79 ppm. 
  
Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)methylene]-1-
methylpyrimidine-2,4,6-trione (H33).   To a 1-propanol (20 mL) suspension of 5-(4-
hydroxybenzoyl)-1-methylpyrimidine-2,4,6-trione ( 0.894 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 84%.  
1H-NMR (DMSO-d6, 500 MHz) δ 11.40 (1H, s), 10.34(1H, s), 8.85 (1H, d J= 3.0 Hz), 
8.33 (1H, d, J1=12.5 Hz, J2=3.0 Hz), 7.99 (1H, d, J= 9.5 Hz), 7.61 (2H, d, J= 8.5 Hz), 
and 6.75 ppm (2H, d, J= 8.5 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 158, 157, 155, 153, 
149, 140, 132, 126, 126, 125, 124, 119, 112, 111, and 78, 24 ppm. 
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Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)methylene]-1,3-
dimethylpyrimidine-2,4,6-trione (H34).  To a 1-propanol (20 mL) suspension of 5-(4-
hydroxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione ( 0.941 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 91%.  
1H-NMR (DMSO-d6, 500 MHz) δ 11.40 (1H, s), 10.35 (1H, s), 8.34 (1H, d of d, J1=16 
Hz, J2=4 Hz), 8.00 (1H, d, J= 16 Hz), 7.61(2H, d of d, J1=11 Hz, J2=4 Hz), and 6.70 ppm 
(2H, d of d, J1=11 Hz, J2=3 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 157.1, 155.6, 153.7, 
149.1, 140.4, 132.5, 126.3, 126.2, 125.2, 124.9, 120.0, 113.0, 111.4, 78.2, and 23.8 ppm. 
  
Preparation of 5-[[(2,4-dinitrophenyl)hydrazono]-(4-nitrophenyl)methyl]pyrimidine-
2,4,6-trione (H35).  To a 250 mL round bottom flask charged with 20 mL propanol, 5(4-
nitro-benzoyl)-pyrimidine-2,4,6-trione (0.277 g; 1.00 mmol), 2,4-dinitrophenylhydrazine 
(0.198 g; 1.00 mmol), and drop of sulfuric acid was stirred with refluxing for six hours.  
After cooling to room temperature orange solid product was separated by filtration, 
washed with 1-propanol (1 x10 mL), ether (3×15 mL) and dried at 110º C for two hours.  
The yield of pure product was 0.409 g (89%). Product decomposes at temperatures above 
275º C.  1H-NMR (DMSO-d6, 500 MHz), δ 11.51 (1H, s, NH), 10.59 (2H, s, NH), 8.87 
(1H, d, J= 1.0 Hz), 8.40 (1H, d, J= 5.5 Hz), 8.20 (2H, d, J= 4.5 Hz), 8.14 (1H, d, J= 5.0 
Hz), 8.00 (2H, d, J= 4.5 Hz).  13C-NMR (DMSO-d6, 500 MHz), δ 159, 147, 146, 143, 
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140, 140, 133, 126, 126, 125, 119, 119, 113, and 78 ppm.  MS-ES+ (MeOH) m/z 408 
(100%). Anal. Calcd.  for C17H11N7O9: C, 44.65; H, 2.42; N, 21.44.  Found C, 44.65; H, 
2.54; N, 21.20. 
  
Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-
nitrophenyl)methylene]pyrimidine-2,4,6-trione (H36).  To a 1-propanol (20 mL) 
suspension of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6-trione (0.945 g; 3.4 mmol) and 2,4-
dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added.  The 
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.  
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.  
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5 
mL), ether (3×10 mL) and dried at 50º C for twenty minutes.  The isolated yield is 91%.  
1H-NMR (DMSO-d6, 500 MHz) δ 11.51 (1H, s), 10.59 (2H, s), 8.87 (1H, d, J= 2.5 Hz), 
8.40 (1H, d, J= 11.5 Hz), 8.20 (2H, d, J= 8.5 Hz), 8.14 (1H, d, J= 10.0 Hz), and 8.00 
ppm (2H, d, J= 9.0 Hz).  13C-NMR (DMSO-d6, 500 MHz) δ 159, 147, 146, 143, 140, 
140, 133, 126, 126, 125, 119, 119, 113, and 78 ppm. 
  
Preparation of 5-(4-nitrobenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione morpholinium 
salt (H47).  Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-1,3-
dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and morpholine (191 mg; 2.2 mmol) 
was stirred at room temperature for half an hour.  Solvent was evaporated.  Solid residue 
was mixed with ether (100 mL), and resulting suspension was stirred at room temperature 
for ten minutes.  Solid product was separated by filtration, washed with ether (3×15 mL) 
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and dried at 110º C for half an hour. The yield of product is 740 mg (94%). Product 
decomposes at temperatures above 220º C.  1H-NMR (DMSO-d6, 500 MHz) δ 8.12 (2H, 
d, J= 8.5 Hz), 7.52 (2H, d, J= 8.5 Hz), 3.77 (4H, m) , 3.13 (4H, m), and 3.06 ppm (6H, 
s).  13C-NMR (DMSO-d6, 500 MHz) δ 191.0, 163.0, 152.2, 151.4, 146.9, 127.9, 122.6, 
93.7, 63.4, 43.1, and 26.9 ppm.  Anal. Calcd.  for C17H20N4O7 (392.36) C, 52.04; H, 5.14; 
N, 14.28; Found C, 51.96; H, 5.12; N, 14.15. 
  
Preparation of 5-benzoylpyrimidine-2,4,6-trione piperidinium salt (H37).  
Tetrahydrofuran (200 mL) solution of 5-benzoyl-1,3-dimethylpyrimidine-2,4,6-trione 
(522 mg; 2 mmol) and piperidine (191 mg; 2.2 mmol) was stirred at room temperature for 
half an hour.  Solvent was evaporated.  Solid residue was mixed with ether (100 mL), and 
resulting suspension was stirred at room temperature for ten minutes.  Solid product was 
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour. 
The yield of product is 556 mg (80%). Product decomposes at temperatures above 220º 
C.  1H-NMR (DMSO-d6, 500 MHz) δ 7.47 (2H, d, J= 7.0 Hz), 7.36 (1H, t, J= 7.5 Hz), 
7.30 (2H, t, J= 7.5 Hz), 2.97 (4H, t, J= 5.5 Hz), 1.61 (4H, m), and 1.51 ppm (2H, m).  
13C-NMR (DMSO-d6, 500 MHz) δ 190, 162, 148, 139, 126, 125, 124, 90, 41, 19, and 18 
ppm. 
  
Preparation of 5-benzoyl-1-methylpyrimidine-2,4,6-trione piperidinium salt (H38).  
Tetrahydrofuran (200 mL) solution of 5-benzoyl-1-methylpyrimidine-2,4,6-trione (494 
mg; 2 mmol) and piperidine (191 mg; 2.2 mmol) was stirred at room temperature for half 
an hour.  Solvent was evaporated.  Solid residue was mixed with ether (100 mL), and 
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resulting suspension was stirred at room temperature for ten minutes.  Solid product was 
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour. 
The yield of product is 317 mg (95%). Product decomposes at temperatures above 220º 
C.  1H-NMR (DMSO-d6, 500 MHz) δ 9.69(1H, s), 8.52(2H, s), 7.45 (2H, d, J= 9.9 Hz), 
7.28(3H, m) 3.01 (4H, t, J= 6.0 Hz), 2.99 (3H, s), 1.64 (4H m), and 1.54 ppm (2H, m).  
13C-NMR (DMSO-d6, 500 MHz) δ 189, 160, 159, 148, 140, 125, 124, 123, 89, 40, 22, 18, 
and 18 ppm. 
  
Preparation of 5-(4-methoxybenzoyl)pyrimidine-2,4,6-trione piperidinium salt (H39).  
Tetrahydrofuran (200 mL) solution of 5-(4-methoxybenzoyl)-pyrimidine-2,4,6-trione 
(610 mg; 2 mmol) and piperidine (191 mg; 2.2 mmol) was stirred at room temperature for 
half an hour.  Solvent was evaporated.  Solid residue was mixed with ether (100 mL), and 
resulting suspension was stirred at room temperature for ten minutes.  Solid product was 
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour. 
The yield of product is 88%. Product decomposes at temperatures above 220º C.  1H-
NMR (DMSO-d6, 500 MHz) δ 9.70 (2H, s,), 8.58 (2H, s), 7.51 (2H, d, J= 8.7 Hz), 6.83 
(2H, d, J= 8.7 Hz), 3.76 (3H, s), 2.98 (4H, t, J= 5.4 Hz), 1.61 (4H, m), and 1.51 ppm 
(2H, m).  13C-NMR (DMSO-d6, 500 MHz) δ 188, 161, 157, 147, 131, 127, 108, 89, 51, 
40, 18, and 18 ppm. 
  
Preparation of 5-(4-methoxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione piperidinium 
salt (H40).  Tetrahydrofuran (200 mL) solution of 5-(4-methoxybenzoyl)-1,3-
dimethylpyrimidine-2,4,6-trione (582 mg; 2 mmol) and piperidine (191 mg; 2.2 mmol) 
 252
was stirred at room temperature for half an hour.  Solvent was evaporated.  Solid residue 
was mixed with ether (100 mL), and resulting suspension was stirred at room temperature 
for ten minutes.  Solid product was separated by filtration, washed with ether (3×15 mL) 
and dried at 110º C for half an hour. The yield of product is 93%. Product decomposes at 
temperatures above 220º C.  1H-NMR (DMSO-d6, 500 MHz) δ 8.40 (2H, s), 7.52 (2H, d 
J= 8.7 Hz), 6.85 (2H, d, J= 8.7 Hz), 3.77 (3H, s), 3.07 (6H, s), 3.00 (4H, t, J= 5.4 Hz), 
1.63 (4H, m), and 1.54 ppm (2H, m).  13C-NMR (DMSO-d6, 500 MHz) δ 188, 159, 157, 
148, 130, 127, 109, 89, 51, 40, 23, 18, and 18 ppm. 
  
Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione piperidinium salt (H41).  
Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6-trione (558 
mg; 2 mmol) and piperidine (191 mg; 2.2 mmol) was stirred at room temperature for half 
an hour.  Solvent was evaporated.  Solid residue was mixed with ether (100 mL), and 
resulting suspension was stirred at room temperature for ten minutes.  Solid product was 
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour. 
The yield of product is 95%. Product decomposes at temperatures above 220º C.  1H-
NMR (DMSO-d6, 500 MHz) δ 9.65 (2H, s), 8.50 (2H, s), 8.12 (2H, d, J= 8 Hz), 7.51 
(2H, d, J= 8 Hz), 3.00 (4H, m), 1.61 (4H, m), and 1.52 ppm (2H, m).  13C-NMR (DMSO-
d6, 500 MHz) δ 190.5, 165.3, 151.5, 151.3, 147.1, 128.3, 122.8, 93.6, 44.1, 22.3, and 21.8 
ppm. 
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Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione morpholinium salt (H42).  
Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)- pyrimidine-2,4,6-trione (558 
mg; 2 mmol) and morpholine (191 mg; 2.2 mmol) was stirred at room temperature for 
half an hour.  Solvent was evaporated.  Solid residue was mixed with ether (100 mL), and 
resulting suspension was stirred at room temperature for ten minutes.  Solid product was 
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour. 
The yield of product is 90%. Product decomposes at temperatures above 220º C. 1H-
NMR (DMSO-d6, 500 MHz) δ 9.75 (2H, s), 8.11 (2H, d, J= 8.0 Hz), 7.52 (d, 2H, J= 
8.0), 3.74 (4H, m), and 3.09 ppm (4H, m).  13C-NMR (DMSO-d6, 500 MHz) δ 190.9, 
165.6, 151.5, 151.2, 147.2, 128.4, 122.9, 93.9, 63.5, and 43.3 ppm. 
  
Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione N-methylmorpholinium salt 
(H43).  Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6-trione 
(558 mg; 2 mmol) and N-methylmorpholine (224 mg; 2.2 mmol) was stirred at room 
temperature for half an hour.  Solvent was evaporated.  Solid residue was mixed with 
ether (100 mL), and resulting suspension was stirred at room temperature for ten minutes.  
Solid product was separated by filtration, washed with ether (3×15 mL) and dried at 110º 
C for half an hour. The yield of product is 91%. Product decomposes at temperatures 
above 220º C.  1H-NMR (DMSO-d6, 500 MHz) δ 9.68 (2H, s), 8.12 (2H, d, J= 8 Hz), 
7.52 (2H, d, J= 8 Hz), 3.80 (4H, m), 3.20 (4H, m), and 2.79 ppm (3H, s).  13C-NMR 
(DMSO-d6, 500 MHz) δ 190.5, 165.3, 151.4, 151.0, 147.2, 128.4, 122.8, 93.7, 63.6, 53.0, 
and 40.0 ppm. 
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Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione ethanolammonium salt 
(H44).  Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6-trione  
(558 mg; 2 mmol) and ethanolamine ( 140 mg; 2.2 mmol) was stirred at room 
temperature for half an hour.  Solvent was evaporated.  Solid residue was mixed with 
ether (100 mL), and resulting suspension was stirred at room temperature for ten minutes.  
Solid product was separated by filtration, washed with ether (3×15 mL) and dried at 110º 
C for half an hour. The yield of product is 98%. Product decomposes at temperatures 
above 220º C. 1H-NMR (DMSO-d6, 500 MHz) δ 9.62 (2H, s), 8.12 (2H, d, J= 8 Hz), 
7.79 (3H, s), 7.52 (2H, d, J= 8 Hz), 3.67 (2H, m), and 2.85 ppm (2H, m).  13C-NMR 
(DMSO-d6, 500 MHz) δ 190.3, 165.2, 151.5, 151.0, 147.2, 128.4, 122.8, 93.5, 57.6, and 
41.5 ppm. 
  
Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione 4-dimethylaminopyridinium 
salt (H45).  Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6-
trione (558 mg; 2 mmol) and 4-(dimethylamino)benzaldehyde (328 mg; 2.2 mmol) was 
stirred at room temperature for half an hour.  Solvent was evaporated.  Solid residue was 
mixed with ether (100 mL), and resulting suspension was stirred at room temperature for 
ten minutes.  Solid product was separated by filtration, washed with ether (3×15 mL) and 
dried at 110º C for half an hour. The yield of product is 97%. Product decomposes at 
temperatures above 220º C.  1H-NMR (DMSO-d6, 500 MHz) δ 9.50 (2H, s), 8.17 (2H, d, 
J= 7 Hz), 8.11 (2H, d, J= 8 Hz), 7.51 (2H, d, J= 8 Hz), 6.95 (2H, d, J= 7Hz), and 3.16 
ppm (6H, s).  13C-NMR (DMSO-d6, 500 MHz) δ 190.1, 165.0, 157.1, 151.5, 151.3, 
147.1, 139.3, 128.4, 122.8, 107.1 93.3, and 39.8 ppm. 
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Preparation of 5-(4-nitrobenzoyl)1,3-dimethylpyrimidine-2,4,6-trione piperidinium salt 
(H46).  Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-1,3-
dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and piperidine ( 187 mg; 2.2 mmol) 
was stirred at room temperature for half an hour.  Solvent was evaporated.  Solid residue 
was mixed with ether (100 mL), and resulting suspension was stirred at room temperature 
for ten minutes.  Solid product was separated by filtration, washed with ether (3×15 mL) 
and dried at 110º C for half an hour. The yield of product is 92%. Product decomposes at 
temperatures above 220º C.  1H-NMR (DMSO-d6, 500 MHz) δ 8.13 (2H, d, J= 8.5 Hz), 
7.52 (2H, d, J= 8.5 Hz), 3.07 (6H, s), 3.03 (4H, m), 1.65 (4H, m), and 1.54 ppm (2H, m).  
13C-NMR (DMSO-d6, 500 MHz) δ 191.0, 163.0, 152.2, 151.5, 146.9, 127.9, 122.6, 93.7, 
44.0, 26.3, 22.3, and 21.8 ppm. 
  
Preparation of 5-(4-nitrobenzoyl)1,3-dimethylpyrimidine-2,4,6-trione N-
methylmorpholinium salt (H48).  Tetrahydrofuran (200 mL) solution of 5-(4-
nitrobenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and N-
methylmorpholine (224 mg; 2.2 mmol) was stirred at room temperature for half an hour.  
Solvent was evaporated.  Solid residue was mixed with ether (100 mL), and resulting 
suspension was stirred at room temperature for ten minutes.  Solid product was separated 
by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour. The yield 
of product is 89%. Product decomposes at temperatures above 220º C.  1H-NMR 
(DMSO-d6, 500 MHz) δ 8.13 (2H, d, J= 8.5 Hz), 7.54 (2H, d, J= 8.5 Hz), 3.81 (4H, m), 
3.22 (4H, m), 3.08 (6H, s), and 2.80 ppm (3H, s).  13C-NMR (DMSO-d6, 500 MHz) δ 
191.2, 163.1, 152.1, 151.4, 146.9, 127.9, 122.6, 93.8, 63.5, 52.9, 43.1, and 26.9 ppm. 
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Preparation of 5-(4-nitrobenzoyl)1,3-dimethylpyrimidine-2,4,6-trione N-
ethanolammonium salt (H49).  Tetrahydrofuran (200 mL) solution of 5-(4-
nitrobenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and ethanolamine 
(140 mg; 2.2 mmol) was stirred at room temperature for half an hour.  Solvent was 
evaporated.  Solid residue was mixed with ether (100 mL), and resulting suspension was 
stirred at room temperature for ten minutes.  Solid product was separated by filtration, 
washed with ether (3×15 mL) and dried at 110º C for half an hour. The yield of product 
92%. Product decomposes at temperatures above 220º C.  1H-NMR (DMSO-d6, 500 
MHz) δ 8.31 (2H, d, J= 8 Hz), 7.56 (2H, d, J= 8 Hz), 3.48 (2H, m), .3.06 (6H, s), and 
2.98 ppm (2H, m).  13C-NMR (DMSO-d6, 500 MHz) δ 170.1, 150.9, 147.4, 141.3, 128.0, 
123.6, 89.3, 59.2, 47.3, and 27.3 ppm. 
  
Preparation of 5-(4-nitrobenzoyl)1,3-dimethylpyrimidine-2,4,6-trione N-4-
diemethylaminopyridinium salt (H50).  Tetrahydrofuran (200 mL) solution of 5-(4-
nitrobenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and N-4-
dimethylaminopyridine (328 mg; 2.2 mmol) was stirred at room temperature for half an 
hour.  Solvent was evaporated.  Solid residue was mixed with ether (100 mL), and 
resulting suspension was stirred at room temperature for ten minutes.  Solid product was 
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour. 
The yield of product 93%. Product decomposes at temperatures above 220º C.  1H-NMR 
(DMSO-d6, 500 MHz) δ 8.22 (2H, d, J= 8 Hz), 8.11 (2H, d, J= 8.5 Hz), 7.52 (2H, d, J= 
8.5 Hz), 6.97 (2H, d, J= 8.0 Hz), 3.18 (6H, s), and 3.04 ppm (6H, s).  13C-NMR (DMSO-
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d6, 500 MHz) δ 190.4, 162.5, 156.9, 152.4, 151.4, 146.9, 139.2, 128.1, 122.6, 106.9, 93.1, 
and 26.8 ppm. 
  
General Procedure O.  Preparation of piperidinium salt of 5-[[2,4-
dinitrophenyl)hydrazono]-(4-hydroxyphenyl)methyl]-1,3-dimethyl-pyrimidine-2,4,6-
trione (H52).  1-Propanol (20 mL) suspension of 5-[[2,4-dinitrophenyl)hydrazono]-(4-
hydroxyphenyl)methyl]-1,3-dimethyl-pyrimidine-2,4,6-trione (0.50 g; 1.09 mmol) and 
piperidine (1.3 mL; 0.111 g; 1.30 mmol) was stirred at room temperature for 2 hours.  
Reaction suspension was diluted with ether (50 mL) and solid precipitate was separated 
by filtration, washed with ether (3 x 15 m), and dried at 110º C for 2 hours to give 0.535 
g (98%) of pure product.  Product decomposes at temperatures above 250º C.   1H-
NMR(DMSO-d6, 500 MHz), δ  11.48(1H, NH), 8.85(1H, d, J= 3.5 Hz), 8.31 (1H, d, J= 
11.0 Hz), 8.03 (1H, d, J= 16 Hz), 7.56 (2H, d, J= 14 Hz), 6.72 (2H, d, J= 14 Hz), 3.10 
(6H, s), 2.98 (4H, t, J= 9 Hz), 1.61 (4H, m), and 1.54 ppm (2H, m).  13C-NMR (DMSO-
d6, 500 MHz), δ 157.1, 155.0, 153.8, 149.5, 140.4, 132.1, 126.3, 126.1, 125.9, 124.5, 
120.0, 113.0, 111.2, 77.2, 40.3, 23.5, 18.7, and 18.1 ppm.  MS-ES+ (CH3COOH) m/z 360 
(100%).  Anal. Calcd.  for C24H27N7O8*0.3 H2O: C, 52.71; H, 5.09; N, 17.93; Found C, 
52.82; H, 5.07; N, 17.97. 
  
Preparation of piperidinium salt of 5-[[2,4-dinitrophenyl)hydrazono]-(3-
hydroxyphenyl)methyl]pyrimidine-2,4,6-trione (H51).  This compound was prepared in 
93% isolated yield by following General Procedure O.  1H-NMR (DMSO-d6, 500 MHz) 
δ 11.48(1H, s), 10.31 (2H, s), 8.87 (1H, d, J= 2.7 Hz), 8.37 (1H, d, J= 12.3 Hz), 8.05 
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(1H, d, J= 9.6 Hz), 7.24 (1H, t, J= 7.8 Hz), 7.16 (2H, m. J= 7.8), 6.76 (1H, d, J= 10.2 
Hz), 2.91 (4H, t, J= 5.1 Hz), 1.57 (4H, m), and 1.48 ppm (2H, m).  13C-NMR (DMSO-d6, 
500 MHz) δ 159.2, 153.7, 150.6, 148.2, 140.6, 135.9, 133.0, 126.5, 125.5, 125.2, 119.9, 
115.0, 113.1, 112.9, 111.1, 78.0, 40.4, 18.7, and 18.2 ppm. 
  
Preparation of piperidinium salt of 5-[[2,4-dinitrophenyl)hydrazono]-(4-
hydroxyphenyl)methyl]-1-phenylpyrimidine-2,4,6-trione (H53).  This compound was 
prepared in 81% isolated yield by following General Procedure O.  1H-NMR (DMSO-
d6, 500 MHz) δ 8.89 (1H, d, J= 2.7 Hz), 8.31(1H, d, J= 12.3 Hz), 8.04 (1H, d, J= 10.2 
Hz), 7.65 (2H, d, J= 8.7 Hz), 7.37 (2H, t, J= 7.5 Hz), 7.27 (1H, t, J= 7.5 Hz), 7.19 (2H, 
d, J= 8.1 Hz), 6.75 (2H, d, J= 8.4 Hz), 2.91 (4H, t, J= 5.2 Hz), 1.56 (4H, m), and 1.50 
ppm (2H, m).  13C-NMR (DMSO-d6, 500 MHz) δ 158.4, 158.2, 155.1, 153.3, 148.6, 
140.4, 133.8, 132.2, 126.3, 126.1, 126.0, 125.9, 124.6, 124.5, 123.3, 120.0, 113.1, 111.2, 
77.1, 40.4, 18.8, and 18.2 ppm. 
 
Synthesis of methyl L-lysine salt of 5-{(4-methoxyphenyl)[2-(4-
nitrophenyl)hydrazino]methylene}pyrimidine-2,4,6-trione (H54).  Methanol (500 mL) 
suspension of 5-{(4-methoxyphenyl)[2-(4-nitrophenyl)hydrazino]methylene}pyrimidine-
2,4,6-trione (0.397 g; 1.00 mmol) and L-lysine (0.146 g; 1.00 mmol) was stirred at 50º C 
for ten minutes until reaction mixture becomes solution.  Solvent was evaporated to solid 
residue.  Solid residue was mixed with ether (50 mL).  Solid was separated by filtration 
from resulting suspension, washed with ether (3×20 mL) and dried at 110º C for ten 
minutes to give 0.525 g (97%).  Product decomposes at temperatures above 200º C.   1H-
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NMR (DMSO-d6, 500 MHz) δ 10.09 (1H, s), 9.44 (2H, s), 8.06 (2H, d, J= 9.5 Hz), 7.56 
(2H, d, J= 9 Hz), 7.14 (2H, d, J= 7.5 Hz), 6.84 (2H, d, J= 7.0 Hz), 3.76 (3H, s), 3.26 
(1H, t, J= 6 Hz), 2.74 (2H, d, J= 7 Hz), 1.65 (2H, m), 1.51 (2H, m), and 1.37 ppm (2H 
m). 13C-NMR (DMSO-d6, 500 MHz) δ 171.4, 163.6, 159.1, 152.4, 151.6, 149.6, 137.1, 
132.6, 128.3, 126.0, 113.0, 111.5, 81.7, 55.1, 53.5, 38.5, 30.1, 26.6, and 21.7 ppm.  MS-
ES+ (CH3OH), m/z: 381 (M-H2O-Lysine, 100%), 632 (MNa3 +Na+), 654 (MNa4 + Na+), 
676 (MNa5 + Na+), 708 (MNa5 + CH3OH + Na+), 984 (2MNa-Lysine).  Anal. Calcd.  for 
C24H31N7O8 (545.22): C, 52.84; H, 5.73; N, 17.97; Found C, 52.82; H, 5.07; N, 17.97. 
 
Synthesis of 5,5’-(2-pyrilidene)bis(1,3-dimethylbarbituric acid)(I-1) A methanol 
solution (400 mL) of 2,2’-pyridil (0.212 g, 1.00 mmol) and 1,3-dimethylbarbituric acid 
(0.468 g, 3.00 mmol) was refluxed for 5 h.  The resulting dark reaction mixture was 
concentrated to a 50 mL volume at atmospheric pressure and left at room temperature in 
an open beaker overnight.  The resulting crystalline product was slurred in ice-cold 
methanol (3 x 10 mL), separated by filtration, washed with cold methanol (3 x 10 mL), 
and dried at 90º C for 30 min to afford 0.350 g (87%) pure product.  If necessary further 
crystallization can be performed in acetic acid.  1H NMR (DMSO-d6)  8.58 (1H, d, J= 
5.2 Hz), 8.41 (1H, t, J= 7.1 Hz), 7.88 (1H, d, J= 5.4 Hz), 7.81 (1H, t, J= 7.1 Hz), 6.33 
(1H, s), 3.13 (12H, s) ppm.  13C-NMR (DMSO-d6)  159.3, 155.9, 147.9, 142.4, 137.5, 
122.3, 120.6, 81.1, 32.0, 24.5 ppm.  MS-ESI+ in methanol 424 (M + Na)+.  Anal. Calcd. . 
For C18H19N5O6:  C, 53.75; H, 4.83; N, 17.33.  Found: C, 53.86; H, 4.77; N, 17.45. 
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Synthesis of 5,5’-(2-pyrilidene)bis(1-phenylbarbituric acid)(I-2) A methanol solution 
(400 mL) of 2,2’-pyridil (0.212 g, 1.00 mmol) and 1-phenylbarbituric acid (0.612 g, 3.00 
mmol) was refluxed for 5 h.  The resulting dark reaction mixture was concentrated to a 
50 mL volume at atmospheric pressure and left at room temperature in an open beaker 
overnight.  The resulting crystalline product was slurred in ice-cold methanol (3 x 10 
mL), separated by filtration, washed with cold methanol (3 x 10 mL), and dried at 90º C. 
Yield=78%.  1H-NMR(DMSO-d6) δ 10.84 (2H, s, NH), 8.64 (2H, d, J= 6.9Hz, pyridine 
6-H), 8.44 (1H, t, J= 6.9 Hz, pyridine 4-H), 7.98 (1H, d, J= 6.9Hz, pyridine 3-H), 7.83 
(1H, t, J= 6.9Hz, pyridine 4-H), 7.40 (4H, t, J= 6.9 Hz, phenyl m-H), 7.32 (2H, t, J= 6.9 
Hz, phenyl p-H), 7.20 (4H, d, J= 6.9 Hz, phenyl o-H), 6.23 (1H, benzyl). 13C-NMR 
(DMSO-d6) δ 163.0, 159.9, 156.2 (three different carbonyls), 147.9, 147.2, 142.4, 137.6, 
133.0, 125.7, 124.8, 123.9, 122.4 (nine aromatic carbons), 82.30, 30.84 ppm (two 
aliphatic carbons). 
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APPENDIX 
 
X-ray Crystallographic Data, Positional Parameters, General Displacement, Parameter 
Expressions, Bond Distances and Bond Angles 
for 
5-{(4-Methoxyphenyl)-[N'-(4-nitrophenyl)hydrazino]methylene}-1,3-
dimethylpyrimidine-2,4,6-trione (H25) 
 
piperidinium salt of 5-[[2,4-dinitrophenyl)hydrazono]-(4-hydroxyphenyl)methyl]-1,3-
dimethyl-pyrimidine-2,4,6-trione (H52) 
 
Pyridinium-barbiturate Zwitterion (F1) 
 
1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-yl)methyl]pyrimidine-
2,4,6(1H,3H,5H)-trione morpholinium salt (G37) 
 
and 
 
5,5’-(2-pyrilidene)bis(1,3-dimethylbarbituric acid)(I-1) 
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X-ray crystallographic Data- Compound H25  
(5-{(4-Methoxyphenyl)-[N'-(4-nitrophenyl)hydrazino]methylene}-1,3-
dimethylpyrimidine-2,4,6-trione) 
 
Table 1:  Crystal data and structure refinement for compound H25.  
 
      Empirical formula                          C20.55 H21.98 N5 O7.07  
      Formula weight                              452.20  
      Temperature                                   150(2) K  
      Wavelength                                    0.71073 Å  
      Crystal system, space group          Triclinic,  P-1  
      Unit cell dimensions                      a = 10.7707(11) Å    α = 92.675(2) deg.  
                                                             b = 13.4704(14) Å    β = 90.176(3) deg.  
                                                             c = 15.4021(16) Å    γ = 112.341(2) deg.  
      Volume                                          2064.1(4) Å 3  
      Z, Calculated density                     4,  1.455 Mg/m3  
      Absorption coefficient                    0.112 mm-1  
      F(000)                                            947  
      Crystal size                                    0.15 x 0.15 x 0.4 mm  
      Theta range for data collection      2.04 to 22.50 deg.  
      Limiting indices                  -          8<=h<=11, -14<=k<=13, -14<=l<=16  
      Reflections collected / unique        8652 / 5362 [R(int) = 0.0471]  
      Completeness to theta = 22.50       99.1 %  
      Absorption correction                    Empirical  
      Max. and min. transmission           1.000000 and 0.779916  
      Refinement method                        Full-matrix least-squares on F2  
      Data / restraints / parameters         5362 / 1269 / 748  
      Goodness-of-fit on F2                  1.280  
      Final R indices [I2sigma(I)]         R1 = 0.0798, wR2 = 0.1643  
      R indices (all data)                         R1 = 0.0918, wR2 = 0.1814  
      Largest diff. peak and hole            0.706 and -0.426 e. Å -3  
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å 2 x 103) for H25  
 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
 
                                      x                           y                            z                           U(eq)  
 
C(1) 8448(10) 727(7) 164(5) 65(2) 
N(2) 8350(7) -71(6) -472(4) 55(2)  
C(3) 8172(9) -1090(7) -307(5) 60(2) 
N(4) 8085(7)  -1366(5) 555(4) 58(2) 
C(5) 8110(8) -645(6) 1237(5) 48(2)  
C(6) 8352(8) 435(6) 1068(5) 48(2)  
C(7) 8615(7) 1233(6) 1734(4) 46(2)  
N(8) 8645(6) 995(5) 2559(3) 45(2)  
N(9) 8935(6) 1754(5) 3246(3) 43(2)  
C(10) 10242(6) 2176(5) 3619(4) 42(2)  
C(11) 11341(6) 2125(5) 3180(4) 45(2)  
C(12) 12595(6) 2571(5) 3551(4) 47(2)  
C(13) 12790(6) 3091(6) 4367(4) 46(2)  
C(14) 11691(6) 3143(6) 4810(4) 45(2)  
C(15) 10442(6) 2704(5) 4436(4) 41(2)  
O(16) 8582(10) 1598(6) -71(4) 112(3)  
C(17) 8457(11) 212(8) -1404(5) 76(3)  
O(18) 8072(8) -1767(6) -891(4) 91(2)  
C(19) 7915(11) -2467(7) 762(6) 80(3)  
O(20) 7912(6) -1013(4) 1976(3) 57(2)  
N(21) 14101(6) 3538(5) 4757(4) 55(2)  
O(22) 15063(6) 3495(5) 4338(4) 67(2)  
O(23) 14241(6) 3972(5) 5498(4) 78(2)  
C(24) 8846(8) 2372(6) 1583(5) 50(2)  
C(25) 10175(9) 3135(7) 1560(5)  58(2) 
C(26) 10384(10) 4205(7) 1425(5) 62(2)  
C(27) 9349(10) 4504(7) 1290(5) 61(2)  
C(28) 8032(9) 3771(7) 1330(5) 64(2)  
C(29) 7831(9) 2692(7) 1464(5) 59(2)  
O(30) 9499(7) 5545(5) 1140(4) 79(2)  
C(31) 10836(12) 6312(8) 1040(7) 91(3)  
C(51) 5840(7) 1529(5) 4741(4) 36(2)  
N(52) 5049(6) 1205(4) 3985(3) 37(1)  
C(53) 3688(7) 690(5) 3948(5) 37(2)  
N(54) 3040(6) 527(4) 4728(4) 38(1)  
C(55) 3701(7) 847(6) 5534(4) 38(2)  
C(56) 5112(7) 1411(5) 5540(4) 35(2)  
C(57) 5809(7) 1898(6) 6334(4) 42(2)  
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N(58A) 5080(80) 1880(70) 7030(40) 52(3)  
N(58) 5149(17) 1747(14) 7078(7) 51(3)  
N(59) 5709(7) 2380(6) 7834(4) 53(2)  
N(59A) 5430(40) 2190(20) 7935(11) 61(3)  
C(60) 5616(6) 3401(6) 8032(5) 81(2)  
C(60A) 5260(30) 3163(17) 7785(9) 75(3)  
C(61) 5125(8) 3903(6) 7419(5) 84(2)  
C(61A) 4000(30) 3219(18) 7751(16) 77(4)  
C(62A) 3860(20) 4160(20) 7606(16) 84(3)  
C(62) 5043(8) 4868(7) 7613(5) 87(2)  
C(63) 5445(7) 5384(6) 8427(5) 92(3)  
C(63A) 4990(30) 5090(17) 7491(10) 93(3)  
C(64) 5932(9) 4889(7) 9038(5) 95(3)  
C(64A) 6250(20) 5035(18) 7526(16) 90(3)  
C(65A) 6380(20) 4090(20) 7669(16) 86(3)  
C(65) 6016(8) 3921(7) 8845(5) 89(3)  
O(66) 7067(5) 1868(4) 4668(3) 45(1)  
C(67) 5722(8) 1428(7) 3138(4) 50(2)  
O(68) 3073(5) 370(4) 3257(3) 47(1) 
C(69) 1574(7) -25(7) 4699(5) 55(2) 
O(70) 3002(5) 615(4) 6191(3) 49(1) 
N(71A) 4900(30) 6093(19) 7339(14) 112(4) 
N(71) 5354(10) 6388(8) 8624(6) 108(3)  
O(72A) 5970(30) 6870(20) 7240(20) 122(6)  
O(72) 5493(13) 6736(9) 9395(6) 137(4)  
O(73A) 3800(30) 6170(30) 7300(20) 129(7)  
O(73) 5140(12) 6918(8) 8052(7) 124(3)  
C(74) 7250(7) 2639(6) 6399(4) 39(2)  
C(75) 8176(7) 2288(6) 6742(4) 41(2)  
C(76) 9514(7) 2978(6) 6803(4) 43(2)  
C(77) 9913(7) 4020(6) 6531(4) 41(2)  
C(78) 8987(7) 4373(6) 6213(5) 45(2)  
C(79) 7627(8) 3672(6) 6128(5) 45(2)  
O(80) 11256(5) 4613(4) 6617(3) 48(1)  
C(81) 11727(8) 5698(7) 6364(5) 60(2)  
O(101) 5494(15) 1532(13) 8541(10) 58(3)  
C(102) 5320(30) 1960(30) 9320(20) 50(4)  
C(103) 5160(30) 1260(20) 10056(19) 45(3)  
C(104) 5220(20) 187(18) 9949(19) 30(4)  
O(105) 4978(11) 1389(11) 9526(9) 67(3)  
O(106) 5252(10) 184(10) 8659(9) 76(3)  
O(107) 4996(12) 447(11) 9399(11) 67(4)  
         ________________________________________________________________  
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Table 3:  Bond lengths [Å] and angles [deg] for H25  
_____________________________________________________________  
   
            C(1)-O(16)                      1.200(10)  
            C(1)-N(2)                      1.394(10)  
            C(1)-C(6)                       1.457(11)  
            N(2)-C(3)                       1.348(11)  
            N(2)-C(17)                      1.497(10)  
            C(3)-O(18)                      1.226(10)  
            C(3)-N(4)                      1.389(11)  
            N(4)-C(5)                       1.389(10)  
            N(4)-C(19)                     1.474(11)  
            C(5)-O(20)                      1.249(9)  
            C(5)-C(6)                       1.415(11)  
            C(6)-C(7)                       1.396(10)  
            C(7)-N(8)                       1.328(7)  
            C(7)-C(24)                      1.488(11)  
            N(8)-N(9)                       1.384(7)  
            N(9)-C(10)                      1.412(7)  
            C(10)-C(11)                     1.388(6)  
            C(10)-C(15)                     1.391(6)  
            C(11)-C(12)                     1.363(7)  
            C(12)-C(13)                     1.385(6)  
            C(13)-C(14)                     1.391(6)  
            C(13)-N(21)                     1.426(8)  
            C(14)-C(15)                     1.360(7)  
            N(21)-O(23)                     1.239(6)  
            N(21)-O(22)                     1.241(6)  
            C(24)-C(29)                     1.334(12)  
            C(24)-C(25)                     1.411(11)  
            C(25)-C(26)                     1.397(11)  
            C(26)-C(27)                     1.340(12)  
            C(27)-O(30)                     1.380(10)  
            C(27)-C(28)                     1.390(12)  
            C(28)-C(29)                     1.411(11)  
            O(30)-C(31)                     1.432(12)  
            C(51)-O(66)                    1.230(8)  
            C(51)-N(52)                     1.391(9)  
            C(51)-C(56)                     1.445(9)  
            N(52)-C(53)                     1.362(9)  
            N(52)-C(67)                     1.481(9)  
            C(53)-O(68)                     1.222(8)  
            C(53)-N(54)                     1.375(9)  
            N(54)-C(55)                     1.394(9)  
            N(54)-C(69)                     1.467(9)  
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            C(55)-O(70)                     1.243(8)  
            C(55)-C(56)                     1.417(10)  
            C(56)-C(57)                     1.426(10)  
            C(57)-N(58A)                    1.331(11)  
            C(57)-N(58)                     1.333(8)  
            C(57)-C(74)                    1.492(10)  
            N(58A)-N(59A)                   1.44(8)  
            N(58)-N(59)                     1.399(16)  
            N(59)-C(60)                     1.435(8)  
            N(59A)-O(101)                   1.33(3)  
            N(59A)-C(60A)                   1.425(10)  
            C(60)-C(65)                    1.388(7)  
            C(60)-C(61)                     1.399(7)  
            C(60A)-C(61A)                   1.389(8)  
            C(60A)-C(65A)                   1.393(8)  
            C(61)-C(62)                     1.355(8)  
            C(61A)-C(62A)                   1.362(9)  
            C(62A)-C(63A)                   1.387(8)  
            C(62)-C(63)                     1.389(7)  
            C(63)-C(64)                     1.387(7)  
            C(63)-N(71)                     1.412(10)  
            C(63A)-C(64A)                   1.390(8)  
            C(63A)-N(71A)                   1.419(11)  
            C(64)-C(65)                     1.360(8)  
            C(64A)-C(65A)                   1.357(9)  
            N(71A)-O(73A)                  1.236(9)  
            N(71A)-O(72A)                   1.243(9)  
            N(71)-O(73)                     1.233(8)  
            N(71)-O(72)                     1.243(8)  
            C(74)-C(75)                     1.370(10)  
            C(74)-C(79)                     1.379(10)  
            C(75)-C(76)                     1.386(10)  
            C(76)-C(77)                     1.389(10)  
            C(77)-C(78)                     1.356(11)  
            C(77)-O(80)                     1.364(9)  
            C(78)-C(79)                     1.411(10)  
            O(80)-C(81)                     1.426(9)  
            O(101)-C(102)                   1.35(4)  
            C(102)-C(103)                   1.47(3)  
            C(103)-C(104)                   1.47(3)  
            O(16)-C(1)-N(2)               117.8(7)  
            O(16)-C(1)-C(6)               124.8(8)  
            N(2)-C(1)-C(6)               117.4(8)  
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            C(3)-N(2)-C(1)                124.5(7)  
            C(3)-N(2)-C(17)               117.2(7)  
            C(1)-N(2)-C(17)               118.4(7)  
            O(18)-C(3)-N(2)               121.9(8)  
            O(18)-C(3)-N(4)               120.0(9)  
            N(2)-C(3)-N(4)                118.0(7)  
            C(3)-N(4)-C(5)                122.2(7)  
            C(3)-N(4)-C(19)               119.6(7)  
            C(5)-N(4)-C(19)               118.2(7)  
            O(20)-C(5)-N(4)               116.2(7)  
            O(20)-C(5)-C(6)               124.0(7)  
            N(4)-C(5)-C(6)                119.7(7)  
            C(7)-C(6)-C(5)                122.1(7)  
            C(7)-C(6)-C(1)                119.7(7)  
            C(5)-C(6)-C(1)                117.9(7)  
            N(8)-C(7)-C(6)                120.5(7)  
            N(8)-C(7)-C(24)               115.9(7)  
            C(6)-C(7)-C(24)               123.7(6)  
            C(7)-N(8)-N(9)                123.2(6)  
            N(8)-N(9)-C(10)               119.2(5)  
            C(11)-C(10)-C(15)             119.1(5)  
            C(11)-C(10)-N(9)              122.1(5)  
            C(15)-C(10)-N(9)              118.8(5)  
            C(12)-C(11)-C(10)             120.4(4)  
            C(11)-C(12)-C(13)             120.4(4)  
            C(12)-C(13)-C(14)             119.4(5)  
            C(12)-C(13)-N(21)             120.0(5)  
            C(14)-C(13)-N(21)             120.5(5)  
            C(15)-C(14)-C(13)             120.1(4)  
            C(14)-C(15)-C(10)             120.6(4)  
            O(23)-N(21)-O(22)             122.4(7)  
            O(23)-N(21)-C(13)             118.7(5)  
            O(22)-N(21)-C(13)             118.9(5)  
            C(29)-C(24)-C(25)             119.0(8)  
            C(29)-C(24)-C(7)              121.8(7)  
            C(25)-C(24)-C(7)              119.2(8)  
            C(26)-C(25)-C(24)             118.9(9)  
            C(27)-C(26)-C(25)             121.0(9)  
            C(26)-C(27)-O(30)             123.4(9)  
            C(26)-C(27)-C(28)             121.0(9)  
            O(30)-C(27)-C(28)             115.6(9)  
            C(27)-C(28)-C(29)             117.5(9)  
            C(24)-C(29)-C(28)             122.5(8)  
            C(27)-O(30)-C(31)             117.4(8)  
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            O(66)-C(51)-N(52)             117.9(6)  
            O(66)-C(51)-C(56)             126.7(6)  
            N(52)-C(51)-C(56)             115.4(6)  
            C(53)-N(52)-C(51)             125.7(6)  
            C(53)-N(52)-C(67)             116.0(6)  
            C(51)-N(52)-C(67)             118.3(6)  
            O(68)-C(53)-N(52)             121.7(7)  
            O(68)-C(53)-N(54)             121.5(6)  
            N(52)-C(53)-N(54)             116.8(6)  
            C(53)-N(54)-C(55)             123.6(6)  
            C(53)-N(54)-C(69)             117.4(6)  
            C(55)-N(54)-C(69)             119.0(6)  
            O(70)-C(55)-N(54)             117.2(6)  
            O(70)-C(55)-C(56)             125.1(6)  
            N(54)-C(55)-C(56)             117.7(6)  
            C(55)-C(56)-C(57)             119.9(6)  
            C(55)-C(56)-C(51)             120.2(6)  
            C(57)-C(56)-C(51)             119.8(6)  
            N(58A)-C(57)-C(56)            118(4)  
            N(58)-C(57)-C(56)             119.8(10)  
            N(58A)-C(57)-C(74)            116(4)  
            N(58)-C(57)-C(74)             115.6(10)  
            C(56)-C(57)-C(74)             124.5(6)  
            C(57)-N(58A)-N(59A)           133(7)  
            C(57)-N(58)-N(59)             121.5(13)  
            N(58)-N(59)-C(60)             123.1(10)  
            O(101)-N(59A)-C(60A)         144.8(13)  
            O(101)-N(59A)-N(58A)          125(4)  
            C(60A)-N(59A)-N(58A)          88(4)  
            C(65)-C(60)-C(61)             118.0(6)  
            C(65)-C(60)-N(59)             120.5(6)  
            C(61)-C(60)-N(59)             121.5(6)  
            C(61A)-C(60A)-C(65A)          118.6(7)  
            C(61A)-C(60A)-N(59A)          122.0(10)  
            C(65A)-C(60A)-N(59A)          119.4(10)  
            C(62)-C(61)-C(60)             121.0(5)  
            C(62A)-C(61A)-C(60A)          120.7(6)  
            C(61A)-C(62A)-C(63A)          120.6(6)  
            C(61)-C(62)-C(63)             120.8(5)  
            C(64)-C(63)-C(62)             118.5(6)  
            C(64)-C(63)-N(71)             121.1(6)  
            C(62)-C(63)-N(71)             120.4(6)  
            C(62A)-C(63A)-C(64A)          118.8(7)  
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            C(62A)-C(63A)-N(71A)          122.7(9)  
            C(64A)-C(63A)-N(71A)          118.5(9)  
            C(65)-C(64)-C(63)             120.9(5)  
            C(65A)-C(64A)-C(63A)           120.7(6)  
            C(64A)-C(65A)-C(60A)         120.6(6)  
            C(64)-C(65)-C(60)                   120.9(5)  
            O(73A)-N(71A)-O(72A)         122.2(16)  
            O(73A)-N(71A)-C(63A)         120.4(12)  
            O(72A)-N(71A)-C(63A)        117.4(12)  
            O(73)-N(71)-O(72)            119.9(10)  
            O(73)-N(71)-C(63)             121.6(8)  
            O(72)-N(71)-C(63)             118.5(8)  
            N(71A)-O(72A)-C(12)#1        141.8(17)  
            C(75)-C(74)-C(79)             121.0(7)  
            C(75)-C(74)-C(57)             119.4(7)  
            C(79)-C(74)-C(57)             119.6(7)  
            C(74)-C(75)-C(76)             119.3(7)  
            C(75)-C(76)-C(77)             120.5(7)  
            C(78)-C(77)-O(80)             125.3(7)  
            C(78)-C(77)-C(76)             119.9(7)  
            O(80)-C(77)-C(76)            114.8(7)  
            C(77)-C(78)-C(79)             120.2(7)  
            C(74)-C(79)-C(78)             119.0(7)  
            C(77)-O(80)-C(81)             117.5(6)  
            N(59A)-O(101)-C(102)          108(2)  
            O(101)-C(102)-C(103)          115(3)  
            C(104)-C(103)-C(102)           122(3)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
           #1 -x+2,-y+1,-z+1      
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Table 4.  Anisotropic displacement parameters (A2 x 103) for H25.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
 _______________________________________________________________________  
                 U11        U22         U33         U23         U13         U12 
_______________________________________________________________________
C(1)      98(5)      52(4)      28(3)  -5(3)        2(4)       10(4)  
N(2)      69(4)      63(3)      25(3)  -9(3)        0(3)       17(3)  
C(3)      70(4)      63(4)      42(3)  -11(3)        6(4)       21(4)  
N(4)      72(4)      49(3)      45(3)  -12(3)        5(3)       16(3)  
C(5)      50(4)      43(3)      39(3)  -5(3)        0(3)        3(3)  
C(6)      57(4)      45(3)      31(3)  0(3)       -1(3)        8(3)  
C(7)      51(4)      46(3)      30(3)  2(3)        5(3)        7(3)  
N(8)      58(4)      39(3)      29(3)  -4(2)        0(3)        9(3)  
N(9)      52(3)      44(3)      28(3)  -10(2)        7(2)       13(3)  
C(10)     53(3)      36(4)      32(3)  -2(3)        5(3)       12(3)  
C(11)     53(3)      36(4)      39(4)  -5(3)        3(3)       11(3)  
C(12)     55(4)      36(4)      48(4)  6(3)        7(3)       15(3)  
C(13)     52(3)      39(4)      43(3)  6(3)        1(3)       13(3)  
C(14)     55(3)      44(4)      34(4)  -2(3)        2(3)       15(3)  
C(15)     49(3)      36(4)      32(3)  1(3)        5(3)       10(3)  
O(16)    220(7)      60(4)      38(3)  1(3)       -3(4)       34(5)  
C(17)    108(7)      87(6)      28(4)  -8(4)       -4(4)       33(5)  
O(18)    124(5)      84(4)      63(4)  -24(3)       12(4)       39(4)  
C(19)    116(7)      54(5)      69(6)  -13(4)        2(5)       32(5)  
O(20)     75(4)      37(3)      47(3)  4(2)        9(3)        8(3)  
N(21)     57(3)      53(4)      55(4)  1(3)       -2(3)       21(3)  
O(22)     59(3)      68(4)      77(4)  -3(3)       -1(3)       32(3)  
O(23)     69(4)      93(5)      61(4)  -8(3)      -12(3)       20(3)  
C(24)     65(4)      45(3)      33(3)  5(3)        9(3)       11(3)  
C(25)     66(4)      46(4)      52(4)  5(4)        4(4)       11(3)  
C(26)     77(4)      46(4)      53(4)  4(4)        2(4)       12(3)  
C(27)     90(4)      54(3)      37(4)  7(3)        9(4)       26(3)  
C(28)     81(4)      65(4)      52(4)  10(4)        8(4)       32(4)  
C(29)     68(4)      60(4)      43(4)  10(4)       10(4)     17(3)  
O(30)    120(4)      57(3)      57(3)  13(3)       12(3)     32(3)  
C(31)    132(7)      59(6)      65(6)  11(5)        9(6)       17(5)  
C(51)     47(3)      22(3)      34(3)  1(3)        3(3)        9(3)  
N(52)     48(3)      28(3)      33(3)  0(2)       2(2)       14(2)  
C(53)     50(3)      26(3)      31(3)  -2(3)       -3(3)       11(3)  
N(54)     42(3)      36(3)      32(3)  -1(2)       -2(2)       10(2)  
C(55)     46(3)      32(3)      31(3)  -1(3)       -1(3)        9(3)  
C(56)     45(3)      28(3)      28(3)  4(3)        3(2)        9(3)  
C(57)     49(3)      39(3)      30(3)  5(3)        2(2)        8(3)  
N(58A)   58(5)      57(6)      30(4)  5(5)        2(4)        8(5)  
N(58)     58(4)      56(5)      27(3)  7(3)        0(3)        6(4)  
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N(59)     63(4)      60(4)      26(3)  5(3)       -1(3)       13(3)  
N(59A)   70(5)      66(5)      34(4)  0(4)       -1(4)       12(4)  
C(60)     97(5)      77(4)      55(4)  -2(3)       -3(4)      17(4)  
C(60A)   91(5)      73(5)      52(5)  2(4)       -1(5)       21(4)  
C(61)    105(5)      76(4)      66(4)  5(4)        0(4)       28(4)  
C(61A)   95(6)      78(6)      55(7)  2(7)        3(7)       29(5)  
C(62A)  105(6)      81(6)      64(6)  3(6)        5(6)       32(5)  
C(62)    110(5)      80(5)      65(4)  2(4)       10(5)     29(4)  
C(63)    114(6)      87(5)      68(5)  -3(4)       13(5)     32(4)  
C(63A)  113(5)      86(5)      72(5)  2(5)        8(5)       28(5)  
C(64)    119(7)      88(6)      65(5)  -8(5)        5(5)      28(5)  
C(64A)  110(6)      80(6)      70(6)  5(6)        3(6)       23(5)  
C(65A)  102(6)      77(5)      65(6)  4(6)        1(6)       18(5)  
C(65)    109(7)      87(6)      60(5)  -10(5)        1(5)       26(5)  
O(66)     48(3)      42(3)      38(3)  -1(2)        2(2)        9(2)  
C(67)     55(5)      62(5)      29(4)  9(4)        5(3)       18(4)  
O(68)     57(3)      40(3)      34(3)  -6(2)       -5(2)       10(2)  
C(69)     42(4)      56(5)      52(5)  5(4)        0(3)        3(4)  
O(70)     49(3)      49(3)      33(3)  4(2)        7(2)        2(2)  
N(71A)  132(7)      98(6)     106(8)  9(7)       10(8)      42(6)  
N(71)    143(7)     103(6)      85(5)  -5(4)       22(6)     55(5)  
O(72A)  138(8)     107(8)     116(9)  11(8)       14(8)     39(7)  
O(72)    180(8)     134(7)     101(6)  -20(5)       14(6)   69(6)  
O(73A)  135(9)     120(12)   134(13)  5(11)       4(11)  51(8)  
O(73)    146(6)     123(6)     115(6)  11(5)       17(5)     63(5)  
C(74)     50(3)      33(3)      27(3)  -3(3)       -3(3)        8(3)  
C(75)     53(3)      30(3)      34(4)  1(3)        0(3)        9(3)  
C(76)     53(3)      44(3)      30(4)  1(3)       -1(3)       16(3)  
C(77)     48(3)      37(3)      29(3)  -4(3)        1(3)       8(3)  
C(78)     55(4)      32(3)      41(4)  3(3)        3(3)       10(3)  
C(79)     56(4)      38(3)      37(4)  6(3)       -2(3)       12(3)  
O(80)     47(3)      42(3)      46(3)  -1(2)        3(2)       6(2)  
C(81)     58(5)      49(4)      53(5)  3(4)        2(4)       -1(4)  
O(101)    60(5)      68(5)      36(4)  0(4)        2(4)       13(4)  
C(102)    52(7)      56(7)      36(5)  -2(5)        2(6)       14(6)  
C(103)    49(6)      55(6)      32(5)  -8(6)        1(6)       24(5)  
C(104)    30(8)      52(7)       7(6)  -14(6)      -10(6)       17(6)  
O(105)    64(5)      73(5)      59(5)  -12(5)       -1(4)       23(4)  
O(106)    64(6)      80(6)      80(6)  -63(5)       -1(5)       30(5)  
O(107)    58(5)      70(6)      61(6)  -16(5)       -3(5)       12(4)  
_______________________________________________________________________  
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Table 5.  Hydrogen coordinates ( x 104) and isotropic displacement parameters  
(A2 x 103) for H25. 
________________________________________________________________ 
    x                 y                z            U(eq)  
________________________________________________________________ 
H(8)          8472  322           2674           54  
H(9)          8311  1970           3447           52  
H(11)        11219  1778           2617           54  
H(12)        13340  2524           3249           56  
H(14)        11813  3484           5376           55  
H(15)         9699  2759           4736           49  
H(17A)        9227  99          -1660          113  
H(17B)        8578  968          -1440          113  
H(17C)        7634  -245          -1724          113  
H(19A)        6956  -2910            797          121  
H(19B)        8362  -2448           1321          121  
H(19C)       8313  -2774            305          121  
H(25)        10915  2925           1634           70  
H(26)        11274  4729           1429           74  
H(28)        7296  3988           1268           77  
H(29)        6938  2174           1470           71  
H(31A)     11342  6421           1589          136  
H(31B)     10802  6995            876          136  
H(31C)     11280  6043            584          136  
H(58A)     4211  1620           6923           63  
H(58)        4343  1238           7094           62  
H(59)        6138  2141           8206           63  
H(61)        4845  3563           6859          101  
H(61A)     3218  2592           7828           93  
H(62A)     2996  4190           7584          101  
H(62)        4707  5195           7187          104  
H(64)        6209  5230           9598          114  
H(64A)     7026  5663           7448          108  
H(65A)     7252  4069           7691          103  
H(65)        6353  3596           9272          107  
H(67A)     6044  857           2973           75  
H(67B)     6484  2120           3188           75  
H(67C)    5083  1454           2694           75  
H(69A)    1212  134           4161           82  
H(69B)    1193  224           5201           82  
H(69C)    1337  -802           4714           82  
H(75)       7904  1578           6936           49  
H(76)       10163  2736           7033           51  
H(78)       9255  5095           6048           53  
H(79)       6980  3908           5886  54  
H(81A)    11440  5712           5762  90  
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H(81B)    12709  6015           6410  90  
H(81C)    11353  6112           6746  90  
H(10A)    4521   2147           9283  60  
H(10B)   6108  2635           9453  60  
H(10C)   5845  1669          10502  54  
H(10D)   4274  1150          10309  54  
H(10E)    4775   -167           9400  45  
H(10F)    4772  -247          10433  45  
H(10G)   6164  262           9943  45  
H(101)   5580(150) 1920(120) 9300(150) 80  
H(102)    5200(200) 1150(190) 9980(100) 80  
H(103)    5810(190) 610(140) 8220(120) 91  
H(104)    4500(80)  260(130) 8710(110) 91  
H(105)    5700(300) 490(170) 8260(160) 80  
H(106)    5360(190) -50(120) 9190(120) 80  
________________________________________________________________  
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Table 6.  Torsion angles [deg] for H25.  
_______________________________________________________________  
          O(16)-C(1)-N(2)-C(3)                                     -178.7(10)  
          C(6)-C(1)-N(2)-C(3)                                            0.0(13)  
          O(16)-C(1)-N(2)-C(17)                                           1.8(14)  
          C(6)-C(1)-N(2)-C(17)                                     -179.5(8)  
          C(1)-N(2)-C(3)-O(18)                                        178.9(9)  
          C(17)-N(2)-C(3)-O(18)                                        -1.5(13)  
          C(1)-N(2)-C(3)-N(4)                                          -0.2(13)  
          C(17)-N(2)-C(3)-N(4)                                       179.4(8)  
          O(18)-C(3)-N(4)-C(5)                                     -176.0(8)  
          N(2)-C(3)-N(4)-C(5)                                            3.1(12)  
          O(18)-C(3)-N(4)-C(19)                                          2.0(13)  
          N(2)-C(3)-N(4)-C(19)                                    -178.9(8)  
          C(3)-N(4)-C(5)-O(20)                                       174.3(7)  
          C(19)-N(4)-C(5)-O(20)                                       -3.7(11)  
          C(3)-N(4)-C(5)-C(6)                                         -5.8(12)  
          C(19)-N(4)-C(5)-C(6)                                      176.2(8)  
          O(20)-C(5)-C(6)-C(7)                                       11.1(13)  
          N(4)-C(5)-C(6)-C(7)                                    -168.9(7)  
          O(20)-C(5)-C(6)-C(1)                                   -174.7(8)  
          N(4)-C(5)-C(6)-C(1)                                          5.4(12)  
          O(16)-C(1)-C(6)-C(7)                                      -9.6(15)  
          N(2)-C(1)-C(6)-C(7)                                     171.8(8)  
          O(16)-C(1)-C(6)-C(5)                                  176.0(10)  
          N(2)-C(1)-C(6)-C(5)                                       -2.6(12)  
          C(5)-C(6)-C(7)-N(8)                                       -0.1(12)  
          C(1)-C(6)-C(7)-N(8)                                   -174.2(8)  
          C(5)-C(6)-C(7)-C(24)                                  -178.7(8)  
          C(1)-C(6)-C(7)-C(24)                                         7.2(12)  
          C(6)-C(7)-N(8)-N(9)                                      178.3(7)  
          C(24)-C(7)-N(8)-N(9)                                       -3.0(10)  
          C(7)-N(8)-N(9)-C(10)                                     -99.5(8)  
          N(8)-N(9)-C(10)-C(11)                                     20.1(10)  
          N(8)-N(9)-C(10)-C(15)                                 -163.0(6)  
          C(15)-C(10)-C(11)-C(12)                                      1.1(11)  
          N(9)-C(10)-C(11)-C(12)                                   178.0(7)  
          C(10)-C(11)-C(12)-C(13)                                   -0.8(11)  
          C(10)-C(11)-C(12)-O(72A)#1                          -148.2(11)  
          C(11)-C(12)-C(13)-C(14)                                     0.9(11)  
          O(72A)#1-C(12)-C(13)-C(14)                       148.0(12)  
          C(11)-C(12)-C(13)-N(21)                                 178.8(7)  
          O(72A)#1-C(12)-C(13)-N(21)                         -34.1(14)  
          C(12)-C(13)-C(14)-C(15)                                -1.4(11)  
          N(21)-C(13)-C(14)-C(15)                           -179.3(7)  
          C(13)-C(14)-C(15)-C(10)                                      1.8(11)  
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          C(11)-C(10)-C(15)-C(14)                                   -1.6(11)  
          N(9)-C(10)-C(15)-C(14)                                -178.6(7)  
          C(12)-C(13)-N(21)-O(23)                               -177.9(7)  
          C(14)-C(13)-N(21)-O(23)                                   -0.1(11)  
          C(12)-C(13)-N(21)-O(22)                                      3.3(11)  
          C(14)-C(13)-N(21)-O(22)                               -178.8(7)  
          N(8)-C(7)-C(24)-C(29)                                    -96.8(9)  
          C(6)-C(7)-C(24)-C(29)                                     81.8(11)  
          N(8)-C(7)-C(24)-C(25)                                       83.6(9)  
          C(6)-C(7)-C(24)-C(25)                                     -97.8(9)  
          C(29)-C(24)-C(25)-C(26)                                       0.9(12)  
          C(7)-C(24)-C(25)-C(26)                                 -179.5(7)  
          C(24)-C(25)-C(26)-C(27)                                    -2.3(12)  
          C(25)-C(26)-C(27)-O(30)                                -178.9(7)  
          C(25)-C(26)-C(27)-C(28)                                       3.8(13)  
          C(26)-C(27)-C(28)-C(29)                                    -3.7(13)  
          O(30)-C(27)-C(28)-C(29)                                  178.8(7)  
          C(25)-C(24)-C(29)-C(28)                                    -1.1(12)  
          C(7)-C(24)-C(29)-C(28)                                   179.3(7)  
          C(27)-C(28)-C(29)-C(24)                                      2.4(13)  
          C(26)-C(27)-O(30)-C(31)                                      6.5(12)  
          C(28)-C(27)-O(30)-C(31)                               -176.1(8)  
          O(66)-C(51)-N(52)-C(53)                                 171.3(6)  
          C(56)-C(51)-N(52)-C(53)                                     -7.7(9)  
          O(66)-C(51)-N(52)-C(67)                                     -8.5(9)  
          C(56)-C(51)-N(52)-C(67)                                  172.5(6)  
          C(51)-N(52)-C(53)-O(68)                                -175.2(6)  
          C(67)-N(52)-C(53)-O(68)                                       4.6(10)  
          C(51)-N(52)-C(53)-N(54)                                       3.5(10)  
          C(67)-N(52)-C(53)-N(54)                                -176.7(6)  
          O(68)-C(53)-N(54)-C(55)                                   177.9(6)  
          N(52)-C(53)-N(54)-C(55)                                     -0.8(10)  
          O(68)-C(53)-N(54)-C(69)                                     -1.4(10)  
          N(52)-C(53)-N(54)-C(69)                                   179.9(6)  
          C(53)-N(54)-C(55)-O(70)                                 -177.3(6)  
          C(69)-N(54)-C(55)-O(70)                                        1.9(10)  
          C(53)-N(54)-C(55)-C(56)                                        2.9(10)  
          C(69)-N(54)-C(55)-C(56)                                 -177.8(6)  
          O(70)-C(55)-C(56)-C(57)                                      -9.3(11)  
          N(54)-C(55)-C(56)-C(57)                                    170.4(6)  
          O(70)-C(55)-C(56)-C(51)                                    172.9(7)  
          N(54)-C(55)-C(56)-C(51)                                      -7.3(10)  
          O(66)-C(51)-C(56)-C(55)                                  -169.5(7)  
          N(52)-C(51)-C(56)-C(55)                                          9.4(9)  
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          O(66)-C(51)-C(56)-C(57)                                     12.7(11)  
          N(52)-C(51)-C(56)-C(57)                                 -168.4(6)  
          C(55)-C(56)-C(57)-N(58A)                                       -5(5)  
          C(51)-C(56)-C(57)-N(58A)                                    172(5)  
          C(55)-C(56)-C(57)-N(58)                                      5.4(14)  
          C(51)-C(56)-C(57)-N(58)                             -176.9(10)  
          C(55)-C(56)-C(57)-C(74)                              -170.9(7)  
          C(51)-C(56)-C(57)-C(74)                                     6.9(11)  
          N(58)-C(57)-N(58A)-N(59A)                               68(28)  
          C(56)-C(57)-N(58A)-N(59A)                               173(7)  
          C(74)-C(57)-N(58A)-N(59A)                              -20(11)  
          N(58A)-C(57)-N(58)-N(59)                                  -86(28)  
          C(56)-C(57)-N(58)-N(59)                             -166.2(11)  
          C(74)-C(57)-N(58)-N(59)                                  10.3(19)  
          C(57)-N(58)-N(59)-C(60)                                  85.3(16)  
          C(57)-N(58A)-N(59A)-O(101)                         -94(10)  
          C(57)-N(58A)-N(59A)-C(60A)                          100(9)  
          N(58)-N(59)-C(60)-C(65)                                170.6(8)  
          N(58)-N(59)-C(60)-C(61)                                    -9.4(8)  
          O(101)-N(59A)-C(60A)-C(61A)                            -82(4)  
          N(58A)-N(59A)-C(60A)-C(61A)                             80(3)  
          O(101)-N(59A)-C(60A)-C(65A)                       98(4)  
          N(58A)-N(59A)-C(60A)-C(65A)                    -100(3)  
          C(65)-C(60)-C(61)-C(62)                                  0.1(2)  
          N(59)-C(60)-C(61)-C(62)                      -179.95(14)  
          C(65A)-C(60A)-C(61A)-C(62A)                          0.0(2)  
          N(59A)-C(60A)-C(61A)-C(62A)                 -179.99(14)  
          C(60A)-C(61A)-C(62A)-C(63A)                           0.0(2)  
          C(60)-C(61)-C(62)-C(63)                                    0.0(2)  
          C(61)-C(62)-C(63)-C(64)                                -0.1(2)  
          C(61)-C(62)-C(63)-N(71)                         -179.87(17)  
          C(61A)-C(62A)-C(63A)-C(64A)                            0.0(3)  
          C(61A)-C(62A)-C(63A)-N(71A)                     180.00(17)  
          C(62)-C(63)-C(64)-C(65)                                    0.1(2)  
          N(71)-C(63)-C(64)-C(65)                            179.92(18)  
          C(62A)-C(63A)-C(64A)-C(65A)                       0.0(3)  
          N(71A)-C(63A)-C(64A)-C(65A)             180.00(17)  
          C(63A)-C(64A)-C(65A)-C(60A)                   0.0(2)  
          C(61A)-C(60A)-C(65A)-C(64A)                   0.0(2)  
          N(59A)-C(60A)-C(65A)-C(64A)                  179.99(14)  
          C(63)-C(64)-C(65)-C(60)                              -0.1(2)  
          C(61)-C(60)-C(65)-C(64)                                   0.0(2)  
          N(59)-C(60)-C(65)-C(64)                                 180.00(14)  
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          C(62A)-C(63A)-N(71A)-O(73A)                         0.0(3)  
          C(64A)-C(63A)-N(71A)-O(73A)                      -180.0(2)  
          C(62A)-C(63A)-N(71A)-O(72A)                    -180.0(2)  
          C(64A)-C(63A)-N(71A)-O(72A)                        0.0(3)  
          C(64)-C(63)-N(71)-O(73)                         167.7(10)  
          C(62)-C(63)-N(71)-O(73)                             -12.5(10)  
          C(64)-C(63)-N(71)-O(72)                             -12.4(10)  
          C(62)-C(63)-N(71)-O(72)                             167.4(9)  
          O(73A)-N(71A)-O(72A)-C(12)#1                  -110(3)  
          C(63A)-N(71A)-O(72A)-C(12)#1                     70(3)  
          N(58A)-C(57)-C(74)-C(75)                               86(5)  
          N(58)-C(57)-C(74)-C(75)                           75.6(12)  
          C(56)-C(57)-C(74)-C(75)                        -108.0(9)  
          N(58A)-C(57)-C(74)-C(79)                         -93(5)  
          N(58)-C(57)-C(74)-C(79)                       -103.3(11)  
          C(56)-C(57)-C(74)-C(79)                         73.1(10)  
          C(79)-C(74)-C(75)-C(76)                         -1.0(11)  
          C(57)-C(74)-C(75)-C(76)                      -180.0(6)  
          C(74)-C(75)-C(76)-C(77)                             0.8(10)  
          C(75)-C(76)-C(77)-C(78)                             0.9(10)  
          C(75)-C(76)-C(77)-O(80)                        -179.4(6)  
          O(80)-C(77)-C(78)-C(79)                          177.9(6)  
          C(76)-C(77)-C(78)-C(79)                            -2.5(11)  
          C(75)-C(74)-C(79)-C(78)                            -0.5(11)  
          C(57)-C(74)-C(79)-C(78)                          178.4(6)  
          C(77)-C(78)-C(79)-C(74)                              2.3(11)  
          C(78)-C(77)-O(80)-C(81)                              0.9(10)  
          C(76)-C(77)-O(80)-C(81)                      -178.8(6)  
          C(60A)-N(59A)-O(101)-C(102)                      1(5)  
          N(58A)-N(59A)-O(101)-C(102)                     -156(4)  
          N(59A)-O(101)-C(102)-C(103)                         171(3)  
          O(101)-C(102)-C(103)-C(104)                               2(5)  
________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
         #1 -x+2,-y+1,-z+1      
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X-ray crystallographic Data- Compound H52 
(piperidinium salt of 5-[[2,4-dinitrophenyl)hydrazono]-(4-hydroxyphenyl)methyl]-1,3-
dimethyl-pyrimidine-2,4,6-trione) 
 
Table 7.  Crystal data and structure refinement for compound H52.  
 
Empirical formula                    C24 H27 N7 O8  
Formula weight                       541.53  
Temperature                          150(2) K  
Wavelength                           0.71073 Å  
Crystal system, space group         Monoclinic, P2(1)/n  
Unit cell dimensions                 a = 8.5917(3) Å    alpha = 90 deg.  
                                           b = 17.4016(5) Å  beta  = 101.8980(10) deg.  
                                           c = 16.8982(5) Å  gamma = 90 deg.  
Volume                               2472.16(13) Å 3  
Z, Calculated density                4,  1.455 Mg/m3  
Absorption coefficient              0.112 mm-1  
F(000)                               1136  
Crystal size                         0.3 x 0.4 x 0.5 mm  
Theta range for data collection     2.34 to 27.50 deg.  
Limiting indices                     -11<=h<=11, -22<=k<=22, -21<=l<=21  
Reflections collected / unique      34222 / 5677 [R(int) = 0.0348]  
Completeness to theta = 27.50       100.0 %  
Absorption correction               Empirical  
Max. and min. transmission          1.000000 and 0.705996  
Refinement method                   Full-matrix least-squares on F2  
Data / restraints / parameters      5677 / 374 / 474  
Goodness-of-fit on F^2              1.100  
Final R indices [I>2sigma(I)]      R1 = 0.0470, wR2 = 0.1526  
R indices (all data)                 R1 = 0.0568, wR2 = 0.1689  
Extinction coefficient               0.013(3)  
Largest diff. peak and hole         0.683 and -0.548 e.A-3  
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Table 8.  Atomic coordinates ( x 104) and equivalent isotropic  
displacement parameters (A2 x 103) for H52.  
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________  
                               x                  y                    z            U(eq)  
________________________________________________________________  
          C(1)         11042(2)         701(1)        1889(1)        29(1)  
          N(3)         11211(2)        1472(1)        1651(1)        31(1)  
          C(3)          9975(2)        1983(1)        1480(1)        31(1)  
          N(5)          8530(2)        1746(1)        1615(1)        30(1)  
          C(5)          8258(2)        1016(1)        1928(1)        28(1)  
          C(6)          9562(2)         506(1)        2082(1)        27(1)  
          C(7)          9318(2)        -283(1)        2364(1)        27(1)  
          N(8)          8904(2)        -436(1)        3048(1)        30(1)  
          N(9)          8842(2)         188(1)       3538(1)        30(1)  
          C(10)         8267(2)         117(1)        4221(1)        28(1)  
          C(11)         8226(2)         740(1)        4761(1)        29(1)  
          C(12)         7569(2)         664(1)        5441(1)        32(1)  
          C(13)         6975(2)         -36(1)        5605(1)        34(1)  
          C(14)         7047(2)        -679(1)      5113(1)        36(1)  
          C(15)         7680(2)        -598(1)      4435(1)        32(1)  
          N(16)         8865(2)        1490(1)     4632(1)        36(1)  
          O(17)         9177(2)        1638(1)     3965(1)        49(1)  
          O(18)         9079(2)        1957(1)     5190(1)        48(1)  
          N(19)         6202(2)         -93(1)        6293(1)        47(1)  
          O(20)         5750(3)        -718(1)      6466(1)        76(1)  
          O(21)         6010(2)         497(1)       6654(1)        65(1)  
          O(22)        12173(1)         261(1)       1916(1)        39(1)  
          C(23)        12802(2)        1739(1)     1580(1)        41(1)  
          O(24)        10141(2)        2631(1)     1200(1)        39(1)  
          C(25)         7188(2)        2284(1)     1408(1)        39(1)  
          O(26)         6890(1)        868(1)       2022(1)        34(1)  
          C(27)         9445(2)       -945(1)      1839(1)        27(1)  
          C(28)         9645(2)       -1697(1)    2144(1)        30(1)  
          C(29)         9649(2)       -2321(1)    1640(1)        33(1)  
          C(30)         9495(2)       -2211(1)    810(1)        31(1)  
          C(31)         9325(2)       -1468(1)    495(1)        31(1)  
          C(32)         9294(2)        -847(1)      1008(1)      29(1)  
          O(33)         9551(2)       -2845(1)    347(1)        38(1)  
          N(34)         4978(2)         447(1)       8184(1)      30(1)  
          C(35)         5280(2)         353(1)       9083(1)      35(1)  
          C(36)         6642(2)         861(1)       9489(1)      38(1)  
          C(37)         6355(2)        1702(1)     9237(1)      40(1)  
          C(38)         6014(2)        1770(1)     8318(1)     40(1)  
          C(39)         4634(2)        1268(1)        7938(1)        35(1)  
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_____________________________________________________________  
            C(1)-O(22)                    1.231(2)  
            C(1)-N(3)                     1.416(2)  
            C(1)-C(6)                     1.417(2)  
            N(3)-C(3)                     1.370(2)  
            N(3)-C(23)                    1.472(2)  
            C(3)-O(24)                    1.241(2)  
            C(3)-N(5)                     1.372(2)  
            N(5)-C(5)                     1.413(2)  
            N(5)-C(25)                    1.469(2)  
            C(5)-O(26)                    1.246(2)  
            C(5)-C(6)                     1.411(2)  
            C(6)-C(7)                     1.483(2)  
            C(7)-N(8)                     1.303(2)  
            C(7)-C(27)                    1.473(2)  
            N(8)-N(9)                     1.3729(19)  
            N(9)-C(10)                    1.352(2)  
            C(10)-C(15)                   1.418(2)  
            C(10)-C(11)                   1.422(2)  
            C(11)-C(12)                   1.387(2)  
            C(11)-N(16)                   1.449(2)  
            C(12)-C(13)                   1.370(3)  
            C(13)-C(14)                   1.403(3)  
            C(13)-N(19)                   1.457(2)  
            C(14)-C(15)                   1.373(2)  
            N(16)-O(18)                   1.230(2)  
            N(16)-O(17)                   1.237(2)  
            N(19)-O(20)                   1.212(3)  
            N(19)-O(21)                   1.223(3)  
            C(27)-C(32)                   1.394(2)  
            C(27)-C(28)                   1.403(2)  
            C(28)-C(29)                   1.380(2)  
            C(29)-C(30)                   1.395(2)  
            C(30)-O(33)                   1.358(2)  
            C(30)-C(31)                   1.395(2)  
            C(31)-C(32)                   1.389(2)  
            N(34)-C(35)                   1.497(2)  
            N(34)-C(39)                   1.499(2)  
            C(35)-C(36)                   1.514(3)  
            C(36)-C(37)                   1.529(3)  
            C(37)-C(38)                   1.524(3)  
            C(38)-C(39)                   1.507(3)  
            O(22)-C(1)-N(3)             118.29(14)  
            O(22)-C(1)-C(6)             125.50(15)  
            N(3)-C(1)-C(6)              116.21(14)  
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            C(3)-N(3)-C(1)              123.68(14)  
            C(3)-N(3)-C(23)             118.09(15)  
            C(1)-N(3)-C(23)             118.24(15)  
            O(24)-C(3)-N(3)             121.65(15)  
            O(24)-C(3)-N(5)             121.04(16)  
            N(3)-C(3)-N(5)              117.30(14)  
            C(3)-N(5)-C(5)              123.89(14)  
            C(3)-N(5)-C(25)             117.50(14)  
            C(5)-N(5)-C(25)             118.60(14)  
            O(26)-C(5)-C(6)             125.46(15)  
            O(26)-C(5)-N(5)             117.87(14)  
            C(6)-C(5)-N(5)              116.63(14)  
            C(5)-C(6)-C(1)              121.51(14)  
            C(5)-C(6)-C(7)              118.82(14)  
            C(1)-C(6)-C(7)              119.30(14)  
            N(8)-C(7)-C(27)             116.23(14)  
            N(8)-C(7)-C(6)              123.84(14)  
            C(27)-C(7)-C(6)             119.83(13)  
            C(7)-N(8)-N(9)              115.11(14)  
            C(10)-N(9)-N(8)             120.65(14)  
            N(9)-C(10)-C(15)            120.64(15)  
            N(9)-C(10)-C(11)            122.73(14)  
            C(15)-C(10)-C(11)           116.62(14)  
            C(12)-C(11)-C(10)           121.80(15)  
            C(12)-C(11)-N(16)           116.28(15)  
            C(10)-C(11)-N(16)           121.92(14)  
            C(13)-C(12)-C(11)           118.96(16)  
            C(12)-C(13)-C(14)           121.76(16)  
            C(12)-C(13)-N(19)           118.12(16)  
            C(14)-C(13)-N(19)           120.08(17)  
            C(15)-C(14)-C(13)           119.02(16)  
            C(14)-C(15)-C(10)           121.74(16)  
            O(18)-N(16)-O(17)           122.29(15)  
            O(18)-N(16)-C(11)           118.71(15)  
            O(17)-N(16)-C(11)           119.01(14)  
            O(20)-N(19)-O(21)           123.42(18)  
            O(20)-N(19)-C(13)           118.37(18)  
            O(21)-N(19)-C(13)           118.19(18)  
            C(32)-C(27)-C(28)           117.62(14)  
            C(32)-C(27)-C(7)            120.55(14)  
            C(28)-C(27)-C(7)            121.76(14)  
            C(29)-C(28)-C(27)           121.48(15)  
            C(28)-C(29)-C(30)           120.09(15)  
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            O(33)-C(30)-C(31)           123.15(15)  
            O(33)-C(30)-C(29)           117.43(15)  
            C(31)-C(30)-C(29)           119.41(15)  
            C(32)-C(31)-C(30)           119.82(15)  
            C(31)-C(32)-C(27)           121.57(15)  
            C(35)-N(34)-C(39)           111.66(13)  
            N(34)-C(35)-C(36)           110.58(15)  
            C(35)-C(36)-C(37)           111.51(15)  
            C(38)-C(37)-C(36)           110.19(15)  
            C(39)-C(38)-C(37)           110.95(15)  
            N(34)-C(39)-C(38)           109.97(14)  
_____________________________________________________________  
   
Symmetry transformations used to generate equivalent atoms: #1 -x+2,-y+1,-z+1      
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Table 10.  Anisotropic displacement parameters (A2 x 103) for H52.  
The anisotropic displacement factor exponent takes the form:  
-2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
_______________________________________________________________________  
                 U11         U22        U33        U23      U13        U12  
____________________________________________________________________ 
    C(1)     30(1)      33(1)      25(1)      -2(1)       8(1)      -1(1)  
    N(3)     32(1)      35(1)      28(1)      -2(1)       9(1)      -5(1)  
    C(3)     39(1)      29(1)      25(1)      -3(1)       8(1)      -5(1)  
    N(5)     36(1)      27(1)      28(1)       0(1)       9(1)       2(1)  
    C(5)     32(1)      29(1)      24(1)      -3(1)       7(1)       0(1)  
    C(6)     29(1)      30(1)      24(1)       0(1)       7(1)       0(1)  
    C(7)     26(1)      30(1)      26(1)       0(1)       7(1)       2(1)  
    N(8)     33(1)      29(1)      29(1)      -2(1)      10(1)       1(1)  
    N(9)     36(1)      27(1)      27(1)      -2(1)      11(1)      -1(1)  
    C(10)    28(1)      30(1)      26(1)       0(1)       6(1)       2(1)  
    C(11)    31(1)      29(1)      28(1)      -2(1)       5(1)       0(1)  
    C(12)    31(1)      40(1)      25(1)      -4(1)       5(1)       4(1)  
    C(13)    32(1)      48(1)      24(1)       1(1)       8(1)      -1(1)  
    C(14)    40(1)      40(1)      29(1)       2(1)       9(1)      -6(1)  
    C(15)    36(1)      32(1)      28(1)      -1(1)       8(1)      -2(1)  
    N(16)    39(1)      32(1)      39(1)      -6(1)      10(1)      -3(1)  
    O(17)    72(1)      35(1)      43(1)      -1(1)      21(1)     -10(1)  
    O(18)    54(1)      41(1)      50(1)     -18(1)      15(1)      -9(1)  
    N(19)    41(1)      71(1)      28(1)       2(1)       9(1)      -2(1)  
    O(20)   102(2)      94(1)      41(1)     -11(1)      34(1)     -55(1)  
    O(21)    85(1)      79(1)      38(1)       7(1)      30(1)      35(1)  
    O(22)    29(1)      42(1)      47(1)      -2(1)      11(1)       4(1)  
    C(23)    34(1)      52(1)      37(1)       0(1)       9(1)     -13(1)  
    O(24)    56(1)      29(1)      34(1)      -1(1)      18(1)      -6(1)  
    C(25)    43(1)      32(1)      43(1)       1(1)      10(1)       7(1)  
    O(26)    29(1)      33(1)      41(1)       1(1)      11(1)       2(1)  
    C(27)    25(1)      30(1)      26(1)      -1(1)       9(1)       2(1)  
    C(28)    34(1)      32(1)      27(1)       2(1)      10(1)       3(1)  
    C(29)    38(1)      29(1)      33(1)       3(1)      11(1)       3(1)  
    C(30)    32(1)      30(1)      32(1)      -3(1)       9(1)       1(1)  
    C(31)    36(1)      33(1)      25(1)       0(1)       7(1)       0(1)  
    C(32)    30(1)      28(1)      29(1)       1(1)       8(1)       1(1)  
    O(33)    54(1)      29(1)      32(1)      -4(1)      11(1)       0(1)  
    N(34)    28(1)      35(1)      30(1)      -1(1)       9(1)       0(1)  
    C(35)    35(1)      42(1)      30(1)       3(1)      11(1)       0(1)  
    C(36)    37(1)      44(1)      33(1)      -2(1)       4(1)       1(1)  
    C(37)    41(1)      41(1)      39(1)      -8(1)      10(1)      -2(1)  
    C(38)    44(1)      35(1)      43(1)       2(1)      17(1)      -1(1)  
    C(39)    35(1)      38(1)      33(1)       3(1)       9(1)       8(1)  
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Table 11.  Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2 x 
103) for H52.  
________________________________________________________________  
                         x             y             z           U(eq)  
________________________________________________________________  
          H(9)         9130(30)       660(14)      3415(13)      40(6)  
          H(12)        7600(30)      1072(13)      5805(15)      48(6)  
          H(14)        6550(30)     -1127(14)      5249(15)      48(6)  
          H(15)        7670(30)     -1044(13)      4050(15)      46(6)  
          H(23A)      12890(30)      2250(16)      1750(16)      55(7)  
          H(23B)      12920(40)      1710(16)      1023(19)      68(8)  
          H(23C)      13630(30)      1448(14)      1948(15)      48(6)  
          H(25A)       7030(40)      2403(18)       832(10)      46(12)  
          H(25B)       7480(40)      2745(13)      1738(15)      39(11)  
          H(25C)       6250(20)      2046(15)      1544(17)      27(9)  
          H(25F)       6330(40)      2000(20)      1050(30)      13(16)  
          H(25E)       7450(80)      2750(30)      1130(30)      60(30)  
          H(25D)       6840(80)      2430(40)      1900(30)     110(40)  
          H(28)        9800(20)     -1787(10)      2728(12)      27(4)  
          H(29)        9810(30)     -2830(13)      1850(14)      38(5)  
          H(31)        9180(30)     -1388(13)       -95(14)      41(6)  
          H(32)        9190(20)      -328(12)       782(12)      30(5)  
          H(33)        9540(30)     -2686(15)      -196(17)      55(7)  
          H(34A)       5870(30)       279(13)      8007(13)      39(5)  
          H(34B)       4150(30)        86(13)      8008(14)      45(6)  
          H(35A)       5510(30)      -197(13)      9194(14)      42(6)  
          H(35B)       4370(30)       467(12)      9236(12)      30(5)  
          H(36A)       6810(30)       795(12)     10060(15)      41(6)  
          H(36B)       7680(30)       693(13)      9332(13)      45(6)  
          H(37A)       7300(30)      2029(12)      9473(13)      37(5)  
          H(37B)       5410(30)      1918(13)      9434(15)      47(6)  
          H(38A)       6930(30)      1623(14)      8146(15)      50(6)  
          H(38B)       5760(30)      2317(15)      8138(15)      55(7)  
          H(39A)       4480(20)      1276(12)      7369(14)      36(5)  
          H(39B)       3610(30)      1393(12)      8104(13)      34(5)  
         ________________________________________________________________  
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Table 12.  Torsion angles [deg] for H52.  
________________________________________________________________  
          O(22)-C(1)-N(3)-C(3)                                169.82(15)  
          C(6)-C(1)-N(3)-C(3)                                 -10.6(2)  
          O(22)-C(1)-N(3)-C(23)                                -9.9(2)  
          C(6)-C(1)-N(3)-C(23)                                169.69(15)  
          C(1)-N(3)-C(3)-O(24)                               -173.12(14)  
          C(23)-N(3)-C(3)-O(24)                                 6.6(2)  
          C(1)-N(3)-C(3)-N(5)                                   5.7(2)  
          C(23)-N(3)-C(3)-N(5)                               -174.57(14)  
          O(24)-C(3)-N(5)-C(5)                                179.68(14)  
          N(3)-C(3)-N(5)-C(5)                                   0.9(2)  
          O(24)-C(3)-N(5)-C(25)                                 0.7(2)  
          N(3)-C(3)-N(5)-C(25)                               -178.10(14)  
          C(3)-N(5)-C(5)-O(26)                               -179.80(14)  
          C(25)-N(5)-C(5)-O(26)                                -0.9(2)  
          C(3)-N(5)-C(5)-C(6)                                  -1.9(2)  
          C(25)-N(5)-C(5)-C(6)                                177.07(14)  
          O(26)-C(5)-C(6)-C(1)                                174.28(15)  
          N(5)-C(5)-C(6)-C(1)                                  -3.5(2)  
          O(26)-C(5)-C(6)-C(7)                                  1.3(2)  
          N(5)-C(5)-C(6)-C(7)                                -176.45(13)  
          O(22)-C(1)-C(6)-C(5)                               -171.20(16)  
          N(3)-C(1)-C(6)-C(5)                                   9.2(2)  
          O(22)-C(1)-C(6)-C(7)                                  1.7(2)  
          N(3)-C(1)-C(6)-C(7)                                -177.83(13)  
          C(5)-C(6)-C(7)-N(8)                                 -63.2(2)  
          C(1)-C(6)-C(7)-N(8)                                 123.66(17)  
          C(5)-C(6)-C(7)-C(27)                                112.97(16)  
          C(1)-C(6)-C(7)-C(27)                                -60.2(2)  
          C(27)-C(7)-N(8)-N(9)                                178.05(13)  
          C(6)-C(7)-N(8)-N(9)                                  -5.6(2)  
          C(7)-N(8)-N(9)-C(10)                                172.95(15)  
          N(8)-N(9)-C(10)-C(15)                                -1.6(2)  
          N(8)-N(9)-C(10)-C(11)                               177.90(14)  
          N(9)-C(10)-C(11)-C(12)                              177.13(16)  
          C(15)-C(10)-C(11)-C(12)                              -3.3(2)  
          N(9)-C(10)-C(11)-N(16)                               -2.7(2)  
          C(15)-C(10)-C(11)-N(16)                             176.81(15)  
          C(10)-C(11)-C(12)-C(13)                               1.5(2)  
          N(16)-C(11)-C(12)-C(13)                            -178.65(15)  
          C(11)-C(12)-C(13)-C(14)                               1.4(3)  
          C(11)-C(12)-C(13)-N(19)                            -176.32(15)  
          C(12)-C(13)-C(14)-C(15)                              -2.2(3)  
          N(19)-C(13)-C(14)-C(15)                             175.42(16)  
          C(13)-C(14)-C(15)-C(10)                               0.2(3)  
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          N(9)-C(10)-C(15)-C(14)                             -178.01(16)  
          C(11)-C(10)-C(15)-C(14)                               2.5(2)  
          C(12)-C(11)-N(16)-O(18)                              14.1(2)  
          C(10)-C(11)-N(16)-O(18)                            -166.04(16)  
          C(12)-C(11)-N(16)-O(17)                            -165.92(16)  
          C(10)-C(11)-N(16)-O(17)                              13.9(2)  
          C(12)-C(13)-N(19)-O(20)                            -176.18(19)  
          C(14)-C(13)-N(19)-O(20)                               6.1(3)  
          C(12)-C(13)-N(19)-O(21)                               5.5(3)  
          C(14)-C(13)-N(19)-O(21)                            -172.21(17)  
          N(8)-C(7)-C(27)-C(32)                               156.20(15)  
          C(6)-C(7)-C(27)-C(32)                               -20.3(2)  
          N(8)-C(7)-C(27)-C(28)                               -20.7(2)  
          C(6)-C(7)-C(27)-C(28)                               162.85(15)  
          C(32)-C(27)-C(28)-C(29)                              -1.7(2)  
          C(7)-C(27)-C(28)-C(29)                              175.28(15)  
          C(27)-C(28)-C(29)-C(30)                               1.7(3)  
          C(28)-C(29)-C(30)-O(33)                             178.28(15)  
          C(28)-C(29)-C(30)-C(31)                              -0.5(3)  
          O(33)-C(30)-C(31)-C(32)                            -179.35(15)  
          C(29)-C(30)-C(31)-C(32)                              -0.6(3)  
          C(30)-C(31)-C(32)-C(27)                               0.6(2)  
          C(28)-C(27)-C(32)-C(31)                               0.5(2)  
          C(7)-C(27)-C(32)-C(31)                             -176.49(15)  
          C(39)-N(34)-C(35)-C(36)                             -57.28(19)  
          N(34)-C(35)-C(36)-C(37)                              54.9(2)  
          C(35)-C(36)-C(37)-C(38)                             -54.3(2)  
          C(36)-C(37)-C(38)-C(39)                              55.9(2)  
          C(35)-N(34)-C(39)-C(38)                              58.86(19)  
          C(37)-C(38)-C(39)-N(34)                             -58.0(2)  
________________________________________________________________  
   
Symmetry transformations used to generate equivalent atoms: #1 -x+2,-y+1,-z+1      
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X-ray crystallographic Data- Compound F1  
(Pyridinium-barbiturate Zwitterion) 
 
 
Table 13.  Crystal data and structure refinement for compound F1 
_________________________________________________________________ 
 
Empirical formula        C24 H22 N6 O6  
Formula weight                490.48  
Temperature           150(2) K 
Wavelength            0.71073 Å 
Crystal system, space group      Monoclinic, P2(1)/n 
Unit cell dimensions     a=11.6777(6) Å, alpha = 90.00 deg. 
b=13.4416(7) Å, beta = 111.6300(10) deg 
c=15.0367(8) Å, gamma = 90.00 deg 
Volume                          2194.1(2) Å3 
Z, calculated density                4, 1.485 Mg/m3 
Absorption coefficient   0.110 mm-1 
F(000)      1024 
Crystal size     0.4 x 0.5 x 0.6 mm 
Theta range for data collection  2.10 to 30.00 deg. 
Limiting indices    -16<=h<=16, -18<=k<=18, -21<=l<=20 
Reflections collected / unique   30679 / 6390 [R(int) = 0.0284] 
Completeness to theta = 30.00  100.0% 
Absorption correction    empirical 
Max. and min. transmission   1.000000 and 0.811722 
Refinement method    Full matrix least squares on F2 
Data / restraints/ parameters   6390 / 0 / 413 
Goodness of fit on F2    1.035 
Final R indices [I>2sigma(I)]   R1=0.0486, wR2=0.1041 
Largest diff. peak and hole   0.388 and -0.241 e.A3 
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Table 14: Atomic coordinates and equivalent isotropic displacement parameters (A2) for 
F1.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
___________________________________________________________________ 
        x                     y                        z                     U(eq) 
___________________________________________________________________ 
C(1)   0.40154(9)  0.76110(7)  0.32067(7)  0.01620(19)  
C(2)    0.37268(9)  0.66438(7)  0.35879(7)  0.0173(2)  
C(3)    0.37981(10)  0.56702(8)  0.33032(8)  0.0217(2)  
C(4)    0.34872(10)  0.49033(8)  0.37943(9)  0.0247(2)  
C(5)    0.31165(10)  0.51147(8)  0.45610(9)  0.0246(2)  
C(6)  0.30312(10)  0.60879(8)  0.48059(8)  0.0215(2)  
N(7)   0.33290(8)  0.68190(6)  0.43083(6)  0.01767(18) 
C(8)   0.32301(9)  0.79020(7)  0.44947(8)  0.0177(2)  
C(9)   0.42018(9)  0.83200(7)  0.41155(7)  0.01618(19)  
C(10)   0.40282(9)  0.93899(8)  0.37796(7)  0.0179(2)  
N(11)   0.50556(8)  0.97972(6)  0.36542(7)  0.01981(19)  
C(12)   0.62265(10)  0.93615(8)  0.40039(8)  0.0203(2)  
N(13)   0.64245(8)  0.86229(7)  0.46952(7)  0.01974(18)  
C(14)   0.54844(9)  0.81456(7)  0.48722(7)  0.0178(2)  
C(15)   0.49643(9)  0.75965(7)  0.27610(7)  0.0169(2)  
C(16)  0.60439(9)  0.70148(7)  0.31489(7)  0.0175(2) 
N(17)   0.68541(8)  0.70188(7)  0.26378(7)  0.02065(19) 
C(18)   0.66641(10)  0.75685(8)  0.18230(8)  0.0203(2) 
N(19)    0.56146(8)  0.81420(7) 0.14951(6)  0.02109(19)   
C(20)    0.47389(9)  0.81994(8)  0.19443(7)  0.0176(2) 
O(21)    0.30749(7)  0.98487(6)  0.35799(6)  0.02502(18) 
C(22)   0.48702(11)  1.06806(8)  0.30363(9)  0.0247(2) 
O(23)    0.70576(7)  0.96754(6)  0.37764(6)  0.02848(19) 
C(24)   0.77081(10)  0.83330(10)  0.52487(10)  0.0264(2) 
O(25)   0.56654(7)  0.76029(6)  0.55579(6)  0.02343(17) 
O(26)   0.63307(7)  0.65141(6)  0.38941(6)  0.02345(17) 
C(27)   0.79630(12)  0.63983(10)  0.29909(10)  0.0295(3)  
O(28)   0.74013(7)  0.75544(7)  0.14071(6)  0.02804(19) 
C(29)   0.54155(13)  0.87453(11)  0.06397(10)  0.0331(3) 
O(30)  0.38443(7)  0.87667(6)  0.15982(6)  0.02363(17)   
C(31)   0.18991(9)  0.82394(8)  0.39900(8)  0.0195(2) 
N(32)   0.13528(8)  0.79654(7)  0.30716(7)  0.0230(2) 
C(33)    0.01985(11)  0.82892(9)  0.25990(9)  0.0277(2) 
C(34)    -0.04474(11)  0.88746(10)  0.30170(10)  0.0317(3) 
C(35)    0.01122(11)  0.91232(9)  0.39715(10)  0.0319(3) 
C(36)    0.13147(11)  0.87981(9)  0.44767(9)  0.0254(2) 
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Table 15: Bond lengths [Å] and angles [deg] for F1. 
 
 
C1-C15     1.4915(13)  
C1-C2       1.5083(14)  
C1-C9       1.6136(14)  
C2-N7      1.3475(13)   
C2-C3       1.3889(14)  
C3-C4       1.3918(15)  
C4-C5       1.4018(17)   
C5-C6       1.3725(16)  
C6-N7      1.3559(13)  
N7-C8      1.4948(13)   
C8-C31      1.5257(15)   
C8-C9       1.5510(13)  
C9-C10      1.5128(14)   
C9-C14      1.5286(14)   
C10-O21      1.2097(13)   
C10-N11      1.3934(13)   
N11-C12      1.3996(14)   
N11-C22      1.4738(14)   
C12-O23      1.2173(13)   
C12-N13      1.3938(14)   
N13-C14      1.3794(13)   
N13-C24      1.4737(14)   
C14-O25      1.2163(13)   
C15-C20      1.4128(14)   
C15-C16      1.4138(14)   
C16-O26      1.2425(12)   
C16-N17      1.4220(13)   
N17-C18      1.3769(14)   
N17-C27      1.4654(14)   
C18-O28      1.2367(13)   
C18-N19      1.3763(14)   
N19-C20      1.4202(13)   
N19-C29      1.4648(14)   
C20-O30      1.2421(12)   
C31-N32      1.3418(14)   
C31-C36      1.3905(15)   
N32-C33      1.3435(15)   
C33-C34      1.3902(17)   
C34-C35      1.3810(19)   
C35-C36      1.3976(17)   
Symmetry transformations used to generate equivalent atoms: #1 -x+2,-y+1,-z+1      
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Table 16:  Anisotropic displacement parameters (A2 ) for F1.  The anisotropic 
displacement factor exponent takes the form: -2 pi2 [h2 a*2U11 + … + h k a*b* U12] 
 
 U11      U22     U33       U23      U13        U12 
______________________________________________________________________ 
C1  0.0174(4)    0.0158(4)  0.0172(5)  0.0002(4)  0.0085(4)  -0.0001(4)  
C2  0.0160(4)    0.0188(5)  0.0182(5)  0.0005(4)  0.0076(4)  -0.0017(4)  
C3  0.0215(5)    0.0197(5)  0.0248(6)  -0.0030(4)  0.0097(4)  -0.0032(4)  
C4  0.0234(5)    0.0171(5)  0.0328(6)  -0.0007(4) 0.0092(5)  -0.0035(4)  
C5  0.0226(5)    0.0226(5)  0.0271(6)  0.0056(4)  0.0073(4)  -0.0048(4)  
C6  0.0209(5)    0.0248(5)  0.0201(5)  0.0040(4)  0.0091(4)  -0.0044(4)  
N7  0.0183(4)    0.0175(4)  0.0190(4)  0.0013(3)  0.0090(3)  -0.0019(3)  
C8  0.0200(5)    0.0178(5)  0.0186(5)  -0.0019(4)  0.0110(4)  -0.0021(4)  
C9  0.0173(4)    0.0159(4)  0.0175(5)  -0.0001(4)  0.0090(4)  -0.0012(4)  
C10 0.0197(5)   0.0172(4)  0.0185(5)  -0.0013(4)  0.0091(4)  -0.0012(4)  
N11 0.0201(4)   0.0165(4)  0.0250(5)  0.0033(3)  0.0108(4)  -0.0007(3)  
C12 0.0199(5)   0.0188(5)  0.0228(5)  -0.0012(4)  0.0085(4)  -0.0029(4)  
N13 0.0165(4)   0.0198(4)  0.0225(5)  0.0011(3)  0.0068(4)  -0.0014(3)  
C14 0.0201(5)   0.0171(4)  0.0176(5)  -0.0021(4)  0.0085(4)  -0.0008(4)  
C15 0.0184(5)   0.0173(4)  0.0177(5)  0.0002(4)  0.0096(4)  -0.0001(4)  
C16 0.0193(5)   0.0167(4)  0.0183(5)  -0.0011(4)  0.0091(4)  -0.0003(4)  
N17 0.0199(4)   0.0235(4)  0.0221(5)  0.0031(3)  0.0120(4)  0.0051(3)  
C18 0.0202(5)   0.0237(5)  0.0192(5)  -0.0016(4)  0.0100(4)  -0.0006(4)  
N19 0.0214(4)   0.0267(5)  0.0184(4)  0.0052(4)  0.0111(4)  0.0026(4)  
C20 0.0183(4)   0.0188(5)  0.0173(5)  -0.0014(4)  0.0085(4)  -0.0014(4)  
O21 0.0233(4)   0.0207(4)  0.0343(5)  0.0031(3)  0.0145(3)  0.0035(3)  
C22 0.0291(6)   0.0185(5)  0.0281(6)  0.0050(4)  0.0125(5)  -0.0012(4)  
O23 0.0222(4)   0.0298(4)  0.0370(5)  0.0050(4)  0.0150(4)  -0.0039(3)  
C24 0.0166(5)   0.0272(6)  0.0317(7)  0.0031(5)  0.0044(5)  0.0012(4)  
O25 0.0258(4)   0.0250(4)  0.0199(4)  0.0044(3)  0.0089(3)  0.0005(3)  
O26 0.0254(4)   0.0237(4)  0.0232(4)  0.0072(3)  0.0112(3)  0.0037(3)  
C27 0.0261(6)   0.0335(6)  0.0326(7)  0.0078(5)  0.0152(5)  0.0120(5)  
O28 0.0253(4)   0.0393(5)  0.0254(4)  0.0007(4)  0.0162(3)  0.0012(3)  
C29 0.0326(6)   0.0459(7)  0.0260(6)  0.0165(6)  0.0168(5)  0.0078(6)  
O30 0.0228(4)   0.0253(4)  0.0230(4)  0.0060(3)  0.0086(3)  0.0059(3)  
C31 0.0197(5)   0.0190(5)  0.0236(5)  -0.0007(4)  0.0124(4)  -0.0026(4)  
N32 0.0200(4)   0.0256(5)  0.0246(5)  -0.0034(4)  0.0096(4)  -0.0014(4)  
C33 0.0226(5)   0.0303(6)  0.0291(6)  -0.0034(5)  0.0082(5)  -0.0019(5)  
C34 0.0204(5)   0.0319(6)  0.0407(8)  -0.0041(5)  0.0086(5)  0.0019(5)  
C35 0.0267(6)   0.0306(6)  0.0433(8)  -0.0085(5)  0.0185(6)  0.0020(5)  
C36 0.0255(5)   0.0276(6)  0.0274(6)  -0.0058(5)  0.0147(5)  -0.0022(4)  
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Table 17:  Hydrogen coordinates and isotropic displacement parameters (A2) for F1. 
 
        x       y       z       U(eq) 
_____________________________________________________________________ 
H1   0.3248(12)  0.7836(9)  0.2719(9)  0.021(3) 
H3    0.4067(12)  0.5553(10)  0.2770(10)  0.023(3) 
H4    0.3552(13)  0.4244(11)  0.3629(10)  0.033(4) 
H5 H   0.2909(12)  0.4636(10)  0.4937(10)  0.028(3)   
H6 H   0.2770(12)  0.6285(10)  0.5332(10)  0.026(3)   
H8 H   0.3469(10)  0.7980(8)  0.5170(9)  0.010(3)  
H22A H  0.5598(15)  1.1079(11)  0.3231(11)  0.041(4) 
H22B H  0.4693(14)  1.0485(12)  0.2381(12)  0.039(4)    
H22C H  0.4188(15)  1.1054(12)  0.3092(11)  0.041(4)    
H24A H  0.8090(16)  0.8214(13)  0.4832(13)  0.054(5)    
H24B H  0.8121(17)  0.8808(14)  0.5627(14)  0.057(5)    
H24C H  0.7714(18)  0.7710(15)  0.5532(14)  0.065(6)    
H27A H  0.7900(16)  0.5899(14)  0.2491(13)  0.054(5)    
H27B H  0.7910(17)  0.6029(14)  0.3546(14)  0.059(5)  
H27C H  0.8673(15)  0.6790(11)  0.3107(11)  0.038(4)    
H29A H  0.6067(17)  0.9293(14)  0.0757(13)  0.059(5)    
H29B H  0.5521(16)  0.8305(13)  0.0117(13)  0.051(5)    
H29C H  0.4543(16)  0.9002(12)  0.0413(12)  0.050(5)    
H33 H  -0.0176(14)  0.8088(11)  0.1926(11)  0.038(4)    
H34 H  -0.1253(14)  0.9100(11)  0.2628(10)  0.035(4)    
H35 H  -0.0328(14)  0.9549(12)  0.4260(11)  0.037(4)   
H36 H  0.1752(13)  0.8971(11)  0.5157(11)  0.033(4) 
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Table 18: Torsion angles [deg] for F1. 
____________________________________________________________  
 
C15 C1 C2       117.82(8)   
C15 C1 C9       119.83(8)   
C2 C1 C9       99.58(8)    
N7 C2 C3       119.35(9)  
N7 C2 C1       110.27(8)  
C3 C2 C1       130.37(9)  
C2 C3 C4       118.51(10)   
C3 C4 C5       120.41(10)   
C6 C5 C4       119.27(10)   
N7 C6 C5       118.94(10)   
C2 N7 C6       123.47(9)  
C2 N7 C8       113.22(8)   
C6 N7 C8       123.31(9)  
N7 C8 C31       109.34(8)   
N7 C8 C9       99.58(7)   
C31 C8 C9       117.31(9)   
C10 C9 C14       111.61(8)   
C10 C9 C8       116.16(8)   
C14 C9 C8       108.64(8)   
C10 C9 C1       108.61(8)   
C14 C9 C1       109.21(8)   
C8 C9 C1       102.05(7)   
O21 C10 N11       121.71(9)   
O21 C10 C9       124.43(9)   
N11 C10 C9       113.74(8)   
C10 N11 C12       123.74(9)   
C10 N11 C22       117.91(9)   
C12 N11 C22       118.04(9)   
O23 C12 N13       121.75(10)  
O23 C12 N11       121.27(10)   
N13 C12 N11       116.66(9)    
C14 N13 C12       123.38(9)    
C14 N13 C24       118.96(9)    
C12 N13 C24       117.65(9)    
O25 C14 N13       122.72(10)   
O25 C14 C9       122.65(9)    
N13 C14 C9       114.59(9)    
C20 C15 C16       121.87(9)    
C20 C15 C1       116.86(9)    
C16 C15 C1       121.27(9)    
O26 C16 C15       125.07(9)    
O26 C16 N17       118.52(9)    
C15 C16 N17       116.40(9)    
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Table 18 (F1) cont. 
 
 
 
C18 N17 C16       124.19(9)    
C18 N17 C27       117.31(9)    
C16 N17 C27       118.50(9)    
O28 C18 N19       121.43(10)  
O28 C18 N17       121.86(10)    
N19 C18 N17       116.71(9)    
C18 N19 C20       124.21(9)   
C18 N19 C29       117.18(9)   
C20 N19 C29       118.59(9)    
O30 C20 C15       125.08(9)   
O30 C20 N19       118.42(9)    
C15 C20 N19       116.50(9)   
N32 C31 C36       123.40(10)    
N32 C31 C8       116.17(9)   
C36 C31 C8       120.43(10)    
C31 N32 C33       117.33(10)    
N32 C33 C34       123.37(12)    
C35 C34 C33       118.62(11)    
C34 C35 C36       119.01(11)   
C31 C36 C35       118.19(11)  
C15 C1 C2 N7      152.38(9)  
C9 C1 C2 N7       21.12(10)  
C15 C1 C2 C3      -28.54(16)  
C9 C1 C2 C3       -159.80(11)  
N7 C2 C3 C4       -1.82(16)  
C1 C2 C3 C4       179.16(10)  
C2 C3 C4 C5       -0.28(17)  
C3 C4 C5 C6       1.76(17)  
C4 C5 C6 N7       -1.12(16)  
C3 C2 N7 C6       2.57(16)  
C1 C2 N7 C6       -178.24(9)  
C3 C2 N7 C8       -176.54(9)  
C1 C2 N7 C8       2.66(12)  
C5 C6 N7 C2       -1.06(16)  
C5 C6 N7 C8       177.96(10)  
C2 N7 C8 C31      97.38(10)  
C6 N7 C8 C31      -81.72(12)  
C2 N7 C8 C9       -26.14(11)  
C6 N7 C8 C9       154.75(9)  
N7 C8 C9 C10      154.65(9)  
C31 C8 C9 C10      36.94(13)  
N7 C8 C9 C14      -78.56(9)  
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Table 18 (F1) cont. 
 
 
C31 C8 C9 C14      163.72(9)  
N7 C8 C9 C1       36.72(9)  
C31 C8 C9 C1      -80.99(10)  
C15 C1 C9 C10      71.12(11)  
C2 C1 C9 C10      -158.91(8)  
C15 C1 C9 C14     -50.81(11)  
C2 C1 C9 C14      79.16(9)  
C15 C1 C9 C8      -165.67(9)  
C2 C1 C9 C8       -35.70(9)  
C14 C9 C10 O21      -143.23(10)  
C8 C9 C10 O21      -17.94(15)  
C1 C9 C10 O21      96.32(12)  
C14 C9 C10 N11      40.87(12)  
C8 C9 C10 N11      166.16(9)  
C1 C9 C10 N11      -79.59(10)  
O21 C10 N11 C12      170.06(10)  
C9 C10 N11 C12      -13.91(14)  
O21 C10 N11 C22      -16.38(15)  
C9 C10 N11 C22      159.65(9)  
C10 N11 C12 O23      170.68(10)  
C22 N11 C12 O23      -2.88(16)  
C10 N11 C12 N13      -15.62(15)  
C22 N11 C12 N13      170.82(9)  
O23 C12 N13 C14     -170.11(10)   
N11 C12 N13 C14      16.22(15)  
O23 C12 N13 C24      8.85(16)   
N11 C12 N13 C24      -164.83(10)  
C12 N13 C14 O25      -169.75(10)  
C24 N13 C14 O25      11.32(16)  
C12 N13 C14 C9      12.61(14)  
C24 N13 C14 C9      -166.33(10)  
C10 C9 C14 O25      141.71(10)  
C8 C9 C14 O25      12.35(13)  
C1 C9 C14 O25      -98.19(11)  
C10 C9 C14 N13      -40.64(12)  
C8 C9 C14 N13      -170.00(8)  
C1 C9 C14 N13      79.46(10)  
C2 C1 C15 C20      141.54(10)  
C9 C1 C15 C20      -97.15(11)  
C2 C1 C15 C16      -39.24(14)  
C9 C1 C15 C16      82.06(12)  
C20 C15 C16 O26      175.71(10)  
C1 C15 C16 O26      -3.46(16)  
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C20 C15 C16 N17      -3.90(15)  
C1 C15 C16 N17      176.92(9)  
O26 C16 N17 C18      -177.66(10)  
C15 C16 N17 C18      1.98(15)  
O26 C16 N17 C27      2.61(15)  
C15 C16 N17 C27      -177.75(10)  
C16 N17 C18 O28      179.37(10)  
C27 N17 C18 O28      -0.89(16)  
C16 N17 C18 N19      -0.22(15)  
C27 N17 C18 N19      179.52(10)  
O28 C18 N19 C20      -179.32(10)  
N17 C18 N19 C20      0.27(15)  
O28 C18 N19 C29      -0.78(16)  
N17 C18 N19 C29      178.81(10)  
C16 C15 C20 O30      -175.99(10)  
C1 C15 C20 O30      3.22(15)  
C16 C15 C20 N19      3.95(15)  
C1 C15 C20 N19      -176.84(9)  
C18 N19 C20 O30      177.86(10)  
C29 N19 C20 O30      -0.66(15)  
C18 N19 C20 C15      -2.09(15)  
C29 N19 C20 C15      179.39(10)  
N7 C8 C31 N32      -48.07(12)  
C9 C8 C31 N32      64.24(12)  
N7 C8 C31 C36      131.94(10)  
C9 C8 C31 C36      -115.76(11)  
C36 C31 N32 C33      2.79(16)  
C8 C31 N32 C33      -177.21(9)  
C31 N32 C33 C34      -0.83(17)  
N32 C33 C34 C35      -1.26(19)  
C33 C34 C35 C36      1.45(19)  
N32 C31 C36 C35      -2.57(17)  
C8 C31 C36 C35      177.43(10)  
C34 C35 C36 C31      0.33(18)  
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X-ray crystallographic Data- Compound G37 
(1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-
yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt) 
 
 
Table 19.  Crystal data and structure refinement for compound  
_________________________________________________________________ 
 
Empirical formula        C26 H34 N6 O9 S2 
Formula weight                638.71  
Temperature           150(2) K 
Wavelength            0.71073 Å 
Crystal system, space group      Monoclinic, P2(1) 
Unit cell dimensions     a=8.5679(2) Å, alpha = 90.00 deg. 
b=15.5485(4) Å, beta = 93.1700(10) deg 
c=11.1461(3) Å, gamma = 90.00 deg 
Volume                          1482.59(7) Å3 
Z, calculated density                2, 1.431 Mg/m3 
Absorption coefficient   0.242 mm-1 
F(000)      672 
Crystal size     0.20 x 0.35 x 0.45 mm 
Theta range for data collection  2.250 to 29.00 deg. 
Limiting indices    -12<=h<=12, -22<=k<=22, -15<=l<=15 
Reflections collected / unique   24322 / 7431 [R(int) = 0.0453] 
Completeness to theta = 29.00  100.0% 
Absorption correction    empirical 
Max. and min. transmission   30.55 and 1.83 
Refinement method    Full matrix least squares on F2 
Data / restraints/ parameters   7431 / 262 / 465 
Goodness of fit on F2    0.691 
Final R indices [I>2sigma(I)]   R1=0.0773, wR2=0.0534 
Largest diff. peak and hole   0.408  and -0.437 e.A3 
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Table 20:  Atomic coordinates and equivalent isotropic displacement parameters (A2) for 
G37.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
_________________________________________________________________ 
        x                       y                       z                    U(eq) 
__________________________________________________________________ 
C1   0.9958(2)  1.07946(11)  0.80317(15)  0.0160(4)  
C2   0.8605(2)  1.04557(12)  0.84230(18)  0.0231(5)  
C3  0.8608(2)  0.99872(14)  0.94918(19)  0.0295(5)  
N4   0.98553(19)  0.98252(10)  1.01896(14)  0.0266(4)  
C5   1.1243(2)  1.01517(12)  0.98316(17)  0.0220(4)  
C6   1.2597(2)  0.99875(13)  1.05799(18)  0.0275(5)  
C7    1.4027(3)  1.02771(13)  1.02718(19)  0.0286(5)  
C8    1.4157(2)  1.07103(13)  0.91878(18)  0.0258(5)  
C9    1.2872(2)  1.08913(12)  0.84473(17)  0.0189(4)  
C10   1.1361(2)  1.06270(11)  0.87514(15)  0.0169(4)  
C11   1.0012(2)  1.13043(11)  0.68623(16)  0.0144(4)  
C12    1.0658(2)  1.22049(11)  0.70650(15)  0.0150(4)  
C13    .1992(2)  1.24491(11)  0.64306(16)  0.0169(4)  
N14    1.26397(18)  1.32472(10)  0.66855(13)  0.0179(3)  
C15    1.2160(2)  1.38107(12)  0.75321(15)  0.0179(4)  
N16    1.08894(17)  1.35404(10)  .81203(13)  0.0174(4)  
C17    1.0126(2)  1.27742(12)  0.79067(16)  0.0176(4)  
O18    1.26202(13)  1.19902(8)  0.56667(11)  0.0196(3)  
O19    1.28122(14)  1.45014(8)  0.77497(10)  0.0211(3)  
O20    0.89068(14)  1.26498(8)  0.85227(10)  0.0203(3)  
C21    0.85373(19)  1.12358(11)  .60455(15)  0.0144(4)  
C22    0.7153(2)  1.16403(12)  0.62423(16)  0.0185(4)  
N23    0.59001(18)  1.15600(11)  0.54215(14)  0.0190(4)  
C24    0.5919(2)  1.11117(12)  0.43690(16)  0.0182(4)  
N25    0.72723(18)  1.06670(11)  0.42348(15)  0.0197(4)  
C26    0.8576(2)  1.06604(11)  0.50437(16)  0.0185(4)  
O27    0.68251(14)  1.21154(8)  0.71602(12)  0.0228(3)  
O28    0.48105(14)  1.11032(8)  0.36287(11)  0.0261(3)  
O29    0.96645(14)  1.01698(8)  0.48339(11)  0.0271(3)  
N30    0.7226(4)  0.7629(2)  0.6817(4)  0.0251(8)  
N30B   0.7549(11)  0.7482(6)  0.6678(11)  0.023(3)  Uiso 0.266(3)  
C31    0.8188(4)  0.8414(2)  0.6758(3)  0.0372(9)  Uani 0.734(3)  
C31B   0.8653(11)  0.8194(6)  0.6439(7)  0.025(2)  Uiso 0.266(3)  
C32   0.9803(4)  0.8175(3)  0.6437(3)  0.0568(11)  0.734(3)  
C32B   0.9564(10)  0.8435(5)  0.7584(7)  0.046(2)  Uiso 0.266(3)  
O33   1.0515(2)  0.75667(16)  0.7250(3)  0.0516(7)  Uani 0.734(3)  
O33B   1.0363(7)  0.7721(4)  0.8089(7)  0.0484(19)  Uiso 0.266(3) 
C34    0.9604(4) 0.6810(2)  0.7239(3)  0.0512(10)  0.734(3)  
C34B    0.9244(10)  0.7082(6)  0.8368(8)  0.053(3)  Uiso 0.266(3)  
C35   0.7997(3)  0.6977(2)  0.7639(3)  0.0313(8)  0.734(3)  
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C35B   0.8398(13)  0.6744(6)  0.7255(8)  0.038(3)  Uiso 0.266(3)  
S36    0.34706(6)  0.87188(3)  0.50932(4)  0.02501(12)  
O36   0.51865(14)  0.85421(9)  0.50005(11)  0.0317(4)  
C37   0.2812(2)  0.92138(13)  0.37130(17)  0.0299(5)  
C38   0.3353(2)  0.96397(12)  0.60254(17)  0.0307(5)  
S39   0.39083(7)  0.81411(4)  0.90142(5)  0.04240(16)  
O39   0.5092(2)  0.83465(11)  0.81213(14)  0.0698(6)  
C40   0.3435(3)  0.70381(14)  0.8803(2)  0.0508(7) 
C41   0.4979(2)  0.80405(15)  1.04116(16)  0.0370(5)  
 299
Table 21: Bond lengths [Å] and angles [deg] for G37 
 
C1 C2     1.367(2)  
C1 C10    1.432(2)  
C1 C11    1.528(2)  
C2 C3     1.396(3)  
C3 N4     1.311(2)  
N4 C5     1.372(2)  
C5 C6     1.414(3)  
C5 C10    1.421(2)  
C6 C7     1.367(3)  
C7 C8     1.393(3)  
C8 C9     1.368(3)  
C9 C10    1.417(2)  
C11 C12    1.518(2)  
C11 C21    1.520(2)  
C12 C17    1.385(2)  
C12 C13    1.428(2)   
C13 O18    1.2548(19)  
C13 N14    1.383(2)   
N14 C15    1.367(2)   
C15 O19    1.229(2)   
C15 N16    1.367(2)   
N16 C17    1.374(2)   
C17 O20    1.296(2)  
C21 C22    1.371(2)  
C21 C26   1.433(2)   
C22 O27    1.305(2)   
C22 N23    1.377(2)   
N23 C24    1.365(2)  
C24 O28    1.223(2)  
C24 N25    1.365(2)   
N25 C26    1.396(2)   
C26 O29    1.237(2)   
N30 C31    1.477(3)   
N30 C35    1.495(4)   
N30B C35B    1.486(7)   
N30B C31B    1.491(7)   
C31 C32    1.496(4)   
C31B C32B    1.506(7)  
C32 O33    1.423(3)  
C32B O33B    1.405(6)  
O33 C34    1.412(4)  
O33B C34B    1.427(7)  
C34 C35    1.494(4)  
C34B C35B    1.497(7)  
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S36 O36    1.5048(13)  
S36 C38    1.7752(19)  
S36 C37    1.7836(18)  
S39 O39    1.4940(17)  
S39 C41    1.7703(18)  
S39 C40    1.775(2)  
 
__________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: #1 -x+2,-y+1,-z+1 
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Table 22:  Anisotropic displacement parameters (A2 ) for G37.  The anisotropic 
displacement factor exponent takes the form: -2 pi2 [h2 a*2U11 + … + h k a*b* U12] 
 
      U11                 U22     U33       U23  U13  U12 
______________________________________________________________________ 
C1  0.0180(10)  0.0140(10)  0.0158(9)  -0.0020(8)    0.0007(8)    0.0007(8)  
C2  0.0135(10)  0.0273(12)  0.0288(12)  0.0055(9)      0.0024(9)    0.0008(9)  
C3  0.0213(12)  0.0315(13)  0.0365(13)  0.0142(10)    0.0089(10) -0.0018(10)  
N4  0.0284(10)  0.0278(10)  0.0242(9)  0.0080(8)      0.0072(8)     0.0027(8)  
C5  0.0249(11)  0.0193(10)  0.0218(10)  0.0009(9)      0.0028(9)     0.0035(9)  
C6  0.0361(13)  0.0273(12)  0.0187(11)  0.0034(10)   -0.0034(10)   0.0040(1)  
C7  0.0277(12)  0.0274(12)  0.0293(12)  0.0007(10)   -0.0118(10)   0.0048(1)  
C8  0.0206(11)  0.0260(12)  0.0304(12)  -0.0019(10)  -0.0010(10)  -0.0012(1)  
C9  0.0222(11)  0.0163(11)  0.0180(10)  0.0010(9)       0.0007(9)     0.0017(8)  
C10  0.0203(10)  0.0143(10)  0.0159(10)  -0.0032(8)    -0.0003(8)     0.0028(8)  
C11  0.0126(9)  0.0148(10)  0.0160(9)  0.0002(8)       0.0025(8)     0.0032(8)  
C12  0.0144(9)  0.0163(9)  0.0143(9)  0.0012(8)       0.0017(7)    -0.0004(8)  
C13  0.0171(10)  0.0184(10)  0.0149(10)  0.0013(8)      -0.0012(8)     0.0011(8)  
N14  0.0147(8)  0.0196(9)  0.0197(8)  0.0001(7)       0.0051(7)    -0.0037(7)  
C15  0.0179(10)  0.0187(10)  0.0163(9)  0.0014(9)      -0.0064(8)     0.0011(9)  
N16  0.0182(9)  0.0174(9)  0.0170(9)  -0.0062(7)      0.0039(7)    -0.0009(7)  
C17  0.0160(10)  0.0200(10)  0.0167(10)  0.0018(8)      -0.0002(8)    0.0007(8)  
O18  0.0169(7)  0.0192(7)  0.0234(7)  -0.0041(6)      0.0086(6)   -0.0008(6)  
O19  0.0236(7)  0.0182(7)  0.0215(7)  -0.0007(6)    -0.0001(6)    -0.0052(6)  
O20  0.0178(7)  0.0248(7)  0.0190(7)  -0.0056(6)     0.0065(6)    -0.0051(6)  
C21  0.0132(9)  0.0143(9)  0.0158(9)  -0.0002(8)     0.0025(8)    -0.0001(7)  
C22  0.0222(11)  0.0152(10)  0.0182(10)  0.0016(8)      0.0021(8)     -0.0010(8)  
N23  0.0122(9)  0.0225(9)  0.0223(9)  -0.0034(7)     0.0005(7)     0.0059(7)  
C24  0.0195(10)  0.0170(10)  0.0183(10)  0.0010(8)      0.0022(8)     -0.0003(8)  
N25  0.0186(9)  0.0232(9)  0.0172(9)  -0.0072(8)    -0.0017(7)      0.0022(7)  
C26  0.0180(10)  0.0161(10)  0.0213(10)  0.0028(9)     -0.0009(8)     -0.0004(9)  
O27  0.0177(7)  0.0288(8)  0.0219(7)  -0.0105(6)     0.0016(6)      0.0024(6)  
O28  0.0201(7)  0.0321(8)  0.0254(7)  -0.0039(7)    -0.0060(6)      0.0044(6)  
O29  0.0193(7)  0.0299(8)  0.0319(8)  -0.0125(7)    -0.0015(6)      0.0094(6)  
N30  0.0181(16)  0.0282(16)  0.0291(16)  -0.0044(14)   0.0013(14)    0.0003(1)  
C31  0.038(2)  0.032(2)  0.040(2)  0.0045(16)   -0.0071(17) -0.0094(15)  
C32  0.0345(19)  0.082(3)  0.053(2)  0.025(2)       -0.0050(16) -0.0193(19)  
O33  0.0170(12)  0.0768(17)  0.0601(19)  0.0120(15)   -0.0049(11) -0.0056(11)  
C34  0.0343(19)  0.053(2)  0.065(3)  -0.0040(19)  -0.0082(17)  0.0174(17)  
C35  0.0285(17)  0.0326(19)  0.0318(19)  0.0059(16)   -0.0071(15) -0.0084(15)  
S36  0.0245(3)  0.0231(3)  0.0284(3)  -0.0006(3)     0.0094(2)     0.0043(2)  
O36  0.0244(8)  0.0459(10)  0.0253(7)  0.0005(7)       0.0076(6)     0.0157(7)  
C37  0.0295(12)  0.0318(13)  0.0277(12)  -0.0024(10)   -0.0060(10) 0.0045(10)  
C38  0.0349(12)  0.0262(12)  0.0317(12)  -0.0004(10)    0.0087(10) 0.0052(10)  
S39  0.0516(4)  0.0426(4)  0.0322(3)  -0.0017(3)     -0.0043(3)   0.0172(3)  
O39  0.1248(17)  0.0484(12)  0.0395(10)  0.0117(9)      0.0343(10)   0.0157(11)  
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C40  0.0461(15)  0.0528(16)  .0516(16)  -0.0150(13)  -0.0134(12)  0.0081(13)  
C41  0.0357(13)  0.0437(14)  0.0315(12)  0.0070(11)    0.0006(10) -0.0069(11)  
   
_  
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Table 23: Hydrogen coordinates and isotropic displacement parameters (A2) for G37 
 
        x         y   z  U(eq) 
___________________________________________________________________ 
H2 H   0.765(2)  1.0508(10)  0.7986(14)  0.016(5) Uiso 1 1 d 
H3 H   0.769(2)  0.9769(13)  0.9725(17)  0.037(6) Uiso 1 1 d 
H6 H   1.2483(19)  0.9680(11)  1.1337(16)  0.022(5) Uiso 1 1 d 
H7 H   1.4889(19)  1.0197(10)  1.0785(15)  0.012(5) Uiso 1 1 d 
H8 H   1.509(2)  1.0946(12)  0.8922(15)  0.023(5) Uiso 1 1 d 
H9 H   1.2946(17)  1.1154(10)  0.7728(13)  0.002(4) Uiso 1 1 d 
H11 H  1.0720(17)  .0997(10)  0.6462(13)  0.004(4) Uiso 1 1 d . 
H14 H  1.346(2)  1.3429(13)  0.6242(18)  0.053(7) Uiso 1 1 d 
H16 H  1.048(2)  1.3894(13)  0.8624(17)  0.034(6) Uiso 1 1 d 
H23 H  0.509(2)  1.1866(14)  0.5502(18)  0.047(7) Uiso 1 1 d 
H25 H  0.724(2)  1.0347(12)  0.3643(17)  0.028(6) Uiso 1 1 d . 
H27 H  0.772(3)  1.2330(16)  0.782(2)  0.083(9) Uiso 1 1 d 
H30A H  0.7076  0.7397  0.6060  0.030 Uiso 0.734(3)  
H30B H  0.6263  0.7768  0.7087  0.030 Uiso 0.734(3) 
H30C H  0.6800  0.7675  0.7173  0.027 Uiso 0.266(3)  
H30D H  0.7053  0.7305  0.5967  0.027 Uiso 0.266(3)  
H31A H  0.8230  0.8711  0.7545  0.045 Uiso 0.734(3)  
H31B H  0.7716  0.8812  0.6146  0.045 Uiso 0.734(3)  
H31C H  0.8063  0.8700  0.6120  0.030 Uiso 0.266(3)  
H31D H  0.9381  0.8009  0.5829  0.030 Uiso 0.266(3)  
H32A H  0.9758  0.7930  0.5616  0.068 Uiso 0.734(3)  
H32B H  1.0457  0.8699  0.6434  0.068 Uiso 0.734(3)  
H32C H  1.0325  0.8892  0.7415  0.055 Uiso 0.266(3)  
H32D H  0.8839  0.8665  0.8167  0.055 Uiso 0.266(3)  
H34A H  1.0125  0.6378  0.7777  0.061 Uiso 0.734(3)  
H34B H  0.9530  0.6569  0.6416  0.061 Uiso 0.734(3)  
H34C H  0.8479  0.7333  0.8903  0.064 Uiso 0.266(3)  
H34D H  0.9782  0.6602  0.8802  0.064 Uiso 0.266(3)  
H35A H  0.8054  0.7196  0.8475  0.038 Uiso 0.734(3)  
H35B H  0.7382  0.6437  0.7615  0.038 Uiso 0.734(3)  
H35C H  0.9149  0.6499  0.6704  0.045 Uiso 0.266(3) 
H35D H  0.7653  0.6287  0.7461  0.045 Uiso 0.266(3)  
H37A H  0.3500  0.9697  0.3543  0.045 Uiso  
H37B H  0.1742  0.9424  0.3777  0.045 Uiso 1 1 calc R . .  
H37C H  0.2834  0.8792  0.3061  0.045 Uiso 1 1 calc R 
H38A H  0.3726  0.9493  0.6847  0.046 Uiso 1 1 calc R . .  
H38B H  0.2265  0.9834  0.6025  0.046 Uiso 1 1 calc R . .  
H38C H  0.4003  1.0100  0.5719  0.046 Uiso 1 1 calc R 
H40A H  0.2901  0.6959  0.8010  0.076 Uiso 1 1 calc R . .  
H40B H  0.2747  0.6852  0.9427  0.076 Uiso 1 1 calc R . .  
H40C H  .4396   0.6695  0.8855  0.076 Uiso 1 1 calc R . .  
H41A H  0.5816  0.7617  1.0340  0.056 Uiso 1 1 calc R . .  
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H41B H  0.4279  0.7850  1.1025  0.056 Uiso 1 1 calc R . .  
H41C H  0.5435  0.8598  1.0643  0.056 Uiso 1 1 calc R . 
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Table 24: Torsion angles [deg] for G37 
 
C2 C1 C10    116.85(17)  
C2 C1 C11    122.58(16)  
C10 C1 C11    120.54(15)  
C1 C2 C3    120.79(19)  
N4 C3 C2    124.7(2)  
C3 N4 C5    116.57(17)  
N4 C5 C6    117.22(18)  
N4 C5 C10    122.85(16)  
C6 C5 C10    119.92(18)  
C7 C6 C5    120.7(2)  
C6 C7 C8    119.5(2)  
C9 C8 C7    121.5(2)  
C8 C9 C10    120.75(18)  
C9 C10 C5    117.56(16)  
C9 C10 C1    124.25(16)  
C5 C10 C1    118.18(17)  
C12 C11 C21    115.98(15)  
C12 C11 C1    112.30(15)  
C21 C11 C1    114.27(14)  
C17 C12 C13    117.90(16)  
C17 C12 C11    124.00(16)  
C13 C12 C11    117.82(16)  
O18 C13 N14    117.87(16)  
O18 C13 C12    124.74(16)  
N14 C13 C12    117.39(16)  
C15 N14 C13    125.75(16)  
O19 C15 N14    123.05(17)  
O19 C15 N16    122.64(17)  
N14 C15 N16    114.31(17)  
C15 N16 C17    124.58(17)  
O20 C17 N16    115.33(16)  
O20 C17 C12    124.66(16)  
N16 C17 C12    119.99(17)  
C22 C21 C26    117.93(16)  
C22 C21 C11    124.76(16)  
C26 C21 C11    117.17(15)  
O27 C22 C21    127.64(17)  
O27 C22 N23    112.25(16)   
C21 C22 N23    120.11(17)   
C24 N23 C22    124.84(16)   
O28 C24 N25    123.58(17)   
O28 C24 N23    122.63(17)   
N25 C24 N23    113.78(16)   
C24 N25 C26    125.94(17)  
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O29 C26 N25    117.84(17)   
O29 C26 C21    125.61(16)  
N25 C26 C21    116.54(16)  
C31 N30 C35    111.1(3)  
C35B N30B C31B   110.5(9)  
N30 C31 C32    109.3(3)  
N30B C31B C32B   109.7(8) 
O33 C32 C31    112.5(2)  
O33B C32B C31B   111.2(7)  
C34 O33 C32    109.3(3)  
C32B O33B C34B   108.6(7)  
O33 C34 C35    111.8(3)  
O33B C34B C35B   111.4(8)  
C34 C35 N30    108.5(3)  
N30B C35B C34B   106.9(9)  
O36 S36 C38    105.94(9)  
O36 S36 C37    106.45(9)  
C38 S36 C37    97.55(9)  
O39 S39 C41    105.50(10)  
O39 S39 C40    106.05(11)  
C41 S39 C40    97.76(11)  
C10 C1 C2 C3   1.5(3)  
C11 C1 C2 C3   179.42(18)  
C1 C2 C3 N4    -0.7(3)  
C2 C3 N4 C5    0.6(3)  
C3 N4 C5 C6    179.56(19)  
C3 N4 C5 C10  -1.3(3)  
N4 C5 C6 C7    178.72(19)  
C10 C5 C6 C7   -0.4(3)  
C5 C6 C7 C8    -2.4(3)  
C6 C7 C8 C9    3.3(3)  
C7 C8 C9 C10  -1.2(3)  
C8 C9 C10 C5   -1.6(3)  
C8 C9 C10 C1   179.61(18)  
N4 C5 C10 C9  -176.72(17)  
C6 C5 C10 C9   2.4(3)  
N4 C5 C10 C1  2.2(3)  
C6 C5 C10 C1   -178.73(17)  
C2 C1 C10 C9   176.66(17)  
C11 C1 C10 C9  -1.3(3)  
C2 C1 C10 C5   -2.2(2)  
C11 C1 C10 C5   179.84(16)  
C2 C1 C11 C12   121.94(19)  
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C10 C1 C11 C12   -60.2(2)  
C2 C1 C11 C21   -12.8(2)  
C10 C1 C11 C21   165.04(15)  
C21 C11 C12 C17   83.2(2)  
C1 C11 C12 C17   -50.8(2)  
C21 C11 C12 C13   -103.03(19)  
C1 C11 C12 C13   123.02(17)  
C17 C12 C13 O18   178.26(17)  
C11 C12 C13 O18   4.1(3)  
C17 C12 C13 N14   -1.3(2)  
C11 C12 C13 N14   -175.46(15)  
O18 C13 N14 C15  -176.46(16)  
C12 C13 N14 C15  3.1(3)  
C13 N14 C15 O19  177.50(16)  
C13 N14 C15 N16  -2.4(2)  
O19 C15 N16 C17  -179.96(16)  
N14 C15 N16 C17  0.0(2)  
C15 N16 C17 O20  -177.30(15)  
C15 N16 C17 C12  1.6(3)  
C13 C12 C17 O20  177.93(16)  
C11 C12 C17 O20  -8.3(3)  
C13 C12 C17 N16  -0.9(2)  
C11 C12 C17 N16   172.91(16)  
C12 C11 C21 C22   -58.6(2)  
C1 C11 C21 C22   74.5(2)  
C12 C11 C21 C26   125.83(18)  
C1 C11 C21 C26   -101.11(18)  
C26 C21 C22 O27   172.53(17)  
C11 C21 C22 O27   -3.0(3)  
C26 C21 C22 N23   -6.8(3)  
C11 C21 C22 N23   177.64(16)  
O27 C22 N23 C24   178.90(16)  
C21 C22 N23 C24   -1.7(3)  
C22 N23 C24 O28   -175.12(18)  
C22 N23 C24 N25   5.9(3)  
O28 C24 N25 C26   179.36(17)  
N23 C24 N25 C26   -1.7(3)  
C24 N25 C26 O29   174.43(17)  
C24 N25 C26 C21   -6.2(3)  
C22 C21 C26 O29   -170.47(18)  
C11 C21 C26 O29   5.4(3)  
C22 C21 C26 N25   10.3(2)  
C11 C21 C26 N25   -173.82(15)  
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C35 N30 C31 C32   53.5(4)  
C35B N30B C31B C32B  -54.5(11)  
N30 C31 C32 O33   56.3(4) .  
N30B C31B C32B O33B  56.8(11)  
C31 C32 O33 C34   60.0(4)  
C31B C32B O33B C34B  -61.2(10)  
C32 O33 C34 C35 -61.5(4)  
C32B O33B C34B C35B 65.0(10)  
O33 C34 C35 N30 59.1(4)  
C31 N30 C35 C34 -54.9(4)  
C31B N30B C35B C34B 56.3(11)  
O33B C34B C35B N30B -62.0(11)  
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X-ray crystallographic Data- Compound I-1 
(5,5’-(2-pyrilidene)bis(1,3-dimethylbarbituric acid)) 
 
 
Table 25.  Crystal data and structure refinement for compound I-1 
 
 
Empirical formula        C18 H21 N5 O7 
Formula weight                419.40 
Temperature           150(2) K 
Wavelength            0.71073 Å 
Crystal system, space group      Monoclinic, P2(1)/n 
Unit cell dimensions     a=8.9107(19) Å, alpha = 90.00 deg. 
b=10.457(2) Å, beta = 93.098(5) deg 
c=20.387(4) Å, gamma = 90.00 deg 
Volume                          1896.9(7) Å3 
Z, calculated density                4, 1.469 Mg/m3 
Absorption coefficient   0.115 mm-1 
F(000)      880 
Crystal size     0.50 x 0.50 x 0.30 mm 
Theta range for data collection  2.1895 to 30.498 deg. 
Limiting indices    -12<=h<=12, -14<=k<=14, -29<=l<=29 
Reflections collected / unique   34737 / 5827 [R(int) = 0.0384] 
Completeness to theta =30.498  100.0% 
Absorption correction    empirical 
Max. and min. transmission   1.000000 and 0.761887 
Refinement method    Full matrix least squares on F2 
Data / restraints/ parameters   5827 / 89 / 310 
Goodness of fit on F2    0.699 
Final R indices [I>2sigma(I)]   R1=0.0383, wR2=0.0987 
R indices (all data)    R1=0.0763, wR2=0.1032 
Largest diff. peak and hole   0.209 to -0.211 e.A3 
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Table 26: Atomic coordinates and equivalent isotropic displacement parameters (A2) for 
I-1.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
_________________________________________________________________ 
       x                                   y                       z                    U(eq) 
__________________________________________________________________ 
C1 C  0.00074(13)   0.35018(11)  0.10837(6)  0.0301(3)  
N1 N  -0.00765(12)   0.12161(10)  0.10799(5)  0.0405(3)  
O1 O  -0.16289(12)   0.01743(9)  0.03357(6)  0.0656(3)  
N2 N  -0.15615(12)   0.23353(10)  0.03006(5)  0.0405(3)  
C2 C  -0.10899(14)   0.35304(12)  0.05472(6)  0.0339(3)  
O2 O  -0.16226(11)   0.45059(9)  0.02920(5)  0.0470(2)  
O3 O  0.14573(11)   0.22187(9)  0.18332(5)  0.0478(3)  
N3 N  -0.13634(12)   0.69623(10)  0.24788(5)  0.0400(3)  
C3 C  -0.11202(16)   0.11818(13)  0.05580(7)  0.0437(3)  
C4 C  0.04728(14)   0.23553(11)  0.13428(6)  0.0345(3)  
O4 O  -0.12521(13)   0.69851(9)  0.13728(5)  0.0578(3)  
N4 N -0.01165(12)   0.54020(10)  0.31164(5)  0.0415(3)  
N5 N  0.30302(13)   0.41658(10)  0.08727(5)  0.0364(3)  
O5 O  -0.14185(13)   0.69880(10)  0.35886(5)  0.0636(3)  
C5 C  0.0376(2)   -0.00107(13)  0.13818(9)  0.0655(5)  
O6 O  0.12712(11)   0.38474(9)  0.26720(4)  0.0475(3)  
C6 C  -0.27107(19)   0.23070(15)  -0.02365(8)  0.0616(4)  
O7 O  0.23413(16)   0.24469(11)  -0.01023(6)  0.0660(4)  
C7 C  0.06328(13)   0.47835(11)  0.13205(6)  0.0300(3)  
C8 C  0.00400(13)   0.53311(11)  0.19488(6)  0.0305(3)  
C9 C  -0.08711(14)   0.64418(12)  0.18923(6)  0.0364(3)  
C10 C  -0.09947(15)   0.64812(13)  0.30917(7)  0.0419(3)  
C11 C  0.04209(14)   0.48342(12)  0.25590(6)  0.0349(3)  
C12 C  -0.23013(18)   0.81121(14)  0.24477(8)  0.0559(4) 
C13 C  0.0225(2)   0.48613(16)  0.37711(7)  0.0682(5)  
C14 C  0.23319(14)   0.48678(11)  0.13125(6)  0.0322(3)  
C15 C  0.32013(16)   0.57057(14)  0.16933(7)  0.0452(3)  
C16 C  0.47168(17)   0.58118(16)  0.16045(8)  0.0560(4)  
C17 C  0.53801(17)   0.50885(15)  0.11395(8)  0.0538(4)  
C18 C  0.45060(16)   0.42533(14)  0.07768(8)  0.0457(3)  
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Table 27: Bond lengths [Å] and angles [deg] for I-1. 
 
C1 C4      1.3656(17)  
C1 C2      1.4275(17)   
C1 C7      1.5201(16)   
N1 C3      1.3752(17)  
N1 C4      1.3848(16)   
N1 C5      1.4698(18)  
O1 C3      1.2242(15)  
N2 C3      1.3648(17)  
N2 C2      1.4030(16)  
N2 C6      1.4585(18)  
C2 O2      1.2288(15)  
O3 C4      1.3018(15)  
N3 C10     1.3704(17)   
N3 C9      1.4055(16)  
N3 C12     1.4637(17)  
O4 C9      1.2332(15)  
N4 C10     1.3727(17)  
N4 C11     1.3900(16)  
N4 C13     1.4662(18)  
N5 C14     1.3381(15)  
N5 C18     1.3431(17)  
O5 C10     1.2211(16)  
O6 C11     1.2935(15)  
C7 C14     1.5175(17)  
C7 C8      1.5236(17)  
C8 C11     1.3736(17)  
C8 C9      1.4182(17)   
C14 C15     1.3804(18)  
C15 C16     1.377(2)  
C16 C17     1.372(2)  
C17 C18     1.362(2) 
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Table 28:  Anisotropic displacement parameters (A2 ) for G37.  The anisotropic 
displacement factor exponent takes the form: -2 pi2 [h2 a*2U11 + … + h k a*b* U12] 
 
      U11                 U22     U33       U23  U13  U12 
______________________________________________________________________ 
 
C1  0.0324(7)   0.0285(6)  0.0294(6)  -0.0034(5)  0.0027(5)  -0.0020(5)  
N1 0.0479(7)   0.0271(5)  0.0470(7)  -0.0024(5)  0.0075(6)  -0.0029(5)  
O1 0.0743(8)   0.0415(6)  0.0809(8)  -0.0224(6)  0.0031(6)  -0.0161(5)  
N2 0.0414(6)   0.0416(6)  0.0382(6)  -0.0104(5)  -0.0010(5)  -0.0082(5)  
C2 0.0328(7)   0.0358(7)  0.0335(7)  -0.0055(6)  0.0060(6)  -0.0042(6)  
O2 0.0498(6)   0.0435(5)  0.0460(6)  0.0008(4)  -0.0129(5)  0.0028(4)  
O3 0.0596(6)   0.0364(5)  0.0459(6)  0.0014(4)  -0.0096(5)  0.0071(5)  
N3 0.0402(6)   0.0358(6)  0.0441(7)  -0.0061(5)  0.0042(5)  0.0061(5)  
C3 0.0454(8)   0.0386(8)  0.0483(8)  -0.0128(6)  0.0122(7) - 0.0084(6)  
C4 0.0374(7)   0.0312(6)  0.0352(7)  -0.0029(5)  0.0044(6)  -0.0019(6)  
O4 0.0889(8)   0.0414(5)  0.0417(6)  0.0003(5)  -0.0102(5)  0.0212(5)  
N4 0.0467(7)   0.0462(7)  0.0317(6)  -0.0005(5)  0.0030(5)  0.0059(5)  
N5 0.0401(7)   0.0342(6)  0.0352(6)  -0.0020(5)  0.0043(5)  -0.0001(5)  
O5 0.0771(8)   0.0674(7)  0.0483(7)  -0.0127(5)  0.0208(6)  0.0127(6)  
C5 0.0878(13)  0.0295(8)  0.0795(12)  0.0036(7)  0.0087(10)  0.0040(8)  
O6 0.0576(6)   0.0460(6)  0.0380(5)  0.0006(4)  -0.0053(5)  0.0181(5)  
C6 0.0632(11)  0.0663(10)  0.0533(10)  -0.0195(8)  -0.0150(8)  -0.0098(8)  
O7 0.1120(11)  0.0432(7)  0.0415(7)  -0.0061(5)  -0.0079(7)  -0.0067(7)  
C7 0.0332(7)   0.0278(6)  0.0286(7)  0.0005(5)  -0.0012(5)  -0.0005(5)  
C8 0.0327(7)   0.0275(6)  0.0312(7)  -0.0016(5)  0.0001(5)  -0.0003(5)  
C9 0.0395(7)   0.0302(6)  0.0391(7)  -0.0028(6)  -0.0015(6)  -0.0006(6)  
C10 0.0409(8)  0.0456(8)  0.0399(8)  -0.0058(6)  0.0089(6)  -0.0012(6)  
C11 0.0336(7)  0.0366(7)  0.0343(7)  -0.0029(6)  0.0009(6)  -0.0011(6)  
C12 0.0554(10) 0.0446(8)  0.0682(11)  -0.0092(8)  0.0066(8)  0.0157(7)  
C13 0.0896(13) 0.0839(12)  0.0310(8)  0.0046(8)  0.0030(8)  0.0233(10)  
C14 0.0392(7)   0.0290(6)  0.0286(7)  0.0016(5)  0.0030(5)  -0.0023(5)  
C15 0.0412(8)   0.0481(8)  0.0465(9)  -0.0138(7)  0.0032(7)  -0.0093(7)  
C16 0.0436(9)   0.0623(10)  0.0613(10)  -0.0099(8)  -0.0031(8)  -0.0146(8)  
C17 0.0334(8)   0.0639(10)  0.0645(11)  0.0038(8)  0.0074(7)  -0.0031(8)  
C18 0.0391(8)   0.0485(8)  0.0503(9)  0.0002(7)  0.0101(7)  0.0046(7)  
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Table 29: Hydrogen coordinates and isotropic displacement parameters (A2) for I-1 
 
        x         y   z  U(eq) 
___________________________________________________________________ 
 
H3 H   0.143(2)   0.3011(19)  0.2212(11)  0.104(6)  
H5 H   0.2501(17)   0.3583(15)  0.0624(7)  0.060(5) 
H5A H  0.0428   0.0077  0.1861  0.098  
H5B H  0.1364   -0.0258  0.1235  0.098  
H5C H  -0.0363   -0.0669  0.1250  0.098 
H6A H  -0.3107  0.3172  -0.0313  0.092  
H6B H  -0.3529   0.1737  -0.0121  0.092  
H6C H  -0.2269   0.1994  -0.0636  0.092 
H7B H  0.204(2)   0.2770(16)  -0.0469(7)  0.082(6)  
H7C H  0.213(2)   0.1657(12)  -0.0135(10)  0.100(7) 
H7 H   0.0276(12)   0.5374(9)  0.0994(4)  0.024(3) 
H12B H  -0.3183   0.7980  0.2707  0.084  
H12A H  -0.2629   0.8286  0.1990  0.084  
H12C H  -0.1720   0.8841  0.2626  0.084 
H13B H  -0.0691   0.4844  0.4016  0.102  
H13C H  0.0986   0.5390  0.4007  0.102  
H13A H  0.0609   0.3989  0.3728  0.102 
H15 H  0.2695(13)   0.6202(11)  0.2003(5)  0.046(4) 
H16 H  0.5255(16)   0.6421(12)  0.1871(6)  0.069(5) 
H17 H  0.6415(8)   0.5216(14)  0.1071(8)  0.070(5) 
H18 H  0.4831(14)   0.3706(11)  0.0441(5)  0.040(4) 
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Table 30.  Torsion angles [deg] for I-1. 
 
C4 C1 C2     119.73(11)  
C4 C1 C7     123.56(11)  
C2 C1 C7     116.68(10)  
C3 N1 C4     122.14(11)  
C3 N1 C5     117.38(12)  
C4 N1 C5     120.36(12)  
C3 N2 C2     125.10(11)  
C3 N2 C6     116.54(11)  
C2 N2 C6     118.14(12)  
O2 C2 N2     119.10(11)  
O2 C2 C1     125.08(11)  
N2 C2 C1     115.81(11)  
C10 N3 C9     124.27(11)  
C10 N3 C12     116.70(11)  
C9 N3 C12     119.01(11)  
O1 C3 N2     121.67(14)  
O1 C3 N1     122.02(13)  
N2 C3 N1     116.31(11)  
O3 C4 C1     124.84(11)  
O3 C4 N1     114.35(11)  
C1 C4 N1     120.79(11)  
C10 N4 C11     122.83(11)  
C10 N4 C13     116.12(11)  
C11 N4 C13     121.05(12)  
C14 N5 C18     123.68(12)  
C14 C7 C1     113.37(10)  
C14 C7 C8     112.25(10)  
C1 C7 C8     117.42(10)  
C11 C8 C9     119.73(11)  
C11 C8 C7     122.64(11)  
C9 C8 C7     117.54(11)  
O4 C9 N3     117.91(11)  
O4 C9 C8     125.24(12)  
N3 C9 C8     116.84(11)  
O5 C10 N3     121.84(13)  
O5 C10 N4     121.85(13)  
N3 C10 N4     116.32(11)  
O6 C11 C8     125.22(11)  
O6 C11 N4     114.80(11)  
C8 C11 N4     119.97(12)  
N5 C14 C15     117.26(12)  
N5 C14 C7     118.40(11)  
C15 C14 C7     124.11(11)  
C16 C15 C14     120.13(13)  
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Table 30 (I-1) cont. 
 
C17 C16 C15     120.59(14)  
C18 C17 C16     118.29(14)  
N5 C18 C17     120.04(14)  
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